

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:35:31 ; Search time 164 Seconds  
(without alignments)  
10.196 Million cell updates/sec

Title: US-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1865214 seqs, 418043040 residues

Total number of hits satisfying chosen parameters: 230398

Minimum DB seq length: 4

Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Listing first 100 summaries

#### Database :

Published Applications AA:\*

1: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pdb.\*

2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pdb.\*

3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pdb.\*

4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pdb.\*

5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pdb.\*

6: /cgn2\_6/ptodata/2/pubpaa/PCTUS\_PUBCOMB.pdb.\*

7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pdb.\*

8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pdb.\*

9: /cgn2\_6/ptodata/2/pubpaa/US09A\_PUBCOMB.pdb.\*

10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pdb.\*

11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pdb.\*

12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pdb.\*

13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pdb.\*

14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pdb.\*

15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pdb.\*

16: /cgn2\_6/ptodata/2/pubpaa/US10D\_PUBCOMB.pdb.\*

17: /cgn2\_6/ptodata/2/pubpaa/US10E\_PUBCOMB.pdb.\*

18: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pdb.\*

19: /cgn2\_6/ptodata/2/pubpaa/US11A\_PUBCOMB.pdb.\*

20: /cgn2\_6/ptodata/2/pubpaa/US11\_NEW\_PUB.pdb.\*

21: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pdb.\*

22: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	100.0	4	9	US-09-808-037-1 Sequence 1, Appli
2	24	100.0	4	9	US-09-975-932-8 Sequence 8, Appli
3	24	100.0	4	14	US-10-084-380A-8 Sequence 1, Appli
4	24	100.0	4	14	US-10-162-889-1 Sequence 1, Appli
5	24	100.0	4	15	US-10-384-788-1 Sequence 1, Appli
6	24	100.0	4	15	US-10-618-856-1 Sequence 5, Appli
7	24	100.0	4	17	US-10-481-642-5 Sequence 1, Appli
8	24	100.0	4	17	US-10-749-522-1 Sequence 27, Appli
9	24	100.0	4	18	US-10-625-854-27 Sequence 1, Appli
10	24	100.0	4	20	US-11-073-526-1 Sequence 287, App
11	24	100.0	5	18	US-10-505-313-287

12	24	100.0	5	18	US-10-625-854-15 Sequence 15, Appli
13	24	100.0	5	18	US-10-625-854-28 Sequence 28, Appli
14	24	100.0	6	9	US-09-808-037-7 Sequence 7, Appli
15	24	100.0	6	9	US-09-975-932-6 Sequence 6, Appli
16	24	100.0	6	14	US-10-084-380A-6 Sequence 6, Appli
17	24	100.0	6	14	US-10-162-889-7 Sequence 7, Appli
18	24	100.0	6	15	US-10-384-788-7 Sequence 7, Appli
19	24	100.0	6	15	US-10-618-856-7 Sequence 75, Appli
20	24	100.0	6	16	US-10-622-087-75 Sequence 84, Appli
21	24	100.0	6	16	US-10-622-087-84 Sequence 85, Appli
22	24	100.0	6	16	US-10-622-087-85 Sequence 88, Appli
23	24	100.0	6	16	US-10-622-087-88 Sequence 90, Appli
24	24	100.0	6	17	US-10-749-522-7 Sequence 7, Appli
25	24	100.0	6	18	US-10-810-881A-101 Sequence 101, App
26	24	100.0	6	18	US-10-810-881A-111 Sequence 111, App
27	24	100.0	6	18	US-10-505-313-285 Sequence 285, App
28	24	100.0	6	18	US-10-625-854-3 Sequence 3, Appli
29	24	100.0	6	18	US-10-625-854-16 Sequence 16, Appli
30	24	100.0	6	18	US-10-625-854-29 Sequence 29, Appli
31	24	100.0	6	18	US-10-625-854-41 Sequence 41, Appli
32	24	100.0	6	20	US-11-073-526-7 Sequence 7, Appli
33	24	100.0	7	9	US-09-867-847-5 Sequence 5, Appli
34	24	100.0	7	14	US-10-337-970-8 Sequence 8, Appli
35	24	100.0	7	16	US-10-481-642-4 Sequence 4, Appli
36	24	100.0	7	17	US-10-825-958-5 Sequence 5, Appli
37	24	100.0	7	18	US-10-810-881A-100 Sequence 100, App
38	24	100.0	7	18	US-10-505-313-256 Sequence 256, App
39	24	100.0	7	18	US-10-505-313-257 Sequence 257, App
40	24	100.0	7	18	US-10-505-313-286 Sequence 286, App
41	24	100.0	7	18	US-10-625-854-4 Sequence 4, Appli
42	24	100.0	7	18	US-10-625-854-17 Sequence 17, Appli
43	24	100.0	7	18	US-10-625-854-30 Sequence 30, Appli
44	24	100.0	7	18	US-10-625-854-42 Sequence 42, Appli
45	24	100.0	7	18	US-10-625-854-228 Sequence 228, App
46	24	100.0	8	9	US-09-975-932-3 Sequence 3, Appli
47	24	100.0	8	14	US-10-084-380A-3 Sequence 3, Appli
48	24	100.0	8	16	US-10-343-389A-23 Sequence 23, Appli
49	24	100.0	8	17	US-10-481-642-1 Sequence 1, Appli
50	24	100.0	8	18	US-10-810-881A-99 Sequence 99, Appli
51	24	100.0	8	18	US-10-810-881A-109 Sequence 109, App
52	24	100.0	8	18	US-10-625-854-5 Sequence 5, Appli
53	24	100.0	8	18	US-10-625-854-18 Sequence 18, Appli
54	24	100.0	8	18	US-10-625-854-31 Sequence 31, Appli
55	24	100.0	8	18	US-10-625-854-43 Sequence 43, Appli
56	24	100.0	8	18	US-10-625-854-229 Sequence 229, App
57	24	100.0	8	18	US-10-625-854-238 Sequence 238, App
58	24	100.0	9	15	US-10-619-454-16 Sequence 16, Appli
59	24	100.0	9	15	US-10-619-454-33 Sequence 33, Appli
60	24	100.0	9	15	US-10-619-454-39 Sequence 39, Appli
61	24	100.0	9	15	US-10-619-454-44 Sequence 44, Appli
62	24	100.0	9	15	US-10-619-454-49 Sequence 49, Appli
63	24	100.0	9	15	US-10-619-454-54 Sequence 54, Appli
64	24	100.0	9	15	US-10-619-454-63 Sequence 63, Appli
65	24	100.0	9	15	US-10-619-454-68 Sequence 68, Appli
66	24	100.0	9	15	US-10-619-454-74 Sequence 74, Appli
67	24	100.0	9	15	US-10-619-454-75 Sequence 75, Appli
68	24	100.0	9	15	US-10-619-454-79 Sequence 79, Appli
69	24	100.0	9	15	US-10-619-454-81 Sequence 81, Appli
70	24	100.0	9	15	US-10-619-454-85 Sequence 85, Appli
71	24	100.0	9	15	US-10-619-454-97 Sequence 97, Appli
72	24	100.0	9	15	US-10-619-454-100 Sequence 100, App
73	24	100.0	9	15	US-10-619-454-103 Sequence 103, App
74	24	100.0	9	15	US-10-619-454-112 Sequence 112, App
75	24	100.0	9	15	US-10-619-454-114 Sequence 114, App
76	24	100.0	9	15	US-10-619-454-122 Sequence 122, App
77	24	100.0	9	15	US-10-619-454-125 Sequence 125, App
78	24	100.0	9	15	US-10-619-454-136 Sequence 136, App
79	24	100.0	9	15	US-10-619-454-153 Sequence 153, App
80	24	100.0	9	15	US-10-619-454-166 Sequence 166, App
81	24	100.0	9	15	US-10-619-454-174 Sequence 174, App
82	24	100.0	9	15	US-10-622-087-77 Sequence 77, Appli
83	24	100.0	9	16	US-10-481-642-2 Sequence 2, Appli
84	24	100.0	9	17	US-10-481-642-2

85 24 100.0 9 18 US-10-810-881A-98 Sequence 98, Appl  
86 24 100.0 9 18 US-10-810-881A-108 Sequence 108, App  
87 24 100.0 9 18 US-10-810-881A-110 Sequence 110, App  
88 24 100.0 9 18 US-10-505-313-1 Sequence 1, Appl  
89 24 100.0 9 18 US-10-625-854-6 Sequence 6, Appl  
90 24 100.0 9 18 US-10-625-854-19 Sequence 19, Appl  
91 24 100.0 9 18 US-10-625-854-32 Sequence 32, Appl  
92 24 100.0 9 18 US-10-625-854-44 Sequence 44, Appl  
93 24 100.0 9 18 US-10-625-854-230 Sequence 230, App  
94 24 100.0 9 18 US-10-625-854-239 Sequence 239, App  
95 24 100.0 9 18 US-10-625-854-247 Sequence 247, App  
96 24 100.0 10 10 US-09-865-294-69 Sequence 69, Appl  
97 24 100.0 10 14 US-10-010-942B-33 Sequence 33, Appl  
98 24 100.0 10 15 US-10-411-544-24 Sequence 24, Appl  
99 24 100.0 10 15 US-10-388-389-33 Sequence 33, Appl  
100 24 100.0 10 16 US-10-703-713-33 Sequence 33, Appl

## ALIGNMENTS

RESULT 1  
US-09-808-037-1  
; Sequence 1, Application US/09808037  
; Patent No. US20020052311A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: HANAN, Eilat  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF  
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS  
; FILE REFERENCE: SOLOMON=20  
; CURRENT APPLICATION NUMBER: US/09/808,037  
; CURRENT FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-09-808-037-1

Query Match 100.0%; Score 24; DB 9; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06; Length 4;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 2  
US-09-975-932-8  
; Sequence 8, Application US/09975932  
; Publication No. US20020086847A1  
; GENERAL INFORMATION:  
; APPLICANT: CHAIN, Daniel G.  
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,  
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF  
; FILE REFERENCE: CHAIN1B  
; CURRENT APPLICATION NUMBER: US/09/975,932  
; CURRENT FILING DATE: 2001-10-15  
; PRIOR APPLICATION NUMBER: 09/402,820  
; PRIOR FILING DATE: 1999-10-12  
; PRIOR APPLICATION NUMBER: PCT/US98/06900  
; PRIOR FILING DATE: 1998-04-09

; PRIOR APPLICATION NUMBER: 60/041,850  
; PRIOR FILING DATE: 1997-04-09  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 8  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-975-932-8

Query Match 100.0%; Score 24; DB 9; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06; Length 4;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

## RESULT 3

US-10-084-380A-8  
; Sequence 8, Application US/10084380A  
; Publication No. US20030073655A1  
; GENERAL INFORMATION:  
; APPLICANT: Mindset Biopharmaceutical Inc.  
; APPLICANT: Chain, Daniel G.  
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide, pharmaceutical compo  
; TITLE OF INVENTION: and methods of use thereof  
; FILE REFERENCE: P-4815-US1  
; CURRENT APPLICATION NUMBER: US/10/084,380A  
; CURRENT FILING DATE: 2002-02-28  
; PRIOR APPLICATION NUMBER: 60/041,850  
; PRIOR FILING DATE: 1997-04-09  
; PRIOR APPLICATION NUMBER: 09/402,820  
; PRIOR FILING DATE: 1999-10-12  
; PRIOR APPLICATION NUMBER: PCT/us98/06900  
; PRIOR FILING DATE: 1998-04-09  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: human  
US-10-084-380A-8

Query Match 100.0%; Score 24; DB 14; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06; Length 4;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

## RESULT 4

US-10-162-889-1  
; Sequence 1, Application US/10162889  
; Publication No. US20030077252A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: HANAN, Eilat  
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME  
; TITLE OF INVENTION: USEFUL IN DIAGNOSING  
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES  
; FILE REFERENCE: SOLOMON=2B  
; CURRENT APPLICATION NUMBER: US/10/162,889  
; CURRENT FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: US/09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03

; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-162-889-1

Query Match 100.0%; Score 24; DB 14; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 1 EFRH 4

RESULT 5  
US-10-384-788-1  
; Sequence 1, Application US/10384788  
; Publication No. US20040013647A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: FRENKEL, Dan  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE  
; FILE REFERENCE: SOLOMON=2D.2  
; CURRENT APPLICATION NUMBER: US/10/384,788  
; PRIOR FILING DATE: 2003-03-11  
; PRIOR FILING DATE: 2002-04-12  
; PRIOR APPLICATION NUMBER: 60/371,735  
; PRIOR FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/808,037  
; PRIOR FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/830,954  
; PRIOR FILING DATE: 2001-06-22  
; PRIOR APPLICATION NUMBER: 10/162,889  
; PRIOR FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; PRIOR APPLICATION NUMBER: PCT/IL00/00518  
; PRIOR FILING DATE: 2000-08-31  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-384-788-1

Query Match 100.0%; Score 24; DB 15; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 1 EFRH 4

RESULT 6  
US-10-618-856-1  
; Sequence 1, Application US/10618856  
; Publication No. US20040052766A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: FRENKEL, Dan  
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY

; FILE REFERENCE: SOLOMON=2A  
; CURRENT APPLICATION NUMBER: US/10/618,856  
; CURRENT FILING DATE: 2003-07-15  
; PRIOR APPLICATION NUMBER: US/09/473,653A  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-618-856-1

Query Match 100.0%; Score 24; DB 15; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 1 EFRH 4

RESULT 7  
US-10-481-642-5  
; Sequence 5, Application US/10481642  
; Publication No. US20050053575A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPTOPE OF A L  
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH  
; TITLE OF INVENTION: USING SAME  
; FILE REFERENCE: SOLOMON=4.1A.PCT  
; CURRENT APPLICATION NUMBER: US/10/481,642  
; CURRENT FILING DATE: 2003-12-22  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 5  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-481-642-5

Query Match 100.0%; Score 24; DB 17; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 1 EFRH 4

RESULT 8  
US-10-749-522-1  
; Sequence 1, Application US/10749522  
; Publication No. US20050089510A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: HANAN, Eilat  
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIA  
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES  
; FILE REFERENCE: SOLOMON=2B  
; CURRENT APPLICATION NUMBER: US/10/749,522  
; CURRENT FILING DATE: 2004-01-02  
; PRIOR APPLICATION NUMBER: US/09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29

; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-749-522-1

Query Match 100.0%; Score 24; DB 17; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 1 EFRH 4

RESULT 9  
US-10-625-854-27  
; Sequence 27, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 27  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-27

Query Match 100.0%; Score 24; DB 18; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 1 EFRH 4

RESULT 10  
US-11-073-526-1  
; Sequence 1, Application US/11073526  
; Publication No. US20050152878A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: FRENKEL, Dan  
; APPLICANT: HANAN, Eliat  
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG  
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES  
; FILE REFERENCE: SOLOMON=2C  
; CURRENT APPLICATION NUMBER: US/11/073,526  
; CURRENT FILING DATE: 2005-03-08  
; PRIOR APPLICATION NUMBER: US/09/830,954  
; PRIOR FILING DATE: 2001-08-07  
; PRIOR APPLICATION NUMBER: PCT/IL00/00518  
; PRIOR FILING DATE: 2000-08-31  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31

; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide  
US-11-073-526-1

Query Match 100.0%; Score 24; DB 20; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 1 EFRH 4

RESULT 11  
US-10-505-313-287  
; Sequence 287, Application US/10505313  
; Publication No. US20050169925A1  
; GENERAL INFORMATION:  
; APPLICANT: F. Hoffmann-La Roche AG  
; APPLICANT: MorphoSys AG  
; TITLE OF INVENTION: Anti A-beta antibodies and their use  
; FILE REFERENCE: F 2842 PCT  
; CURRENT APPLICATION NUMBER: US/10/505,313  
; CURRENT FILING DATE: 2004-08-20  
; PRIOR APPLICATION NUMBER: EP 02003844.4  
; PRIOR FILING DATE: 2002-02-20  
; NUMBER OF SEQ ID NOS: 414  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 287  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: artificial sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic construct; peptide 3 A beta  
US-10-505-313-287

Query Match 100.0%; Score 24; DB 18; Length 5;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 1 EFRH 4

RESULT 12  
US-10-625-854-15  
; Sequence 15, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2



; SEQ ID NO 15  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-15

Query Match 100.0%; Score 24; DB 18; Length 5;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFRH 5

## RESULT 13

US-10-625-854-28  
; Sequence 28, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 28  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-28

Query Match 100.0%; Score 24; DB 18; Length 5;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

## RESULT 14

US-09-808-037-7  
; Sequence 7, Application US/09808037  
; Patent No. US20020052311A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: HANAN, Eliat  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF  
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS  
; FILE REFERENCE: SOLOMON-2D  
; CURRENT APPLICATION NUMBER: US/09/808,037  
; CURRENT FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1998-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:

; OTHER INFORMATION: synthetic peptide  
US-09-808-037-7

Query Match 100.0%; Score 24; DB 9; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

## RESULT 15

US-09-975-932-6  
; Sequence 6, Application US/09975932  
; Publication No. US20020086847A1  
; GENERAL INFORMATION:  
; APPLICANT: CHAIN, Daniel G.  
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,  
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF  
; FILE REFERENCE: CHAIN1B  
; CURRENT APPLICATION NUMBER: US/09/975,932  
; CURRENT FILING DATE: 2001-10-15  
; PRIOR APPLICATION NUMBER: 09/402,820  
; PRIOR FILING DATE: 1999-10-12  
; PRIOR APPLICATION NUMBER: PCT/US98/06900  
; PRIOR FILING DATE: 1998-04-09  
; PRIOR APPLICATION NUMBER: 60/041,850  
; PRIOR FILING DATE: 1997-04-09  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 6  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-975-932-6

Query Match 100.0%; Score 24; DB 9; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

## RESULT 16

US-10-084-380A-6  
; Sequence 6, Application US/10084380A  
; Publication No. US20030073655A1  
; GENERAL INFORMATION:  
; APPLICANT: Mindset Biopharmaceutical Inc.  
; APPLICANT: Chain, Daniel G.  
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide, pharmaceutical comp  
; TITLE OF INVENTION: and methods of use thereof  
; FILE REFERENCE: P-4815-US1  
; CURRENT APPLICATION NUMBER: US/10/084,380A  
; CURRENT FILING DATE: 2002-02-28  
; PRIOR APPLICATION NUMBER: 60/041,850  
; PRIOR FILING DATE: 1997-04-09  
; PRIOR APPLICATION NUMBER: 09/402,820  
; PRIOR FILING DATE: 1999-10-12  
; PRIOR APPLICATION NUMBER: PCT/us98/06900  
; PRIOR FILING DATE: 1998-04-09  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 6  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: human  
US-10-084-380A-6

Query Match 100.0%; Score 24; DB 14; Length 6;

Best Local Similarity 100.0%; Pred. No. 1.7e+06; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0;

Qy 1 EFRH 4  
    ||||  
Db 3 EFRH 6

RESULT 17  
US-10-162-889-7  
; Sequence 7, Application US/10162889  
; Publication No. US20030077252A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: HANAN, Bilal  
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME  
; TITLE OF INVENTION: USEFUL IN DIAGNOSING  
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES  
; FILE REFERENCE: SOLOMON-2B  
; CURRENT APPLICATION NUMBER: US/10/162,889  
; CURRENT FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: US/09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-162-889-7

Query Match 100.0%; Score 24; DB 14; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
    ||||  
Db 3 EFRH 6

RESULT 18  
US-10-384-788-7  
; Sequence 7, Application US/10384788  
; Publication No. US20040013647A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: FRENKEL, Dan  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE  
; FILE REFERENCE: SOLOMON-2D.2  
; CURRENT APPLICATION NUMBER: US/10/384,788  
; CURRENT FILING DATE: 2003-03-11  
; PRIOR APPLICATION NUMBER: 60/371,735  
; PRIOR FILING DATE: 2002-04-12  
; PRIOR APPLICATION NUMBER: 09/808,037  
; PRIOR FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/830,954  
; PRIOR FILING DATE: 2001-06-22  
; PRIOR APPLICATION NUMBER: 10/162,889  
; PRIOR FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; PRIOR APPLICATION NUMBER: PCT/IL00/00518  
; PRIOR FILING DATE: 2000-08-31

; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-384-788-7

Query Match 100.0%; Score 24; DB 15; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
    ||||  
Db 3 EFRH 6

RESULT 19  
US-10-618-856-7  
; Sequence 7, Application US/10618856  
; Publication No. US20040052766A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: FRENKEL, Dan  
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY  
; FILE REFERENCE: SOLOMON-2A  
; CURRENT APPLICATION NUMBER: US/10/618,856  
; CURRENT FILING DATE: 2003-07-15  
; PRIOR APPLICATION NUMBER: US/09/473,653A  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-10-618-856-7

Query Match 100.0%; Score 24; DB 15; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
    ||||  
Db 3 EFRH 6

RESULT 20  
US-10-622-087-75  
; Sequence 75, Application US/10622087  
; Publication No. US20040141984A1  
; GENERAL INFORMATION:  
; APPLICANT: Bachmann, Martin F  
; APPLICANT: Tissot, Alain  
; APPLICANT: Ortman, Rainer  
; APPLICANT: Luond, Rainer  
; APPLICANT: Staufenbiel, Matthias  
; APPLICANT: Frey, Peter  
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays  
; FILE REFERENCE: 1700.0350002  
; CURRENT APPLICATION NUMBER: US/10/622,087  
; CURRENT FILING DATE: 2003-07-18  
; PRIOR APPLICATION NUMBER: US 60/396,639  
; PRIOR FILING DATE: 2002-07-19  
; PRIOR APPLICATION NUMBER: US 60/470,432  
; PRIOR FILING DATE: 2003-05-15  
; NUMBER OF SEQ ID NOS: 93

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-622-087-75

Query Match      100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
DB 3 EFRH 6

RESULT 21
US-10-622-087-84
; Sequence 84, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenberg, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84
; LENGTH: 6
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-622-087-84

Query Match      100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
DB 3 EFRH 6

RESULT 22
US-10-622-087-85
; Sequence 85, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenberg, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 85
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Oryctolagus cuniculus
US-10-622-087-85

Query Match      100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
DB 3 EFRH 6

RESULT 23
US-10-622-087-88
; Sequence 88, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenberg, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 88
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Cavia porcellus
US-10-622-087-88

Query Match      100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
DB 3 EFRH 6

RESULT 24
US-10-622-087-90
; Sequence 90, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenberg, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 90
```

```
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-622-087-90

Query Match      100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 25
US-10-749-522-7
; Sequence 7, Application US/10749522
; Publication No. US20050089510A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Elat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; FILE REFERENCE: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=28
; CURRENT APPLICATION NUMBER: US/10749,522
; CURRENT FILING DATE: 2004-01-02
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/629,971
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: US 60/152,417
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-749-522-7

Query Match      100.0%; Score 24; DB 17; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 26
US-10-810-881A-101
; Sequence 101, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 101
; LENGTH: 6
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; peptide 1 A beta
```

```
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-101

Query Match      100.0%; Score 24; DB 18; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 1 EFRH 4

RESULT 27
US-10-810-881A-111
; Sequence 111, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-111

Query Match      100.0%; Score 24; DB 18; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 28
US-10-505-313-285
; Sequence 285, Application US/10505313
; Publication No. US20050169925A1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: Morphosys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 285
; LENGTH: 6
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; peptide 1 A beta
```

## US-10-505-313-285

Query Match 100.0%; Score 24; DB 18; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFRH 5

## RESULT 29

US-10-625-854-3  
; Sequence 3, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 3  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-3

Query Match 100.0%; Score 24; DB 18; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

## RESULT 30

US-10-625-854-16  
; Sequence 16, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 16  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-16

Query Match 100.0%; Score 24; DB 18; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4

Db 2 EFRH 5

## RESULT 31

US-10-625-854-29  
; Sequence 29, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 29  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-29

Query Match 100.0%; Score 24; DB 18; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

## RESULT 32

US-10-625-854-41  
; Sequence 41, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 41  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: homo sapiens  
; FEATURE: MISC\_FEATURE  
; NAME/KEY: (1)..(1)  
; LOCATION: (1)..(1)  
; OTHER INFORMATION: xaa represents pyroglutamate  
US-10-625-854-41

Query Match 100.0%; Score 24; DB 18; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFRH 5

RESULT 33  
US-11-073-526-7  
; Sequence 7, Application US/11073526  
; Publication No. US20050152878A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: FRENKEL, Dan  
; APPLICANT: HANAN, Eliat  
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG  
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES  
; FILE REFERENCE: SOLOMON=2C  
; CURRENT APPLICATION NUMBER: US/11/073,526  
; CURRENT FILING DATE: 2005-03-08  
; PRIOR APPLICATION NUMBER: US/09/830,954  
; PRIOR FILING DATE: 2001-08-07  
; PRIOR APPLICATION NUMBER: PCT/IL00/00518  
; PRIOR FILING DATE: 2000-08-31  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide  
US-11-073-526-7

Query Match 100.0%; Score 24; DB 20; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 34  
US-09-867-847-5  
; Sequence 5, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-5

Query Match 100.0%; Score 24; DB 9; Length 7;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

## RESULT 35

US-10-337-970-8  
; Sequence 8, Application US/10337970  
; Publication No. US20030148356A1  
; GENERAL INFORMATION:  
; APPLICANT: Cruts, Marc  
; APPLICANT: De Jonghe, Chris  
; APPLICANT: Singh, Samir Kumar  
; APPLICANT: Van Broeckhoven, Christine Kumar  
; TITLE OF INVENTION: A NOVEL APP MUTATION ASSOCIATED WITH AN UNUSUAL ALZHEIMER'S DISEA  
; TITLE OF INVENTION: PATHOLOGY  
; FILE REFERENCE: 2183-5642US  
; CURRENT APPLICATION NUMBER: US/10/337,970  
; CURRENT FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: artificial sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide corresponding to amyloid beta peptide residues  
US-10-337-970-8

Query Match 100.0%; Score 24; DB 14; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

## RESULT 36

US-10-481-954-4  
; Sequence 4, Application US/10481954  
; Publication No. US20040253647A1  
; GENERAL INFORMATION:  
; APPLICANT: New York State Office of Mental Health  
; TITLE OF INVENTION: Cell-based High Throughput Screening Methods  
; FILE REFERENCE: 1079-4014PC  
; CURRENT APPLICATION NUMBER: US/10/481,954  
; CURRENT FILING DATE: 2003-12-23  
; PRIOR APPLICATION NUMBER: US 60/300,959  
; PRIOR FILING DATE: 2001-06-26  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 4  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide containing epitope for JRF/ABN/25 antibody.  
US-10-481-954-4

Query Match 100.0%; Score 24; DB 16; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 37  
US-10-825-958-5  
; Sequence 5, Application US/10825958  
; Publication No. US20050090439A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 50291/004002  
; CURRENT APPLICATION NUMBER: US/10/825,958  
; PRIOR FILING DATE: 2004-04-16  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; NUMBER OF SEQ ID NOS: 63  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-10-825-958-5

Query Match 100.0%; Score 24; DB 17; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
Db 3 EPRH 6

RESULT 38  
US-10-810-881A-100  
; Sequence 100, Application US/10810881A  
; Publication No. US20050129695A1  
; GENERAL INFORMATION:  
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.  
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES  
; FILE REFERENCE: CEN5021 NP  
; CURRENT APPLICATION NUMBER: US/10/810,881A  
; PRIOR FILING DATE: 2004-03-26  
; PRIOR APPLICATION NUMBER: US 60/458,474  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,469  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,509  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,510  
; PRIOR FILING DATE: 2003-03-28  
; NUMBER OF SEQ ID NOS: 131  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 100  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: PEPTIDE  
US-10-810-881A-100

Query Match 100.0%; Score 24; DB 18; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
Db 1 EPRH 4

RESULT 39  
US-10-505-313-256  
; Sequence 256, Application US/10505313  
; Publication No. US20050169925A1  
; GENERAL INFORMATION:  
; APPLICANT: F. Hoffmann-La Roche AG  
; APPLICANT: Morphosys AG  
; TITLE OF INVENTION: Anti A-beta antibodies and their use  
; FILE REFERENCE: F 2842 PCT  
; CURRENT APPLICATION NUMBER: US/10/505,313  
; CURRENT FILING DATE: 2004-08-20  
; PRIOR APPLICATION NUMBER: EP 02003844.4  
; PRIOR FILING DATE: 2002-02-20  
; NUMBER OF SEQ ID NOS: 414  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 256  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: artificial sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic construct  
US-10-505-313-256

Query Match 100.0%; Score 24; DB 18; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
Db 2 EPRH 5

RESULT 40  
US-10-505-313-257  
; Sequence 257, Application US/10505313  
; Publication No. US20050169925A1  
; GENERAL INFORMATION:  
; APPLICANT: F. Hoffmann-La Roche AG  
; APPLICANT: Morphosys AG  
; TITLE OF INVENTION: Anti A-beta antibodies and their use  
; FILE REFERENCE: F 2842 PCT  
; CURRENT APPLICATION NUMBER: US/10/505,313  
; CURRENT FILING DATE: 2004-08-20  
; PRIOR APPLICATION NUMBER: EP 02003844.4  
; PRIOR FILING DATE: 2002-02-20  
; NUMBER OF SEQ ID NOS: 414  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 257  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: artificial sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic construct  
US-10-505-313-257

Query Match 100.0%; Score 24; DB 18; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
Db 1 EPRH 4

RESULT 41  
US-10-505-313-286  
; Sequence 286, Application US/10505313  
; Publication No. US20050169925A1  
; GENERAL INFORMATION:  
; APPLICANT: F. Hoffmann-La Roche AG  
; APPLICANT: Morphosys AG





```
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (1)..(1)
; OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-42

Query Match      100.0%; Score 24; DB 18; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 46
US-10-625-854-228
; Sequence 228, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NFUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228
; LENGTH: 7
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-228

Query Match      100.0%; Score 24; DB 18; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 4 EFRH 7

RESULT 47
US-09-975-932-3
; Sequence 3, Application US/09975932
; Publication No. US20020086647A1
; GENERAL INFORMATION:
; APPLICANT: CHAIN, Daniel G.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
; FILE REFERENCE: CHAIN1B
; CURRENT APPLICATION NUMBER: US/09/975,932
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:HUMAN PEPTIDE
```

```
; OTHER INFORMATION: WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE
US-09-975-932-3

Query Match      100.0%; Score 24; DB 9; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 48
US-10-084-380A-3
; Sequence 3, Application US/10084380A
; Publication No. US20030073655A1
; GENERAL INFORMATION:
; APPLICANT: Mindset Biopharmaceutical Inc.
; APPLICANT: Chain, Daniel G.
; TITLE OF INVENTION: Specific antibodies to amyloid beta peptide, pharmaceutical compo
; FILE REFERENCE: P-4815-US1
; CURRENT APPLICATION NUMBER: US/10/084,380A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: human
US-10-084-380A-3

Query Match      100.0%; Score 24; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 49
US-10-343-389A-23
; Sequence 23, Application US/10343389A
; Publication No. US20040180417A1
; GENERAL INFORMATION:
; APPLICANT: SEIDAH, NABIL G.
; APPLICANT: CHRETIEN, MICHEL
; APPLICANT: CROMLISH, JAMES A.
; TITLE OF INVENTION: SECRETASE/SHEDDASE WITH ASP-ASE ACTIVITY ON THE
; TITLE OF INVENTION: BETA-SITE APP CLEAVING ENZYME (BACE, ASP2, MEMEPSIN 2)
; FILE REFERENCE: G0UD:027US
; CURRENT APPLICATION NUMBER: US/10/343,389A
; CURRENT FILING DATE: 2003-01-30
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-343-389A-23

Query Match      100.0%; Score 24; DB 16; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
```

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||||  
Db 3 EFRH 6

RESULT 50  
US-10-481-642-1  
; Sequence 1, Application US/10481642  
; Publication No. US20050053575A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A D  
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH  
; TITLE OF INVENTION: USING SAME  
; FILE REFERENCE: SOLOMON-4.1A PCT  
; CURRENT APPLICATION NUMBER: US/10/481,642  
; CURRENT FILING DATE: 2003-12-22  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-481-642-1

Query Match 100.0%; Score 24; DB 17; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||||  
Db 3 EFRH 6

RESULT 51  
US-10-810-881A-99  
; Sequence 99, Application US/10810881A  
; Publication No. US20050129695A1  
; GENERAL INFORMATION:  
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.  
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES  
; FILE REFERENCE: CEN5021 NP  
; CURRENT APPLICATION NUMBER: US/10/810,881A  
; CURRENT FILING DATE: 2004-03-26  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,474  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,469  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,509  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,510  
; NUMBER OF SEQ ID NOS: 131  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 99  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: PEPTIDE  
US-10-810-881A-99

Query Match 100.0%; Score 24; DB 18; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||||  
Db 2 EFRH 5

RESULT 52  
US-10-810-881A-109  
; Sequence 109, Application US/10810881A  
; Publication No. US20050129695A1  
; GENERAL INFORMATION:  
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.  
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES  
; FILE REFERENCE: CEN5021 NP  
; CURRENT APPLICATION NUMBER: US/10/810,881A  
; CURRENT FILING DATE: 2004-03-26  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,474  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,469  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,509  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,510  
; PRIOR FILING DATE: 2003-03-28  
; NUMBER OF SEQ ID NOS: 131  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 109  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: PEPTIDE  
US-10-810-881A-109

Query Match 100.0%; Score 24; DB 18; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||||  
Db 2 EFRH 5

RESULT 53  
US-10-625-854-5  
; Sequence 5, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-5

Query Match 100.0%; Score 24; DB 18; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||||  
Db 3 EFRH 6

RESULT 54

```
US-10-625-854-18
; Sequence 18, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 8
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-18

Query Match      100.0%; Score 24; DB 18; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 55
US-10-625-854-31
; Sequence 31, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 8
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-31

Query Match      100.0%; Score 24; DB 18; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 1 EFRH 4

RESULT 56
US-10-625-854-43
; Sequence 43, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
```

```
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
; LENGTH: 8
; TYPE: PRT
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (1)-(1)
; OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-43

Query Match      100.0%; Score 24; DB 18; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 57
US-10-625-854-229
; Sequence 229, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 229
; LENGTH: 8
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-229

Query Match      100.0%; Score 24; DB 18; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 5 EFRH 8

RESULT 58
US-10-625-854-238
; Sequence 238, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
```

```
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 238
; LENGTH: 8
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-238

Query Match          100.0%; Score 24; DB 18; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
   ||||
Db 4 EFRH 7

RESULT 59
US-10-619-454-16
; Sequence 16, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-16

Query Match          100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
   ||||
Db 2 EFRH 5

RESULT 60
US-10-619-454-33
; Sequence 33, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; 
```

```
; SEQ ID NO 33
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-33

Query Match          100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
   ||||
Db 2 EFRH 5

RESULT 61
US-10-619-454-39
; Sequence 39, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 39
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-39

Query Match          100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
   ||||
Db 2 EFRH 5

RESULT 62
US-10-619-454-44
; Sequence 44, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; 
```

; OTHER INFORMATION: algorithm generated  
US-10-619-454-44

Query Match 100.0%; Score 24; DB 15; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 2 EFRH 5

## RESULT 63

US-10-619-454-49  
; Sequence 49, Application US/10619454  
; Publication No. US20040091945A1

; GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 49

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-49

Query Match 100.0%; Score 24; DB 15; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 2 EFRH 5

## RESULT 64

US-10-619-454-54  
; Sequence 54, Application US/10619454  
; Publication No. US20040091945A1

; GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 54

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-54

Query Match 100.0%; Score 24; DB 15; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
Db 2 EFRH 5

## RESULT 65

US-10-619-454-63  
; Sequence 63, Application US/10619454  
; Publication No. US20040091945A1

; GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 63

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-63

Query Match 100.0%; Score 24; DB 15; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 2 EFRH 5

## RESULT 66

US-10-619-454-68  
; Sequence 68, Application US/10619454  
; Publication No. US20040091945A1

; GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 68

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-68

Query Match 100.0%; Score 24; DB 15; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 3 EFRH 6

```
RESULT 67
US-10-619-454-74
; Sequence 74, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 74
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-74

Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      4 EFRH 7

RESULT 68
US-10-619-454-75
; Sequence 75, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 75
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-75

Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      2 EFRH 5

RESULT 69
US-10-619-454-79
; Sequence 79, Application US/10619454
```

```
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 79
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-79

Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      2 EFRH 5

RESULT 70
US-10-619-454-81
; Sequence 81, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 81
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-81

Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      4 EFRH 7

RESULT 71
US-10-619-454-85
; Sequence 85, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
```

```
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 85
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-85

Query Match 100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 72
US-10-619-454-97
; Sequence 97, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 97
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-97

Query Match 100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 73
US-10-619-454-100
; Sequence 100, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
```

```
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 100
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-100

Query Match 100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 74
US-10-619-454-103
; Sequence 103, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 103
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-103

Query Match 100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 75
US-10-619-454-112
; Sequence 112, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 112
```

```
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-112

Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
Db 3 EPRH 6

RESULT 76
US-10-619-454-114
; Sequence 114, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 114
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-114

Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
Db 3 EPRH 6

RESULT 77
US-10-619-454-122
; Sequence 122, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 122
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
```

US-10-619-454-122

```
Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 EPRH 4
Db 2 EPRH 5
```

RESULT 78

```
US-10-619-454-125
; Sequence 125, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 125
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-125
```

```
Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 EPRH 4
Db 2 EPRH 5
```

RESULT 79

```
US-10-619-454-136
; Sequence 136, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 136
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-136
```

```
Query Match      100.0%; Score 24; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```



QY 1 EFRH 4  
|||  
Db 2 EFRH 5

## RESULT 80

US-10-619-454-153  
; Sequence 153, Application US/10619454  
; Publication No. US20040091945A1

## GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 153

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-153

Query Match 100.0%; Score 24; DB 15; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 1 EFRH 4

## RESULT 81

US-10-619-454-166  
; Sequence 166, Application US/10619454  
; Publication No. US20040091945A1

## GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 166

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-166

Query Match 100.0%; Score 24; DB 15; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 2 EFRH 5

## RESULT 82

US-10-619-454-174

; Sequence 174, Application US/10619454

; Publication No. US20040091945A1

## GENERAL INFORMATION:

; APPLICANT: Mindset

; APPLICANT: Fitzer Attas, Cheryl

; APPLICANT: Chain, Daniel

; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A

; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

; FILE REFERENCE: P-5202-US

; CURRENT APPLICATION NUMBER: US/10/619,454

; CURRENT FILING DATE: 2003-07-16

; PRIOR APPLICATION NUMBER: US 60/396,245

; PRIOR FILING DATE: 2002-07-17

; NUMBER OF SEQ ID NOS: 187

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 174

; LENGTH: 9

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: algorithm generated

US-10-619-454-174

Query Match 100.0%; Score 24; DB 15; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 6 EFRH 9

## RESULT 83

US-10-622-087-77

; Sequence 77, Application US/10622087

; Publication No. US20040141984A1

## GENERAL INFORMATION:

; APPLICANT: Bachmann, Martin F

; APPLICANT: Tissot, Alain

; APPLICANT: Ortman, Rainer

; APPLICANT: Luond, Rainer

; APPLICANT: Staufenberg, Matthias

; APPLICANT: Frey, Peter

; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays

; FILE REFERENCE: 1700.0350002

; CURRENT APPLICATION NUMBER: US/10/622,087

; CURRENT FILING DATE: 2003-07-18

; PRIOR APPLICATION NUMBER: US 60/396,639

; PRIOR FILING DATE: 2002-07-19

; PRIOR APPLICATION NUMBER: US 60/470,432

; PRIOR FILING DATE: 2003-05-15

; NUMBER OF SEQ ID NOS: 93

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 77

; LENGTH: 9

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Abeta 1-6 GGC

US-10-622-087-77

Query Match 100.0%; Score 24; DB 16; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 3 EFRH 6

```
RESULT 84
US-10-481-642-2
; Sequence 2, Application US/10481642
; Publication No. US20050053575A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A D
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH
; TITLE OF INVENTION: USING SAME
; FILE REFERENCE: SOLOMON=4.1A PCT
; CURRENT APPLICATION NUMBER: US/10/481.642
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-481-642-2

Query Match 100.0%; Score 24; DB 17; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 85
US-10-810-881A-98
; Sequence 98, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810.881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-98

Query Match 100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 86
US-10-810-881A-108
; Sequence 108, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810.881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 108
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-108

Query Match 100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 87
US-10-810-881A-110
; Sequence 110, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810.881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 110
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-110

Query Match 100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 88
US-10-505-313-1
; Sequence 1, Application US/10505313
; Publication No. US20050169925A1
```

GENERAL INFORMATION:  
; APPLICANT: F. Hoffmann-La Roche AG  
; APPLICANT: MorphoSys AG  
; TITLE OF INVENTION: Anti A-beta antibodies and their use  
; FILE REFERENCE: F 2842 PCT  
; CURRENT APPLICATION NUMBER: US/10/505,313  
; CURRENT FILING DATE: 2004-08-20  
; PRIOR APPLICATION NUMBER: EP 02003844.4  
; PRIOR FILING DATE: 2002-02-20  
; NUMBER OF SEQ ID NOS: 414  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: artificial sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic construct; first region of beta-A4 peptide  
US-10-505-313-1

Query Match 100.0%; Score 24; DB 18; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFRH 5

RESULT 89  
US-10-625-854-6  
; Sequence 6, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 6  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-6

Query Match 100.0%; Score 24; DB 18; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 90  
US-10-625-854-19  
; Sequence 19, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23

; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-19

Query Match 100.0%; Score 24; DB 18; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFRH 5

RESULT 91  
US-10-625-854-32  
; Sequence 32, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 32  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-625-854-32

Query Match 100.0%; Score 24; DB 18; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 92  
US-10-625-854-44  
; Sequence 44, Application US/10625854  
; Publication No. US20050175626A1  
; GENERAL INFORMATION:  
; APPLICANT: Delacourte, Andr  
; APPLICANT: Sergeant, Nicolas  
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with  
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation  
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)  
; CURRENT APPLICATION NUMBER: US/10/625,854  
; CURRENT FILING DATE: 2003-07-23  
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6  
; PRIOR FILING DATE: 2002-07-24  
; PRIOR APPLICATION NUMBER: 60/401,497  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 261  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44

```
; LENGTH: 9
; TYPE: PRT
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: MISC_FEATURE
; LOCATION: (1)..(1)
; OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-44

Query Match      100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 93
US-10-625-854-230
; Sequence 230, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 230
; LENGTH: 9
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-230

Query Match      100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 6 EFRH 9

RESULT 94
US-10-625-854-239
; Sequence 239, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 239
; LENGTH: 9
; TYPE: PRT
; ORGANISM: homo sapiens
```

```
US-10-625-854-239

Query Match      100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 5 EFRH 8

RESULT 95
US-10-625-854-247
; Sequence 247, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 247
; LENGTH: 9
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-247

Query Match      100.0%; Score 24; DB 18; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 4 EFRH 7

RESULT 96
US-09-865-294-69
; Sequence 69, Application US/09865294
; Publication No. US20030068325A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Chang Yi
; TITLE OF INVENTION: Immunogenic peptide composition as vaccines for the
; TITLE OF INVENTION: prevention and treatment of Alzheimer's Disease
; FILE REFERENCE: 1151-4167
; CURRENT APPLICATION NUMBER: US/09/865,294
; CURRENT FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 69
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-865-294-69

Query Match      100.0%; Score 24; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 97
```

US-10-010-942B-33  
; Sequence 33, Application US/10010942B  
; Publication No. US20030165496A1  
; GENERAL INFORMATION:  
; APPLICANT: Basi, Gurig  
; APPLICANT: Saldanha, Jose  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE  
; FILE REFERENCE: ELN-002  
; CURRENT APPLICATION NUMBER: US/10/010,942B  
; CURRENT FILING DATE: 2002-12-06  
; PRIOR APPLICATION NUMBER: US 60/251,892  
; PRIOR FILING DATE: 2000-12-06  
; NUMBER OF SEQ ID NOS: 63  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 33  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: native ABeta peptide  
US-10-010-942B-33

Query Match 100.0%; Score 24; DB 14; Length 10;  
Best Local Similarity 100.0%; Pred. No. 80;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
|||  
Db 3 EPRH 6

RESULT 98  
US-10-411-544-24  
; Sequence 24, Application US/10411544  
; Publication No. US20030232758A1  
; GENERAL INFORMATION:  
; APPLICANT: St. George-Hyslop, Peter  
; APPLICANT: McLaurin, JoAnne  
; TITLE OF INVENTION: Immunological Methods and Compositions for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: L101547  
; CURRENT APPLICATION NUMBER: US/10/411,544  
; CURRENT FILING DATE: 2003-04-10  
; NUMBER OF SEQ ID NOS: 52  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-411-544-24

Query Match 100.0%; Score 24; DB 15; Length 10;  
Best Local Similarity 100.0%; Pred. No. 80;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
|||  
Db 3 EPRH 6

RESULT 99  
US-10-388-389-33  
; Sequence 33, Application US/10388389  
; Publication No. US20040087777A1  
; GENERAL INFORMATION:  
; APPLICANT: Basi, Gurig  
; APPLICANT: Saldanha, Jose  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE  
; FILE REFERENCE: ELN-002CP

; CURRENT APPLICATION NUMBER: US/10/388,389  
; CURRENT FILING DATE: 2003-03-12  
; PRIOR APPLICATION NUMBER: US 10/010,942  
; PRIOR FILING DATE: 2001-12-06  
; PRIOR APPLICATION NUMBER: US 60/251,892  
; PRIOR FILING DATE: 2000-12-06  
; NUMBER OF SEQ ID NOS: 63  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 33  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: native ABeta peptide  
US-10-388-389-33

Query Match 100.0%; Score 24; DB 15; Length 10;  
Best Local Similarity 100.0%; Pred. No. 80;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
|||  
Db 3 EPRH 6

RESULT 100  
US-10-703-713-33  
; Sequence 33, Application US/10703713  
; Publication No. US20040171815A1  
; GENERAL INFORMATION:  
; APPLICANT: Basi, Gurig  
; APPLICANT: Saldanha, Jose  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE  
; FILE REFERENCE: ELN-002CP  
; CURRENT APPLICATION NUMBER: US/10/703,713  
; CURRENT FILING DATE: 2003-11-07  
; PRIOR APPLICATION NUMBER: US/10/388,389  
; PRIOR FILING DATE: 2003-03-12  
; PRIOR APPLICATION NUMBER: US 10/010,942  
; PRIOR FILING DATE: 2001-12-06  
; PRIOR APPLICATION NUMBER: US 60/251,892  
; PRIOR FILING DATE: 2000-12-06  
; NUMBER OF SEQ ID NOS: 63  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 33  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: native ABeta peptide  
US-10-703-713-33

Query Match 100.0%; Score 24; DB 16; Length 10;  
Best Local Similarity 100.0%; Pred. No. 80;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
|||  
Db 3 EPRH 6

Search completed: November 2, 2005, 09:45:23  
Job time : 166 secs

Handwritten text, possibly a signature or date, located in the center of the page.

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:27:59 ; Search time 161 Seconds  
(without alignments)  
9.609 Million cell updates/sec

Title: US-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 463897

Minimum DB seq length: 4

Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database :

A\_Geneseq\_16Dec04:\*

1: Geneseqp1980s:\*

2: Geneseqp1990s:\*

3: Geneseqp2000s:\*

4: Geneseqp2001s:\*

5: Geneseqp2002s:\*

6: Geneseqp2003as:\*

7: Geneseqp2003bs:\*

8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	24	100.0	4	2	AAW70870
2	24	100.0	4	6	AAO16062
3	24	100.0	4	6	ABP70744
4	24	100.0	4	7	ABP70744
5	24	100.0	4	7	ABP70744
6	24	100.0	4	8	ADJ88108
7	24	100.0	4	8	ADJ71364
8	24	100.0	4	8	ADJ71377
9	24	100.0	4	8	ADP90808
10	24	100.0	5	6	ADA90172
11	24	100.0	5	8	ADJ71378
12	24	100.0	5	8	ADJ71365
13	24	100.0	5	8	ADJ71352
14	24	100.0	6	2	AAW70868
15	24	100.0	6	4	AAW70868
16	24	100.0	6	6	AAO16067
17	24	100.0	6	6	ADA90170
18	24	100.0	6	7	ADB75165
19	24	100.0	6	8	ADJ88114
20	24	100.0	6	8	ADJ71366
21	24	100.0	6	8	ADJ71379
22	24	100.0	6	8	ADJ71340
23	24	100.0	6	8	ADJ71353
24	24	100.0	6	8	ADK52251
25	24	100.0	6	8	ADK52264

26	24	100.0	6	8	ADK52261	Adk52261	Rabbit am
27	24	100.0	6	8	ADK52260	Adk52260	Primate a
28	24	100.0	6	8	ADK52266	Adk52266	Amyloid b
29	24	100.0	6	8	ADQ82427	Adq82427	N-termina
30	24	100.0	6	8	ADQ82432	Adq82432	N-termina
31	24	100.0	6	8	ADQ82430	Adq82430	N-termina
32	24	100.0	6	8	ADQ82433	Adq82433	N-termina
33	24	100.0	6	8	ADQ82434	Adq82434	N-termina
34	24	100.0	6	8	ADQ82436	Adq82436	N-termina
35	24	100.0	6	8	ADQ82431	Adq82431	N-termina
36	24	100.0	6	8	ADQ82423	Adq82423	N-termina
37	24	100.0	6	8	ADQ82424	Adq82424	N-termina
38	24	100.0	6	8	ADQ82428	Adq82428	N-termina
39	24	100.0	6	8	ADQ82435	Adq82435	N-termina
40	24	100.0	6	8	ADQ82429	Adq82429	N-termina
41	24	100.0	6	8	ADQ82425	Adq82425	N-termina
42	24	100.0	6	8	ADQ82422	Adq82422	N-termina
43	24	100.0	6	8	ADQ82421	Adq82421	N-termina
44	24	100.0	6	8	ADQ82437	Adq82437	N-termina
45	24	100.0	6	8	ADQ82386	Adq82386	Natural N
46	24	100.0	6	8	ADQ82426	Adq82426	N-termina
47	24	100.0	7	4	AAAB46202	AAAB46202	Human APP
48	24	100.0	7	5	AAO14421	AAO14421	Synthetic
49	24	100.0	7	6	AAO19884	AAO19884	Human amy
50	24	100.0	7	6	AAE35432	AAE35432	Abeta pep
51	24	100.0	7	6	ADA90925	ADA90925	Solid-pha
52	24	100.0	7	6	ADA90142	ADA90142	Anti-Abet
53	24	100.0	7	6	ADA90141	ADA90141	Anti-Abet
54	24	100.0	7	6	ADA90924	ADA90924	Solid-pha
55	24	100.0	7	6	ADA90171	ADA90171	Anti-Abet
56	24	100.0	7	8	ADJ71565	Adj71565	N-termina
57	24	100.0	7	8	ADJ71380	Adj71380	N-termina
58	24	100.0	7	8	ADJ71341	Adj71341	N-termina
59	24	100.0	7	8	ADJ71367	Adj71367	N-termina
60	24	100.0	7	8	ADJ71354	Adj71354	N-termina
61	24	100.0	7	8	ADQ37256	Adq37256	Vaccine a
62	24	100.0	7	8	ADQ82412	Adq82412	Natural N
63	24	100.0	7	8	ADS09217	ADS09217	Amyloid b
64	24	100.0	8	2	AAW70865	AAW70865	Beta-amyli
65	24	100.0	8	5	AAU78518	AAU78518	N terminu
66	24	100.0	8	6	ABP70740	ABP70740	Antigenic
67	24	100.0	8	7	ABW75162	ABW75162	Human amy
68	24	100.0	8	7	ABW75174	ABW75174	Amyloid b
69	24	100.0	8	8	ADJ71355	Adj71355	N-termina
70	24	100.0	8	8	ADJ71368	Adj71368	N-termina
71	24	100.0	8	8	ADJ71575	Adj71575	N-termina
72	24	100.0	8	8	ADJ71381	Adj71381	N-termina
73	24	100.0	8	8	ADJ71342	Adj71342	N-termina
74	24	100.0	8	8	ADJ71566	Adj71566	N-termina
75	24	100.0	8	8	ADQ82413	Adq82413	Natural N
76	24	100.0	9	6	ABP70741	ABP70741	Antigenic
77	24	100.0	9	6	ADA89886	ADA89886	Beta-A4 f
78	24	100.0	9	7	ADP36577	ADP36577	APP epit
79	24	100.0	9	7	ADP36575	ADP36575	Beta-amyli
80	24	100.0	9	8	ADJ35862	Adj35862	Amyloid b
81	24	100.0	9	8	ADJ35931	Adj35931	Amyloid b
82	24	100.0	9	8	ADJ35943	Adj35943	Amyloid b
83	24	100.0	9	8	ADJ36020	Adj36020	Amyloid b
84	24	100.0	9	8	ADJ35949	Adj35949	Amyloid b
85	24	100.0	9	8	ADJ36012	Adj36012	Amyloid b
86	24	100.0	9	8	ADJ35946	Adj35946	Amyloid b
87	24	100.0	9	8	ADJ35890	Adj35890	Amyloid b
88	24	100.0	9	8	ADJ35900	Adj35900	Amyloid b
89	24	100.0	9	8	ADJ35960	Adj35960	Amyloid b
90	24	100.0	9	8	ADJ35921	Adj35921	Amyloid b
91	24	100.0	9	8	ADJ35958	Adj35958	Amyloid b
92	24	100.0	9	8	ADJ35925	Adj35925	Amyloid b
93	24	100.0	9	8	ADJ35968	Adj35968	Amyloid b
94	24	100.0	9	8	ADJ35999	Adj35999	Amyloid b
95	24	100.0	9	8	ADJ35895	Adj35895	Amyloid b
96	24	100.0	9	8	ADJ35982	Adj35982	Amyloid b
97	24	100.0	9	8	ADJ35885	Adj35885	Amyloid b
98	24	100.0	9	8	ADJ35920	Adj35920	Amyloid b

99 24 100.0 9 8 ADI35879 AdI35879 Amyloid b  
100 24 100.0 9 8 ADI35971 AdI35971 Amyloid b

ALIGNMENTS

RESULT 1  
AAW70870  
ID AAW70870 standard; peptide; 4 AA.  
XX AC AAW70870;  
XX AC AAW70870;  
DT 04-FEB-1999 (first entry)  
XX DE Beta-amyloid peptide epitope.  
XX KW Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;  
XX KW amyloid deposit; Alzheimer's disease.  
XX OS Synthetic.  
XX OS Homo sapiens.  
XX PN W09844955-A1.  
XX PN 15-OCT-1998.  
XX PF 09-APR-1998; 98WO-US006900.  
XX PF 09-APR-1997; 97US-0041850P.  
XX PA (MIND-) MINDSET LTD.  
XX PA (MCIN/) MCINNIS P A.  
XX PI Chain DG;  
XX DR WPI; 1998-594476/50.  
XX PT Preventing or inhibiting progression of Alzheimer's Disease - comprises  
XX PT use of recombinant DNA encoding an antibody specific for the N- or C-  
XX PT terminus of an amyloid-beta peptide.  
XX PS Example 1; Page 47; 58pp; English.  
XX CC The present sequence represents a peptide epitope derived from beta-  
XX CC amyloid precursor protein peptide. The specification describes a method  
XX CC for prevention or inhibition of progression of Alzheimer's disease. The  
XX CC method comprises administering a composition comprising a recombinant DNA  
XX CC molecule containing a gene encoding a recombinant antibody end-specific  
XX CC for the N-terminus or the C-terminus of an amyloid-beta peptide, operably  
XX CC linked to a promoter which is expressed in the central nervous system.  
XX CC The recombinant antibody molecules prevent the accumulation of beta-  
XX CC amyloid peptides in the extracellular space, interstitial fluid and  
XX CC cerebrospinal fluid and the aggregation of such peptides into amyloid  
XX CC deposits in the brain. They also inhibit the progression of Alzheimer's  
XX CC disease by inhibiting the interaction of beta-amyloid peptides mediating  
XX CC Alzheimer's disease induced neurotoxicity and inhibiting the Alzheimer's  
XX CC disease induced complement activation and cytokine release involved in  
XX CC the inflammatory process  
SQ Sequence 4 AA;  
Query Match 100.0%; Score 24; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 2  
AAO16062  
ID AAO16062 standard; peptide; 4 AA.  
XX AC AAO16062;  
XX DE 27-FEB-2003 (first entry)  
XX DE Neurological/CNS disease treatment method-related peptide #1.  
XX KW Vaccine; gene therapy; neurological disease; CNS disorder;  
XX KW central nervous system disorder; Olfactory system; Alzheimer's disease;  
XX KW Creutzfeld-Jakob disease; Huntington's chorea; Parkinson's disease;  
XX KW viral infection of the brain; brain tumour; lysosomal storage disease;  
XX KW multiple sclerosis.  
XX OS Unidentified.  
XX PN W0200274243-A2.  
XX PN 26-SEP-2002.  
XX PF 15-MAR-2002; 2002WO-US008042.  
XX PF 15-MAR-2001; 2001US-00808037.  
XX PR (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.  
XX PR (MCIN/) MCINNIS P.  
XX PI Solomon B, Frenkel D;  
XX DR WPI; 2003-040542/03.  
XX PT Treating or diagnosing neurological diseases of the central nervous  
XX PT system, e.g. Alzheimer's disease, comprises displaying a polypeptide or  
XX PT diagnostic agent on viral display vehicle and introducing or detecting  
XX PT the display vehicle.  
XX PS Example 9; Page 138; 214pp; English.  
XX CC The invention comprises a method for treating a neurological disease or a  
XX CC central nervous system (CNS) disorder. The method involves displaying a  
XX CC therapeutic molecule capable of treating the neurological disease or CNS  
XX CC disorder on a viral display vehicle. The viral display vehicle is then  
XX CC introduced into the olfactory system of a subject to treat the disease or  
XX CC disorder. The method of the invention is useful for preventing, treating  
XX CC and diagnosing neurological diseases or CNS disorders, such as:  
XX CC Alzheimer's disease; Creutzfeld-Jakob disease; Huntington's chorea; viral  
XX CC infections of the brain; brain tumours; lysosomal storage diseases;  
XX CC Parkinson's disease; and multiple sclerosis. The present amino acid  
XX CC sequence represents a peptide which was used in the invention  
SQ Sequence 4 AA;  
Query Match 100.0%; Score 24; DB 6; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 3  
ABP70744  
ID ABP70744 standard; peptide; 4 AA.  
XX AC ABP70744;  
XX DT 15-MAY-2003 (first entry)  
XX DE Antigenic peptide, SEQ ID 5.  
XX KW Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;  
KW plaque-forming disease; Alzheimer's disease; SAA amyloidosis;



KW hereditary Icelandic syndrome; senility; multiple myeloma;  
KW Creutzfeldt-Jakob disease; Kuru; Gerstmann-Strausler-Scheinker disease;  
KW fatal familial insomnia; scrapie; bovine spongiform encephalitis;  
KW antigenic; multiantigen.  
XX  
OS Synthetic.  
XX  
XX WO2003000719-A2.  
XX  
XX 03-JAN-2003.  
XX  
XX 20-JUN-2002; 2002WO-US019567.  
XX  
XX 20-JUN-2001; 2001US-0292201P.  
PR 12-APR-2002; 2002US-0371717P.  
XX  
XX (UVRA-) UNIV RAMOT.  
PA (MCIN/) MCINNIS P.  
XX  
XX Mcinnis P, Solomon B;  
PI  
XX  
XX WPI; 2003-239139/23.  
XX  
XX Antigenic product has dendritic polymer built on core molecule having  
PT terminal functional groups to which antigenic peptide that has epitope of  
PT deposit-forming polypeptide involved in plaque-forming disease is joined.  
XX  
XX Claim 6; Page 44; 70pp; English.  
XX  
XX The present invention relates to antigenic products (A), comprising a  
CC dendritic polymer built on a core molecule which is at least difunctional  
CC to provide branching and containing up to 16 terminal functional groups  
CC to which an antigenic peptide, that comprises an epitope of a deposit-  
CC forming polypeptide involved in plaque-forming disease, is joined by  
CC covalent bonds. The antigenic products are useful for eliciting an immune  
CC response against a deposit-forming polypeptide involved in a plaque-  
CC forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,  
CC hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-  
CC Jakob disease, Kuru, Gerstmann-Strausler-Scheinker disease, fatal  
CC familial insomnia, scrapie or bovine spongiform encephalitis, by  
CC administering the antigenic product to a subject in need of it. The  
CC present sequence is one such antigenic peptide, which was used to  
XX illustrate the invention  
XX  
SQ Sequence 4 AA;  
  
Query Match 100.0%; Score 24; DB 6; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 EPRH 4  
DB 1 EPRH 4  
  
RESULT 4  
ADEB75167  
ID ADB75167 standard; peptide; 4 AA.  
XX  
XX ADB75167;  
AC  
DT 04-DEC-2003 (first entry)  
XX  
DE Human amyloid beta peptide SEQ ID NO:8.  
XX  
XX antibody; amyloid beta peptide; amyloid beta; neurotropic; neuroprotective;  
KW antibody therapy; Alzheimer's disease; mild cognitive impairment;  
KW cerebral amyloid angiopathy; congophilic angiopathy; Down's syndrome;  
KW inclusion body myositis; neurotoxicity; beta amyloid precursor protein;  
KW APP; human.  
XX  
XX Homo sapiens.  
OS  
XX

PN WO2003074081-A1.  
XX  
PD 12-SEP-2003.  
XX  
XX 21-OCT-2002; 2002WO-US031590.  
XX  
XX 28-FEB-2002; 2002US-00084380.  
PR  
XX (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.  
XX  
XX Chain DG;  
PI  
XX WPI; 2003-731651/69.  
DR  
XX  
XX New antibody that is targeted to amyloid beta peptide, or its fragment,  
PT useful for treating a subject having Alzheimer's disease, or a disease or  
PT disorder characterized by amyloid beta deposition, e.g. cognitive  
PT impairment or dementia.  
XX  
XX PS Disclosure; Page 60; 63pp; English.  
XX  
XX The present invention describes an antibody that is targeted to amyloid  
CC beta peptide, or its fragment. Also described: (1) an antibody that is  
CC free-end specific and is targeted to: (a) the free N-terminus of amyloid  
CC beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the  
CC first amino acid of amyloid beta-peptide is aspartate; (c) the free N-  
CC terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;  
CC (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,  
CC Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-  
CC terminus-truncated amyloid beta-peptide fragment; (2) a single chain or  
CC artificial antibody that is free-end specific and is targeted to the free  
CC C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a  
CC pharmaceutical composition comprising the antibody, and a carrier. The  
CC antibody targeted to amyloid beta peptide has neurotropic and  
CC neuroprotective activities, and can be used in antibody therapy. The  
CC antibody or its fragment is useful for manufacturing a medicament for  
CC treating a subject having Alzheimer's disease, or a disease or disorder  
CC characterised by amyloid beta deposition (e.g. mild cognitive impairment,  
CC cerebral amyloid angiopathy or congophilic angiopathy, Alzheimer's  
CC disease associated with Down's syndrome, or inclusion body myositis), or  
CC for delaying inhibiting or suppressing accumulation of amyloid beta  
CC peptide, or the neurotoxicity of amyloid beta peptide or its fragment.  
CC Amyloid beta peptide are derived from beta amyloid precursor protein  
CC (APP). The present sequence represents an amyloid beta peptide which is  
CC used in the exemplification of the present invention.  
XX  
XX Sequence 4 AA;  
SQ  
  
Query Match 100.0%; Score 24; DB 7; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 EPRH 4  
DB 1 EPRH 4  
  
RESULT 5  
ADE36574  
ID ADE36574 standard; peptide; 4 AA.  
XX  
XX ADE36574;  
AC  
XX 29-JAN-2004 (first entry)  
DT  
DE Beta-amyloid (Abeta) peptide 3-6 SEQ ID NO:2.  
XX  
XX immune response; beta-secretase cleavage site; amyloid precursor protein;  
KW APP; neurotropic; neuroprotective; vaccine; passive immunisation;  
KW Alzheimer's disease.  
XX  
XX OS Synthetic.  
XX

```
PN WO2003076455-A2.
XX 18-SEP-2003.
XX 04-MAR-2003; 2003WO-US006388.
XX 05-MAR-2002; 2002US-0361344P.
XX (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX (MCIN/) MCINNIS P.
XX Solomon B;
XX WPI; 2003-865017/80.
XX
XX Immunizing composition, useful for treating Alzheimer's disease by
XX inhibiting processing of amyloid precursor protein, also antibodies for
XX passive immunization.
XX
XX Disclosure; SEQ ID NO 2; 76pp; English.
XX
XX The present invention describes an immunising composition (A) comprising:
XX (a) an antigenic product (I) which induces an immune response against the
XX beta-secretase cleavage site of amyloid precursor protein (APP); and (b)
XX a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)
XX a molecule (II) comprising the antigen-binding part of an antibody (Ab)
XX directed against the beta-secretase cleavage site of APP; (2) a
XX filamentous bacteriophage (FB) that displays (II), where this is a single
XX -chain Ab, on its surface; and (3) a composition containing FB. (A) has
XX neurotropic and neuroprotective activities, and can be used in vaccines or
XX passive immunisation. (A) inhibits the cleavage of APP and so prevents
XX the formation of beta-amyloid. (A) can be used to induce an immune
XX response against the beta-secretase cleavage site of APP, specifically
XX for treatment and prevention of Alzheimer's disease. The molecule (II)
XX that contains the antigen-binding part of an Ab directed against the
XX cleavage site, or a filamentous phage that displays such an Ab (as a
XX single-chain molecule) can be used similarly, for passive immunisation.
XX The present sequence represents a beta-amyloid (beta) peptide which is
XX used in the exemplification of the present invention.
XX
XX Sequence 4 AA;
XX
XX Query Match 100.0%; Score 24; DB 7; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 EFRH 4
XX ||||
XX 1 EFRH 4
XX
XX Db
XX
XX
XX RESULT 6
XX ADJ88108
XX ID ADJ88108 standard; peptide; 4 AA.
XX
XX AC ADJ88108;
XX
XX XX 06-MAY-2004 (first entry)
XX
XX Human beta amyloid peptide anti-aggregating epitope.
XX
XX Neurological disease; central nervous system; CNS disorder;
XX plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
XX hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;
XX bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;
XX CJD; Gerstmann-Straussler-Scheinker disease; GSS; fatal familial insomnia;
XX FFI; non-plaque-forming disease; Huntington's chorea; viral infection;
XX brain tumour; lysosomal storage disease; neurodegeneration;
XX multiple sclerosis; vaccine; beta amyloid peptide; epitope; beta AP;
XX human.
XX
XX Homo sapiens.
XX
XX OS
XX XX
```

```
PN US2004013647-A1.
XX 22-JAN-2004.
XX 11-MAR-2003; 2003US-00384788.
XX 03-SEP-1999; 99US-0152417P.
XX 29-DEC-1999; 99US-00473653.
XX 31-JUL-2000; 2000US-00629971.
XX 31-AUG-2000; 2000WO-IL000518.
XX 15-MAR-2001; 2001US-00808037.
XX 07-AUG-2001; 2001US-00830954.
XX 12-APR-2002; 2002US-0371735P.
XX 06-JUN-2002; 2002US-00162889.
XX
XX (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX Solomon B, Frenkel D;
XX WPI; 2004-108188/11.
XX
XX Treating neurological disease CNS e.g., Alzheimer's disease, by
XX displaying therapeutic molecule capable of treating the disease on viral
XX display vehicle which is then administered to subject through olfactory
XX system.
XX
XX Example 10; SEQ ID NO 1; 68pp; English.
XX
XX The invention relates to a method of treating a neurological disease or
XX disorder of the central nervous system (CNS). The method involves
XX displaying a therapeutic molecule capable of treating the neurological
XX disease or disorder of the CNS on a viral display vehicle and introducing
XX the viral display vehicle into a subject by applying an effective amount of
XX the viral display vehicle displaying the therapeutic molecule to an
XX olfactory system of the subject. The method is useful for treating a
XX neurological disease or disorder of CNS such as Alzheimer's disease,
XX such as Alzheimer's disease, late onset Alzheimer's disease,
XX presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary
XX syndrome, senility, multiple myeloma, scrapie, bovine spongiform
XX encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-
XX Streussler-Scheinker disease (GSS) or fatal familial insomnia (FFI). The
XX method is also useful for treating a non plaque forming disease or
XX disorder e.g. Huntington's chorea, viral infections of the brain, brain
XX tumours, lysosomal storage diseases which cause neurodegeneration and are
XX manifested by enzyme deficiencies and multiple sclerosis. The invention
XX is also used in the preparation of vaccines. The present sequence is
XX human beta amyloid peptide (beta AP) anti-aggregating epitope. This
XX sequence is used to illustrate the method of the invention.
XX
XX Sequence 4 AA;
XX
XX Query Match 100.0%; Score 24; DB 8; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 EFRH 4
XX ||||
XX 1 EFRH 4
XX
XX Db
XX
XX
XX RESULT 7
XX ADJ71364
XX ID ADJ71364 standard; peptide; 4 AA.
XX
XX AC ADJ71364;
XX
XX XX 06-MAY-2004 (first entry)
XX
XX N-terminal truncated beta-amyloid peptide, SEQ ID 27.
XX
XX Neurotropic; Neuroprotective; Vaccine; beta Amyloid;
XX amyloid precursor protein; APP; Alzheimer's disease.
XX
XX
```

OS Homo sapiens.  
PN WO2004013172-A2.  
XX  
XX 12-FEB-2004.  
XX  
XX 18-JUL-2003; 2003WO-EP007833.  
XX  
XX 24-JUL-2002; 2002EP-00447147.  
PR  
PR 06-AUG-2002; 2002US-0401497P.  
XX  
XX (INNO-) INNOGENETICS NV.  
XX  
XX Delacourte A, Sergeant N;  
XX  
XX WPI; 2004-180423/17.  
XX  
XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.  
XX  
XX Claim 4; Page 61; 104pp; English.  
XX  
XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.  
XX  
XX Sequence 4 AA;  
PS  
XX Query Match 100.0%; Score 24; DB 8; Length 4;  
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
Db ||||  
1 EFRH 4  
RESULT 8  
ADJ711377  
ID ADJ711377 standard; peptide; 4 AA.  
XX  
XX ADJ711377;  
AC  
XX  
XX 06-MAY-2004 (first entry)  
DT  
XX N-terminal truncated beta-amyloid peptide, SEQ ID 40.  
DE  
XX Nootropic; Neuroprotective; Vaccine; beta Amyloid;  
XX amyloid precursor protein; APP; Alzheimer's disease.  
KW  
XX Homo sapiens.  
OS  
XX  
XX Key Location/Qualifiers  
FH Modified-site 1  
FT /note= "Pyroglutamic acid"  
XX  
XX WO2004013172-A2.  
PN  
XX  
XX 12-FEB-2004.  
PD  
XX  
XX 18-JUL-2003; 2003WO-EP007833.  
XX  
XX 24-JUL-2002; 2002EP-00447147.  
PR  
PR 06-AUG-2002; 2002US-0401497P.  
XX  
XX (INNO-) INNOGENETICS NV.  
PA

XX Delacourte A, Sergeant N;  
PI  
XX WPI; 2004-180423/17.  
XX  
XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.  
XX  
XX Claim 4; Page 62; 104pp; English.  
XX  
XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.  
XX  
XX Sequence 4 AA;  
PS  
XX Query Match 100.0%; Score 24; DB 8; Length 4;  
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
Db ||||  
1 EFRH 4  
RESULT 9  
ADP90808  
ID ADP90808 standard; peptide; 4 AA.  
XX  
XX ADP90808;  
AC  
XX  
XX 09-SEP-2004 (first entry)  
DT  
XX  
XX Protein/peptide labelling method-related affinity tag peptide #3.  
DE  
XX protein labelling; peptide labelling;  
XX irreversible affinity tagging residue;  
KW reversible affinity tagging residue; high throughput screening assay;  
KW pharmaceutical agent; affinity tag.  
XX  
XX Unidentified.  
OS  
XX  
XX Key Location/Qualifiers  
FH Modified-site 4  
FT /note= "C-terminal amide"  
XX  
XX WO2004051270-A2.  
PN  
XX  
XX 17-JUN-2004.  
PD  
XX  
XX 04-DEC-2003; 2003WO-EP013715.  
XX  
XX 05-DEC-2002; 2002GB-00028429.  
PR  
XX (NOVS ) NOVARTIS AG.  
PA (NOVS ) NOVARTIS PHARMA GMBH.  
XX  
XX Auer M, Meisner N, Seifert J;  
PI  
XX WPI; 2004-480677/45.  
DR  
XX Providing labeled target protein or target peptide by contacting chemical  
XX compound with affinity support, removing impurities in reaction mixture  
PT surrounding affinity support, cleaving or eluting chemical molecule from  
PT affinity support.  
PT  
XX

PS Claim 4; Page 70; 81pp; English.

XX The invention comprises a method for providing a labelled target

CC protein/peptide. The method involves contacting a chemical compound with

CC affinity support, removing impurities in the reaction mixture surrounding

CC the affinity support to which the chemical molecule is bound, and

CC cleaving or eluting the molecule from the affinity support to obtain

CC irreversible or reversible affinity tagging residue, labelled target

CC protein or labelled peptide. The method of the invention is useful for

CC labelling a target protein/peptide or high throughput screening assay.

CC The method of the invention is useful for identifying agents that

CC modulate the activity or characteristics of a target protein/peptide -

CC such agents are useful as pharmaceuticals. The present amino acid

CC sequence represents an affinity tag peptide of the invention.

XX Sequence 4 AA;

SQ

Query Match 100.0%; Score 24; DB 8; Length 4;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4

Db ||||

1 EPRH 4

RESULT 10

ADA90172

ID ADA90172 standard; peptide; 5 AA.

AC ADA90172;

XX

XX 20-NOV-2003 (first entry)

DT

DE Anti-Abeta antibody related amino acid sequence SEQ ID NO:287.

XX

XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;

KW

KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;

KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;

KW Alzheimer's disease; motor neuropathy; Down's syndrome;

KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;

KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;

KW neuronal disorder; aging.

XX

OS Synthetic.

OS Homo sapiens.

XX

XX WO2003070760-A2.

PN

PD 28-AUG-2003.

XX

PF 20-FEB-2003; 2003WO-EP001759.

XX

PR 20-FEB-2002; 2002EP-00003844.

XX

XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.

PA (MORP-) MORPHOSYS AG.

XX

XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;

PI Loehning C, Loetscher H, Nordstedt C, Rothe C;

XX

XX WPI; 2003-663848/62.

XX

XX New antibody molecule capable of specifically recognizing two regions of

PT the beta-A4 peptide, useful for diagnosing, preventing or treating

PT diseases associated with amyloidogenesis or amyloid-plaque formation

PT (e.g. dementia).

XX

XX Disclosure; Page 265; 312pp; English.

PS

XX The present invention describes an antibody molecule (I) capable of

CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The

CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-

CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the

CC amino acid sequence Val-His-His-Gln-Lys-Val-Phe-Phe-Ala-Glu-Asp-Val-

CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule

CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host

CC cell comprising the vector of (2); (4) preparing (1), comprising

CC culturing the host cell of (3) under conditions that allow synthesis of

CC (1) and recovering (1) from the culture; (5) a composition comprising (1),

CC or an antibody molecule produced by method (4); (6) a kit comprising (1),

CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising

CC (1); (8) testing the resulting Fab optimisation library by panning

CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing

CC of selected, optimised clones; (11) preparing a pharmaceutical

CC composition, comprising optimisation of (1), and formulating the

CC optimised antibody/antibody molecule with a carrier; and (12) a

CC pharmaceutical composition prepared by method (8). (1) has

CC neuroprotective, neurotropic and antiparkinsonian activities, and can be

CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,

CC vector or host is useful in preparing a pharmaceutical composition for

CC the prevention and/or treatment of a disease associated with

CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule

CC may also be used in preparing a diagnostic composition for the detection

CC of the disease mentioned above. The antibody is used for the

CC disintegration of beta-amyloid plaques or for passive immunisation

CC against beta-amyloid plaque formation. In particular, the disease is

CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,

CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with

CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,

CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The

CC present sequence is used in the exemplification of the present invention.

XX

SQ Sequence 5 AA;

Query Match 100.0%; Score 24; DB 6; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4

Db ||||

1 EPRH 4

RESULT 11

ADJ71378

ID ADJ71378 standard; peptide; 5 AA.

AC ADJ71378;

XX

XX 06-MAY-2004 (first entry)

DT

DE N-terminal truncated beta-amyloid peptide, SEQ ID 41.

XX

XX Neurotropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX

XX Homo sapiens.

OS

XX Key Location/Qualifiers

FT Modified-site 1 /note= "Pyroglutamic acid"

FT

XX WO2004013172-A2.

PN

XX 12-FEB-2004.

PD

XX 18-JUL-2003; 2003WO-EP007833.

PF

XX 24-JUL-2002; 2002EP-00447147.

PR

XX 06-AUG-2002; 2002US-0401497P.

XX

XX (INNO-) INNOGENETICS NV.

PA

XX Delacourte A, Sergeant N;

XX

```
DR WPI; 2004-180423/17.
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a
PT prophylactic vaccine or a therapeutic for preventing or treating a
PT disease associated with beta-amyloid formation and/or aggregation, e.g.
PT Alzheimer's disease.
XX
XX
PS Claim 4; Page 62; 104pp; English.
XX
CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 5 AA;
XX
Query Match 100.0%; Score 24; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EFRH 4
Db ||||
1 EFRH 4
XX
RESULT 12
ADJ71365
ID ADJ71365 standard; peptide; 5 AA.
XX
AC ADJ71365;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE N-terminal truncated beta-amyloid peptide, SEQ ID 28.
XX
XX
KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW amyloid precursor protein; APP; Alzheimer's disease.
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004013172-A2.
XX
XX
PD 12-FEB-2004.
XX
XX
PF 18-JUL-2003; 2003WO-EP007833.
XX
XX
PR 24-JUL-2002; 2002EP-00447147.
PR 06-AUG-2002; 2002US-0401497P.
XX
XX
PA (INNO-) INNOGENETICS NV.
XX
XX
PI Delacourte A, Sergeant N;
XX
XX
DR WPI; 2004-180423/17.
XX
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a
PT prophylactic vaccine or a therapeutic for preventing or treating a
PT disease associated with beta-amyloid formation and/or aggregation, e.g.
PT Alzheimer's disease.
XX
XX
PS Claim 4; Page 61; 104pp; English.
XX
XX
CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 5 AA;
XX
Query Match 100.0%; Score 24; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EFRH 4
Db ||||
2 EFRH 5
XX
RESULT 13
ADJ71352
ID ADJ71352 standard; peptide; 5 AA.
XX
AC ADJ71352;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE N-terminal truncated beta-amyloid peptide, SEQ ID 15.
XX
XX
KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW amyloid precursor protein; APP; Alzheimer's disease.
XX
XX
OS Homo sapiens.
XX
XX
PH Key Location/Qualifiers
FT Modified-site 1 /note= "Optionally methylated"
XX
XX
PN WO2004013172-A2.
XX
XX
PD 12-FEB-2004.
XX
XX
PF 18-JUL-2003; 2003WO-EP007833.
XX
XX
PR 24-JUL-2002; 2002EP-00447147.
PR 06-AUG-2002; 2002US-0401497P.
XX
XX
PA (INNO-) INNOGENETICS NV.
XX
XX
PI Delacourte A, Sergeant N;
XX
XX
DR WPI; 2004-180423/17.
XX
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a
PT prophylactic vaccine or a therapeutic for preventing or treating a
PT disease associated with beta-amyloid formation and/or aggregation, e.g.
PT Alzheimer's disease.
XX
XX
PS Claim 4; Page 61; 104pp; English.
XX
XX
CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 5 AA;
XX
Query Match 100.0%; Score 24; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EFRH 4
Db ||||
2 EFRH 5
XX
```

```

XX DE
XX DE
XX KW Human, prion protein; plaque forming disease; display vehicle; kuru;
XX KW aggregating protein; amyloid plaque; brain; early onset; senility;
XX KW Alzheimer's disease; late onset; pre-symptomatic; SAA amyloidosis;
XX KW hereditary Icelandic syndrome; multiple myeloma; scrapie; BSE; CJD;
XX KW bovine spongiform encephalopathy; Creutzfeldt-Jakob Disease; FFI;
XX KW Gerstmann-Strausler-Sheinker Disease; GSS; fatal familial insomnia.
XX OS Synthetic.
XX PN WO200118169-A2.
XX PD 15-MAR-2001.
XX PF 31-AUG-2000; 2000WO-IL000518.
XX PR 03-SEP-1999; 99US-0152417P.
XX PR 29-DEC-1999; 99US-00473653.
XX PR 31-JUL-2000; 2000US-00629971.
XX PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
XX PI Solomon B, Frenkel D, Hanan E;
XX DR WPI; 2001-244564/25.
XX PT Treating amyloidogenic disease such as Alzheimer's disease, BSE or CJD
XX PT comprises presentation of plaque derived antigens or epitopes on a
XX PT display vehicle, and introducing the vehicle into the recipient.
XX PS Example; Page 50; 120pp; English.
XX CC This peptide is based on the N-terminal fragment of beta-amyloid peptide
XX CC (beta-AP) and was fused to the minor coat protein of fd phage. This
XX CC peptide may be used in the method of the invention. The invention
XX CC provides an agent for treating a plaque forming disease. The polypeptide
XX CC is displayed on a display vehicle and is capable of eliciting antibodies
XX CC capable of disaggregating the aggregating protein and/or of preventing
XX CC aggregation of the aggregating protein. This reduces formation of amyloid
XX CC plaques in the brain of victims of plaque forming diseases, e.g. early
XX CC onset Alzheimer's disease, late onset Alzheimer's disease, pre-
XX CC symptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
XX CC syndrome, senility, multiple myeloma, scrapie, bovine spongiform
XX CC encephalopathy (BSE), kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-
XX CC Streussler-Sheinker Disease (GSS) and fatal familial insomnia (FFI)
XX SQ Sequence 6 AA;
XX Query Match 100.0%; Score 24; DB 4; Length 6;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 EFRH 4
XX Db |||||
XX 3 EFRH 6
XX RESULT 16
XX AAO16067
XX ID AAO16067 standard; peptide; 6 AA.
XX XX
XX AC AAO16067;
XX XX
XX DT 27-FEB-2003 (first entry)
XX XX
XX DE Neurological/CNS disease treatment method-related peptide #4.
XX KW Vaccine; gene therapy; neurological disease; CNS disorder;
XX KW central nervous system disorder; olfactory system; Alzheimer's disease;
XX KW Creutzfeldt-Jakob disease; Huntington's chorea; Parkinson's disease;
XX KW viral infection of the brain; brain tumour; lysosomal storage disease;
XX KW

RESULT 14
AAW70868
ID AAW70868 standard; peptide; 6 AA.
XX AC
XX AC AAW70868;
XX DT 04-FEB-1999 (first entry)
XX DE
XX DE Beta-amyloid peptide to create a monoclonal antibody.
XX KW Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
XX KW amyloid deposit; Alzheimer's disease.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9844955-A1.
XX PD 15-OCT-1998.
XX PF 09-APR-1998; 98WO-US006900.
XX PR 09-APR-1997; 97US-0041850P.
XX PA (MIND-) MINDSET LTD.
XX PA (MCIN/) MCINNIS P A.
XX PI Chain DG;
XX DR WPI; 1998-594476/50.
XX PT Preventing or inhibiting progression of Alzheimer's Disease - comprises
XX PT use of recombinant DNA encoding an antibody specific for the N- or C-
XX PT terminus of an amyloid-beta peptide.
XX PS Example 1; Page 47; 58pp; English.
XX CC The present sequence represents a peptide derived from beta-amyloid
XX CC precursor protein (beta-APP, see AAW70863). The peptide is a beta-amyloid
XX CC peptide and is used to produce a monoclonal antibody. The specification
XX CC describes a method for prevention or inhibition of progression of
XX CC Alzheimer's disease. The method comprises administering a composition
XX CC comprising a recombinant DNA molecule containing a gene encoding a
XX CC recombinant antibody end-specific for the N-terminus or the C-terminus of
XX CC an amyloid-beta peptide, operably linked to a promoter which is expressed
XX CC in the central nervous system. The recombinant antibody molecules prevent
XX CC the accumulation of beta-amyloid peptides in the extracellular space,
XX CC interstitial fluid and cerebrospinal fluid and the aggregation of such
XX CC peptides into amyloid deposits in the brain. They also inhibit the
XX CC progression of Alzheimer's disease by inhibiting the interaction of beta-
XX CC amyloid peptides mediating Alzheimer's disease induced neurotoxicity and
XX CC inhibiting the Alzheimer's disease induced complement activation and
XX CC cytokine release involved in the inflammatory process
XX SQ Sequence 6 AA;
XX Query Match 100.0%; Score 24; DB 2; Length 6;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 EFRH 4
XX Db |||||
XX 3 EFRH 6
XX RESULT 15
AAB47109
ID AAB47109 standard; peptide; 6 AA.
XX AC
XX AC AAB47109;
XX DT 04-JUN-2001 (first entry)

```

KW multiple sclerosis.  
XX Unidentified.  
OS  
XX WO200274243-A2.  
PN  
XX 26-SEP-2002.  
PD  
XX 15-MAR-2002; 2002WO-US008042.  
PF  
XX 15-MAR-2001; 2001US-00808037.  
PR  
XX (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.  
PA (MCIN/) MCINNIS P.  
PA  
XX Solomon B, Frenkel D;  
PI  
XX WPI; 2003-040542/03.  
DR  
XX  
XX Treating or diagnosing neurological diseases of the central nervous  
PT system, e.g. Alzheimer's disease, comprises displaying a polypeptide or  
PT diagnostic agent on viral display vehicle and introducing or detecting  
PT the display vehicle.  
XX  
XX Example 9; Page 138; 214pp; English.  
PS  
XX The invention comprises a method for treating a neurological disease or a  
CC central nervous system (CNS) disorder. The method involves displaying a  
CC therapeutic molecule capable of treating the neurological disease or CNS  
CC disorder on a viral display vehicle. The viral display vehicle is then  
CC introduced into the olfactory system of a subject to treat the disease or  
CC disorder. The method of the invention is useful for preventing, treating  
CC and diagnosing neurological diseases or CNS disorders, such as:  
CC Alzheimer's disease; Creutzfeldt-Jakob disease; Huntington's chorea; viral  
CC infections of the brain; brain tumours; lysosomal storage diseases;  
CC Parkinson's disease; and multiple sclerosis. The present amino acid  
CC sequence represents a peptide which was used in the invention  
XX  
XX Sequence 6 AA;  
SQ  
Query Match 100.0%; Score 24; DB 6; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
3 EPRH 6  
RESULT 17  
ADA90170  
ID ADA90170 standard; peptide; 6 AA.  
XX  
XX ADA90170;  
AC  
XX  
XX 20-NOV-2003 (first entry)  
DT  
XX  
XX Anti-Abeta antibody related amino acid sequence SEQ ID NO:285.  
DE  
XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
KW neuronal disorder; aging.  
XX  
XX Synthetic.  
OS  
XX Homo sapiens.  
OS  
XX WO2003070760-A2.  
PN  
XX 28-AUG-2003.  
XX

XX 20-FEB-2003; 2003WO-EP001759.  
PF  
XX 20-FEB-2002; 2002EP-00003844.  
PR  
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.  
PA (MORP-) MORPHOSYS AG.  
PA  
XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
PI  
XX WPI; 2003-663848/62.  
DR  
XX New antibody molecule capable of specifically recognising two regions of  
XX the beta-A4 peptide, useful for diagnosing, preventing or treating  
PT diseases associated with amyloidogenesis or amyloid-plaque formation  
PT (e.g. dementia).  
PT  
XX Disclosure; Page 264; 312pp; English.  
PS  
XX The present invention describes an antibody molecule (I) capable of  
CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
CC Ser-Gly-Tyr ADA9886 or its fragment, and the second region comprises the  
CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
CC Gly ADA9887 or its fragment. Also described: (1) a nucleic acid molecule  
CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
CC cell comprising the vector of (2); (4) preparing (1), comprising  
CC culturing the host cell of (3) under conditions that allow synthesis of  
CC (1) and recovering (1) from the culture; (5) a composition comprising (1)  
CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
CC (1); (8) testing the resulting Fab optimisation library by panning  
CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
CC of selected, optimised clones; (11) preparing a pharmaceutical  
CC composition, comprising optimisation of (1), and formulating the  
CC optimised antibody/antibody molecule with a carrier; and (12) a  
CC pharmaceutical composition prepared by method (8). (1) has  
CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
CC vector or host is useful in preparing a pharmaceutical composition for  
CC the prevention and/or treatment of a disease associated with  
CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
CC may also be used in preparing a diagnostic composition for the detection  
CC of the disease mentioned above. The antibody is used for the  
CC disintegration of beta-amyloid plaques or for passive immunisation  
CC against beta-amyloid plaque formation. In particular, the disease is  
CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with,  
CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
CC present sequence is used in the exemplification of the present invention.  
XX  
XX Sequence 6 AA;  
SQ  
Query Match 100.0%; Score 24; DB 6; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
2 EPRH 5  
RESULT 18  
ADB75165  
ID ADB75165 standard; peptide; 6 AA.  
XX  
XX ADB75165;  
AC  
XX  
XX 04-DEC-2003 (first entry)  
DT  
XX Human amyloid beta peptide SEQ ID NO:6.  
XX

XX antibody; amyloid beta peptide; amyloid beta; neurotropic; neuroprotective;  
 KW antibody therapy; Alzheimer's disease; mild cognitive impairment;  
 KW cerebral amyloid angiopathy; congophilic angiopathy; Down's syndrome;  
 KW inclusion body myositis; neurotoxicity; beta amyloid precursor protein;  
 KW APP; human.  
 XX Homo sapiens.  
 OS  
 XX W02003074081-A1.  
 PN  
 XX 12-SEP-2003.  
 PD  
 XX 21-OCT-2002; 2002WO-US031590.  
 XX  
 XX 28-FEB-2002; 2002US-00084380.  
 XX  
 XX (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.  
 XX Chain DG;  
 XX WPI; 2003-731651/69.  
 XX  
 XX New antibody that is targeted to amyloid beta peptide, or its fragment,  
 PT useful for treating a subject having Alzheimer's disease, or a disease or  
 PT disorder characterized by amyloid beta deposition, e.g. cognitive  
 PT impairment or dementia.  
 XX  
 XX Example 2; Page 29; 63pp; English.  
 PS  
 XX The present invention describes an antibody that is targeted to amyloid  
 CC beta peptide, or its fragment. Also described: (1) an antibody that is  
 CC free-end specific and is targeted to: (a) the free N-terminus of amyloid  
 CC beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the  
 CC first amino acid of amyloid beta-peptide is aspartate; (c) the free N-  
 CC terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;  
 CC (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,  
 CC Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-  
 CC terminus-truncated amyloid beta-peptide fragment; (2) a single chain or  
 CC artificial antibody that is free-end specific and is targeted to the free  
 CC C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a  
 CC pharmaceutical composition comprising the antibody, and a carrier. The  
 CC antibody targeted to amyloid beta peptide has neurotropic and  
 CC neuroprotective activities, and can be used in antibody therapy. The  
 CC antibody or its fragment is useful for manufacturing a medicament for  
 CC treating a subject having Alzheimer's disease, or a disease or disorder  
 CC characterised by amyloid beta deposition (e.g. mild cognitive impairment,  
 CC cerebral amyloid angiopathy or congophilic angiopathy, Alzheimer's  
 CC disease associated with Down's syndrome, or inclusion body myositis), or  
 CC for delaying, inhibiting or suppressing accumulation of amyloid beta  
 CC peptide, or the neurotoxicity of amyloid beta peptide or its fragment.  
 CC Amyloid beta peptide are derived from beta amyloid precursor protein  
 CC (APP). The present sequence represents an amyloid beta peptide which is  
 CC used in the exemplification of the present invention.  
 XX  
 XX Sequence 6 AA;  
 SQ  
 Query Match 100.0%; Score 24; DB 7; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 EFRH 4  
 Db 3 EFRH 6  
 RESULT 19  
 ID ADJ88114 standard; peptide; 6 AA.  
 XX ADJ88114;  
 AC  
 XX 06-MAY-2004 (first entry)  
 DT

XX fd phage peptide #1 used to raise non-aggregating beta AP antibody.  
 DE  
 XX Neurological disease; central nervous system; CNS disorder;  
 KW plaque-forming disease; Alzheimer's disease; SAA amyloidosis;  
 KW hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;  
 KW bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;  
 KW CJD; Gerstmann-Sträussler-Scheinker disease; GSS; fatal familial insomnia;  
 KW FFI; non-plaque-forming disease; Huntington's chorea; viral infection;  
 KW brain tumour; lysosomal storage disease; neurodegeneration;  
 KW multiple sclerosis; vaccine; beta amyloid peptide; beta AP.  
 XX  
 XX Enterobacteria phage fd.  
 XX  
 XX US2004013647-A1.  
 PN  
 XX 22-JAN-2004.  
 PD  
 XX 11-MAR-2003; 2003US-00384788.  
 XX  
 XX 03-SEP-1999; 99US-0152417P.  
 PR 29-DEC-1999; 99US-00473653.  
 PR 31-JUL-2000; 2000US-00629971.  
 PR 31-AUG-2000; 2000WO-IL000518.  
 PR 15-MAR-2001; 2001US-00808037.  
 PR 07-AUG-2001; 2001US-00830954.  
 PR 12-APR-2002; 2002US-0371735P.  
 PR 06-JUN-2002; 2002US-00162889.  
 XX  
 XX (UYVA-) UNIV RAMOT AT TEL AVIV LTD.  
 PA  
 XX Solomon B, Frenkel D;  
 PI  
 XX WPI; 2004-108188/11.  
 XX  
 XX Treating neurological disease CNS e.g., Alzheimer's disease, by  
 PT displaying therapeutic molecule capable of treating the disease on viral  
 PT display vehicle which is then administered to subject through olfactory  
 PT system.  
 XX  
 XX Example 9; SEQ ID NO 7; 69pp; English.  
 PS  
 XX The invention relates to a method of treating a neurological disease or  
 CC disorder of the central nervous system (CNS). The method involves  
 CC displaying a therapeutic molecule capable of treating the neurological  
 CC disease or disorder of the CNS on a viral display vehicle and introducing  
 CC viral display vehicle into a subject by applying an effective amount of  
 CC the viral display vehicle displaying the therapeutic molecule to an  
 CC olfactory system of the subject. The method is useful for treating a  
 CC neurological disease or disorder of CNS such as a plaque-forming disease  
 CC such as Alzheimer's disease, late onset Alzheimer's disease, hereditary Icelandic  
 CC presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic  
 CC syndrome, senility, multiple myeloma, scrapie, bovine spongiform  
 CC encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-  
 CC Sträussler-Scheinker disease (GSS) or fatal familial insomnia (FFI). The  
 CC method is also useful for treating a non plaque forming disease or  
 CC disorder e.g. Huntington's chorea, viral infections of the brain, brain  
 CC tumours, lysosomal storage diseases which cause neurodegeneration and are  
 CC manifested by enzyme deficiencies and multiple sclerosis. The invention  
 CC is also used in the preparation of vaccines. The present sequence is fd  
 CC phage peptide used to raise non-aggregating beta AP (beta amyloid  
 CC peptide) antibody. This sequence is used to illustrate the method of the  
 CC invention.  
 XX  
 XX Sequence 6 AA;  
 SQ  
 Query Match 100.0%; Score 24; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 EFRH 4  
 Db 3 EFRH 6





PR 06-AUG-2002; 2002US-0401497P.  
XX (INNO-) INNOGENETICS NV.  
XX Delacourte A, Sergeant N;  
XX WPI; 2004-180423/17.  
XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.  
XX  
XX  
PS Claim 4; Page 61; 104pp; English.  
XX  
XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.  
XX  
XX Sequence 6 AA;  
PS  
XX Claim 4; Page 61; 104pp; English.  
XX  
XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.  
XX  
XX Sequence 6 AA;  
PS  
XX Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
DB |||||  
3 EFRH 6  
RESULT 23  
ADJ71353  
ID ADJ71353 standard; peptide; 6 AA.  
XX  
AC ADJ71353;  
XX  
XX 06-MAY-2004 (first entry)  
DT  
XX N-terminal truncated beta-amyloid peptide, SEQ ID 16.  
DE  
XX Nootropic; Neuroprotective; Vaccine; beta Amyloid;  
KW amyloid precursor protein; APP; Alzheimer's disease.  
XX  
XX Homo sapiens.  
OS  
XX  
XX Key Location/Qualifiers  
FH Modified-site 1 /note= "Optionally methylated"  
FT  
XX  
XX WO2004013172-A2.  
PN  
XX  
PD 12-FEB-2004.  
XX  
XX 18-JUL-2003; 2003WO-EP007833.  
PF  
XX  
XX 24-JUL-2002; 2002EP-00447147.  
PR  
XX 06-AUG-2002; 2002US-0401497P.  
PR  
XX (INNO-) INNOGENETICS NV.  
PA  
XX Delacourte A, Sergeant N;  
XX  
XX WPI; 2004-180423/17.  
XX  
XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.  
XX  
XX  
XX Claim 4; Page 61; 104pp; English.  
XX  
XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.  
XX  
XX Sequence 6 AA;  
PS  
XX Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
DB |||||  
3 EFRH 6  
RESULT 24  
ADK52251  
ID ADK52251 standard; peptide; 6 AA.  
XX  
AC ADK52251;  
XX  
XX 20-MAY-2004 (first entry)  
DT  
XX Human amyloid beta (Abeta) 1-6 peptide seqid 75.  
DE  
XX Neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;  
KW core particle; antigen array; Alzheimer's disease; human.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2004016282-A1.  
PN  
XX  
PD 26-FEB-2004.  
XX  
XX 18-JUL-2003; 2003WO-EP007864.  
PF  
XX  
PR 19-JUL-2002; 2002US-0396639P.  
PR  
XX 15-MAY-2003; 2003US-0470432P.  
XX  
XX (CYTO-) CYTOS BIOTECHNOLOGY AG.  
PA (NOVS ) NOVARTIS PHARMA AG.  
XX  
XX Bachmann MF, Tissot A, Ortmann R, Lueoend R, Staufenbiel M;  
PI Frey P;  
PI  
XX WPI; 2004-203731/19.  
XX  
XX Composition comprising a core particle with at least one attachment site,  
PT and an antigenic amyloid beta 1-6 peptide, useful for treating diseases  
PT such as Alzheimer's disease.  
PT  
XX  
XX Claim 22; SEQ ID NO 75; 184pp; English.  
PS  
XX  
XX The invention describes a novel composition comprising a core particle  
CC with at least one attachment site, and an antigenic amyloid beta 1-6  
CC peptide. The new composition comprises: a core particle with at least one  
CC first attachment site; and at least one antigen or antigenic determinant  
CC with at least one second attachment site, where the antigen or antigenic  
CC determinant is a Amyloid beta 1-6 peptide, and where the second  
CC attachment site comprises: an attachment site not naturally occurring  
CC with the antigen or antigenic determinant; or an attachment site  
CC naturally occurring with the antigen or antigenic determinant. The second  
CC attachment site is capable of association to the first attachment site  
CC and the beta 1-6 peptide and the core particle interact through the  
CC association to form an ordered and repetitive antigen array. The

CC composition is useful for the manufacture of a medicament for treating  
 CC Alzheimer's disease and related diseases. This is the amino acid sequence  
 CC of an amyloid beta (Abeta) 1-6 peptide that can be used in the creation  
 CC of the compositions and vaccines of the invention.  
 XX  
 XX  
 SQ Sequence 6 AA;

Query Match 100.0%; Score 24; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 ||||  
 Db 3 EPRH 6

RESULT 25  
 ADK52264  
 ID ADK52264 standard; peptide; 6 AA.

XX AC ADK52264;

XX DT 20-MAY-2004 (first entry)

XX DE Guinea pig amyloid beta (Abeta) 1-6 peptide.

XX KW neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;  
 KW core particle; antigen array; Alzheimer's disease; guinea pig.

XX OS Cavia porcellus.

XX PN WO2004016282-A1.

XX PD 26-FEB-2004.

XX PF 18-JUL-2003; 2003WO-EP007864.

XX PR 19-JUL-2002; 2002US-0396639P.

XX PR 15-MAY-2003; 2003US-0470432P.

XX XX (CYTO-) CYTOS BIOTECHNOLOGY AG.

XX PA (NOVS ) NOVARTIS PHARMA AG.

XX PI Bachmann MF, Tissot A, Ortman R, Lueoend R, Staufenbiel M;

XX PI Frey P;

XX XX WPI; 2004-203731/19.

XX CC Composition comprising a core particle with at least one attachment site,  
 PT and an antigenic amyloid beta 1-6 peptide, useful for treating diseases  
 PT such as Alzheimer's disease.

XX PS Claim 22; SEQ ID NO 88; 184pp; English.

XX CC The invention describes a novel composition comprising a core particle  
 CC with at least one attachment site, and an antigenic amyloid beta 1-6  
 CC peptide. The new composition comprises: a core particle with at least one  
 CC first attachment site; and at least one antigen or antigenic determinant  
 CC with at least one second attachment site, where the antigen or antigenic  
 CC determinant is a Amyloid beta 1-6 peptide, and where the second  
 CC attachment site comprises: an attachment site not naturally occurring  
 CC with the antigen or antigenic determinant; or an attachment site  
 CC naturally occurring with the antigen or antigenic determinant. The second  
 CC attachment site is capable of association to the first attachment site  
 CC and the beta 1-6 peptide and the core particle interact through the  
 CC association to form an ordered and repetitive antigen array. The  
 CC composition is useful for the manufacture of a medicament for treating  
 CC Alzheimer's disease and related diseases. This is the amino acid sequence  
 CC of an amyloid beta (Abeta) 1-6 peptide that can be used as an alternative  
 CC to the human sequence in the compositions and vaccines of the invention.

XX SQ Sequence 6 AA;

Query Match 100.0%; Score 24; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 ||||  
 Db 3 EPRH 6

RESULT 26  
 ADK52261  
 ID ADK52261 standard; peptide; 6 AA.

XX AC ADK52261;

XX DT 20-MAY-2004 (first entry)

XX DE Rabbit amyloid beta (Abeta) 1-6 peptide.

XX KW neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;  
 KW core particle; antigen array; Alzheimer's disease; rabbit.

XX OS Oryctolagus cuniculus.

XX PN WO2004016282-A1.

XX PD 26-FEB-2004.

XX PF 18-JUL-2003; 2003WO-EP007864.

XX PR 19-JUL-2002; 2002US-0396639P.

XX PR 15-MAY-2003; 2003US-0470432P.

XX XX (CYTO-) CYTOS BIOTECHNOLOGY AG.

XX PA (NOVS ) NOVARTIS PHARMA AG.

XX PI Bachmann MF, Tissot A, Ortman R, Lueoend R, Staufenbiel M;

XX PI Frey P;

XX XX WPI; 2004-203731/19.

XX CC Composition comprising a core particle with at least one attachment site,  
 PT and an antigenic amyloid beta 1-6 peptide, useful for treating diseases  
 PT such as Alzheimer's disease.

XX PS Claim 22; SEQ ID NO 85; 184pp; English.

XX CC The invention describes a novel composition comprising a core particle  
 CC with at least one attachment site, and an antigenic amyloid beta 1-6  
 CC peptide. The new composition comprises: a core particle with at least one  
 CC first attachment site; and at least one antigen or antigenic determinant  
 CC with at least one second attachment site, where the antigen or antigenic  
 CC determinant is a Amyloid beta 1-6 peptide, and where the second  
 CC attachment site comprises: an attachment site not naturally occurring  
 CC with the antigen or antigenic determinant; or an attachment site  
 CC naturally occurring with the antigen or antigenic determinant. The second  
 CC attachment site is capable of association to the first attachment site  
 CC and the beta 1-6 peptide and the core particle interact through the  
 CC association to form an ordered and repetitive antigen array. The  
 CC composition is useful for the manufacture of a medicament for treating  
 CC Alzheimer's disease and related diseases. This is the amino acid sequence  
 CC of an amyloid beta (Abeta) 1-6 peptide that can be used as an alternative  
 CC to the human sequence in the compositions and vaccines of the invention.

XX SQ Sequence 6 AA;

Query Match 100.0%; Score 24; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 ||||  
 Db 3 EPRH 6

RESULT 28  
ADK52266  
ID ADK52266 standard; peptide; 6 AA.  
XX  
AC ADK52266;



```

Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 EFRH 4
      ||||
Db      3 EFRH 6

RESULT 32
ADQ82433
ID      ADQ82433 standard; peptide; 6 AA.
XX      AC      ADQ82433;
XX      DT      21-OCT-2004 (first entry)
XX      DE      N-terminal amyloid-beta (AB42) peptide mimotope #44.
XX      KW      amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
XX      KW      Alzheimer's disease.
XX      OS      Synthetic.
XX      PN      WO2004062556-A2.
XX      PD      29-JUL-2004.
XX      PF      13-JAN-2004; 2004WO-EP000162.
XX      PR      14-JAN-2003; 2003AT-00000036.
XX      PR      17-SEP-2003; 2003AT-00001464.
XX      PA      (MATT/) MATTNER F.
XX      PI      Mattner F;
XX      DR      WPI; 2004-561715/54.
XX      PT      Use of a compound having a binding capacity to an antibody specific for
XX      PT      the natural N-terminal AB42 sequence, for preparing a vaccine for
XX      PT      preventing and treating Alzheimer's disease.
XX      PS      Example 2.4; Fig 1B; 29pp; English.
XX      CC      The invention comprises peptides which mimic the N-terminal region of
XX      CC      amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
XX      CC      the invention have the capacity to bind to an antibody which is specific
XX      CC      for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
XX      CC      of the invention are useful in the preparation of a vaccine for
XX      CC      Alzheimer's disease. The present amino acid sequence represents an N-
XX      CC      terminal AB42 peptide mimotope of the invention.
XX      SQ      Sequence 6 AA;
XX      PI      Mattner F;
XX      DR      WPI; 2004-561715/54.
XX      PT      Use of a compound having a binding capacity to an antibody specific for
XX      PT      the natural N-terminal AB42 sequence, for preparing a vaccine for
XX      PT      preventing and treating Alzheimer's disease.
XX      PS      Example 2.4; Fig 1B; 29pp; English.
XX      CC      The invention comprises peptides which mimic the N-terminal region of
XX      CC      amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
XX      CC      the invention have the capacity to bind to an antibody which is specific
XX      CC      for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
XX      CC      of the invention are useful in the preparation of a vaccine for
XX      CC      Alzheimer's disease. The present amino acid sequence represents an N-
XX      CC      terminal AB42 peptide mimotope of the invention.
XX      SQ      Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 EFRH 4
      ||||
Db      3 EFRH 6

RESULT 33
ADQ82434
ID      ADQ82434 standard; peptide; 6 AA.
XX      AC      ADQ82434;
XX      DT      21-OCT-2004 (first entry)
XX      DE      N-terminal amyloid-beta (AB42) peptide mimotope #45.
XX      KW      amyloid-beta peptide; AB42 peptide; mimotope; vaccine;

```

```

KW      Alzheimer's disease.
XX      OS      Synthetic.
XX      PN      WO2004062556-A2.
XX      PD      29-JUL-2004.
XX      PF      13-JAN-2004; 2004WO-EP000162.
XX      PR      14-JAN-2003; 2003AT-00000036.
XX      PR      17-SEP-2003; 2003AT-00001464.
XX      PA      (MATT/) MATTNER F.
XX      PI      Mattner F;
XX      DR      WPI; 2004-561715/54.
XX      PT      Use of a compound having a binding capacity to an antibody specific for
XX      PT      the natural N-terminal AB42 sequence, for preparing a vaccine for
XX      PT      preventing and treating Alzheimer's disease.
XX      PS      Example 2.4; Fig 1B; 29pp; English.
XX      CC      The invention comprises peptides which mimic the N-terminal region of
XX      CC      amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
XX      CC      the invention have the capacity to bind to an antibody which is specific
XX      CC      for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
XX      CC      of the invention are useful in the preparation of a vaccine for
XX      CC      Alzheimer's disease. The present amino acid sequence represents an N-
XX      CC      terminal AB42 peptide mimotope of the invention.
XX      SQ      Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 EFRH 4
      ||||
Db      3 EFRH 6

RESULT 34
ADQ82436
ID      ADQ82436 standard; peptide; 6 AA.
XX      AC      ADQ82436;
XX      DT      21-OCT-2004 (first entry)
XX      DE      N-terminal amyloid-beta (AB42) peptide mimotope #47.
XX      KW      amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
XX      KW      Alzheimer's disease.
XX      OS      Synthetic.
XX      PN      WO2004062556-A2.
XX      PD      29-JUL-2004.
XX      PF      13-JAN-2004; 2004WO-EP000162.
XX      PR      14-JAN-2003; 2003AT-00000036.
XX      PR      17-SEP-2003; 2003AT-00001464.
XX      PA      (MATT/) MATTNER F.
XX      PI      Mattner F;
XX      DR      WPI; 2004-561715/54.

```

XX Use of a compound having a binding capacity to an antibody specific for  
PT the natural N-terminal AB42 sequence, for preparing a vaccine for  
PT preventing and treating Alzheimer's disease.  
XX  
XX Example 2.4; Fig 1B; 29pp; English.  
XX  
CC The invention comprises peptides which mimic the N-terminal region of  
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
CC the invention have the capacity to bind to an antibody which is specific  
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
CC of the invention are useful in the preparation of a vaccine for  
CC Alzheimer's disease. The present amino acid sequence represents an N-  
CC terminal AB42 peptide mimotope of the invention.  
XX  
SQ Sequence 6 AA;  
Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
3 EPRH 6  
RESULT 35  
ADQ82431  
ID ADQ82431 standard; peptide; 6 AA.  
AC ADQ82431;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
XX  
DE N-terminal amyloid-beta (AB42) peptide mimotope #42.  
XX  
XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;  
KW Alzheimer's disease.  
XX  
OS Synthetic.  
XX  
PN WO2004062556-A2.  
XX  
XX 29-JUL-2004.  
PD  
XX  
XX 13-JAN-2004; 2004WO-EP000162.  
PF  
XX  
XX 14-JAN-2003; 2003AT-00000036.  
PR  
XX 17-SEP-2003; 2003AT-00001464.  
PR  
XX (MATT/) MATTNER F.  
PA  
XX  
XX Mattner F;  
PI  
XX  
XX WPI; 2004-561715/54.  
DR  
XX  
XX Use of a compound having a binding capacity to an antibody specific for  
PT the natural N-terminal AB42 sequence, for preparing a vaccine for  
PT preventing and treating Alzheimer's disease.  
XX  
XX Example 2.4; Fig 1B; 29pp; English.  
XX  
CC The invention comprises peptides which mimic the N-terminal region of  
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
CC the invention have the capacity to bind to an antibody which is specific  
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
CC of the invention are useful in the preparation of a vaccine for  
CC Alzheimer's disease. The present amino acid sequence represents an N-  
CC terminal AB42 peptide mimotope of the invention.  
XX  
SQ Sequence 6 AA;  
Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
3 EPRH 6  
RESULT 35  
ADQ82431  
ID ADQ82431 standard; peptide; 6 AA.  
AC ADQ82431;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
XX  
DE N-terminal amyloid-beta (AB42) peptide mimotope #42.  
XX  
XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;  
KW Alzheimer's disease.  
XX  
OS Synthetic.  
XX  
PN WO2004062556-A2.  
XX  
XX 29-JUL-2004.  
PD  
XX  
XX 13-JAN-2004; 2004WO-EP000162.  
PF  
XX  
XX 14-JAN-2003; 2003AT-00000036.  
PR  
XX 17-SEP-2003; 2003AT-00001464.  
PR  
XX (MATT/) MATTNER F.  
PA  
XX  
XX Mattner F;  
PI  
XX  
XX WPI; 2004-561715/54.  
DR  
XX  
XX Use of a compound having a binding capacity to an antibody specific for  
PT the natural N-terminal AB42 sequence, for preparing a vaccine for  
PT preventing and treating Alzheimer's disease.  
XX  
XX Example 2.4; Fig 1B; 29pp; English.  
XX  
CC The invention comprises peptides which mimic the N-terminal region of  
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
CC the invention have the capacity to bind to an antibody which is specific  
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
CC of the invention are useful in the preparation of a vaccine for  
CC Alzheimer's disease. The present amino acid sequence represents an N-  
CC terminal AB42 peptide mimotope of the invention.  
XX  
SQ Sequence 6 AA;  
Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
3 EPRH 6  
RESULT 37  
ADQ82424  
ID ADQ82424 standard; peptide; 6 AA.  
AC ADQ82424;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
XX  
DE N-terminal amyloid-beta (AB42) peptide mimotope #35.  
XX

Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
3 EPRH 6  
RESULT 36  
ADQ82423  
ID ADQ82423 standard; peptide; 6 AA.  
XX  
AC ADQ82423;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
XX  
DE N-terminal amyloid-beta (AB42) peptide mimotope #34.  
XX  
XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;  
KW Alzheimer's disease.  
XX  
OS Synthetic.  
XX  
PN WO2004062556-A2.  
XX  
XX 29-JUL-2004.  
PD  
XX  
XX 13-JAN-2004; 2004WO-EP000162.  
PF  
XX  
XX 14-JAN-2003; 2003AT-00000036.  
PR  
XX 17-SEP-2003; 2003AT-00001464.  
PR  
XX (MATT/) MATTNER F.  
PA  
XX  
XX Mattner F;  
PI  
XX  
XX WPI; 2004-561715/54.  
DR  
XX  
XX Use of a compound having a binding capacity to an antibody specific for  
PT the natural N-terminal AB42 sequence, for preparing a vaccine for  
PT preventing and treating Alzheimer's disease.  
XX  
XX Example 2.4; Fig 1B; 29pp; English.  
XX  
CC The invention comprises peptides which mimic the N-terminal region of  
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
CC the invention have the capacity to bind to an antibody which is specific  
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
CC of the invention are useful in the preparation of a vaccine for  
CC Alzheimer's disease. The present amino acid sequence represents an N-  
CC terminal AB42 peptide mimotope of the invention.  
XX  
SQ Sequence 6 AA;  
Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4  
Db |||||  
3 EPRH 6  
RESULT 37  
ADQ82424  
ID ADQ82424 standard; peptide; 6 AA.  
AC ADQ82424;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
XX  
DE N-terminal amyloid-beta (AB42) peptide mimotope #35.  
XX





```

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EPRH 4
Db 3 EPRH 6

RESULT 40
ADQ82429
ID ADQ82429 standard; peptide; 6 AA.
XX
AC ADQ82429;
XX
DT 21-OCT-2004 (first entry)
XX
DE N-terminal amyloid-beta (AB42) peptide mimotope #40.
XX
KW amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW Alzheimer's disease.
XX
OS Synthetic.
XX
PN WO2004062556-A2.
XX
PD 29-JUL-2004.
XX
PF 13-JAN-2004; 2004WO-EP000162.
XX
PR 14-JAN-2003; 2003AT-00000036.
XX
PR 17-SEP-2003; 2003AT-00001464.
XX
PA (MATT/) MATTNER F.
XX
PI Mattner F;
XX
DR WPI; 2004-561715/54.
XX
PT Use of a compound having a binding capacity to an antibody specific for
PT the natural N-terminal AB42 sequence, for preparing a vaccine for
PT preventing and treating Alzheimer's disease.
XX
PS Example 2.4; Fig 1B; 29pp; English.
XX
CC The invention comprises peptides which mimic the N-terminal region of
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC the invention have the capacity to bind to an antibody which is specific
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC of the invention are useful in the preparation of a vaccine for
CC Alzheimer's disease. The present amino acid sequence represents an N-
CC terminal AB42 peptide mimotope of the invention.
XX
SQ Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EPRH 4
Db 3 EPRH 6

RESULT 41
ADQ82425
ID ADQ82425 standard; peptide; 6 AA.
XX
AC ADQ82425;
XX
DT 21-OCT-2004 (first entry)
XX
DE N-terminal amyloid-beta (AB42) peptide mimotope #36.

```

```

XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW Alzheimer's disease.
XX
OS Synthetic.
XX
PN WO2004062556-A2.
XX
PD 29-JUL-2004.
XX
PF 13-JAN-2004; 2004WO-EP000162.
XX
PR 14-JAN-2003; 2003AT-00000036.
XX
PR 17-SEP-2003; 2003AT-00001464.
XX
PA (MATT/) MATTNER F.
XX
PI Mattner F;
XX
DR WPI; 2004-561715/54.
XX
PT Use of a compound having a binding capacity to an antibody specific for
PT the natural N-terminal AB42 sequence, for preparing a vaccine for
PT preventing and treating Alzheimer's disease.
XX
PS Example 2.4; Fig 1B; 29pp; English.
XX
CC The invention comprises peptides which mimic the N-terminal region of
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC the invention have the capacity to bind to an antibody which is specific
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC of the invention are useful in the preparation of a vaccine for
CC Alzheimer's disease. The present amino acid sequence represents an N-
CC terminal AB42 peptide mimotope of the invention.
XX
SQ Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EPRH 4
Db 3 EPRH 6

RESULT 42
ADQ82422
ID ADQ82422 standard; peptide; 6 AA.
XX
AC ADQ82422;
XX
DT 21-OCT-2004 (first entry)
XX
DE N-terminal amyloid-beta (AB42) peptide mimotope #33.
XX
KW amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW Alzheimer's disease.
XX
OS Synthetic.
XX
PN WO2004062556-A2.
XX
PD 29-JUL-2004.
XX
PF 13-JAN-2004; 2004WO-EP000162.
XX
PR 14-JAN-2003; 2003AT-00000036.
XX
PR 17-SEP-2003; 2003AT-00001464.
XX
PA (MATT/) MATTNER F.
XX
PI Mattner F;

```

```

XX DR WPI; 2004-561715/54.
XX PT Use of a compound having a binding capacity to an antibody specific for
XX PT the natural N-terminal AB42 sequence, for preparing a vaccine for
XX PT preventing and treating Alzheimer's disease.
XX XX Example 2.4; Fig 1B; 29pp; English.
XX PS
XX CC The invention comprises peptides which mimic the N-terminal region of
XX CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
XX CC the invention have the capacity to bind to an antibody which is specific
XX CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
XX CC of the invention are useful in the preparation of a vaccine for
XX CC Alzheimer's disease. The present amino acid sequence represents an N-
XX CC terminal AB42 peptide mimotope of the invention.
XX SQ Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. NO. 1.8e+06; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 43
ADQ82421
ID ADQ82421 standard; peptide; 6 AA.
XX AC ADQ82421;
XX DT 21-OCT-2004 (first entry)
XX DE N-terminal amyloid-beta (AB42) peptide mimotope #32.
XX KW amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
XX OS Alzheimer's disease.
XX OS Synthetic.
XX PN WO2004062556-A2.
XX PD 29-JUL-2004.
XX PF 13-JAN-2004; 2004WO-EP000162.
XX PR 14-JAN-2003; 2003AT-00000036.
XX PR 17-SEP-2003; 2003AT-00001464.
XX PA (MATT/) MATTNER F.
XX PI Mattner F;
XX DR WPI; 2004-561715/54.
XX PT Use of a compound having a binding capacity to an antibody specific for
XX PT the natural N-terminal AB42 sequence, for preparing a vaccine for
XX PT preventing and treating Alzheimer's disease.
XX XX Example 2.4; Fig 1B; 29pp; English.
XX PS
XX CC The invention comprises peptides which mimic the N-terminal region of
XX CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
XX CC the invention have the capacity to bind to an antibody which is specific
XX CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
XX CC of the invention are useful in the preparation of a vaccine for
XX CC Alzheimer's disease. The present amino acid sequence represents an N-
XX CC terminal AB42 peptide mimotope of the invention.
XX SQ Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. NO. 1.8e+06; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 44
ADQ82437
ID ADQ82437 standard; peptide; 6 AA.
XX AC ADQ82437;
XX DT 21-OCT-2004 (first entry)
XX DE N-terminal amyloid-beta (AB42) peptide mimotope #48.
XX KW amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
XX OS Alzheimer's disease.
XX OS Synthetic.
XX PN WO2004062556-A2.
XX PD 29-JUL-2004.
XX PF 13-JAN-2004; 2004WO-EP000162.
XX PR 14-JAN-2003; 2003AT-00000036.
XX PR 17-SEP-2003; 2003AT-00001464.
XX PA (MATT/) MATTNER F.
XX PI Mattner F;
XX DR WPI; 2004-561715/54.
XX PT Use of a compound having a binding capacity to an antibody specific for
XX PT the natural N-terminal AB42 sequence, for preparing a vaccine for
XX PT preventing and treating Alzheimer's disease.
XX XX Example 2.4; Fig 1B; 29pp; English.
XX PS
XX CC The invention comprises peptides which mimic the N-terminal region of
XX CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
XX CC the invention have the capacity to bind to an antibody which is specific
XX CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
XX CC of the invention are useful in the preparation of a vaccine for
XX CC Alzheimer's disease. The present amino acid sequence represents an N-
XX CC terminal AB42 peptide mimotope of the invention.
XX SQ Sequence 6 AA;

Query Match      100.0%; Score 24; DB 8; Length 6;
Best Local Similarity 100.0%; Pred. NO. 1.8e+06; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 45
ADQ82386
ID ADQ82386 standard; peptide; 6 AA.
XX AC ADQ82386;
XX DT 21-OCT-2004 (first entry)
XX XX

```

DE Natural N-terminal amyloid-beta (AB42) peptide #1.  
XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;  
KW Alzheimer's disease.  
XX Unidentified.  
OS WO2004062556-A2.  
PN XX  
XX 29-JUL-2004.  
PD XX  
XX 13-JAN-2004; 2004WO-EP000162.  
PF XX  
XX 14-JAN-2003; 2003AT-00000036.  
PR XX  
XX 17-SEP-2003; 2003AT-00001464.  
XX (MATT/) MATTNER F.  
PA XX  
XX Mattner F;  
PI XX  
XX WPI; 2004-561715/54.  
DR XX  
XX Use of a compound having a binding capacity to an antibody specific for  
PT the natural N-terminal AB42 sequence, for preparing a vaccine for  
PT preventing and treating Alzheimer's disease.  
XX  
XX Claim 1; Page 22; 29pp; English.  
PS  
XX The invention comprises peptides which mimic the N-terminal region of  
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
CC the invention have the capacity to bind to an antibody which is specific  
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
CC of the invention are useful in the preparation of a vaccine for  
CC Alzheimer's disease. The present amino acid sequence represents the  
CC natural N-terminal AB42 peptide.  
XX  
XX Sequence 6 AA;  
SQ

Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
Db ||||  
3 EFRH 6

RESULT 46  
ADQ82426  
ID ADQ82426 standard; peptide; 6 AA.  
XX  
XX AC ADQ82426;  
XX  
XX 21-OCT-2004 (first entry)  
XX  
XX N-terminal amyloid-beta (AB42) peptide mimotope #37.  
DE  
XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;  
KW Alzheimer's disease.  
XX Synthetic.  
OS  
XX WO2004062556-A2.  
PN  
XX 29-JUL-2004.  
PD  
XX 13-JAN-2004; 2004WO-EP000162.  
PF  
XX 14-JAN-2003; 2003AT-00000036.  
PR  
XX 17-SEP-2003; 2003AT-00001464.  
XX (MATT/) MATTNER F.  
PA  
XX

Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
Db ||||  
3 EFRH 6

RESULT 47  
AAB46202  
ID AAB46202 standard; peptide; 7 AA.  
XX  
XX AC AAB46202;  
XX  
XX 04-APR-2001 (first entry)  
XX  
XX Human APP A-beta protein N-terminal fragment.  
XX  
XX Amyloid deposit; APP; Abeta; brain; human; clearing response; nootropic;  
KW Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;  
KW amyloid precursor protein; Alzheimer's disease.  
XX  
XX Homo sapiens.  
OS  
XX WO200072880-A2.  
PN  
XX 07-DEC-2000.  
PD  
XX 26-MAY-2000; 2000WO-US014810.  
PF  
XX 28-MAY-1999; 99US-00322289.  
PR  
XX (NEUR-) NEURALAB LTD.  
PA  
XX Schenk DB, Bard F, Vasquez NJ, Yednock T;  
PI  
XX WPI; 2001-032104/04.  
DR  
XX Preventing or treating a disease associated with amyloid deposits,  
PT especially Alzheimer's disease, comprises administering amyloid specific  
PT antibody.  
XX  
XX Claim 59; Page 119; 143pp; English.  
PS  
XX This invention describes a novel method of preventing or treating a  
CC disease associated with amyloid deposits of amyloid precursor protein  
CC (APP) Abeta fragments in the brain of a patient, which comprises  
CC administering to the patient: (a) an antibody that binds to Abeta, the  
CC antibody binds to an amyloid deposit and induces a clearing response (Fc  
CC receptor mediated phagocytosis) against it (b) a polypeptide containing  
CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent  
CC that induces an immunogenic response against residues 1-3 to 7-11 of

PI Mattner F;  
XX  
XX WPI; 2004-561715/54.  
DR  
XX Use of a compound having a binding capacity to an antibody specific for  
PT the natural N-terminal AB42 sequence, for preparing a vaccine for  
PT preventing and treating Alzheimer's disease.  
XX  
XX Example 2.4; Fig 1B; 29pp; English.  
PS  
XX The invention comprises peptides which mimic the N-terminal region of  
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
CC the invention have the capacity to bind to an antibody which is specific  
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
CC of the invention are useful in the preparation of a vaccine for  
CC Alzheimer's disease. The present amino acid sequence represents an N-  
CC terminal AB42 peptide mimotope of the invention.  
XX  
XX Sequence 6 AA;  
SQ

Query Match 100.0%; Score 24; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
Db ||||  
3 EFRH 6

RESULT 47  
AAB46202  
ID AAB46202 standard; peptide; 7 AA.  
XX  
XX AC AAB46202;  
XX  
XX 04-APR-2001 (first entry)  
XX  
XX Human APP A-beta protein N-terminal fragment.  
XX  
XX Amyloid deposit; APP; Abeta; brain; human; clearing response; nootropic;  
KW Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;  
KW amyloid precursor protein; Alzheimer's disease.  
XX  
XX Homo sapiens.  
OS  
XX WO200072880-A2.  
PN  
XX 07-DEC-2000.  
PD  
XX 26-MAY-2000; 2000WO-US014810.  
PF  
XX 28-MAY-1999; 99US-00322289.  
PR  
XX (NEUR-) NEURALAB LTD.  
PA  
XX Schenk DB, Bard F, Vasquez NJ, Yednock T;  
PI  
XX WPI; 2001-032104/04.  
DR  
XX Preventing or treating a disease associated with amyloid deposits,  
PT especially Alzheimer's disease, comprises administering amyloid specific  
PT antibody.  
XX  
XX Claim 59; Page 119; 143pp; English.  
PS  
XX This invention describes a novel method of preventing or treating a  
CC disease associated with amyloid deposits of amyloid precursor protein  
CC (APP) Abeta fragments in the brain of a patient, which comprises  
CC administering to the patient: (a) an antibody that binds to Abeta, the  
CC antibody binds to an amyloid deposit and induces a clearing response (Fc  
CC receptor mediated phagocytosis) against it (b) a polypeptide containing  
CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent  
CC that induces an immunogenic response against residues 1-3 to 7-11 of

CC Abeta. The products of the invention have neurotropic and neuroprotective  
CC activity. The method is also useful for monitoring a course of treatment  
CC being administered to a patient e.g. active and passive immunization. The  
CC methods are useful for prophylactic and therapeutic treatment of  
CC Alzheimer's disease  
XX  
SQ Sequence 7 AA;

Query Match 100.0%; Score 24; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|  
|  
|  
|  
Db 3 EFRH 6

RESULT 48  
AAO14421  
ID AAO14421 standard; peptide; 7 AA.  
XX  
AC AAO14421;  
XX  
DT 02-MAY-2002 (first entry)  
XX  
DE Synthetic peptide of A-Beta residues 1-7 (DAEFRHD).  
XX  
KW Neurodegenerative disorder; Alzheimer's disease; AD; T714I; APP; APP714;  
KW amyloid precursor protein; amyloid Beta peptide; A-Beta; A-Beta40; brain;  
KW A-Beta42; plaque pathology; pre-amyloid; cerebral amyloid angiopathy;  
KW Dense-cored plaque; CAA; senile plaque core; amyloid cascade; murine;  
KW mouse; DAEFRHD; monoclonal antibody.  
XX  
Mus sp.  
OS  
OS Synthetic.  
XX  
PN WO200202769-A1.  
XX  
PD 10-JAN-2002.  
XX  
XX 06-JUL-2001; 2001WO-EP007830.  
XX  
XX 06-JUL-2000; 2000EP-00202362.  
XX  
XX (VLAAs) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.  
XX  
XX Cruts M, De Jonghe C, Kumar Singh S, Van Broeckhoven C;  
XX  
XX WPI; 2002-154742/20.  
XX  
XX Novel polynucleotide sequence encoding a mutant of amyloid precursor  
PT protein 70, useful for screening for a molecule capable of reducing the  
PT formation of beta amyloid 42 peptide.  
XX  
XX Disclosure; Page 21; 42pp; English.

CC The invention relates to the field of the neurodegenerative disorder of  
CC Alzheimer's disease (AD). In particular, the invention provides a novel  
CC mutation (T714I) identified in the amyloid precursor protein (APP),  
CC APP714, which leads to a very aggressive form of AD. The mutation  
CC involves the 43rd codon of the amyloid Beta peptide (A-Beta)  
CC corresponding to the putative gamma 42-secretase cleavage site. The novel  
CC mutation alters both A-Beta40 and A-Beta42 secretion elevating the A-  
CC Beta42/A-Beta40 ratio by 10-fold in vitro. Furthermore, the main amyloid  
CC plaque pathology in brains of these patients is of the diffuse 'pre-  
CC amyloid' type composed primarily of N-truncated A-Beta42. Dense-  
CC cored plaques although not absent, were significantly reduced. Also, the usual  
CC sites in brain where A-Beta40 is predominantly deposited, for instance,  
CC in vessels as cerebral amyloid angiopathy (CAA) or senile plaque cores,  
CC were composed entirely of A-Beta42 form. Together, these indicate that  
CC deposition of N-truncated A-Beta42 in one of the earliest amyloid  
CC deposited in the brain, the diffuse plaques, is fully competent of  
CC inciting AD either through the well-established 'amyloid cascade' or by a

CC yet unknown mechanism(s). This sequence represents a synthetic peptide of  
CC A-Beta, residues 1-7 (DAEFRHD). This sequence was used for raising a  
CC monoclonal antibody specific for the N-terminus of A-Beta40 and A-Beta42  
CC by immunising mice with the synthetic peptide  
XX  
SQ Sequence 7 AA;

Query Match 100.0%; Score 24; DB 5; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|  
|  
|  
|  
Db 3 EFRH 6

RESULT 49  
AAO19884  
ID AAO19884 standard; peptide; 7 AA.  
XX  
AC AAO19884;  
XX  
DT 11-AUG-2003 (first entry)  
XX  
DE Human amyloid precursor protein APP immunogenic peptide #4.  
XX  
KW Human; APP; amyloid precursor protein; immunogen; Alzheimer's disease;  
KW high-throughput screening; neuroprotective; nootropic; antiparkinsonian.  
XX  
OS Homo sapiens.  
XX  
PN WO2003001881-A2.  
XX  
XX 09-JAN-2003.  
XX  
XX 26-JUN-2002; 2002WO-US020267.  
XX  
XX 26-JUN-2001; 2001US-0300959P.  
XX  
XX (NYME-) NEW YORK STATE OFFICE MENTAL HEALTH.  
XX  
XX Mathews PM, Nixon RA, Schmidt SD, Jiang Y;  
XX  
XX WPI; 2003-210182/20.  
XX  
XX Identifying compounds that modulates the generation of metabolites  
PT associated with a disease or disorder, for treating e.g. Alzheimer's  
PT disease by determining levels of a cellular component protein, or its  
PT conformation state.  
XX  
XX Example 1; Page 29; 69pp; English.

CC The present invention relates to a method of identifying compounds that  
CC modulate the generation of one or more metabolites associated with a  
CC disease or disorder comprising determining levels of a cellular component  
CC protein or a conformation state of a cellular precursor protein. In  
CC particular, the method can be used to determine levels of amyloid  
CC precursor protein (APP), which is associated with Alzheimer's disease. It  
CC is also useful for identifying compounds as drugs for treating diseases  
CC or disorders associated with metabolic and/or proteolytic pathways, e.g.  
CC Alzheimer's disease, Parkinson's disease, Huntington's disease, lysosomal  
CC storage disorders, prion diseases, the tau-based neurodegenerative  
CC disorders, and other non-AD amyloidoses. The present sequence is an  
CC immunogenic portion of human APP  
XX  
SQ Sequence 7 AA;

Query Match 100.0%; Score 24; DB 6; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|  
|  
|  
|

Db 3 EPRH 6

RESULT 50  
AAE35432  
ID AAE35432 standard; peptide; 7 AA.  
XX  
AC AAE35432;  
XX  
DT 17-JUN-2003 (first entry)  
XX  
DE Abeta peptide #3.  
XX  
KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
XX  
OS Unidentified.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1..7 /note= "D-form residues"  
FT  
XX  
PN WO200296937-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 29-MAY-2002; 2002WO-CA0000763.  
XX  
PR 29-MAY-2001; 2001US-00867847.  
XX  
PA (NEUR-) NEUROCHEM INC.  
XX  
PI Gervais F, Hebert L, Chalifour RJ, Kong X;  
XX  
WPI; 2003-201269/19.  
XX  
XX  
PT Prevention and/or treatment of an amyloid-related disease e.g.  
PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
XX  
PS Claim 1; Page 58; 44pp; English.  
XX  
CC The invention relates to a method for prevention and/or treatment of an  
CC amyloid-related disease which comprises administration of an all-D-  
CC amyloid-beta peptide. The method is used for preventing and/or treating  
CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
CC the mammal; and reducing or inhibiting the formation of plaques. It is  
CC also used for treating AA (reactive) amyloid diseases including  
CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
CC disease. AA deposits are also produced as a result of chronic microbial  
CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
CC present sequence is an Abeta peptide used to illustrate the method of the  
CC invention  
XX  
SQ Sequence 7 AA;  
Query Match 100.0%; Score 24; DB 6; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EPRH 4

Db 3 EPRH 6

RESULT 51  
ADA90925  
ID ADA90925 standard; peptide; 7 AA.  
XX  
AC ADA90925;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Solid-phase synthesis heptapeptide #2.  
XX  
KW antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
KW nontropic; antiparkinsonian; gene therapy; amyloidogenesis;  
KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
KW neuronal disorder; aging.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO2003070760-A2.  
XX  
PD 28-AUG-2003.  
XX  
PF 20-FEB-2003; 2003WO-EP001759.  
XX  
PR 20-FEB-2002; 2002EP-00003844.  
XX  
PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
XX (MORP-) MORPHOSYS AG.  
XX  
PI Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
XX  
WPI; 2003-663848/62.  
XX  
XX  
PT New antibody molecule capable of specifically recognizing two regions of  
PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
PT diseases associated with amyloidogenesis or amyloid-plaque formation  
PT (e.g. dementia).  
XX  
XX Example 12; Page 82; 312pp; English.  
XX  
CC The present invention describes an antibody molecule (I) capable of  
CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
CC Ser-Gly-Tyr ADA9886 or its fragment, and the second region comprises the  
CC amino acid sequence Val-His-His-Gln-Lys-Leu-Phe-Phe-Ala-Glu-Asp-Val-  
CC Gly ADA8987 or its fragment. Also described: (1) a nucleic acid molecule  
CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
CC cell comprising the vector of (2); (4) preparing (1), comprising  
CC culturing the host cell of (3) under conditions that allow synthesis of  
CC (1) and recovering (1) from the culture; (5) a composition comprising (1)  
CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
CC (1); (8) testing the resulting Fab optimisation library by panning  
CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
CC of selected, optimised clones; (11) preparing a pharmaceutical  
CC composition, comprising optimisation of (1), and formulating the  
CC optimised antibody/antibody molecule with a carrier; and (12) a  
CC pharmaceutical composition prepared by method (8). (1) has  
CC neuroprotective, nontropic and antiparkinsonian activities, and can be  
CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
CC vector or host is useful in preparing a pharmaceutical composition for  
CC the prevention and/or treatment of a disease associated with  
CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
CC may also be used in preparing a diagnostic composition for the detection  
CC of the disease mentioned above. The antibody is used for the

CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 7 AA;

Query Match 100.0%; Score 24; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 52  
 ADA90142  
 ID ADA90142 standard; peptide; 7 AA.  
 XX  
 AC ADA90142;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Anti-Abeta antibody related amino acid sequence SEQ ID NO:257.  
 XX  
 KW antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
 KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
 KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
 KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
 KW neuronal disorder; aging.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO2003070760-A2.  
 XX  
 PD 28-AUG-2003.  
 XX  
 XX 20-FEB-2003; 2003WO-EP001759.  
 XX  
 PR 20-FEB-2002; 2002EP-00003844.  
 XX  
 PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 PA (MORP-) MORPHOSYS AG.  
 XX  
 FI Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
 PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
 XX  
 DR WPI; 2003-663848/62.  
 XX  
 XX New antibody molecule capable of specifically recognizing two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 FT diseases associated with amyloidogenesis or amyloid-plaque formation  
 PT (e.g. dementia).  
 XX  
 XX Disclosure; Page 259; 312pp; English.  
 PS  
 XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA9886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA9887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (i); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (i), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (I) and recovering (I) from the culture; (5) a composition comprising (I)

CC or an antibody molecule produced by method (4); (6) a kit comprising (I),  
 CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (1); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta4/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (1), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (I) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 7 AA;

Query Match 100.0%; Score 24; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 53  
 ADA90141  
 ID ADA90141 standard; peptide; 7 AA.  
 XX  
 AC ADA90141;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Anti-Abeta antibody related amino acid sequence SEQ ID NO:256.  
 XX  
 KW antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
 KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
 KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
 KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
 KW neuronal disorder; aging.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO2003070760-A2.  
 XX  
 PD 28-AUG-2003.  
 XX  
 XX 20-FEB-2003; 2003WO-EP001759.  
 XX  
 PR 20-FEB-2002; 2002EP-00003844.  
 XX  
 PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 PA (MORP-) MORPHOSYS AG.  
 XX  
 FI Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
 PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
 XX  
 DR WPI; 2003-663848/62.  
 XX  
 XX New antibody molecule capable of specifically recognizing two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 FT diseases associated with amyloidogenesis or amyloid-plaque formation  
 PT (e.g. dementia).  
 XX  
 XX Disclosure; Page 259; 312pp; English.  
 PS  
 XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA9886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA9887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (i); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (i), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (I) and recovering (I) from the culture; (5) a composition comprising (I)

PT diseases associated with amyloidogenesis or amyloid-plaque formation  
 XX (e.g. dementia).

XX Disclosure; Page 257; 312pp; English.

XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (1), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (1) and recovering (1) from the culture; (5) a composition comprising (1)  
 CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
 CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (1); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (1), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (1) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.

XX Sequence 7 AA;

Query Match 100.0%; Score 24; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 EPRH 4  
 ||||  
 Db 2 EPRH 5

RESULT 54  
 ADA90924

ID ADA90924 standard; peptide; 7 AA.

XX ADA90924;

XX 20-NOV-2003 (first entry)

XX Solid-phase synthesis heptapeptide #1.

XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
 KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
 KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
 KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
 KW neuronal disorder; aging.

XX Synthetic.

OS Homo sapiens.

XX WO2003070760-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-EP001759.

XX 20-FEB-2002; 2002EP-00003844.

XX (HOFF) HOFFMANN LA ROCHE & CO AG F.  
 PA (MORP-) MORPHOSYS AG.

XX Bardeff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;

PI Loehning C, Loetscher H, Nordstedt C, Rothe C;

XX WPI; 2003-663848/62.

XX New antibody molecule capable of specifically recognising two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 PT diseases associated with amyloidogenesis or amyloid-plaque formation  
 PT (e.g. dementia).

XX Example 12; Page 82; 312pp; English.

XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (1), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (1) and recovering (1) from the culture; (5) a composition comprising (1)  
 CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
 CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (1); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (1), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (1) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.

XX Sequence 7 AA;

Query Match 100.0%; Score 24; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 EPRH 4  
 ||||  
 Db 2 EPRH 5

RESULT 55

ADA90171

ID ADA90171 standard; peptide; 7 AA.

XX ADA90171;

XX 20-NOV-2003 (first entry)

XX Anti-Abeta antibody related amino acid sequence SEQ ID NO:286.

XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
 KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
 KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
 KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
 KW neuronal disorder; aging.  
 XX Synthetic.  
 OS Homo sapiens.  
 XX WO2003070760-A2.  
 PN 28-AUG-2003.  
 XX 20-FEB-2003; 2003WO-EP001759.  
 XX 20-FEB-2002; 2002EP-00003844.  
 PR (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 PA (MORP-) MORPHOSYS AG.  
 XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
 PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
 XX WPI; 2003-663848/62.  
 DR New antibody molecule capable of specifically recognizing two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 PT diseases associated with amyloidogenesis or amyloid-plaque formation  
 PT (e.g. dementia).  
 XX Disclosure; Page 264; 312pp; English.  
 XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (1), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (1) and recovering (1) from the culture; (5) a composition comprising (1)  
 CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
 CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (1); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta4/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (1), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (1) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (1), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX Sequence 7 AA;  
 SQ Query Match 100.0%; Score 24; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 Db 1 EFRH 4  
 RESULT 56  
 ADJ71565  
 ID ADJ71565 standard; peptide; 7 AA.  
 XX  
 AC ADJ71565;  
 XX 06-MAY-2004 (first entry)  
 DT  
 XX N-terminal APP peptide C-terminal fragment, SEQ ID 228.  
 DE  
 XX Neurotropic; Neuroprotective; Vaccine; beta Amyloid;  
 KW amyloid precursor protein; APP; Alzheimer's disease.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2004013172-A2.  
 PN 12-FEB-2004.  
 XX 18-JUL-2003; 2003WO-EP007833.  
 PF 24-JUL-2002; 2002EP-00447147.  
 PR 06-AUG-2002; 2002US-0401497P.  
 XX (INNO-) INNOGENETICS NV.  
 PA  
 XX Delacourte A, Sergeant N;  
 PI WPI; 2004-180423/17.  
 DR New beta-amyloid or amyloid precursor protein preparation, useful as a  
 PT prophylactic vaccine or a therapeutic for preventing or treating a  
 PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
 PT Alzheimer's disease.  
 XX Claim 7; Page 67; 104pp; English.  
 PS The present invention relates to preparations (I) comprising a beta-  
 CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
 CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
 CC fragment. The beta-amyloid or APP preparations are useful for  
 CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
 CC prophylactic vaccine for the prevention, or as a therapeutic for the  
 CC treatment of a disease associated with beta-amyloid formation and/or  
 CC aggregation, such as Alzheimer's disease.  
 XX Sequence 7 AA;  
 SQ Query Match 100.0%; Score 24; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 EFRH 4  
 Db 4 EFRH 7  
 RESULT 57  
 ADJ71380  
 ID ADJ71380 standard; peptide; 7 AA.  
 XX  
 AC ADJ71380;  
 XX 06-MAY-2004 (first entry)  
 DT  
 XX N-terminal truncated beta-amyloid peptide, SEQ ID 43.  
 DE  
 XX



KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;  
KW amyloid precursor protein; APP; Alzheimer's disease.

OS Homo sapiens.

FH Key Location/Qualifiers

FT Modified-site 1 /note= "Pyroglutamic acid"

PN WO2004013172-A2.

XX 12-FEB-2004.

XX 18-JUL-2003; 2003WO-EP007833.

XX 24-JUL-2002; 2002EP-00447147.

PR 06-AUG-2002; 2002US-0401497P.

XX (INNO-) INNOGENETICS NV.

XX Delacourte A, Sergeant N;

XX WPI; 2004-180423/17.

XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.

XX Claim 4; Page 62; 104pp; English.

XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.

XX Sequence 7 AA;

Query Match 100.0%; Score 24; DB 8; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4

DB |||||  
1 EFRH 4

RESULT 58

ADJ71341

ID ADJ71341 standard; peptide; 7 AA.

XX AC ADJ71341;

XX 06-MAY-2004 (first entry)

XX N-terminal truncated beta-amyloid peptide, SEQ ID 4.

XX Nootropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Modified-site 1 /note= "Methylated"

XX WO2004013172-A2.

XX 12-FEB-2004.

XX 18-JUL-2003; 2003WO-EP007833.

XX 24-JUL-2002; 2002EP-00447147.

PR 06-AUG-2002; 2002US-0401497P.

XX (INNO-) INNOGENETICS NV.

XX Delacourte A, Sergeant N;

XX WPI; 2004-180423/17.

XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.

XX Claim 4; Page 61; 104pp; English.

XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.

XX Sequence 7 AA;

Query Match 100.0%; Score 24; DB 8; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4

DB |||||  
3 EFRH 6

RESULT 59

ADJ71367

ID ADJ71367 standard; peptide; 7 AA.

XX AC ADJ71367;

XX 06-MAY-2004 (first entry)

XX N-terminal truncated beta-amyloid peptide, SEQ ID 30.

XX Nootropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX OS Homo sapiens.

XX WO2004013172-A2.

XX 12-FEB-2004.

XX 18-JUL-2003; 2003WO-EP007833.

XX 24-JUL-2002; 2002EP-00447147.

PR 06-AUG-2002; 2002US-0401497P.

XX (INNO-) INNOGENETICS NV.

XX Delacourte A, Sergeant N;

XX WPI; 2004-180423/17.

XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.



CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiac, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.

XX SQ Sequence 7 AA;

Query Match 100.0%; Score 24; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 Db ||||  
 3 EFRH 6

RESULT 62

AD082412  
 ID AD082412 standard; peptide; 7 AA.

AC ADQ82412;

XX 21-OCT-2004 (first entry)

DE Natural N-terminal amyloid-beta (AB42) peptide #2.

XX amyloid-beta peptide; AB42 peptide; mimotope; vaccine;  
 KW Alzheimer's disease.

XX Unidentified.

XX WO2004062556-A2.

XX 29-JUL-2004.

XX 13-JAN-2004; 2004WO-EF000162.

XX 14-JAN-2003; 2003AT-00000036.

PR 17-SEP-2003; 2003AT-00001464.

XX (MATT/) MATTNER F.

PA Mattner F;

XX WPI; 2004-561715/54.

XX Use of a compound having a binding capacity to an antibody specific for  
 PT the natural N-terminal AB42 sequence, for preparing a vaccine for

PT preventing and treating Alzheimer's disease.

XX Example 2; Page 12; 29pp; English.

XX The invention comprises peptides which mimic the N-terminal region of  
 CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of  
 CC the invention have the capacity to bind to an antibody which is specific  
 CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)  
 CC of the invention are useful in the preparation of a vaccine for  
 CC Alzheimer's disease. The present amino acid sequence represents the  
 CC natural N-terminal AB42 peptide.

XX Sequence 7 AA;

Query Match 100.0%; Score 24; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 Db ||||  
 4 EFRH 7

RESULT 63

ADS09217  
 ID ADS09217 standard; peptide; 7 AA.

XX ADS09217;

AC 16-DEC-2004 (first entry)

DE Amyloid beta 1-7 peptide.

XX antibacterial; vaccine; immunogenic composition; cholera holotoxin; CT;  
 KW immunogenicity; heat labile toxin; pertussis toxin; A sub-unit;  
 KW amyloid beta; human.

XX Homo sapiens.

XX WO2004083251-A2.

PN 30-SEP-2004.

XX 11-MAR-2004; 2004WO-US007673.

XX 17-MAR-2003; 2003US-0455214P.

XX (AMHP ) WYETH HOLDINGS CORP.

XX Hagen M;

XX WPI; 2004-699805/68.

XX Immunogenic composition for immunizing mammalian host against cholera,  
 PT Escherichia coli and pertussis, comprises a mutated cholera holotoxin  
 PT subunit, Escherichia coli heat labile toxin, pertussis toxin and their  
 PT covalent antigens.

XX Example 5; SEQ ID NO 8; 82pp; English.

XX The invention describes an immunogenic composition (I) comprising a  
 CC cholera holotoxin (CT) and an antigen covalently associated with CT. CT  
 CC comprises A subunit (CT-A) having a mutation at amino acid residue 29 of  
 CC a sequence (S1) of 240 amino acids fully defined in the specification,  
 CC where the mutation is not aspartic acid, where CT increases  
 CC immunogenicity of the antigen, (b) CT and an antigen covalently  
 CC associated with CT, where CT comprises one or more mutations in CT-A,  
 CC where CT increases immunogenicity of the antigen, (c) Escherichia coli  
 CC heat labile toxin (LT) and an antigen covalently associated with LT,  
 CC where LT increases immunogenicity of the antigen, or (d) a pertussis  
 CC toxin (PT) and an antigen covalently associated with PT, where PT  
 CC increases immunogenicity of the antigen. Isolated and purified CT, LT and  
 CC PT polynucleotides and polypeptides, are also disclosed. (I) is useful

CC for immunising a mammalian host against cholera, Escherichia coli,  
 CC Bordetella pertussis, which involves administering (I) to the host. (I)  
 CC has reduced or minimal toxicity. This is the amino acid sequence of an  
 CC amyloid beta 1-7 peptide used in the creation of holotoxin conjugates.  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 24; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 EFRH 4  
 Db 3 EFRH 6  
 RESULT 64  
 AAW70865  
 ID AAW70865 standard; peptide; 8 AA.  
 AC AAW70865;  
 DT 04-FEB-1999 (first entry)  
 XX Beta-amyloid peptide to create a monoclonal antibody.  
 DE  
 KW Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;  
 KW amyloid deposit; Alzheimer's disease.  
 XX Synthetic.  
 OS Homo sapiens.  
 OS  
 PN W09844955-A1.  
 XX 15-OCT-1998.  
 XX  
 XX 09-APR-1998; 98WO-US006900.  
 XX  
 XX 09-APR-1997; 97US-0041850P.  
 XX (MIND-) MINDSET LTD.  
 PA (MCIN/) MCINNIS P A.  
 XX Chain DG;  
 XX WPI; 1998-594476/50.  
 XX Preventing or inhibiting progression of Alzheimer's Disease - comprises  
 PT use of recombinant DNA encoding an antibody specific for the N- or C-  
 PT terminus of an amyloid-beta peptide.  
 XX Example 1; Page 46; 58pp; English.  
 PS  
 XX The present sequence represents a peptide derived from beta-amyloid  
 CC precursor protein (beta-APP, see AAW70863). The peptide is a beta-amyloid  
 CC peptide and is used to produce a monoclonal antibody designated  
 CC antineurin N1/7. The specification describes a method for prevention or  
 CC inhibition of progression of Alzheimer's disease. The method comprises  
 CC administering a composition comprising a recombinant DNA molecule  
 CC containing a gene encoding a recombinant antibody end-specific for the N-  
 CC terminus or the C-terminus of an amyloid-beta peptide, operably linked to  
 CC a promoter which is expressed in the central nervous system. The  
 CC recombinant antibody molecules prevent the accumulation of beta-amyloid  
 CC peptides in the extracellular space, interstitial fluid and cerebrospinal  
 CC fluid and the aggregation of such peptides into amyloid deposits in the  
 CC brain. They also inhibit the progression of Alzheimer's disease by  
 CC inhibiting the interaction of beta-amyloid peptides mediating Alzheimer's  
 CC disease induced neurotoxicity and inhibiting the Alzheimer's disease  
 CC induced complement activation and cytokine release involved in the  
 CC inflammatory process  
 XX Sequence 8 AA;  
 SQ

Query Match 100.0%; Score 24; DB 2; Length 8;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 EFRH 4  
 Db 3 EFRH 6  
 RESULT 65  
 AAU78518  
 ID AAU78518 standard; peptide; 8 AA.  
 XX  
 AC AAU78518;  
 XX  
 DT 18-JUN-2002 (first entry)  
 XX N terminus of beta amyloid.  
 XX Alzheimer's disease; beta amyloid precursor protein; mouse; BACE;  
 KW beta-site APP cleaving enzyme; nootropic; neuroprotective;  
 KW beta-site amyloid precursor protein (APP)-cleaving enzyme; APP;  
 KW BACE secretase/sheddase; neurodegenerative disorder.  
 XX Mus sp.  
 OS  
 PN W0200210354-A2.  
 XX  
 PD 07-FEB-2002.  
 XX  
 XX 01-AUG-2001; 2001WO-CA001118.  
 XX  
 XX 01-AUG-2000; 2000CA-02313828.  
 XX (RECL-) INST RECH CLINIQUES MONTREAL.  
 XX Seidah NG, Chretien M, Cromlish JA;  
 XX WPI; 2002-280632/32.  
 XX  
 XX Modulating activity of beta-site amyloid precursor protein-cleaving  
 PT enzyme secretase/sheddase for treatment of neurodegenerative disorder  
 PT characterized by generation of Abeta protein, by preventing cleavage of  
 PT enzyme.  
 XX Disclosure; Page 28; 64pp; English.  
 PS  
 XX This invention relates to a novel method for modulating activity of beta-  
 CC site amyloid precursor protein (APP)-cleaving enzyme (BACE)  
 CC secretase/sheddase. Cleavage of BACE by this enzyme results in the  
 CC generation of a soluble BACE which enhances the production of the  
 CC amyloidogenic peptide Abeta which has been shown to be involved in the  
 CC aetiology of Alzheimer's disease. Inhibition of BACE secretase can be  
 CC achieved by administration of an antisense nucleotide molecule capable of  
 CC hybridising with BACE mRNA, by using a ribozyme that targets and degrades  
 CC BACE secretase mRNA, with a peptide that can interfere with binding of  
 CC the enzyme with BACE or using an antibody or antagonist that can function  
 CC as an inhibitor of BACE secretase activation. The methods of the  
 CC invention modulate the activity of BACE secretase/sheddase by preventing  
 CC cleavage of BACE, which is useful for the treatment of a  
 CC neurodegenerative disorder characterised by the generation of Abeta  
 CC protein, especially Alzheimer's disease. The invention also comprises a  
 CC method for identification of an agent that can alter the ability of BACE  
 CC secretase to associate with and process a known substrate, this method  
 CC can be used for high throughput screening of candidate molecules. The  
 CC invention also comprises a method for determining whether an individual  
 CC is at risk of developing a neurodegenerative disorder characterised by  
 CC the generation of Abeta protein by measuring the levels of BACE C  
 CC terminal cleavage products in a sample or tissue where an increase in  
 CC cleavage products indicates a person at risk. The present sequence  
 CC represents the N terminal of a beta amyloid protein of the invention  
 XX Sequence 8 AA;  
 SQ

Query Match 100.0%; Score 24; DB 5; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
DB 3 EFRH 6

RESULT 66  
ID ABP70740 standard; peptide; 8 AA.

AC ABP70740;  
XX 15-MAY-2003 (first entry)  
XX Antigenic peptide, SEQ ID 1.  
DE Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;  
KW plaque-forming disease; Alzheimer's disease; SAA amyloidosis;  
KW hereditary Icelandic syndrome; senility; multiple myeloma;  
KW Creutzfeldt-Jakob disease; Kuru; Gerstmann-Strausler-Scheinker disease;  
KW fatal familial insomnia; scrapie; bovine spongiform encephalitis;  
KW antigenic; multiantigen.

OS Synthetic.

XX WO2003000719-A2.

PN 03-JAN-2003.

XX 20-JUN-2002; 2002WO-US019567.

XX 20-JUN-2001; 2001US-0299201P.

PR 12-APR-2002; 2002US-037171P.

XX (UYRA-) UNIV RAMOT.

PA (MCIN/) MCINNIS P.

XX Mcinnis P, Solomon B;

PI WPI; 2003-239139/23.

XX Antigenic product has dendritic polymer built on core molecule having  
DR terminal functional groups to which antigenic peptide that has epitope of  
PT deposit-forming polypeptide involved in plaque-forming disease is joined.

XX Claim 7; Page 42; 70pp; English.

PS The present invention relates to antigenic products (A), comprising a  
XX dendritic polymer built on a core molecule which is at least difunctional  
CC to provide branching and containing up to 16 terminal functional groups  
CC to which an antigenic peptide, that comprises an epitope of a deposit-  
CC forming polypeptide involved in plaque-forming disease, is joined by  
CC covalent bonds. The antigenic products are useful for eliciting an immune  
CC response against a deposit-forming polypeptide involved in a plaque-  
CC forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,  
CC hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-  
CC Jakob disease, Kuru, Gerstmann-Strausler-Scheinker disease, fatal  
CC familial insomnia, scrapie or bovine spongiform encephalitis, by  
CC administering the antigenic product to a subject in need of it. The  
CC present sequence is one such antigenic peptide, which can be used in the  
CC antigenic product of the invention (see ABP70747)

XX Sequence 8 AA;

Query Match 100.0%; Score 24; DB 6; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4

DB 3 EFRH 6

RESULT 67

ADB75162  
ID ADB75162 standard; peptide; 8 AA.

XX ADB75162;

XX 04-DEC-2003 (first entry)

XX Human amyloid beta peptide SEQ ID NO:3.

XX antibody; amyloid beta peptide; amyloid beta; neurotropic; neuroprotective;  
KW antibody therapy; Alzheimer's disease; mild cognitive impairment;  
KW cerebral amyloid angiopathy; congophilic angiopathy; Down's syndrome;  
KW inclusion body myositis; neurotoxicity; beta amyloid precursor protein;  
KW APP; human.

XX Homo sapiens.

XX WO2003074081-A1.

XX 12-SEP-2003.

XX 21-OCT-2002; 2002WO-US031590.

XX 28-FEB-2002; 2002US-00084380.

XX (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.

XX Chain DG;

XX WPI; 2003-731651/69.

XX New antibody that is targeted to amyloid beta peptide, or its fragment,  
PT useful for treating a subject having Alzheimer's disease, or a disease or  
PT disorder characterized by amyloid beta deposition, e.g. cognitive  
PT impairment or dementia.

PS Disclosure; Page 18; 63pp; English.

XX The present invention describes an antibody that is targeted to amyloid  
CC beta peptide, or its fragment. Also described: (1) an antibody that is  
CC free-end specific and is targeted to: (a) the free N-terminus of amyloid  
CC beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the  
CC first amino acid of amyloid beta-peptide is aspartate; (c) the free N-  
CC terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;  
CC (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,  
CC Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-  
CC terminus-truncated amyloid beta-peptide fragment; (2) a single chain or  
CC artificial antibody that is free-end specific and is targeted to the free  
CC C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a  
CC pharmaceutical composition comprising the antibody, and a carrier. The  
CC antibody targeted to amyloid beta peptide has neurotropic and  
CC neuroprotective activities, and can be used in antibody therapy. The  
CC antibody or its fragment is useful for manufacturing a medicament for  
CC treating a subject having Alzheimer's disease, or a disease or disorder  
CC characterised by amyloid beta deposition (e.g. mild cognitive impairment,  
CC cerebral amyloid angiopathy or congophilic angiopathy, Alzheimer's  
CC disease associated with Down's syndrome, or inclusion body myositis), or  
CC for delaying, inhibiting or suppressing accumulation of amyloid beta  
CC peptide, or the neurotoxicity of amyloid beta peptide or its fragment.  
CC Amyloid beta peptide are derived from beta amyloid precursor protein  
CC (APP). The present sequence represents an amyloid beta peptide which is  
CC used in the exemplification of the present invention.

XX Sequence 8 AA;

Query Match 100.0%; Score 24; DB 7; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db |||||  
3 EFRH 6

RESULT 68  
ADB75174  
ID ADB75174 standard; peptide; 8 AA.  
XX AC ADB75174;  
XX DT 04-DEC-2003 (first entry)  
XX DE Amyloid beta peptide related peptide.  
XX antitbody; amyloid beta peptide; amyloid beta; neurotropic; neuroprotective;  
KW antibody therapy; Alzheimer's disease; mild cognitive impairment;  
KW cerebral amyloid angiopathy; congophilic angiopathy; Down's syndrome;  
KW inclusion body myositis; neurotoxicity; beta amyloid precursor protein;  
KW APP; human.  
XX Synthetic.  
OS Homo sapiens.  
XX Key Location/Qualifiers  
FT Modified-site 7 /note= "aminohexanoate"  
FT Modified-site 8  
FT /label= amidated  
XX W02003074081-A1.  
XX 12-SEP-2003.  
XX 21-OCT-2002; 2002WO-US031590.  
XX 28-FEB-2002; 2002US-00084380.  
XX (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.  
XX Chain DG;  
XX WPI; 2003-731651/69.  
XX New antibody that is targeted to amyloid beta peptide, or its fragment,  
PT useful for treating a subject having Alzheimer's disease, or a disease or  
PT disorder characterized by amyloid beta deposition, e.g. cognitive  
PT impairment or dementia.  
XX Example 2; Page 29; 63pp; English.  
XX The present invention describes an antibody that is targeted to amyloid  
CC beta peptide, or its fragment. Also described: (1) an antibody that is  
CC free-end specific and is targeted to: (a) the free N-terminus of amyloid  
CC beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the  
CC first amino acid of amyloid beta-peptide is aspartate; (c) the free N-  
CC terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;  
CC (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,  
CC Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-  
CC terminus-truncated amyloid beta-peptide fragment; (2) a single chain or  
CC artificial antibody that is free-end specific and is targeted to the free  
CC C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a  
CC pharmaceutical composition comprising the antibody, and a carrier. The  
CC antibody targeted to amyloid beta peptide has neurotropic and  
CC neuroprotective activities, and can be used in antibody therapy. The  
CC antibody or its fragment is useful for manufacturing a medicament for  
CC treating a subject having Alzheimer's disease, or a disease or disorder  
CC characterised by amyloid beta deposition (e.g. mild cognitive impairment,  
CC cerebral amyloid angiopathy or congophilic angiopathy, Alzheimer's  
CC disease associated with Down's syndrome, or inclusion body myositis), or  
CC for delaying, inhibiting or suppressing accumulation of amyloid beta  
CC peptide, or the neurotoxicity of amyloid beta peptide or its fragment.

CC Amyloid beta peptides are derived from beta amyloid precursor protein  
CC (APP). The present sequence represents an amyloid beta peptide related  
CC peptide, which is used in an example from the present invention.  
XX Sequence 8 AA;  
SQ Query Match 100.0%; Score 24; DB 7; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db |||||  
3 EFRH 6

RESULT 69  
ADJ71355  
ID ADJ71355 standard; peptide; 8 AA.  
XX AC ADJ71355;  
XX DT 06-MAY-2004 (first entry)  
XX N-terminal truncated beta-amyloid peptide, SEQ ID 18.  
XX Neurotropic; Neuroprotective; Vaccine; beta Amyloid;  
KW amyloid precursor protein; APP; Alzheimer's disease.  
XX Homo sapiens.  
XX Key Location/Qualifiers  
FT Modified-site 1 /note= "Optionally methylated"  
FT WO2004013172-A2.  
XX 12-FEB-2004.  
XX 18-JUL-2003; 2003WO-EP007833.  
XX 24-JUL-2002; 2002EP-00447147.  
XX 06-AUG-2002; 2002US-0401497P.  
XX (INNO-) INNOGENETICS NV.  
XX Delacourte A, Sergeant N;  
XX WPI; 2004-180423/17.  
XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
PT prophylactic vaccine or a therapeutic for preventing or treating a  
PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
PT Alzheimer's disease.  
XX Claim 4; Page 61; 104pp; English.  
XX The present invention relates to preparations (I) comprising a beta-  
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
CC fragment. The beta-amyloid or APP preparations are useful for  
CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
CC prophylactic vaccine for the prevention, or as a therapeutic for the  
CC treatment of a disease associated with beta-amyloid formation and/or  
CC aggregation, such as Alzheimer's disease.  
XX Sequence 8 AA;  
SQ Query Match 100.0%; Score 24; DB 8; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db |||||

```

Db      2 EFRH 5

RESULT 70
ADJ71368
ID   ADJ71368 standard; peptide; 8 AA.
XX
XX   ADJ71368;
XX
XX   06-MAY-2004 (first entry)
XX
XX   N-terminal truncated beta-amyloid peptide, SEQ ID 31.
XX
XX   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
XX   Homo sapiens.
OS
XX   WO2004013172-A2.
PN
XX   12-FEB-2004.
PD
XX   18-JUL-2003; 2003WO-EP007833.
PF
XX   24-JUL-2002; 2002EP-00447147.
PR
XX   06-AUG-2002; 2002US-0401497P.
PP
XX   (INNO-) INNOGENETICS NV.
PA
XX   Delacourte A, Sergeant N;
XX   WPI; 2004-180423/17.
XX
XX   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
XX   Claim 4; Page 61; 104pp; English.
XX
XX   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
XX   Sequence 8 AA;
XX
XX   Query Match      100.0%; Score 24; DB 8; Length 8;
XX   Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX   Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
        ||||
Db      1 EFRH 4

RESULT 71
ADJ71575
ID   ADJ71575 standard; peptide; 8 AA..
XX
XX   ADJ71575;
XX
XX   06-MAY-2004 (first entry)
XX
XX   N-terminal APP peptide C-terminal fragment, SEQ ID 238.
XX
XX   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
XX

```





Db	 5 EFRH 8	
RESULT 75		
ADQ82413		
ID	ADQ82413 standard; peptide; 8 AA.	
XX	AC	
XX	ADQ82413;	
XX	21-OCT-2004 (first entry)	
XX	Natural N-terminal amyloid-beta (AB42) peptide #3.	
XX	amyloid-beta peptide; AB42 peptide; mimotope; vaccine;	
XX	Alzheimer's disease.	
XX	Unidentified.	
XX	WO2004062556-A2.	
XX	29-JUL-2004.	
XX	13-JAN-2004; 2004WO-EP000162.	
XX	14-JAN-2003; 2003AT-00000036.	
XX	17-SEP-2003; 2003AT-00001464.	
XX	(MATT/) MATTNER F.	
XX	Mattner F;	
XX	WPI; 2004-561715/54.	
XX	Use of a compound having a binding capacity to an antibody specific for	
XX	the natural N-terminal AB42 sequence, for preparing a vaccine for	
XX	preventing and treating Alzheimer's disease.	
XX	Example 2; Page 12; 29pp; English.	
XX	The invention comprises peptides which mimic the N-terminal region of	
XX	amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of	
XX	the invention have the capacity to bind to an antibody which is specific	
XX	for the N-terminal region of the AB42 peptide. The peptides (mimotopes)	
XX	of the invention are useful in the preparation of a vaccine for	
XX	Alzheimer's disease. The present amino acid sequence represents the	
XX	natural N-terminal AB42 peptide.	
XX	Sequence 8 AA;	
Query Match	100.0%; Score 24; DB 8; Length 8;	
Best Local Similarity	100.0%; Pred. No. 1.8e+06;	
Matches	4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 EFRH 4	
Db	 5 EFRH 8	
RESULT 76		
ABP70741		
ID	ABP70741 standard; peptide; 9 AA.	
XX	AC	
XX	ABP70741;	
XX	15-MAY-2003 (first entry)	
XX	Antigenic peptide, SEQ ID 2.	
XX	Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;	
XX	plaque-forming disease; Alzheimer's disease; SAA amyloidosis;	
XX	hereditary Icelandic syndrome; senility; multiple myeloma;	
XX	Creutzfeldt-Jakob disease; Kuru; Gerstmann-Strausler-Scheinker disease;	
XX	fatal familial insomnia; scrapie; bovine spongiform encephalitis;	
XX	antigenic; multiantigen.	
XX	Synthetic.	
XX	WO2003000719-A2.	
XX	03-JAN-2003.	
XX	20-JUN-2002; 2002WO-US019567.	
XX	20-JUN-2001; 2001US-0299201P.	
XX	12-APR-2002; 2002US-0371717P.	
XX	(UYRA-) UNIV RAMOT.	
XX	(MCIN/) MCINNIS P.	
XX	Mcinnis P, Solomon B;	
XX	WPI; 2003-239139/23.	
XX	Antigenic product has dendritic polymer built on core molecule having	
XX	terminal functional groups to which antigenic peptide that has epitope of	
XX	deposit-forming polypeptide involved in plaque-forming disease is joined.	
XX	Disclosure; Page 8; 70pp; English.	
XX	The present invention relates to antigenic products (A), comprising a	
XX	dendritic polymer built on a core molecule which is at least difunctional	
XX	to provide branching and containing up to 16 terminal functional groups	
XX	to which an antigenic peptide, that comprises an epitope of a deposit-	
XX	forming polypeptide involved in plaque-forming disease, is joined by	
XX	covalent bonds. The antigenic products are useful for eliciting an immune	
XX	response against a deposit-forming polypeptide involved in a plaque-	
XX	forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,	
XX	hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-	
XX	Jakob disease, Kuru, Gerstmann-Strausler-Scheinker disease, fatal	
XX	familial insomnia, scrapie or bovine spongiform encephalitis, by	
XX	administering the antigenic product to a subject in need of it. The	
XX	present sequence is one such antigenic peptide, which was used to	
XX	illustrate the invention	
XX	Sequence 9 AA;	
Query Match	100.0%; Score 24; DB 6; Length 9;	
Best Local Similarity	100.0%; Pred. No. 1.8e+06;	
Matches	4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 EFRH 4	
Db	 3 EFRH 6	
RESULT 77		
ADA89886		
ID	ADA89886 standard; peptide; 9 AA.	
XX	AC	
XX	ADA89886;	
XX	20-NOV-2003 (first entry)	
XX	Beta-A4 first region peptide SEQ ID NO:1.	
XX	antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;	
XX	nootropic; antiparkinsonian; gene therapy; amyloidogenesis;	
XX	amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;	
XX	Alzheimer's disease; motor neuropathy; Down's syndrome;	
XX	Creutzfeldt Jakob disease; hereditary cerebral haemorrhage; amyloidosis;	
XX	Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;	
XX	neuronal disorder; aging.	
XX	Synthetic.	
XX	Homo sapiens.	

XX PN WO2003070760-A2.  
XX XX  
XX PD 28-AUG-2003.  
XX XX  
XX PF 20-FEB-2003; 2003WO-EP001759.  
XX PF  
XX PR 20-FEB-2002; 2002EP-00003844.  
XX PR  
XX XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
XX PA (MORP-) MORPHOSYS AG.  
XX PA  
XX PI Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
XX PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
XX XX WPI; 2003-663848/62.  
XX DR  
XX XX  
XX XX New antibody molecule capable of specifically recognizing two regions of  
PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
PT diseases associated with amyloidogenesis or amyloid-plaque formation  
PT (e.g. dementia).  
XX PT  
XX PS Claim 1; Page 99; 312pp; English.  
XX XX  
XX CC The present invention describes an antibody molecule (I) capable of  
CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
CC cell comprising the vector of (2); (4) preparing (1), comprising  
CC culturing the host cell of (3) under conditions that allow synthesis of  
CC (1) and recovering (1) from the culture; (5) a composition comprising (1)  
CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
CC (1); (8) testing the resulting Fab optimisation library by panning  
CC against Abeta4/Abeta4; (9) identifying optimised clones; (10) expressing  
CC of selected, optimised clones; (11) preparing a pharmaceutical  
CC composition, comprising optimisation of (1), and formulating the  
CC optimised antibody/antibody molecule with a carrier; and (12) a  
CC pharmaceutical composition prepared by method (8). (1) has  
CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
CC vector or host is useful in preparing a pharmaceutical composition for  
CC the prevention and/or treatment of a disease associated with  
CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
CC may also be used in preparing a diagnostic composition for the detection  
CC of the disease mentioned above. The antibody is used for the  
CC disintegration of beta-amyloid plaques or for passive immunisation  
CC against beta-amyloid plaque formation. In particular, the disease is  
CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
XX present sequence is used in the exemplification of the present invention.  
XX SQ Sequence 9 AA;  
XX  
XX Query Match 100.0%; Score 24; DB 6; Length 9;  
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 1 EFRH 4  
XX Db 2 EFRH 5  
XX  
XX RESULT 78  
XX ADE36577  
XX ID ADE36577 standard; peptide; 9 AA.  
XX XX  
XX AC ADE36577;

XX XX 29-JAN-2004 (first entry)  
XX DT  
XX DE APP epitope spanning the beta-secretase cleavage site SEQ ID NO:5.  
XX XX  
XX KW immune response; beta-secretase cleavage site; amyloid precursor protein;  
XX KW APP; neurotropic; neuroprotective; vaccine; passive immunisation;  
XX KW Alzheimer's disease.  
XX XX  
XX OS Synthetic.  
XX OS Homo sapiens.  
XX XX WO2003076455-A2.  
XX PN  
XX PD 18-SEP-2003.  
XX XX  
XX PF 04-MAR-2003; 2003WO-US006388.  
XX PF  
XX PR 05-MAR-2002; 2002US-0361344P.  
XX PR  
XX PA (UYRA-) UNIV RAMOT AT TEL AVIV LTD.  
XX PA (MCIN/) MCINNIS P.  
XX PI Solomon B;  
XX PI WPI; 2003-865017/80.  
XX DR  
XX XX Immunizing composition, useful for treating Alzheimer's disease by  
PT inhibiting processing of amyloid precursor protein, also antibodies for  
PT passive immunization.  
XX PT  
XX PS Claim 5; SEQ ID NO 5; 76pp; English.  
XX XX  
XX CC The present invention describes an immunising composition (A) comprising:  
CC (a) an antigenic product (I) which induces an immune response against the  
CC beta-secretase cleavage site of amyloid precursor protein (APP); and (b)  
CC a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)  
CC a molecule (II) comprising the antigen-binding part of an antibody (Ab)  
CC directed against the beta-secretase cleavage site of APP; (2) a  
CC filamentous bacteriophage (FB) that displays (II), where this is a single  
CC -chain Ab, on its surface; and (3) a composition containing FB. (A) has  
CC neurotropic and neuroprotective activities, and can be used in vaccines or  
CC passive immunisation. (A) inhibits the cleavage of APP and so prevents  
CC the formation of beta-amyloid. (A) can be used to induce an immune  
CC response against the beta-secretase cleavage site of APP, specifically  
CC for treatment and prevention of Alzheimer's disease. The molecule (II)  
CC that contains the antigen-binding part of an Ab directed against the  
CC single-chain molecule) can be used similarly, for passive immunisation.  
XX The present sequence represents an APP epitope spanning the beta-  
XX secretase cleavage site, which is used in the exemplification of the  
XX present invention.  
XX SQ Sequence 9 AA;  
XX  
XX Query Match 100.0%; Score 24; DB 7; Length 9;  
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 1 EFRH 4  
XX Db 6 EFRH 9  
XX  
XX RESULT 79  
XX ADE36575  
XX ID ADE36575 standard; peptide; 9 AA.  
XX XX  
XX AC ADE36575;  
XX XX  
XX DT 29-JAN-2004 (first entry)  
XX XX  
XX DE Beta-amyloid (Abeta) peptide 1-9 SEQ ID NO:3.

XX immune response; beta-secretase cleavage site; amyloid precursor protein;  
 KW APP; neurotrophic; neuroprotective; vaccine; passive immunisation;  
 KW Alzheimer's disease.  
 XX Synthetic.  
 XX WO2003076455-A2.  
 XX 18-SEP-2003.  
 XX 04-MAR-2003; 2003WO-US006388.  
 XX 05-MAR-2002; 2002US-0361344P.  
 XX (UYRA-) UNIV RAMOT AT TEL AVIV LTD.  
 XX (MCIN/) MCINNIS P.  
 XX Solomon B;  
 XX WPI; 2003-865017/80.  
 XX Immunizing composition, useful for treating Alzheimer's disease by  
 PT inhibiting processing of amyloid precursor protein, also antibodies for  
 PT passive immunization.  
 XX Disclosure; SEQ ID NO 3; 76pp; English.  
 XX The present invention describes an immunising composition (A) comprising:  
 CC (a) an antigenic product (I) which induces an immune response against the  
 CC beta-secretase cleavage site of amyloid precursor protein (APP); and (b)  
 CC a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)  
 CC a molecule (II) comprising the antigen-binding part of an antibody (Ab)  
 CC directed against the beta-secretase cleavage site of APP; (2) a  
 CC filamentous bacteriophage (FB) that displays (II) where this is a single  
 CC chain Ab, on its surface; and (3) a composition containing FB. (A) has  
 CC neurotropic and neuroprotective activities, and can be used in vaccines or  
 CC passive immunisation. (A) inhibits the cleavage of APP and so prevents  
 CC the formation of beta-amyloid. (A) can be used to induce an immune  
 CC response against the beta-secretase cleavage site of APP, specifically  
 CC for treatment and prevention of Alzheimer's disease. The molecule (II)  
 CC that contains the antigen-binding part of an Ab directed against the  
 CC cleavage site, or a filamentous phage that displays such an Ab (as a  
 CC single-chain molecule) can be used similarly, for passive immunisation.  
 CC The present sequence represents a beta-amyloid (Abeta) peptide which is  
 CC used in the exemplification of the present invention.  
 XX Sequence 9 AA;  
 SQ Query Match 100.0%; Score 24; DB 7; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 EPRH 4  
 Db 3 EPRH 6  
 RESULT 80  
 ADI35862  
 ID ADI35862 standard; peptide; 9 AA.  
 AC ADI35862;  
 XX 22-APR-2004 (first entry)  
 DE Amyloid beta peptide SEQ ID NO:16.  
 XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease.  
 XX Synthetic.

PN WO2004006861-A2.  
 XX 22-JAN-2004.  
 XX 16-JUL-2003; 2003WO-US022280.  
 XX 17-JUL-2002; 2002US-0396245P.  
 XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.  
 XX Chain DG, Fitzer-Attas C;  
 XX WPI; 2004-122759/12.  
 XX New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.  
 XX Example 1; SEQ ID NO 16; 69pp; English.  
 XX The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 XX from the present invention.  
 SQ Sequence 9 AA;  
 Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 EPRH 4  
 Db 2 EPRH 5  
 RESULT 81  
 ADI35931  
 ID ADI35931 standard; peptide; 9 AA.  
 XX ADI35931;  
 AC 22-APR-2004 (first entry)  
 DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:85.  
 XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease; epitope.  
 XX Synthetic.  
 XX WO2004006861-A2.  
 XX 22-JAN-2004.  
 XX 16-JUL-2003; 2003WO-US022280.

```

XX PR 17-JUL-2002; 2002US-0396245P.
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX PT Chain DG, Fitzer-Attas C;
XX PI WPI; 2004-122759/12.
XX XX
XX PT New amyloid beta peptide, useful for preparing a composition for
XX PT preventing the formation or progression of amyloid plaques for preventing
XX PT or treating Alzheimer's disease.
XX PS Example 4; SEQ ID NO 85; 69pp; English.
XX XX
XX CC The present invention describes an isolated amyloid beta peptide or its
XX CC homologue which is selected by a method comprising: (a) determining the
XX CC binding value of each amino acid of a subsequence of amyloid beta peptide
XX CC upon binding to a HLA class I and/or class II molecule of interest; (b)
XX CC determining the resulting score of all amino acids of the subsequence,
XX CC based on the binding value of each amino acid obtained in step (1); and
XX CC (c) comparing the resulting score to a preselected value. Also described:
XX CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
XX CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
XX CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
XX CC vaccine comprising a beta amyloid or homologue peptide to an individual,
XX CC for immunisation of an individual based on the HLA haplotype of the
XX CC individual; (5) a kit for matching a vaccine comprising amyloid beta
XX CC peptide to an individual based on the HLA haplotype of the individual;
XX CC and (6) preventing the formation or progression of amyloid plaques. The
XX CC amyloid beta peptide has neuroprotective activity, and can be used in
XX CC vaccines. The amyloid beta peptide is useful for preparing a composition
XX CC for preventing the formation or progression of amyloid plaques for
XX CC preventing or treating Alzheimer's disease. The present sequence
XX CC represents an amyloid beta (Abeta) peptide, which is used in an example
XX CC from the present invention.
XX SQ Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db |||||
2 EFRH 5

RESULT 82
ADI35943
ID ADI35943 standard; peptide; 9 AA.
XX AC ADI35943;
XX DT 22-APR-2004 (first entry)
XX XX Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:97.
XX DE amyloid beta peptide; vaccine; immunisation; neuroprotective;
XX KW Alzheimer's disease; epitope.
XX OS Synthetic.
XX FN WO2004006861-A2.
XX PD 22-JAN-2004.
XX XX 16-JUL-2003; 2003WO-US022280.
XX PF 17-JUL-2002; 2002US-0396245P.
XX PR (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX PA Chain DG, Fitzer-Attas C;
XX XX WPI; 2004-122759/12.
XX PT New amyloid beta peptide, useful for preparing a composition for

```

PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

Example 6; SEQ ID NO 174; 69pp; English.

XX The present invention describes an isolated amyloid beta peptide or its  
 XX homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 DB 6 EFRH 9

RESULT 84  
 ADI35949  
 ID ADI35949 standard; peptide; 9 AA.

XX ADI35949;

XX 22-APR-2004 (first entry)

XX Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:103.

XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease; epitope.

XX Synthetic.

OS WO2004006861-A2.

PN 22-JAN-2004.

XX 16-JUL-2003; 2003WO-US022280.

XX 17-JUL-2002; 2002US-0396245P.

XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX Chain DG, Fitzer-Attas C;

XX WPI; 2004-122759/12.

XX New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

XX Example 5; SEQ ID NO 103; 69pp; English.

XX

CC The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 DB 3 EFRH 6

RESULT 85  
 ADI36012  
 ID ADI36012 standard; peptide; 9 AA.

XX ADI36012;

XX 22-APR-2004 (first entry)

XX Amyloid beta peptide SEQ ID NO:166.

XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease.

XX Synthetic.

PN WO2004006861-A2.

XX 22-JAN-2004.

XX 16-JUL-2003; 2003WO-US022280.

XX 17-JUL-2002; 2002US-0396245P.

XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX Chain DG, Fitzer-Attas C;

XX WPI; 2004-122759/12.

XX New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

XX Example 6; SEQ ID NO 166; 69pp; English.

XX The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

CC based on the binding value of each amino acids obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 Db ||||  
 2 EPRH 5

RESULT 86  
 ADI35946

ID ADI35946 standard; peptide; 9 AA.

AC ADI35946;

DT 22-APR-2004 (first entry)

DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:100.

KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease; epitope.

OS Synthetic.

PN WO2004006861-A2.

PD 22-JAN-2004.

PF 16-JUL-2003; 2003WO-US022280.

PR 17-JUL-2002; 2002US-0396245P.

PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

PI Chain DG, Fitzer-Attas C;

DR WPI; 2004-122759/12.

XX New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

PS Example 5; SEQ ID NO 100; 69pp; English.

XX The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acids obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a

CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 Db ||||  
 2 EPRH 5

RESULT 87

ADI35890

ID ADI35890 standard; peptide; 9 AA.

AC ADI35890;

DT 22-APR-2004 (first entry)

DE Amyloid beta LV/KK modification peptide SEQ ID NO:44.

KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease.

OS Synthetic.

PN WO2004006861-A2.

PD 22-JAN-2004.

PF 16-JUL-2003; 2003WO-US022280.

PR 17-JUL-2002; 2002US-0396245P.

PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

PI Chain DG, Fitzer-Attas C;

DR WPI; 2004-122759/12.

XX New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

PS Example 2; SEQ ID NO 44; 69pp; English.

XX The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acids obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The

CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.  
 XX  
 CC  
 CC Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 Db ||||  
 2 EPRH 5

RESULT 88  
 ADI35900  
 ID ADI35900 standard; peptide; 9 AA.

XX AC ADI35900;

XX DT 22-APR-2004 (first entry)

XX DE Amyloid beta LVF/EDD modification peptide SEQ ID NO:54.

XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 XX KW Alzheimer's disease.

XX OS Synthetic.

XX PN WO2004006861-A2.

XX XX 22-JAN-2004.

XX PF 16-JUL-2003; 2003WO-US022280.

XX PR 17-JUL-2002; 2002US-0396245P.

XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX PI Chain DG, Fitzer-Attas C;

XX DR WPI; 2004-122759/12.

XX PT New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

XX PS Example 2; SEQ ID NO 54; 69pp; English.

XX CC The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example

CC from the present invention.

XX SQ Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
 Db ||||  
 2 EPRH 5

RESULT 89

ADI35960

ID ADI35960 standard; peptide; 9 AA.

XX AC ADI35960;

XX DT 22-APR-2004 (first entry)

XX DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:114.

XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 XX KW Alzheimer's disease; epitope.

XX OS Synthetic.

XX PN WO2004006861-A2.

XX PD 22-JAN-2004.

XX XX 16-JUL-2003; 2003WO-US022280.

XX PR 17-JUL-2002; 2002US-0396245P.

XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX PI Chain DG, Fitzer-Attas C;

XX DR WPI; 2004-122759/12.

XX PT New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

XX PS Example 5; SEQ ID NO 114; 69pp; English.

XX CC The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX SQ Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;

Thu Nov 3 12:26:04 2005

us-10-618-856-1.max10.rag

Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0;

Qy 1 EFRH 4  
|  
|  
|  
|  
Db 3 EFRH 6

RESULT 90  
ADI35921  
ID ADI35921 standard; peptide; 9 AA.  
XX  
XX AC ADI35921;  
XX  
XX DT 22-APR-2004 (first entry)  
XX  
XX DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:75.  
XX  
XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
XX KW Alzheimer's disease; epitope.

XX OS Synthetic.  
XX  
XX PN WO2004006861-A2.  
XX  
XX PD 22-JAN-2004.  
XX  
XX PF 16-JUL-2003; 2003WO-US022280.  
XX  
XX PR 17-JUL-2002; 2002US-0396245P.  
XX  
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX PI Chain DG, Fitzer-Attas C;  
XX  
XX DR WPI; 2004-122759/12.  
XX  
XX PT New amyloid beta peptide, useful for preparing a composition for  
XX PT preventing the formation or progression of amyloid plaques for preventing  
XX PT or treating Alzheimer's disease.

XX PS Example 4; SEQ ID NO 75; 69pp; English.  
XX  
XX CC The present invention describes an isolated amyloid beta peptide or its  
XX CC homologue which is selected by a method comprising: (a) determining the  
XX CC binding value of each amino acid of a subsequence of amyloid beta peptide  
XX CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
XX CC determining the resulting score of all amino acids of the subsequence,  
XX CC based on the binding value of each amino acid obtained in step (1); and  
XX CC (c) comparing the resulting score to a preselected value. Also described:  
XX CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
XX CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
XX CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
XX CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
XX CC for immunisation of an individual based on the HLA haplotype of the  
XX CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
XX CC peptide to an individual based on the HLA haplotype of the individual;  
XX CC and (6) preventing the formation or progression of amyloid plaques. The  
XX CC amyloid beta peptide has neuroprotective activity, and can be used in  
XX CC vaccines. The amyloid beta peptide is useful for preparing a composition  
XX CC for preventing the formation or progression of amyloid plaques for  
XX CC preventing or treating Alzheimer's disease. The present sequence  
XX CC represents an amyloid beta (Abeta) peptide, which is used in an example  
XX CC from the present invention.

XX SQ Sequence 9 AA;  
Query Match 100.0%; Score 24; DB 8; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|  
|  
|  
|  
Db 3 EFRH 6

Db 2 EFRH 5

RESULT 91  
ADI35958  
ID ADI35958 standard; peptide; 9 AA.  
XX  
XX AC ADI35958;  
XX  
XX DT 22-APR-2004 (first entry)  
XX  
XX DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:112.  
XX  
XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
XX KW Alzheimer's disease; epitope.

XX OS Synthetic.  
XX  
XX PN WO2004006861-A2.  
XX  
XX PD 22-JAN-2004.  
XX  
XX PF 16-JUL-2003; 2003WO-US022280.  
XX  
XX PR 17-JUL-2002; 2002US-0396245P.  
XX  
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX PI Chain DG, Fitzer-Attas C;  
XX  
XX DR WPI; 2004-122759/12.  
XX  
XX PT New amyloid beta peptide, useful for preparing a composition for  
XX PT preventing the formation or progression of amyloid plaques for preventing  
XX PT or treating Alzheimer's disease.

XX PS Example 5; SEQ ID NO 112; 69pp; English.  
XX  
XX CC The present invention describes an isolated amyloid beta peptide or its  
XX CC homologue which is selected by a method comprising: (a) determining the  
XX CC binding value of each amino acid of a subsequence of amyloid beta peptide  
XX CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
XX CC determining the resulting score of all amino acids of the subsequence,  
XX CC based on the binding value of each amino acid obtained in step (1); and  
XX CC (c) comparing the resulting score to a preselected value. Also described:  
XX CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
XX CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
XX CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
XX CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
XX CC for immunisation of an individual based on the HLA haplotype of the  
XX CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
XX CC peptide to an individual based on the HLA haplotype of the individual;  
XX CC and (6) preventing the formation or progression of amyloid plaques. The  
XX CC amyloid beta peptide has neuroprotective activity, and can be used in  
XX CC vaccines. The amyloid beta peptide is useful for preparing a composition  
XX CC for preventing the formation or progression of amyloid plaques for  
XX CC preventing or treating Alzheimer's disease. The present sequence  
XX CC represents an amyloid beta (Abeta) peptide, which is used in an example  
XX CC from the present invention.

XX SQ Sequence 9 AA;  
Query Match 100.0%; Score 24; DB 8; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|  
|  
|  
|  
Db 3 EFRH 6

RESULT 92  
ADI35925



ID ADI35925 standard; peptide; 9 AA.  
AC ADI35925;  
XX  
XX  
DT 22-APR-2004 (first entry)  
XX  
XX Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:79.  
DE amyloid beta peptide; vaccine; immunisation; neuroprotective;  
XX Alzheimer's disease; epitope.  
XX  
XX Synthetic.  
OS  
XX WO2004006861-A2.  
PN 22-JAN-2004.  
XX  
XX 16-JUL-2003; 2003WO-US022280.  
PF  
XX 17-JUL-2002; 2002US-0396245P.  
XX  
XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.  
PA  
XX Chain DG, Fitzer-Attas C;  
PI  
XX WPI; 2004-122759/12.  
DR  
XX New amyloid beta peptide, useful for preparing a composition for  
PT preventing the formation or progression of amyloid plaques for preventing  
PT or treating Alzheimer's disease.  
XX  
PS Example 4; SEQ ID NO 79; 69pp; English.  
XX  
XX The present invention describes an isolated amyloid beta peptide or its  
CC homologue which is selected by a method comprising: (a) determining the  
CC binding value of each amino acid of a subsequence of amyloid beta peptide  
CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
CC determining the resulting score of all amino acids of the subsequence,  
CC based on the binding value of each amino acid obtained in step (1); and  
CC (c) comparing the resulting score to a preselected value. Also described:  
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
CC for immunisation of an individual based on the HLA haplotype of the  
CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
CC peptide to an individual based on the HLA haplotype of the individual;  
CC and (6) preventing the formation or progression of amyloid plaques. The  
CC amyloid beta peptide has neuroprotective activity, and can be used in  
CC vaccines. The amyloid beta peptide is useful for preparing a composition  
CC for preventing the formation or progression of amyloid plaques for  
CC preventing or treating Alzheimer's disease. The present sequence  
CC represents an amyloid beta (Abeta) peptide, which is used in an example  
CC from the present invention.  
XX  
SQ Sequence 9 AA;  
Query Match 100.0%; Score 24; DB 8; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0;  
QY 1 EFRH 4  
Db |||||  
2 EFRH 5  
RESULT 93  
ADI35968  
ID ADI35968 standard; peptide; 9 AA.  
XX  
AC ADI35968;  
XX  
DT 22-APR-2004. (first entry)

XX Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:122.  
DE  
XX  
XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
KW Alzheimer's disease; epitope.  
XX  
XX Synthetic.  
OS  
XX WO2004006861-A2.  
PN 22-JAN-2004.  
XX  
XX 16-JUL-2003; 2003WO-US022280.  
PF  
XX 17-JUL-2002; 2002US-0396245P.  
XX  
XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.  
PA  
XX Chain DG, Fitzer-Attas C;  
PI  
XX WPI; 2004-122759/12.  
DR  
XX New amyloid beta peptide, useful for preparing a composition for  
PT preventing the formation or progression of amyloid plaques for preventing  
PT or treating Alzheimer's disease.  
XX  
PS Example 5; SEQ ID NO 122; 69pp; English.  
XX  
XX The present invention describes an isolated amyloid beta peptide or its  
CC homologue which is selected by a method comprising: (a) determining the  
CC binding value of each amino acid of a subsequence of amyloid beta peptide  
CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
CC determining the resulting score of all amino acids of the subsequence,  
CC based on the binding value of each amino acid obtained in step (1); and  
CC (c) comparing the resulting score to a preselected value. Also described:  
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
CC for immunisation of an individual based on the HLA haplotype of the  
CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
CC peptide to an individual based on the HLA haplotype of the individual;  
CC and (6) preventing the formation or progression of amyloid plaques. The  
CC amyloid beta peptide has neuroprotective activity, and can be used in  
CC vaccines. The amyloid beta peptide is useful for preparing a composition  
CC for preventing the formation or progression of amyloid plaques for  
CC preventing or treating Alzheimer's disease. The present sequence  
CC represents an amyloid beta (Abeta) peptide, which is used in an example  
CC from the present invention.  
XX  
SQ Sequence 9 AA;  
Query Match 100.0%; Score 24; DB 8; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0;  
QY 1 EFRH 4  
Db |||||  
2 EFRH 5  
RESULT 94  
ADI35999  
ID ADI35999 standard; peptide; 9 AA.  
XX  
XX ADI35999;  
AC  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Amyloid beta peptide SEQ ID NO:153.  
XX  
KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
KW Alzheimer's disease.

XX OS Synthetic.  
 XX PF WO2004006861-A2.  
 XX PD 22-JAN-2004.  
 XX PF 16-JUL-2003; 2003WO-US022280.  
 XX PR 17-JUL-2002; 2002US-0396245P.  
 XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.  
 XX Chain DG, Fitzer-Attas C;  
 XX WPI; 2004-122759/12.  
 XX New amyloid beta peptide, useful for preparing a composition for preventing the formation or progression of amyloid plaques for preventing or treating Alzheimer's disease.  
 XX Example 6; SEQ ID NO 153; 69pp; English.  
 XX The present invention describes an isolated amyloid beta peptide or its homologue which is selected by a method comprising: (a) determining the binding value of each amino acid of a subsequence of amyloid beta peptide upon binding to a HLA class I and/or class II molecule of interest; (b) determining the resulting score of all amino acids obtained in step (1); and (c) comparing the resulting score to a preselected value. Also described: (1) a vaccine comprising the isolated amyloid beta peptide and a carrier or diluent; (2) determining T-cell epitopes within amyloid beta peptide; (3) predicting the reaction of an individual to a vaccine; (4) matching a vaccine comprising a beta amyloid or homologue peptide to an individual, for immunisation of an individual based on the HLA haplotype of the individual; (5) a kit for matching a vaccine comprising amyloid beta peptide to an individual based on the HLA haplotype of the individual; and (6) preventing the formation or progression of amyloid plaques. The amyloid beta peptide has neuroprotective activity, and can be used in vaccines. The amyloid beta peptide is useful for preparing a composition for preventing the formation or progression of amyloid plaques for preventing or treating Alzheimer's disease. The present sequence represents an amyloid beta (Abeta) peptide, which is used in an example from the present invention.  
 XX Sequence 9 AA;  
 Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;  
 Matches 4; Conservative 0;  
 Qy 1 EFRH 4  
 Db 1 EFRH 4  
 RESULT 95  
 ADI35895  
 ID ADI35895 standard; peptide; 9 AA.  
 XX AC ADI35895;  
 XX 22-APR-2004 (first entry)  
 XX Amyloid beta LVF/EEE modification peptide SEQ ID NO:49.  
 XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 XX Alzheimer's disease.  
 XX Synthetic.  
 XX WO2004006861-A2.  
 XX

PD 22-JAN-2004.  
 XX 16-JUL-2003; 2003WO-US022280.  
 XX PR 17-JUL-2002; 2002US-0396245P.  
 XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.  
 XX Chain DG, Fitzer-Attas C;  
 XX WPI; 2004-122759/12.  
 XX New amyloid beta peptide, useful for preparing a composition for preventing the formation or progression of amyloid plaques for preventing or treating Alzheimer's disease.  
 XX Example 2; SEQ ID NO 49; 69pp; English.  
 XX The present invention describes an isolated amyloid beta peptide or its homologue which is selected by a method comprising: (a) determining the binding value of each amino acid of a subsequence of amyloid beta peptide upon binding to a HLA class I and/or class II molecule of interest; (b) determining the resulting score of all amino acids obtained in step (1); and (c) comparing the resulting score to a preselected value. Also described: (1) a vaccine comprising the isolated amyloid beta peptide and a carrier or diluent; (2) determining T-cell epitopes within amyloid beta peptide; (3) predicting the reaction of an individual to a vaccine; (4) matching a vaccine comprising a beta amyloid or homologue peptide to an individual, for immunisation of an individual based on the HLA haplotype of the individual; (5) a kit for matching a vaccine comprising amyloid beta peptide to an individual based on the HLA haplotype of the individual; and (6) preventing the formation or progression of amyloid plaques. The amyloid beta peptide has neuroprotective activity, and can be used in vaccines. The amyloid beta peptide is useful for preparing a composition for preventing the formation or progression of amyloid plaques for preventing or treating Alzheimer's disease. The present sequence represents an amyloid beta (Abeta) peptide, which is used in an example from the present invention.  
 XX Sequence 9 AA;  
 Query Match 100.0%; Score 24; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;  
 Matches 4; Conservative 0;  
 Qy 1 EFRH 4  
 Db 2 EFRH 5  
 RESULT 96  
 ADI35982  
 ID ADI35982 standard; peptide; 9 AA.  
 XX AC ADI35982;  
 XX 22-APR-2004 (first entry)  
 XX Amyloid beta peptide SEQ ID NO:136.  
 XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 XX Alzheimer's disease.  
 XX Synthetic.  
 XX WO2004006861-A2.  
 XX 22-JAN-2004.  
 XX 16-JUL-2003; 2003WO-US022280.  
 XX 17-JUL-2002; 2002US-0396245P.  
 XX

```

XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX PI Chain DG, Fitzer-Attas C;
XX PT WPI; 2004-122759/12.
XX DR
XX PT New amyloid beta peptide, useful for preparing a composition for
XX PT preventing the formation or progression of amyloid plaques for preventing
XX PT or treating Alzheimer's disease.
XX PS Example 6; SEQ ID NO 136; 69pp; English.
XX CC The present invention describes an isolated amyloid beta peptide or its
XX CC homologue which is selected by a method comprising: (a) determining the
XX CC binding value of each amino acid of a subsequence of amyloid beta peptide
XX CC upon binding to a HLA class I and/or class II molecule of interest; (b)
XX CC determining the resulting score of all amino acids of the subsequence,
XX CC based on the binding value of each amino acid obtained in step (1); and
XX CC (c) comparing the resulting score to a preselected value. Also described:
XX CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
XX CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
XX CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
XX CC vaccine comprising a beta amyloid or homologue peptide to an individual,
XX CC for immunisation of an individual based on the HLA haplotype of the
XX CC individual; (5) a kit for matching a vaccine comprising amyloid beta
XX CC peptide to an individual based on the HLA haplotype of the individual;
XX CC and (6) preventing the formation or progression of amyloid plaques. The
XX CC amyloid beta peptide has neuroprotective activity, and can be used in
XX CC vaccines. The amyloid beta peptide is useful for preparing a composition
XX CC for preventing the formation or progression of amyloid plaques for
XX CC preventing or treating Alzheimer's disease. The present sequence
XX CC represents an amyloid beta (Abeta) peptide, which is used in an example
XX CC from the present invention.
XX SQ Sequence 9 AA;
Query Match 100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EFRH 4
Db 2 EFRH 5
RESULT 97
ADI35885
ID ADI35885 standard; peptide; 9 AA.
XX AC ADI35885;
XX DT 22-APR-2004 (first entry)
XX DE Amyloid beta LV/DD modification peptide SEQ ID NO:39.
XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;
XX KW Alzheimer's disease.
XX OS Synthetic.
XX PN WO2004006861-A2.
XX PD 22-JAN-2004.
XX PF 16-JUL-2003; 2003WO-US022280.
XX PR 17-JUL-2002; 2002US-0396245P.
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX PI Chain DG, Fitzer-Attas C;
XX PT WPI; 2004-122759/12.
XX PT New amyloid beta peptide, useful for preparing a composition for
XX PT preventing the formation or progression of amyloid plaques for preventing
XX PT or treating Alzheimer's disease.
XX PS Example 2; SEQ ID NO 39; 69pp; English.
XX CC The present invention describes an isolated amyloid beta peptide or its
XX CC homologue which is selected by a method comprising: (a) determining the
XX CC binding value of each amino acid of a subsequence of amyloid beta peptide
XX CC upon binding to a HLA class I and/or class II molecule of interest; (b)
XX CC determining the resulting score of all amino acids of the subsequence,
XX CC based on the binding value of each amino acid obtained in step (1); and
XX CC (c) comparing the resulting score to a preselected value. Also described:
XX CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
XX CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
XX CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
XX CC vaccine comprising a beta amyloid or homologue peptide to an individual,
XX CC for immunisation of an individual based on the HLA haplotype of the
XX CC individual; (5) a kit for matching a vaccine comprising amyloid beta
XX CC peptide to an individual based on the HLA haplotype of the individual;
XX CC and (6) preventing the formation or progression of amyloid plaques. The
XX CC amyloid beta peptide has neuroprotective activity, and can be used in
XX CC vaccines. The amyloid beta peptide is useful for preparing a composition
XX CC for preventing the formation or progression of amyloid plaques for
XX CC preventing or treating Alzheimer's disease. The present sequence
XX CC represents an amyloid beta (Abeta) peptide, which is used in an example
XX CC from the present invention.
XX SQ Sequence 9 AA;
Query Match 100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EFRH 4
Db 2 EFRH 5
RESULT 98
ADI35920
ID ADI35920 standard; peptide; 9 AA.
XX AC ADI35920;
XX DT 22-APR-2004 (first entry)
XX DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:74.
XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;
XX KW Alzheimer's disease; epitope.
XX OS Synthetic.
XX PN WO2004006861-A2.
XX PD 22-JAN-2004.
XX PF 16-JUL-2003; 2003WO-US022280.
XX PR 17-JUL-2002; 2002US-0396245P.
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX PI Chain DG, Fitzer-Attas C;
XX PT WPI; 2004-122759/12.
XX PT New amyloid beta peptide, useful for preparing a composition for
XX PT preventing the formation or progression of amyloid plaques for preventing
XX PT or treating Alzheimer's disease.

```

```

XX Example 4; SEQ ID NO 74; 69pp; English.
PS
XX
CC The present invention describes an isolated amyloid beta peptide or its
CC homologue which is selected by a method comprising: (a) determining the
CC binding value of each amino acid of a subsequence of amyloid beta peptide
CC upon binding to a HLA class I and/or class II molecule of interest; (b)
CC determining the resulting score of all amino acids of the subsequence,
CC based on the binding value of each amino acid obtained in step (1); and
CC (c) comparing the resulting score to a preselected value. Also described:
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC vaccine comprising a beta amyloid or homologue peptide to an individual,
CC for immunisation of an individual based on the HLA haplotype of the
CC individual; (5) a kit for matching a vaccine comprising amyloid beta
CC peptide to an individual based on the HLA haplotype of the individual;
CC and (6) preventing the formation or progression of amyloid plaques. The
CC amyloid beta peptide has neuroprotective activity, and can be used in
CC vaccines. The amyloid beta peptide is useful for preparing a composition
CC for preventing the formation or progression of amyloid plaques for
CC preventing or treating Alzheimer's disease. The present sequence
CC represents an amyloid beta (Abeta) peptide, which is used in an example
CC from the present invention.
XX
SQ Sequence 9 AA;

Query Match      100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 4 EFRH 7

RESULT 99
ADI35879
ID ADI35879 standard; peptide; 9 AA.
XX
AC ADI35879;
XX
DT 22-APR-2004 (first entry)
XX
DE Amyloid beta LV/EE modification peptide SEQ ID NO:33.
XX
KW amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW Alzheimer's disease.
XX
OS Synthetic.
XX
PN WO2004006861-A2.
XX
PD 22-JAN-2004.
XX
PF 16-JUL-2003; 2003WO-US022280.
XX
PR 17-JUL-2002; 2002US-0396245P.
XX
PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI Chain DG, Fitzer-Attas C;
XX
DR WPI; 2004-122759/12.
XX
PS New amyloid beta peptide, useful for preparing a composition for
PT preventing the formation or progression of amyloid plaques for preventing
PT or treating Alzheimer's disease.
XX
XX Example 2; SEQ ID NO 33; 69pp; English.
XX
XX The present invention describes an isolated amyloid beta peptide or its
XX homologue which is selected by a method comprising: (a) determining the
XX binding value of each amino acid of a subsequence of amyloid beta peptide
XX upon binding to a HLA class I and/or class II molecule of interest; (b)
XX determining the resulting score of all amino acids of the subsequence,
XX based on the binding value of each amino acid obtained in step (1); and
XX (c) comparing the resulting score to a preselected value. Also described:
XX (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
XX or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
XX (3) predicting the reaction of an individual to a vaccine; (4) matching a
XX vaccine comprising a beta amyloid or homologue peptide to an individual,
XX for immunisation of an individual based on the HLA haplotype of the
XX individual; (5) a kit for matching a vaccine comprising amyloid beta
XX peptide to an individual based on the HLA haplotype of the individual;
XX and (6) preventing the formation or progression of amyloid plaques. The
XX amyloid beta peptide has neuroprotective activity, and can be used in
XX vaccines. The amyloid beta peptide is useful for preparing a composition
XX for preventing the formation or progression of amyloid plaques for
XX preventing or treating Alzheimer's disease. The present sequence
XX represents an amyloid beta (Abeta) peptide, which is used in an example
XX from the present invention.
XX
SQ Sequence 9 AA;

Query Match      100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 4 EFRH 7

RESULT 100
ADI35971
ID ADI35971 standard; peptide; 9 AA.
XX
AC ADI35971;
XX
DT 22-APR-2004 (first entry)
XX
DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:125.
XX
KW amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW Alzheimer's disease; epitope.
XX
OS Synthetic.
XX
PN WO2004006861-A2.
XX
PD 22-JAN-2004.
XX
PF 16-JUL-2003; 2003WO-US022280.
XX
PR 17-JUL-2002; 2002US-0396245P.
XX
PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI Chain DG, Fitzer-Attas C;
XX
DR WPI; 2004-122759/12.
XX
PS New amyloid beta peptide, useful for preparing a composition for
PT preventing the formation or progression of amyloid plaques for preventing
PT or treating Alzheimer's disease.
XX
XX Example 5; SEQ ID NO 125; 69pp; English.
XX
XX The present invention describes an isolated amyloid beta peptide or its
XX homologue which is selected by a method comprising: (a) determining the
XX binding value of each amino acid of a subsequence of amyloid beta peptide
XX upon binding to a HLA class I and/or class II molecule of interest; (b)
XX determining the resulting score of all amino acids of the subsequence,
XX based on the binding value of each amino acid obtained in step (1); and
XX (c) comparing the resulting score to a preselected value. Also described:

```

CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
CC for immunisation of an individual based on the HLA haplotype of the  
CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
CC peptide to an individual based on the HLA haplotype of the individual;  
CC and (6) preventing the formation or progression of amyloid plaques. The  
CC amyloid beta peptide has neuroprotective activity, and can be used in  
CC vaccines. The amyloid beta peptide is useful for preparing a composition  
CC for preventing the formation or progression of amyloid plaques for  
CC preventing or treating Alzheimer's disease. The present sequence  
CC represents an amyloid beta (Abeta) peptide, which is used in an example  
XX from the present invention.

SQ Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFRH 5

Search completed: November 2, 2005, 09:38:09  
Job time : 164 secs

the beginning

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:12:35 ; Search time 41 Seconds  
(without alignments)  
7.283 Million cell updates/sec

Title: US-10-618-856-1  
Perfect score: 24  
Sequence: 1 EFRH 4

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 114581

Minimum DB seq length: 4  
Maximum DB seq length: 10

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 100 summaries

Database : Issued Patents\_AA\*  
1: /cgn2\_6/ptodata/1/iaa/5A-COMB.pep:\*  
2: /cgn2\_6/ptodata/1/iaa/5B-COMB.pep:\*  
3: /cgn2\_6/ptodata/1/iaa/6A-COMB.pep:\*  
4: /cgn2\_6/ptodata/1/iaa/6B-COMB.pep:\*  
5: /cgn2\_6/ptodata/1/iaa/PTUS-COMB.pep:\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	100.0	4	US-09-579-012-24	Sequence 24, Appl
2	24	100.0	7	US-09-579-012-25	Sequence 25, Appl
3	24	100.0	10	US-08-371-930-12	Sequence 12, Appl
4	24	100.0	10	US-09-724-961-5	Sequence 5, Appl
5	24	100.0	10	US-09-724-961-6	Sequence 6, Appl
6	24	100.0	10	US-09-724-961-7	Sequence 7, Appl
7	24	100.0	10	US-09-724-961-8	Sequence 8, Appl
8	24	100.0	10	US-09-724-961-9	Sequence 9, Appl
9	24	100.0	10	US-09-724-961-10	Sequence 10, Appl
10	24	100.0	10	US-09-724-961-11	Sequence 11, Appl
11	24	100.0	10	US-09-580-018-5	Sequence 5, Appl
12	24	100.0	10	US-09-580-018-6	Sequence 6, Appl
13	24	100.0	10	US-09-580-018-7	Sequence 7, Appl
14	24	100.0	10	US-09-580-018-8	Sequence 8, Appl
15	24	100.0	10	US-09-580-018-9	Sequence 9, Appl
16	24	100.0	10	US-09-580-018-10	Sequence 10, Appl
17	24	100.0	10	US-09-580-018-11	Sequence 11, Appl
18	24	100.0	10	US-09-724-551-5	Sequence 5, Appl
19	24	100.0	10	US-09-724-551-6	Sequence 6, Appl
20	24	100.0	10	US-09-724-551-7	Sequence 7, Appl
21	24	100.0	10	US-09-724-551-8	Sequence 8, Appl
22	24	100.0	10	US-09-724-551-9	Sequence 9, Appl
23	24	100.0	10	US-09-724-551-10	Sequence 10, Appl
24	24	100.0	10	US-09-724-551-11	Sequence 11, Appl
25	24	100.0	10	PT-US94-01712-12	Sequence 12, Appl
26	21	87.5	9	US-08-159-339A-76	Sequence 76, Appl
27	21	87.5	9	US-08-159-339A-134	Sequence 134, Appl

28	21	87.5	9	US-08-159-339A-234	Sequence 234, Appl
29	21	87.5	9	US-08-159-339A-247	Sequence 247, Appl
30	21	87.5	9	US-09-601-729-277	Sequence 277, Appl
31	21	87.5	10	US-08-764-640-113	Sequence 113, Appl
32	21	87.5	10	US-08-159-339A-75	Sequence 75, Appl
33	21	87.5	10	US-08-973-225-113	Sequence 113, Appl
34	21	87.5	10	US-09-244-288A-113	Sequence 113, Appl
35	21	87.5	10	US-09-516-704-113	Sequence 113, Appl
36	21	87.5	10	US-09-549-090-113	Sequence 113, Appl
37	21	87.5	10	US-08-832-230A-113	Sequence 113, Appl
38	20	83.3	7	US-09-526-738A-5	Sequence 5, Appl
39	19	79.2	5	US-08-637-759B-303	Sequence 303, Appl
40	19	79.2	5	US-08-871-355A-303	Sequence 303, Appl
41	19	79.2	5	US-09-201-945-303	Sequence 303, Appl
42	19	79.2	6	US-08-014-979-78	Sequence 78, Appl
43	19	79.2	6	US-08-478-386A-52	Sequence 52, Appl
44	19	79.2	6	US-08-292-597-52	Sequence 52, Appl
45	19	79.2	6	US-08-388-653-52	Sequence 52, Appl
46	19	79.2	6	US-08-473-985-52	Sequence 52, Appl
47	19	79.2	6	US-08-483-898-52	Sequence 52, Appl
48	19	79.2	6	US-09-087-716-52	Sequence 52, Appl
49	19	79.2	6	US-09-157-753-52	Sequence 52, Appl
50	19	79.2	6	US-09-157-230-52	Sequence 52, Appl
51	19	79.2	6	US-09-087-811-52	Sequence 52, Appl
52	19	79.2	6	US-09-156-855-52	Sequence 52, Appl
53	19	79.2	6	US-09-158-010-52	Sequence 52, Appl
54	19	79.2	6	US-09-087-647-52	Sequence 52, Appl
55	19	79.2	6	US-09-302-629-52	Sequence 52, Appl
56	19	79.2	6	US-09-526-738A-8	Sequence 8, Appl
57	19	79.2	8	US-08-875-533-57	Sequence 57, Appl
58	19	79.2	8	US-09-464-152A-14	Sequence 14, Appl
59	19	79.2	8	US-09-589-483-28	Sequence 28, Appl
60	19	79.2	9	US-08-134-198E-12	Sequence 12, Appl
61	19	79.2	9	US-09-502-600-117	Sequence 117, Appl
62	19	79.2	9	US-09-149-476-663	Sequence 663, Appl
63	19	79.2	9	US-09-918-243-117	Sequence 117, Appl
64	19	79.2	9	US-09-601-729-103	Sequence 103, Appl
65	19	79.2	9	PT-US95-16415-30	Sequence 30, Appl
66	19	79.2	9	5514558-10	Patent No. 5514558
67	19	79.2	9	5514558-10	Patent No. 5514558
68	19	79.2	10	US-08-338-634-19	Sequence 19, Appl
69	19	79.2	10	US-08-637-759B-417	Sequence 417, Appl
70	19	79.2	10	US-08-556-597-171	Sequence 171, Appl
71	19	79.2	10	US-08-434-664-1	Sequence 1, Appl
72	19	79.2	10	US-08-239-428A-1	Sequence 1, Appl
73	19	79.2	10	US-08-871-355A-417	Sequence 417, Appl
74	19	79.2	10	US-09-201-945-417	Sequence 417, Appl
75	19	79.2	10	US-09-103-671-1	Sequence 1, Appl
76	19	79.2	10	US-09-724-961-12	Sequence 12, Appl
77	19	79.2	10	US-09-580-018-12	Sequence 12, Appl
78	19	79.2	10	US-09-724-551-12	Sequence 12, Appl
79	19	79.2	10	PT-US95-05787-1	Sequence 1, Appl
80	18	75.0	8	US-09-020-065A-13	Sequence 13, Appl
81	18	75.0	9	US-09-809-517A-5	Sequence 5, Appl
82	18	75.0	10	US-08-553-579-2	Sequence 2, Appl
83	18	75.0	10	US-08-159-339A-88	Sequence 88, Appl
84	18	75.0	10	US-09-406-781-2	Sequence 2, Appl
85	18	75.0	10	US-09-468-738A-5	Sequence 5, Appl
86	18	75.0	10	US-09-020-065A-30	Sequence 30, Appl
87	18	75.0	10	US-09-940-019-5	Sequence 5, Appl
88	18	75.0	10	US-09-940-037A-5	Sequence 5, Appl
89	18	75.0	10	US-09-880-132-2	Sequence 2, Appl
90	17	70.8	5	US-08-134-231C-37	Sequence 37, Appl
91	17	70.8	4	US-08-728-160-37	Sequence 37, Appl
92	17	70.8	8	US-09-460-676B-3	Sequence 3, Appl
93	17	70.8	10	US-08-199-508-57	Sequence 57, Appl
94	16	66.7	4	PT-US93-01669-16	Sequence 16, Appl
95	16	66.7	4	US-09-260-190-2	Sequence 2, Appl
96	16	66.7	5	US-09-029-267-15	Sequence 15, Appl
97	16	66.7	5	US-09-794-927A-72	Sequence 72, Appl
98	16	66.7	5	US-09-795-847B-72	Sequence 72, Appl
99	16	66.7	5	US-09-869-414-72	Sequence 72, Appl
100	16	66.7	5		

## ALIGNMENTS

RESULT 1  
US-09-579-012-24  
; Sequence 24, Application US/09579012  
; Patent No. 6670195  
; GENERAL INFORMATION:  
; APPLICANT: Jorge GHISO  
; APPLICANT: Ruben VIDAL  
; APPLICANT: Blas FRANGIONE  
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish  
; TITLE OF INVENTION: Dementia  
; FILE REFERENCE: 32004-16277  
; CURRENT APPLICATION NUMBER: US/09/579,012  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/136238  
; PRIOR FILING DATE: 1999-05-26  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 24  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: consensus sequence  
US-09-579-012-24

Query Match 100.0%; Score 24; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 2  
US-09-579-012-25  
; Sequence 25, Application US/09579012  
; Patent No. 6670195  
; GENERAL INFORMATION:  
; APPLICANT: Jorge GHISO  
; APPLICANT: Ruben VIDAL  
; APPLICANT: Blas FRANGIONE  
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish  
; TITLE OF INVENTION: Dementia  
; FILE REFERENCE: 32004-16277  
; CURRENT APPLICATION NUMBER: US/09/579,012  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/136238  
; PRIOR FILING DATE: 1999-05-26  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 25  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: epitope  
US-09-579-012-25

Query Match 100.0%; Score 24; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 3  
US-08-371-930-12  
; Sequence 12, Application US/08371930  
; Patent No. 5578451

GENERAL INFORMATION:  
; APPLICANT: Nishimoto, Ikuro  
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS  
; NUMBER OF SEQUENCES: 30  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM PS/2 Model 50Z or 55SX  
; OPERATING SYSTEM: MS-DOS (Version 5.0)  
; SOFTWARE: WordPerfect (Version 5.1)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/371,930  
; FILING DATE:  
; CLASSIFICATION: 436  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/019,208  
; FILING DATE: February 18, 1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clark, Paul T.  
; REGISTRATION NUMBER: 30,162  
; REFERENCE/DOCKET NUMBER: 00786/154001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 542-5070  
; TELEFAX: (617) 542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
US-08-371-930-12

Query Match 100.0%; Score 24; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 4  
US-09-724-961-5  
; Sequence 5, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02



NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence

FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-5

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 7 EFRH 10

## RESULT 5

US-09-724-961-6  
; Sequence 6, Application US/09724961  
; Patent No. 6743427

GENERAL INFORMATION:

APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Vasquez, Nicki  
APPLICANT: Yednock, Ted

FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide

OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid

OTHER INFORMATION: peptide)  
US-09-724-961-6

FILE REFERENCE: 15270J-004750UC

CURRENT APPLICATION NUMBER: US/09/724,961

CURRENT FILING DATE: 2000-11-28

PRIOR APPLICATION NUMBER: US 09/580,015

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: US 09/322,289

PRIOR FILING DATE: 1999-05-28

PRIOR APPLICATION NUMBER: US 09/201,430

PRIOR FILING DATE: 1998-11-30

PRIOR APPLICATION NUMBER: WO PCT/US00/14810

PRIOR FILING DATE: 1998-11-30

PRIOR APPLICATION NUMBER: US 60/080,970

PRIOR FILING DATE: 1998-04-07

PRIOR APPLICATION NUMBER: US 60/067,740

PRIOR FILING DATE: 1997-12-02

NUMBER OF SEQ ID NOS: 77

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 6

LENGTH: 10

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide

OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid

OTHER INFORMATION: peptide)  
US-09-724-961-6

Query Match 100.0%; Score 24; DB 4; Length 10;

Best Local Similarity 100.0%; Pred. No. 19;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 6 EFRH 9

## RESULT 6

US-09-724-961-7

; Sequence 7, Application US/09724961

; Patent No. 6743427

GENERAL INFORMATION:

APPLICANT: Schenk, Dale B.

APPLICANT: Bard, Frederique  
APPLICANT: Vasquez, Nicki  
APPLICANT: Yednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 15270J-004750UC  
CURRENT APPLICATION NUMBER: US/09/724,961  
CURRENT FILING DATE: 2000-11-28

PRIOR APPLICATION NUMBER: US 09/580,015

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: US 09/322,289

PRIOR FILING DATE: 1999-05-28

PRIOR APPLICATION NUMBER: US 09/201,430

PRIOR FILING DATE: 1998-11-30

PRIOR APPLICATION NUMBER: WO PCT/US00/14810

PRIOR FILING DATE: 1998-11-30

PRIOR APPLICATION NUMBER: US 60/080,970

PRIOR FILING DATE: 1998-04-07

PRIOR APPLICATION NUMBER: US 60/067,740

PRIOR FILING DATE: 1997-12-02

NUMBER OF SEQ ID NOS: 77

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 7

LENGTH: 10

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide

OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid

OTHER INFORMATION: peptide)  
US-09-724-961-7

Query Match 100.0%; Score 24; DB 4; Length 10;

Best Local Similarity 100.0%; Pred. No. 19;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 5 EFRH 8

## RESULT 7

US-09-724-961-8

; Sequence 8, Application US/09724961

; Patent No. 6743427

GENERAL INFORMATION:

APPLICANT: Schenk, Dale B.

APPLICANT: Bard, Frederique

APPLICANT: Vasquez, Nicki

APPLICANT: Yednock, Ted

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide

OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid

OTHER INFORMATION: peptide)  
US-09-724-961-8

FILE REFERENCE: 15270J-004750UC

CURRENT APPLICATION NUMBER: US/09/724,961

CURRENT FILING DATE: 2000-11-28

PRIOR APPLICATION NUMBER: US 09/580,015

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: US 09/322,289

PRIOR FILING DATE: 1999-05-28

PRIOR APPLICATION NUMBER: US 09/201,430

PRIOR FILING DATE: 1998-11-30

PRIOR APPLICATION NUMBER: WO PCT/US00/14810

PRIOR FILING DATE: 1998-11-30

PRIOR APPLICATION NUMBER: US 60/080,970

PRIOR FILING DATE: 1998-04-07

PRIOR APPLICATION NUMBER: US 60/067,740

PRIOR FILING DATE: 1997-12-02

NUMBER OF SEQ ID NOS: 77

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 8

LENGTH: 10

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide

```
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-8

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
    ||||
Db 4 EFRH 7

RESULT 8
US-09-724-961-9
; Sequence 9, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-9

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
    ||||
Db 3 EFRH 6

RESULT 9
US-09-724-961-10
; Sequence 10, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-10

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
    ||||
Db 2 EFRH 5

RESULT 10
US-09-724-961-11
; Sequence 11, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-11

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 EPRH 4  
||||  
Db 1 EPRH 4

RESULT 11  
US-09-580-018-5  
; Sequence 5, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-5

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
||||  
Db 7 EPRH 10

RESULT 12  
US-09-580-018-6  
; Sequence 6, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 6  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-6

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
||||  
Db 6 EPRH 9

RESULT 13  
US-09-580-018-7  
; Sequence 7, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-7

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
||||  
Db 5 EPRH 8

RESULT 14  
US-09-580-018-8  
; Sequence 8, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 8  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-8

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4  
||||  
Db 4 EPRH 7

RESULT 15

```
US-09-580-018-9
; Sequence 9, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid)
; OTHER INFORMATION: peptide)
US-09-580-018-9
Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 16
US-09-580-018-10
; Sequence 10, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid)
; OTHER INFORMATION: peptide)
US-09-580-018-10
Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFRH 5

RESULT 17
US-09-580-018-11
; Sequence 11, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid)
; OTHER INFORMATION: peptide)
US-09-580-018-11
Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 7 EFRH 10

RESULT 18
US-09-724-551-5
; Sequence 5, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US/09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid)
; OTHER INFORMATION: peptide)
US-09-724-551-5
Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 7 EFRH 10

RESULT 19
US-09-724-551-6
; Sequence 6, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid)
; OTHER INFORMATION: peptide)
US-09-724-551-6
Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 7 EFRH 10
```

; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 6  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-6

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 6 EFRH 9

RESULT 20  
US-09-724-551-7  
; Sequence 7, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-7

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 5 EFRH 8

RESULT 21  
US-09-724-551-8  
; Sequence 8, Application US/09724551  
; Patent No. 6787637

; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 8  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-8

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 4 EFRH 7

RESULT 22  
US-09-724-551-9  
; Sequence 9, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 9  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-9

Query Match 100.0%; Score 24; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|||  
Db 3 EFRH 6

RESULT 23  
US-09-724-551-10  
; Sequence 10, Application US/09724551

```
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-10

Query Match          100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EFRH 4
        ||||
Db       2 EFRH 5

RESULT 24
US-09-724-551-11
; Sequence 11, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-11

Query Match          100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EFRH 4
        ||||
Db       1 EFRH 4

RESULT 25
PCT-US94-01712-12
```

```
; Sequence 12, Application PC/TUS9401712
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/01712
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/019,208
; FILING DATE: February 18, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/154001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
PCT-US94-01712-12

Query Match          100.0%; Score 24; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EFRH 4
        ||||
Db       3 EFRH 6

RESULT 26
US-08-159-339A-76
; Sequence 76, Application US/08159339A
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
```

; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/159,339A  
 ; FILING DATE: 29-NOV-1993  
 ; CLASSIFICATION: 424  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/926,666  
 ; FILING DATE: 07-AUG-1992  
 ; APPLICATION NUMBER: US 08/027,746  
 ; FILING DATE: 05-MAR-1993  
 ; APPLICATION NUMBER: US 08/103,396  
 ; FILING DATE: 06-AUG-1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Weber, Ellen Lauver  
 ; REGISTRATION NUMBER: 32,762  
 ; REFERENCE/DOCKET NUMBER: 018623-005030US  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 576-0200  
 ; TELEFAX: (415) 576-0300  
 ; TELEX:  
 ; INFORMATION FOR SEQ ID NO: 76:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 9 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; US-08-159-339A-76

Query Match 87.5%; Score 21; DB 3; Length 9;  
 Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 | : ||  
 Db 3 EYRH 6

RESULT 27  
 US-08-159-339A-134  
 ; Sequence 134, Application US/08159339A  
 ; Patent No. 6037135  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Kubo, Ralph T.  
 ; APPLICANT: Grey, Howard M.  
 ; APPLICANT: Sette, Alessandro  
 ; APPLICANT: Celis, Esteban  
 ; TITLE OF INVENTION: HLA Binding peptides and Their  
 ; NUMBER OF SEQUENCES: 1254  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Townsend and Townsend and Crew LLP  
 ; STREET: Two Embarcadero Center, Eighth Floor  
 ; CITY: San Francisco  
 ; STATE: CA  
 ; COUNTRY: USA  
 ; ZIP: 94111-3834  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette  
 ; COMPUTER: IBM Compatible  
 ; OPERATING SYSTEM: DOS  
 ; SOFTWARE: FastSeq for Windows Version 2.0  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/159,339A  
 ; FILING DATE: 29-NOV-1993  
 ; CLASSIFICATION: 424  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/926,666  
 ; FILING DATE: 07-AUG-1992  
 ; APPLICATION NUMBER: US 08/027,746  
 ; FILING DATE: 05-MAR-1993  
 ; APPLICATION NUMBER: US 08/103,396  
 ; FILING DATE: 06-AUG-1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Weber, Ellen Lauver  
 ; REGISTRATION NUMBER: 32,762  
 ; REFERENCE/DOCKET NUMBER: 018623-005030US  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 576-0200  
 ; TELEFAX: (415) 576-0300  
 ; TELEX:  
 ; INFORMATION FOR SEQ ID NO: 234:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 9 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single

; NAME: Weber, Ellen Lauver  
 ; REGISTRATION NUMBER: 32,762  
 ; REFERENCE/DOCKET NUMBER: 018623-005030US  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 576-0200  
 ; TELEFAX: (415) 576-0300  
 ; TELEX:  
 ; INFORMATION FOR SEQ ID NO: 134:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 9 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; US-08-159-339A-134

Query Match 87.5%; Score 21; DB 3; Length 9;  
 Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 | : ||  
 Db 3 EYRH 6

RESULT 28  
 US-08-159-339A-234  
 ; Sequence 234, Application US/08159339A  
 ; Patent No. 6037135  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Kubo, Ralph T.  
 ; APPLICANT: Grey, Howard M.  
 ; APPLICANT: Sette, Alessandro  
 ; APPLICANT: Celis, Esteban  
 ; TITLE OF INVENTION: HLA Binding peptides and Their  
 ; NUMBER OF SEQUENCES: 1254  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Townsend and Townsend and Crew LLP  
 ; STREET: Two Embarcadero Center, Eighth Floor  
 ; CITY: San Francisco  
 ; STATE: CA  
 ; COUNTRY: USA  
 ; ZIP: 94111-3834  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette  
 ; COMPUTER: IBM Compatible  
 ; OPERATING SYSTEM: DOS  
 ; SOFTWARE: FastSeq for Windows Version 2.0  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/159,339A  
 ; FILING DATE: 29-NOV-1993  
 ; CLASSIFICATION: 424  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/926,666  
 ; FILING DATE: 07-AUG-1992  
 ; APPLICATION NUMBER: US 08/027,746  
 ; FILING DATE: 05-MAR-1993  
 ; APPLICATION NUMBER: US 08/103,396  
 ; FILING DATE: 06-AUG-1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Weber, Ellen Lauver  
 ; REGISTRATION NUMBER: 32,762  
 ; REFERENCE/DOCKET NUMBER: 018623-005030US  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 576-0200  
 ; TELEFAX: (415) 576-0300  
 ; TELEX:  
 ; INFORMATION FOR SEQ ID NO: 234:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 9 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single

TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-159-339A-234

Query Match 87.5%; Score 21; DB 3; Length 9;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|:|  
Db 4 EYRH 7

RESULT 29  
US-08-159-339A-247  
Sequence 247, Application US/08159339A  
Patent No. 6037135  
GENERAL INFORMATION:  
APPLICANT: Kubo, Ralph T.  
APPLICANT: Grey, Howard M.  
APPLICANT: Sette, Alessandro  
APPLICANT: Celis, Esteban  
TITLE OF INVENTION: HLA Binding peptides and Their  
TITLE OF INVENTION: Uses  
NUMBER OF SEQUENCES: 1254  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94111-3834

COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/159,339A  
FILING DATE: 29-NOV-1993  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/926,666  
FILING DATE: 07-AUG-1992  
APPLICATION NUMBER: US 08/027,746  
FILING DATE: 05-MAR-1993  
APPLICATION NUMBER: US 08/103,396  
FILING DATE: 06-AUG-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Weber, Ellen Lauver  
REGISTRATION NUMBER: 32,762  
REFERENCE/DOCKET NUMBER: 018623-005030US  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
TELEX:  
INFORMATION FOR SEQ ID NO: 247:

SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-159-339A-247

Query Match 87.5%; Score 21; DB 3; Length 9;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|:|  
Db 1 EYRH 4

RESULT 30  
US-09-601-729-277  
Sequence 277, Application US/09601729  
Patent No. 6683052  
GENERAL INFORMATION:  
APPLICANT: THIAM, KADER  
APPLICANT: AURIAULT, CLAUDE  
APPLICANT: GRAS-MASSE, HELENE  
APPLICANT: LOING, ESTELLE  
APPLICANT: VERWAERDE, CLAUDIE  
APPLICANT: GUILLET, JEAN GERARD  
TITLE OF INVENTION: LIPOPEPTIDES CONTAINING AN INTERFERON FRAGMENT AND USES  
TITLE OF INVENTION: THEREOF IN PHARMACEUTICAL COMPOSITIONS  
FILE REFERENCE: USB-97-AU-IN  
CURRENT APPLICATION NUMBER: US/09/601,729  
CURRENT FILING DATE: 2000-11-20  
PRIOR APPLICATION NUMBER: PCT/FR99/00259  
PRIOR FILING DATE: 1999-02-05  
PRIOR APPLICATION NUMBER: 98 01439  
PRIOR FILING DATE: 1998-02-06  
NUMBER OF SEQ ID NOS: 281  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 277  
LENGTH: 9  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: peptide  
US-09-601-729-277

Query Match 87.5%; Score 21; DB 4; Length 9;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
|:|  
Db 3 EYRH 6

RESULT 31  
US-08-764-640-113  
Sequence 113, Application US/08764640  
Patent No. 5869451  
Patent No. 5869451 5837683  
GENERAL INFORMATION:  
APPLICANT: Dower, William J.  
APPLICANT: Barrett, Ronald W.  
APPLICANT: Cwirla, Steven E.  
APPLICANT: Gates, Christian  
APPLICANT: Schatz, Peter J.  
APPLICANT: Balasubramanian, Palaniappan  
APPLICANT: Wagstrom, Christopher R.  
APPLICANT: Hendren, Richard W.  
APPLICANT: Deprence, Randolph B.  
APPLICANT: Poddaturi, Surekha  
APPLICANT: Yin, Qun  
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
TITLE OF INVENTION: RECEPTOR  
NUMBER OF SEQUENCES: 244  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA  
ZIP: 27709  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30



```
;
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/764,640
; FILING DATE: 11-DEC-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrubiec, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-764-640-113

Query Match      87.5%; Score 21; DB 2; Length 10;
Best Local Similarity 75.0%; Pred. No. 91;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      |||
        5 EFKH 8

RESULT 32
US-08-159-339A-75
; Sequence 75, Application US/08159339A
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/159,339A
; FILING DATE: 29-NOV-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/926,666
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US 08/027,746
; FILING DATE: 05-MAR-1993
; APPLICATION NUMBER: US 08/103,396
; FILING DATE: 06-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 75:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-159-339A-75

Query Match      87.5%; Score 21; DB 3; Length 10;
Best Local Similarity 75.0%; Pred. No. 91;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      |||
        5 EFKH 8

;
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/764,640
; FILING DATE: 11-DEC-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrubiec, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-764-640-113

Query Match      87.5%; Score 21; DB 3; Length 10;
Best Local Similarity 75.0%; Pred. No. 91;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      |||
        5 EFKH 8

RESULT 33
US-08-973-225-113
; Sequence 113, Application US/08973225A
; Patent No. 6083913
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
; APPLICANT: Barrett, Ronald W.
; APPLICANT: Cwirila, Steven E.
; APPLICANT: Duffin, David J.
; APPLICANT: Gates, Christian
; APPLICANT: Haselden, Sherril S.
; APPLICANT: Mattheakis, Larry C.
; APPLICANT: Schatz, Peter J.
; APPLICANT: Wagstrom, Christopher R.
; APPLICANT: Wrighton, Nicholas C.
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; TITLE OF INVENTION: THROMBOPOIETIN RECEPTOR
; NUMBER OF SEQUENCES: 232
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Glaxo Wellcome
; STREET: Five Moore Drive, P.O. Box 13398
; CITY: Research Triangle Park
; STATE: NC
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/973,225A
; FILING DATE: 04-Dec-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrubiec, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3065USW
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 113:
US-08-973-225-113

Query Match      87.5%; Score 21; DB 3; Length 10;
Best Local Similarity 75.0%; Pred. No. 91;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      |||
        5 EFKH 8
```

RESULT 34  
US-09-244-298A-113  
; Sequence 113, Application US/09244298A  
; Patent No. 6121238  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwiria, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wagstrom, Christopher R.  
; APPLICANT: Hendren, Richard W.  
; APPLICANT: Deprince, Randolph B.  
; APPLICANT: Podduturi, Surekha  
; APPLICANT: Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.30  
; CURRENT APPLICATION NUMBER: US/09/244,298A  
; FILING DATE: 11-DEC-1996  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 113:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: linear  
; MOLECULE TYPE: peptide  
US-09-244-298A-113  
Query Match 87.5%; Score 21; DB 3; Length 10;  
Best Local Similarity 75.0%; Pred. No. 91;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 EFRH 4  
Db 5 EFKH 8  
RESULT 35  
US-09-516-704-113  
; Sequence 113, Application US/09516704  
; Patent No. 6251864  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwiria, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wagstrom, Christopher R.  
; APPLICANT: Hendren, Richard W.

; Deprince, Randolph B.  
; Podduturi, Surekha  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.30  
; CURRENT APPLICATION NUMBER: US/09/516,704  
; FILING DATE: 01-Mar-2000  
; CLASSIFICATION: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 113:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 113:  
US-09-516-704-113  
Query Match 87.5%; Score 21; DB 3; Length 10;  
Best Local Similarity 75.0%; Pred. No. 91;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 EFRH 4  
Db 5 EFKH 8  
RESULT 36  
US-09-549-090-113  
; Sequence 113, Application US/09549090  
; Patent No. 6465430  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwiria, Steven E.  
; APPLICANT: Duffin, David J.  
; APPLICANT: Gates, Christian  
; APPLICANT: Haselden, Sherril S.  
; APPLICANT: Mattheakis, Larry C.  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Wagstrom, Christopher R.  
; APPLICANT: Wrighton, Nicholas C.  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: THROMBOPOIETIN RECEPTOR  
; NUMBER OF SEQUENCES: 232  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/549,090  
FILING DATE: 13-Apr-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/973,225  
FILING DATE: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3065USW  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 113:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 113:  
US-09-549-090-113

Query Match 87.5%; Score 21; DB 4; Length 10;  
Best Local Similarity 75.0%; Pred. No. 91;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 5 EFKH 8

RESULT 37  
US-09-832-230A-113  
; Sequence 113, Application US/09832230A  
; Patent No. 6506362  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J. et al  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/832,230A  
; FILING DATE: 10-Apr-2001  
; CLASSIFICATION: <unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 113:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 113:

US-09-832-230A-113

Query Match 87.5%; Score 21; DB 4; Length 10;  
Best Local Similarity 75.0%; Pred. No. 91;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 5 EFKH 8

RESULT 38  
US-09-526-738A-5  
; Sequence 5, Application US/09526738A  
; Patent No. 6630584  
; GENERAL INFORMATION:  
; APPLICANT: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT  
; APPLICANT: LTD.  
; TITLE OF INVENTION: SINGLE CHAIN ANTIBODY AGAINST MUTANT P53  
; FILE REFERENCE: 1196336  
; CURRENT APPLICATION NUMBER: US/09/526,738A  
; CURRENT FILING DATE: 2000-03-16  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: Patent In version 3.1  
; SEQ ID NO 5  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Humanus  
US-09-526-738A-5

Query Match 83.3%; Score 20; DB 4; Length 7;  
Best Local Similarity 75.0%; Pred. No. 4.1e-05;  
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
DB 1 KFRH 4

RESULT 39  
US-08-637-759B-303  
; Sequence 303, Application US/08637759B  
; Patent No. 5876931  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; STREET: 1201 West Peachtree Street  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/637,759B  
; FILING DATE: 03-MAY-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB95/02875  
; FILING DATE: 11-DEC-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101  
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795  
; INFORMATION FOR SEQ ID NO: 303:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
US-08-637-759B-303

Query Match 79.2%; Score 19; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 1 FRH 3

## RESULT 40

US-08-871-355A-303  
; Sequence 303, Application US/08871355A  
; Patent No. 6015669  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450

COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/871,355A  
; FILING DATE: 09-JUN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB95/02875  
; FILING DATE: 11-DEC-1995  
; CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101 CON  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795  
; INFORMATION FOR SEQ ID NO: 303:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
US-08-871-355A-303

Query Match 79.2%; Score 19; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 1 FRH 3

Db 1 FRH 3

## RESULT 41

US-09-201-945-303  
; Sequence 303, Application US/09201945  
; Patent No. 6342215  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450

COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/201,945  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/637,759  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795

INFORMATION FOR SEQ ID NO: 303:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
US-09-201-945-303

Query Match 79.2%; Score 19; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 1 FRH 3

## RESULT 42

US-08-014-979-78  
; Sequence 78, Application US/08014979  
; Patent No. 5510240  
; GENERAL INFORMATION:  
; APPLICANT: Lam, Kit S. et al.  
; TITLE OF INVENTION: Random Bio-Oligomer Library, A Method of  
; TITLE OF INVENTION: Synthesis Thereof, and a Method of Use Thereof  
; NUMBER OF SEQUENCES: 121  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: U.S.A.

Query Match 79.2%; Score 19; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 1 FRH 3

```

/ ZIP: 10036-2711
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA: US/08/014,979
/ APPLICATION NUMBER: 19930208
/ FILING DATE: 19930208
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mirock, S. Leslie
/ REGISTRATION NUMBER: 18,872
/ REFERENCE/DOCKET NUMBER: 7156-041
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212 790-9090
/ TELEFAX: 212 869-8864/9741
/ TELEX: 66141 PENNIE
/ INFORMATION FOR SEQ ID NO: 78:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 6 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: unknown
/ MOLECULE TYPE: peptide
/ US-08-014-979-78

Query Match 79.2%; Score 19; DB 1; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.le+05;
Matches 3; Conservative 0; Mismatches 0; Indels

QY 2 FRH 4
    |||
Db 2 FRH 4

RESULT 43
US-08-478-386A-52
/ Sequence 52, Application US/08478386A
/ Patent No. 5830462
/ GENERAL INFORMATION:
/ APPLICANT: Crabtree, Gerald R.
/ APPLICANT: Schreiber, Stuart L.
/ APPLICANT: Spencer, David M.
/ APPLICANT: Wandless, Thomas J.
/ APPLICANT: Belshaw, Peter
/ TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
/ NUMBER OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
/ NUMBER OF SEQUENCES: 81
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ARIAD Pharmaceuticals, Inc.
/ STREET: 26 Landsdowne Street
/ CITY: Cambridge
/ STATE: Massachusetts
/ COUNTRY: USA
/ ZIP: 02139
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC/DOS/MS/DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/478,386A
/ FILING DATE: 07/JUN/1995
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Figg, E. Anthony
/ REGISTRATION NUMBER: 27,195
/ REFERENCE/DOCKET NUMBER: 2054-114A
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202) 783-6040
/ TELEFAX: (202) 783-6031
/ INFORMATION FOR SEQ ID NO: 52:

```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-478-386A-52

Query Match          79.2%; Score 19; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels

QY      2 FRH 4
DB      2 FRH 4

RESULT 44
US-08-292-597-52
; Sequence 52, Application US/08292597
; Patent No. 5834266
; GENERAL INFORMATION:
; APPLICANT: Gerald R. Crabtree
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: Regulated Apoptosis
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,597
; FILING DATE: 18/AUG/1994
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Figg, E. Anthony
; REGISTRATION NUMBER: 27,195
; REFERENCE/DOCKET NUMBER: 2054-108A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 783-6040
; TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; .LENGTH: 6 amino acids
; .TYPE: amino acid
; .TOPOLOGY: linear
; .MOLECULE TYPE: protein
US-08-292-597-52

Query Match          79.2%; Score 19; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels

QY      2 FRH 4
DB      2 FRH 4

RESULT 45
US-08-386-653-52

```

; Sequence 52, Application US/08388653  
; Patent No. 5869337  
; GENERAL INFORMATION:  
; APPLICANT: Crabtree, Gerald R.  
; APPLICANT: Schreiber, Stuart L.  
; APPLICANT: Spencer, David M.  
; APPLICANT: Wandless, Thomas J.  
; APPLICANT: Belshaw, Peter  
; TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED  
; TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS  
; NUMBER OF SEQUENCES: 81  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
; STREET: 26 Landsdowne Street  
; CITY: Cambridge  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02139  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC/DOS/MS/DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/388,653  
; FILING DATE: 14-FEB-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,386  
; FILING DATE: 07-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Figg, E. Anthony  
; REGISTRATION NUMBER: 27,195  
; REFERENCE/DOCKET NUMBER: 2054-114A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 783-6040  
; TELEFAX: (202) 783-6031  
; INFORMATION FOR SEQ ID NO: 52:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-388-653-52

Query Match 79.2%; Score 19; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 46  
US-08-473-985-52  
; Sequence 52, Application US/08473985  
; Patent No. 5871753  
; GENERAL INFORMATION:  
; APPLICANT: Crabtree, Gerald R.  
; APPLICANT: Schreiber, Stuart L.  
; APPLICANT: Spencer, David M.  
; APPLICANT: Wandless, Thomas J.  
; APPLICANT: Belshaw, Peter  
; APPLICANT: Ho, Steffan  
; TITLE OF INVENTION: Regulated Transcription of Targeted Genes and  
; TITLE OF INVENTION: Other Biological Events  
; NUMBER OF SEQUENCES: 66  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Campbell and Flores  
; STREET: 4370 La Jolla Village Drive, Suite 700  
; CITY: San Diego  
; STATE: California

; COUNTRY: USA  
; ZIP: 92122  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/473,985  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/179,748  
; FILING DATE: 07-JAN-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Campbell, Cathryn A.  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-SU 9863  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 535-9001  
; TELEFAX: (619) 535-8949  
; INFORMATION FOR SEQ ID NO: 52:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-473-985-52

Query Match 79.2%; Score 19; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 47  
US-08-483-898-52  
; Sequence 52, Application US/08483898  
; Patent No. 5994313  
; GENERAL INFORMATION:  
; APPLICANT: Gerald R. Crabtree  
; APPLICANT: Schreiber, Stuart L.  
; APPLICANT: Spencer, David M.  
; APPLICANT: Wandless, Thomas J.  
; APPLICANT: Belshaw, Peter  
; TITLE OF INVENTION: Regulated Apoptosis  
; NUMBER OF SEQUENCES: 81  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
; STREET: 26 Landsdowne Street  
; CITY: Cambridge  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02139  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC/DOS/MS/DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/483,898  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/292,597  
; FILING DATE: 18-AUG-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Figg, E. Anthony  
; REGISTRATION NUMBER: 27,195  
; REFERENCE/DOCKET NUMBER: 2054-108A

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 783-6040  
TELEFAX: (202) 783-6031  
INFORMATION FOR SEQ ID NO: 52:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-483-898-52

Query Match 79.2%; Score 19; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0;  
Matches 3; Conservative 0; Mismatches 0; Gaps 0;

QY 2 FRH 4  
Db 2 FRH 4  
|||

RESULT 48  
US-09-087-716-52  
Sequence 52, Application US/09087716  
Patent No. 601018  
GENERAL INFORMATION:  
APPLICANT: Crabtree, Gerald R.  
APPLICANT: Schreiber, Stuart L.  
APPLICANT: Spencer, David M.  
APPLICANT: Wandless, Thomas J.  
APPLICANT: Belshaw, Peter  
TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED  
NUMBER OF SEQUENCES: 81  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
STREET: 26 Landsdowne Street  
CITY: Cambridge  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02139  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC/DOS/MS/DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/087,716  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/388,653  
FILING DATE: 14-FEB-1995  
APPLICATION NUMBER: US 08/478,386  
FILING DATE: 07-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Figg, E. Anthony  
REGISTRATION NUMBER: 27,195  
REFERENCE/DOCKET NUMBER: 2054-114A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 783-6040  
TELEFAX: (202) 783-6031  
INFORMATION FOR SEQ ID NO: 52:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-087-716-52

Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0;  
Matches 3; Conservative 0; Mismatches 0; Gaps 0;

QY 2 FRH 4  
Db 2 FRH 4  
|||

RESULT 49  
US-09-157-753-52  
Sequence 52, Application US/09157753  
Patent No. 6043082  
GENERAL INFORMATION:  
APPLICANT: Crabtree, Gerald R.  
APPLICANT: Schreiber, Stuart L.  
APPLICANT: Spencer, David M.  
APPLICANT: Wandless, Thomas J.  
APPLICANT: Belshaw, Peter  
TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED  
NUMBER OF SEQUENCES: 81  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
STREET: 26 Landsdowne Street  
CITY: Cambridge  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02139  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC/DOS/MS/DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/157,753  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/388,653  
FILING DATE: 14-FEB-1995  
APPLICATION NUMBER: US 08/478,386  
FILING DATE: 07-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Figg, E. Anthony  
REGISTRATION NUMBER: 27,195  
REFERENCE/DOCKET NUMBER: 2054-114A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 783-6040  
TELEFAX: (202) 783-6031  
INFORMATION FOR SEQ ID NO: 52:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-157-753-52

Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0;  
Matches 3; Conservative 0; Mismatches 0; Gaps 0;

QY 2 FRH 4  
Db 2 FRH 4  
|||

RESULT 50  
US-09-157-230-52  
Sequence 52, Application US/09157230  
Patent No. 6046047  
GENERAL INFORMATION:  
APPLICANT: Crabtree, Gerald R.  
APPLICANT: Schreiber, Stuart L.  
APPLICANT: Spencer, David M.  
APPLICANT: Wandless, Thomas J.  
APPLICANT: Belshaw, Peter  
TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED  
NUMBER OF SEQUENCES: 81  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
STREET: 26 Landsdowne Street  
CITY: Cambridge  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02139  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC/DOS/MS/DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/087,716  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/388,653  
FILING DATE: 02/14/1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Figg, E. Anthony  
REGISTRATION NUMBER: 27,195  
REFERENCE/DOCKET NUMBER: 2054-114A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 783-6040  
TELEFAX: (202) 783-6031  
INFORMATION FOR SEQ ID NO: 52:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-087-716-52

Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0;  
Matches 3; Conservative 0; Mismatches 0; Gaps 0;

QY 2 FRH 4  
Db 2 FRH 4  
|||

```
;
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/157,230
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,386
; FILING DATE: 07/JUN/1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Figg, E. Anthony
; REGISTRATION NUMBER: 27,195
; REFERENCE/DOCKET NUMBER: 2054-114A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 783-6040
; TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-157-230-52

Query Match 79.2%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 2 FRH 4
|||

RESULT 51
US-09-817-811-52
; Sequence 52, Application US/09087811
; Patent No. 6054436
; GENERAL INFORMATION:
; APPLICANT: Gerald R. Crabtree
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: Regulated Apoptosis
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/087,811
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
```

```
;
; APPLICATION NUMBER: US 08/292,597
; FILING DATE: 18-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Figg, E. Anthony
; REGISTRATION NUMBER: 27,195
; REFERENCE/DOCKET NUMBER: 2054-108A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 783-6040
; TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-087-811-52

Query Match 79.2%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 2 FRH 4
|||

RESULT 52
US-09-156-855-52
; Sequence 52, Application US/09156855
; Patent No. 6063625
; GENERAL INFORMATION:
; APPLICANT: Gerald R. Crabtree
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: Regulated Transcription of Targeted
; GENES AND OTHER BIOLOGICAL EVENTS
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MSDOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/156,855
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/196,043
; FILING DATE: 11-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Berstein, David L.
; REGISTRATION NUMBER: 31,235
; REFERENCE/DOCKET NUMBER: ARIAD 316C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 494-0400
; TELEFAX: (617) 494-8144
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-156-855-52
```



Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 53  
US-09-158-010-52  
; Sequence 52, Application US/09158010  
; Patent No. 6140120  
; GENERAL INFORMATION:  
; APPLICANT: Gerald R. Crabtree  
; APPLICANT: Schreiber, Stuart L.  
; APPLICANT: Spencer, David M.  
; APPLICANT: Wandless, Thomas J.  
; APPLICANT: Belshaw, Peter  
; TITLE OF INVENTION: Regulated Transcription of Targeted  
; TITLE OF INVENTION: Genes and Other Biological Events  
; NUMBER OF SEQUENCES: 76  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
; STREET: 26 Landsdowne Street  
; CITY: Cambridge  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02139  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC/DOS/MSDOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09158,010  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/196,043  
; FILING DATE: 11-FEB-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Berstein, David L.  
; REGISTRATION NUMBER: 31,235  
; REFERENCE/DOCKET NUMBER: ARIAD 316C  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 494-0400  
; TELEFAX: (617) 494-8144  
; INFORMATION FOR SEQ ID NO: 52:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-158-010-52

Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 54  
US-09-087-647-52  
; Sequence 52, Application US/09087647  
; Patent No. 6165787  
; GENERAL INFORMATION:  
; APPLICANT: Crabtree, Gerald R.  
; APPLICANT: Schreiber, Stuart L.  
; APPLICANT: Spencer, David M.

; APPLICANT: Wandless, Thomas J.  
; APPLICANT: Belshaw, Peter  
; TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED  
; TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS  
; NUMBER OF SEQUENCES: 81  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
; STREET: 26 Landsdowne Street  
; CITY: Cambridge  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02139  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC/DOS/MS/DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/087,647  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,386  
; FILING DATE: 07/JUN/1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Figg, E. Anthony  
; REGISTRATION NUMBER: 27,195  
; REFERENCE/DOCKET NUMBER: 2054-114A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 783-6040  
; TELEFAX: (202) 783-6031  
; INFORMATION FOR SEQ ID NO: 52:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-087-647-52

Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 55  
US-09-302-629-52  
; Sequence 52, Application US/09302629  
; Patent No. 6316418  
; GENERAL INFORMATION:  
; APPLICANT: Gerald R. Crabtree  
; APPLICANT: Schreiber, Stuart L.  
; APPLICANT: Spencer, David M.  
; APPLICANT: Wandless, Thomas J.  
; APPLICANT: Belshaw, Peter  
; TITLE OF INVENTION: Regulated Apoptosis  
; NUMBER OF SEQUENCES: 81  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.  
; STREET: 26 Landsdowne Street  
; CITY: Cambridge  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02139  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC/DOS/MS/DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/302,629  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/087,811  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Figg, E. Anthony  
; REGISTRATION NUMBER: 27,195  
; REFERENCE/DOCKET NUMBER: 2054-108A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 783-6040  
; TELEFAX: (202) 783-6031  
; INFORMATION FOR SEQ ID NO: 52:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-302-629-52

Query Match 79.2%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 56  
US-09-526-738A-8  
; Sequence 8, Application US/09526738A  
; Patent No. 6630584  
; GENERAL INFORMATION:  
; APPLICANT: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT  
; APPLICANT: LTD.  
; TITLE OF INVENTION: SINGLE CHAIN ANTIBODY AGAINST MUTANT P53  
; FILE REFERENCE: 1196336  
; CURRENT APPLICATION NUMBER: US/09/526,738A  
; CURRENT FILING DATE: 2000-03-16  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Humanus  
US-09-526-738A-8

Query Match 79.2%; Score 19; DB 4; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 1 FRH 3

RESULT 57  
US-08-875-533-57  
; Sequence 57, Application US/08875533  
; Patent No. 6254870  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: NO. 6254870a1 c-MPL Ligands  
; NUMBER OF SEQUENCES: 73  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/875,533

; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/383,035  
; FILING DATE: 04-FEB-1995  
; INFORMATION FOR SEQ ID NO: 57:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-875-533-57

Query Match 79.2%; Score 19; DB 3; Length 8;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 58  
US-09-464-152A-14  
; Sequence 14, Application US/09464152A  
; Patent No. 6498020  
; GENERAL INFORMATION:  
; APPLICANT: Walker, John  
; APPLICANT: Miroux, Bruno  
; TITLE OF INVENTION: Fusion Proteins Comprising Coiled-Coil Structures Derived of Bovine  
; FILE REFERENCE: 3789/85128  
; CURRENT APPLICATION NUMBER: US/09/464,152A  
; CURRENT FILING DATE: 1999-12-27  
; PRIOR APPLICATION NUMBER: PCT/GB98/02041  
; PRIOR FILING DATE: 1998-07-10  
; PRIOR APPLICATION NUMBER: GB971460.7  
; PRIOR FILING DATE: 1997-07-11  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 14  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: Histidine tag  
US-09-464-152A-14

Query Match 79.2%; Score 19; DB 4; Length 8;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 EFRH 4

RESULT 59  
US-09-589-483-28  
; Sequence 28, Application US/09589483  
; Patent No. 6797488  
; GENERAL INFORMATION:  
; APPLICANT: Sukhatme, Vikas P.  
; TITLE OF INVENTION: METHODS OF PRODUCING ANTI-ANGIOGENIC  
; FILE REFERENCE: 1440.1031010  
; CURRENT APPLICATION NUMBER: US/09/589,483  
; CURRENT FILING DATE: 2000-06-07  
; PRIOR APPLICATION NUMBER: US 60/108,536  
; PRIOR FILING DATE: 1998-11-16  
; PRIOR APPLICATION NUMBER: US 60/082,663  
; PRIOR FILING DATE: 1998-04-22

;; PRIOR APPLICATION NUMBER: US 60/067,888  
;; PRIOR FILING DATE: 1997-12-08  
;; PRIOR APPLICATION NUMBER: PCT/US98/25892  
;; PRIOR FILING DATE: 1998-12-08  
;; NUMBER OF SEQ ID NOS: 34  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 28  
;; LENGTH: 8  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Leader peptide on protein produced by eukaryotic  
;; OTHER INFORMATION: Yeast expression system pPICZa  
US-09-589-483-28  
  
Query Match 79.2%; Score 19; DB 4; Length 8;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 EFRH 4  
Db 1 EFRH 4  
  
RESULT 60  
US-08-134-198E-12  
;; Sequence 12, Application US/08134198E  
;; Patent No. 6190885  
;; GENERAL INFORMATION:  
;; APPLICANT: CANCER RESEARCH FUND  
;; APPLICANT: OF CONTRA COSTA  
;; APPLICANT: PETERSON, JERRY A.  
;; APPLICANT: LAROCCA, DAVID J.  
;; TITLE OF INVENTION: FUSION PROTEIN CONTAINING HMFG  
;; NUMBER OF SEQUENCES: 42  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Pretty, Schroeder & Poplawski  
;; STREET: 444 South Flower Street, Suite 1900  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: USA  
;; ZIP: 90071  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: 3.5" Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0,  
;; SOFTWARE: Version #1.25  
;; CURRENT APPLICATION DATA:  
;; FILING DATE: October 8, 1993  
;; CLASSIFICATION: 530  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Amzel, Viviana  
;; REGISTRATION NUMBER: 30,930  
;; REFERENCE/DOCKET NUMBER: P66 38208 (CRFC-003C)  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 622-7700  
;; TELEFAX: (213) 489-4210  
;; INFORMATION FOR SEQ ID NO: 12:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 9  
;; TYPE: amino acid  
;; STRANDEDNESS:  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-134-198E-12  
  
Query Match 79.2%; Score 19; DB 3; Length 9;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 EFRH 4

Db 1 EFRH 4  
  
RESULT 61  
US-09-502-600-117  
;; Sequence 117, Application US/09502600A  
;; Patent No. 6294344  
;; GENERAL INFORMATION:  
;; APPLICANT: O'Brien, Timothy J.  
;; TITLE OF INVENTION: Compositions and Methods for the Early Diagnosis of  
;; FILE REFERENCE: D6223CIP-C  
;; CURRENT FILING DATE: 2000-02-11  
;; CURRENT APPLICATION NUMBER: US/09/502,600A  
;; PRIOR FILING DATE: 03-14-1998  
;; PRIOR APPLICATION NUMBER: 09/039,211  
;; NUMBER OF SEQ ID NOS: 136  
;; SEQ ID NO 117  
;; LENGTH: 9  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
;; FEATURE:  
;; OTHER INFORMATION: Residues 99-107 of the SCEE protein  
US-09-502-600-117  
  
Query Match 79.2%; Score 19; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 2 FRH 4  
Db 1 FRH 3  
  
RESULT 62  
US-09-149-476-663  
;; Sequence 663, Application US/09149476  
;; Patent No. 6420526  
;; GENERAL INFORMATION:  
;; APPLICANT: Rosen et al.  
;; TITLE OF INVENTION: 186 Human Secreted proteins  
;; FILE REFERENCE: P2002P1  
;; CURRENT APPLICATION NUMBER: US/09/149,476  
;; CURRENT FILING DATE: 1998-09-08  
;; EARLIER APPLICATION NUMBER: PCT/US98/04493  
;; EARLIER FILING DATE: 1998-03-06  
;; EARLIER APPLICATION NUMBER: 60/040,162  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/040,333  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/038,621  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/040,626  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/040,334  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/040,336  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/040,163  
;; EARLIER FILING DATE: 1997-03-07  
;; EARLIER APPLICATION NUMBER: 60/047,600  
;; EARLIER FILING DATE: 1997-05-23  
;; EARLIER APPLICATION NUMBER: 60/047,615  
;; EARLIER FILING DATE: 1997-05-23  
;; EARLIER APPLICATION NUMBER: 60/047,597  
;; EARLIER FILING DATE: 1997-05-23  
;; EARLIER APPLICATION NUMBER: 60/047,502  
;; EARLIER FILING DATE: 1997-05-23  
;; EARLIER APPLICATION NUMBER: 60/047,633  
;; EARLIER FILING DATE: 1997-05-23  
;; EARLIER APPLICATION NUMBER: 60/047,583  
;; EARLIER FILING DATE: 1997-05-23

/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,882
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,637
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,903
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,888
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,879
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,880
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,894
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,911
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,636
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,874
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,910
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,864
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,631
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/057,761
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/047,595
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,599
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,588
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,585
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,586
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,590
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,594
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,589
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,593
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/047,614
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/043,578
/	EARLIER FILING DATE:	1997-04-11
/	EARLIER APPLICATION NUMBER:	60/043,576
/	EARLIER FILING DATE:	1997-04-11
/	EARLIER APPLICATION NUMBER:	60/047,501
/	EARLIER FILING DATE:	1997-05-23
/	EARLIER APPLICATION NUMBER:	60/043,670
/	EARLIER FILING DATE:	1997-04-11
/	EARLIER APPLICATION NUMBER:	60/056,632
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,664
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,876
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,881
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,909
/	EARLIER FILING DATE:	1997-08-22
/	EARLIER APPLICATION NUMBER:	60/056,875
/	EARLIER FILING DATE:	1997-08-22

; EARLIER APPLICATION NUMBER: 60/056,862  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,887  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,908  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/048,964  
; EARLIER FILING DATE: 1997-06-06  
; EARLIER APPLICATION NUMBER: 60/057,650  
; EARLIER FILING DATE: 1997-09-05  
; EARLIER APPLICATION NUMBER: 60/056,884  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/057,669  
; EARLIER FILING DATE: 1997-09-05  
; EARLIER APPLICATION NUMBER: 60/049,610  
; EARLIER FILING DATE: 1997-06-13  
; EARLIER APPLICATION NUMBER: 60/061,060  
; EARLIER FILING DATE: 1997-10-02

Query Match 79.2%; Score 19; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 5 FRH 7

RESULT 63  
US-09-918-243-117  
; Sequence 117, Application US/09918243  
; Patent No. 6627403  
; GENERAL INFORMATION:  
; APPLICANT: O'Brien, Timothy J.  
; APPLICANT: Cannon, Martin J.  
; APPLICANT: Santin, Alessandro  
; TITLE OF INVENTION: Methods for the early diagnosis of ovarian cancer  
; FILE REFERENCE: D6223GP/C/D/CIP  
; CURRENT APPLICATION NUMBER: US/09/918,243  
; CURRENT FILING DATE: 2001-07-30  
; PRIOR APPLICATION NUMBER: US  
; PRIOR FILING DATE: 2001-07-13  
; NUMBER OF SEQ ID NOS: 136  
; SEQ ID NO 117  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CHAIN  
; OTHER INFORMATION: Residues 99-107 of the SCCE protein  
US-09-918-243-117

Query Match 79.2%; Score 19; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 1 FRH 3

RESULT 64  
US-09-601-729-103  
; Sequence 103, Application US/09601729  
; Patent No. 6683052  
; GENERAL INFORMATION:  
; APPLICANT: THIAM, KADER  
; APPLICANT: AURIAULT, CLAUDE  
; APPLICANT: GRAS-MASSE, HELENE  
; APPLICANT: LOING, ESTELLE  
; APPLICANT: VERWAERDE, CLAUDIE  
; APPLICANT: GUILLET, JEAN GERARD  
; TITLE OF INVENTION: LIPOPEPTIDES CONTAINING AN INTERFERON FRAGMENT AND USES

Query Match 79.2%; Score 19; DB 5; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

; TITLE OF INVENTION: THEREOF IN PHARMACEUTICAL COMPOSITIONS  
; FILE REFERENCE: USB-97-AU-IN  
; CURRENT APPLICATION NUMBER: US/09/601,729  
; CURRENT FILING DATE: 2000-11-20  
; PRIOR APPLICATION NUMBER: PCT/FR99/00259  
; PRIOR FILING DATE: 1999-02-05  
; PRIOR APPLICATION NUMBER: 98 01439  
; PRIOR FILING DATE: 1998-02-06  
; NUMBER OF SEQ ID NOS: 281  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 103  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: peptide  
US-09-601-729-103

Query Match 79.2%; Score 19; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 3 FRH 5

RESULT 65  
PCT-US95-16415-30  
; Sequence 30, Application PC/TUS9516415  
; GENERAL INFORMATION:  
; APPLICANT: The Scripps Research Institute  
; TITLE OF INVENTION: IN VIVO ACTIVATION OF TUMOR-SPECIFIC  
; TITLE OF INVENTION: CYTOTOXIC T CELLS  
; NUMBER OF SEQUENCES: 38  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: The Scripps Research Institute  
; STREET: 10666 North Torrey Pines Road, TPC-8  
; CITY: La Jolla  
; STATE: California  
; COUNTRY: US  
; ZIP: 92037  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US95/16415  
; FILING DATE: 13-DEC-1995  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/355,558  
; FILING DATE: 14-DEC-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Logan, April C.  
; REGISTRATION NUMBER: 33,950  
; REFERENCE/DOCKET NUMBER: 433.1PC  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 554-2937  
; TELEFAX: (619) 554-6312  
; INFORMATION FOR SEQ ID NO: 30:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
PCT-US95-16415-30

Query Match 79.2%; Score 19; DB 5; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
Db 3 FRH 5

RESULT 66  
5514558-10  
; Patent No. 5514558  
; APPLICANT: CERIANI, ROBERTO L.; PETERSON, JERRY A.;  
; LAROCCA, DAVID J.  
; TITLE OF INVENTION: HIGHLY SENSITIVE AND SPECIFIC SOLID-PHASE  
; COMPETITIVE ASSAY UTILIZING A FUSION PROTEIN  
; NUMBER OF SEQUENCES: 11  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/129,540  
; FILING DATE: 30-SEP-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 46,103  
; FILING DATE: 08-APR-1993  
; APPLICATION NUMBER: 473,673  
; FILING DATE: 02-FEB-1990  
; SEQ ID NO:10:  
; LENGTH: 9  
5514558-10

Query Match 79.2%; Score 19; DB 6; Length 9;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 1 EFHH 4

RESULT 67  
5514558-10  
; Patent No. 5514558  
; APPLICANT: CERIANI, ROBERTO L.; PETERSON, JERRY A.;  
; LAROCCA, DAVID J.  
; TITLE OF INVENTION: HIGHLY SENSITIVE AND SPECIFIC SOLID-PHASE  
; COMPETITIVE ASSAY UTILIZING A FUSION PROTEIN  
; NUMBER OF SEQUENCES: 11  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/129,540  
; FILING DATE: 30-SEP-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 46,103  
; FILING DATE: 08-APR-1993  
; APPLICATION NUMBER: 473,673  
; FILING DATE: 02-FEB-1990  
; SEQ ID NO:10:  
; LENGTH: 9  
5514558-10

Query Match 79.2%; Score 19; DB 6; Length 9;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 1 EFHH 4

RESULT 68  
US-08-338-634-19  
; Sequence 19, Application US/08338634  
; Patent No. 5679641  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: Peptides of human p53 protein for use  
; in human T cell response inducing compositions, and  
; human p53 protein-specific cytotoxic T-lymphocytes.

QY 2 FRH 4  
Db 5 FRH 7

Query Match 79.2%; Score 19; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
Db 5 FRH 7

RESULT 69  
US-08-637-759B-417  
; Sequence 417, Application US/08637759B  
; Patent No. 5876931  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; STREET: 1201 West Peachtree Street  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/637,759B  
; FILING DATE: 03-MAY-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB95/02875  
; FILING DATE: 11-DEC-1995

CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Fabst, Patrea L.  
REGISTRATION NUMBER: 31,284  
REFERENCE/DOCKET NUMBER: RPMs 101  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (404) 873-8794  
TELEFAX: (404) 873-8795  
INFORMATION FOR SEQ ID NO: 417:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
HYPOTHETICAL: NO  
US-08-637-759B-417

Query Match 79.2%; Score 19; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
DB 6 FRH 8

RESULT 70  
US-08-556-597-171  
Sequence 171, Application US/08556597  
Patent No. 5877155  
GENERAL INFORMATION:  
APPLICANT: Miller, Jonathan L.  
APPLICANT: Lyle, Vicki A.  
TITLE OF INVENTION: MINOTOPES AND ANTI-MINOTOPES OF  
HUMAN PLATELET GLYCOPROTEIN 1b/IX  
NUMBER OF SEQUENCES: 173  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Nixon, Hargrave, Devans & Doyle LLP  
STREET: Clinton Square, P.O. Box 1051  
CITY: Rochester  
STATE: New York  
COUNTRY: USA  
ZIP: 14603  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/556,597  
FILING DATE:  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/406,330  
FILING DATE: 17-MAR-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Timian, Susan J.  
REGISTRATION NUMBER: 34,103  
REFERENCE/DOCKET NUMBER: 20884/101  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (716) 263-1636  
TELEFAX: (716) 263-1600  
INFORMATION FOR SEQ ID NO: 171:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-556-597-171

Query Match 79.2%; Score 19; DB 2; Length 10;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
DB 4 FRH 6

RESULT 71  
US-08-434-664-1  
Sequence 1, Application US/08434664  
Patent No. 5879917  
GENERAL INFORMATION:  
APPLICANT: ESSIGMANN, JOHN M.  
APPLICANT: CROY, ROBERT G.  
APPLICANT: YAREMA, KEVIN J.  
APPLICANT: TREIBER, DANIEL K.  
APPLICANT: CHEN, ZHENGHUAN  
APPLICANT: MORNINGSTAR, MARSHALL  
APPLICANT: ZHAI, XIAOGUAN  
TITLE OF INVENTION: PROGRAMMABLE GENOTOXIC AGENTS AND USES  
THEREFOR  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &  
ADDRESSEE: THIBEAULT  
STREET: 53 STATE STREET  
CITY: BOSTON  
STATE: MA  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/434,664  
FILING DATE:  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: FENTON, GILLIAN M.  
REGISTRATION NUMBER: 36,508  
REFERENCE/DOCKET NUMBER: MIT-018  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 248-7000  
TELEFAX: (617) 248-7100  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-434-664-1

Query Match 79.2%; Score 19; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
DB 2 FRH 4

RESULT 72  
US-08-239-428A-1  
Sequence 1, Application US/08239428A  
Patent No. 5882941  
GENERAL INFORMATION:  
APPLICANT: ESSIGMANN, JOHN M.  
APPLICANT: CROY, ROBERT G.  
APPLICANT: YAREMA, KEVIN J.

; APPLICANT: TREIBER, DANIEL K.  
; APPLICANT: CHEN, ZHENGHUAN  
; APPLICANT: MORNINGSTAR, MARSHALL  
; APPLICANT: ZHAI, XIAOQUAN  
; TITLE OF INVENTION: PROGRAMMABLE GENOTOXIC AGENTS AND USES  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &  
; ADDRESSEE: THIBEAULT  
; STREET: 53 STATE STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/239,428A  
; FILING DATE:  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: FENTON, GILLIAN M.  
; REGISTRATION NUMBER: 36,508  
; REFERENCE/DOCKET NUMBER: MIT-018  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 248-7000  
; TELEFAX: (617) 248-7100  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; US-08-239-428A-1

Query Match 79.2%; Score 19; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 2 FRH 4

RESULT 73  
US-08-871-355A-417  
; Sequence 417, Application US/08871355A  
; Patent No. 6015669  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; STREET: 1201 West Peachtree Street  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/871.355A  
; FILING DATE: 09-JUN-1997

; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB95/02875  
; FILING DATE: 11-DEC-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101 CON  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795  
; INFORMATION FOR SEQ ID NO: 417:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
; US-08-871-355A-417

Query Match 79.2%; Score 19; DB 3; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 6 FRH 8

RESULT 74  
US-09-201-945-417  
; Sequence 417, Application US/09201945  
; Patent No. 6342215  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; STREET: 1201 West Peachtree Street  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/201,945  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/637,759  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795  
; INFORMATION FOR SEQ ID NO: 417:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear



```

; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
US-09-201-945-417

Query Match 79.2%; Score 19; DB 3; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 3; Conservative 0; Mismatches 0;

Qy 2 FRH 4
Db |||
6 FRH 8

RESULT 75
US-09-103-671-1
; Sequence 12, Application US/09103671
; Patent No. 6500669
; GENERAL INFORMATION:
; APPLICANT: Essigmann, John
; APPLICANT: Yarema, Kevin
; APPLICANT: Morningstar, Marshall
; APPLICANT: Croy, Robert
; TITLE OF INVENTION: Programmable Genotoxic Agents and Uses Therefor
; FILE REFERENCE: MIT-018CP2
; CURRENT APPLICATION NUMBER: US/09/103,671
; CURRENT FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: US 08/239,428
; PRIOR FILING DATE: 1994-05-04
; PRIOR APPLICATION NUMBER: US 08/434,664
; PRIOR FILING DATE: 1995-05-04
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: EP240-Cys peptide
US-09-103-671-1

Query Match 79.2%; Score 19; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 3; Conservative 0; Mismatches 0;

Qy 2 FRH 4
Db |||
2 FRH 4

RESULT 76
US-09-724-961-12
; Sequence 12, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740

; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-12

Query Match 79.2%; Score 19; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 3; Conservative 0; Mismatches 0;

Qy 2 FRH 4
Db |||
1 FRH 3

RESULT 77
US-09-580-018-12
; Sequence 12, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-12

Query Match 79.2%; Score 19; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 3; Conservative 0; Mismatches 0;

Qy 2 FRH 4
Db |||
1 FRH 3

RESULT 78
US-09-724-551-12
; Sequence 12, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
```

; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 12  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-12

Query Match 79.2%; Score 19; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
Db 1 FRH 3

RESULT 79  
PCT-US95-05787-1  
; Sequence 1, Application PC/TUS9505787  
; GENERAL INFORMATION:  
; APPLICANT: ESSIGMANN, JOHN M.  
; APPLICANT: CROY, ROBERT G.  
; APPLICANT: YAREMA, KEVIN J.  
; APPLICANT: TREIBER, DANIEL K.  
; APPLICANT: CHEN, ZHENGHUAN  
; APPLICANT: MORNINGSTAR, MARSHALL  
; APPLICANT: ZHAI, XIAOQUAN  
; TITLE OF INVENTION: PROGRAMMABLE GENOTOXIC AGENTS AND USES  
; TITLE OF INVENTION: THEREFOR  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &  
; ADDRESSEE: THIBEAULT  
; STREET: 53 STATE STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US95/05787  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: PENTON, GILLIAN M.  
; REGISTRATION NUMBER: 36,508  
; REFERENCE/DOCKET NUMBER: MIT-018  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 248-7000  
; TELEFAX: (617) 248-7100  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
PCT-US95-05787-1

Query Match 79.2%; Score 19; DB 5; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4

Db 2 FRH 4

RESULT 80  
US-09-020-065A-13  
; Sequence 13, Application US/09020065A  
; Patent No. 6346602  
; GENERAL INFORMATION:  
; APPLICANT: Townsend, Robert M.  
; APPLICANT: Koringold, Robert  
; TITLE OF INVENTION: Peptide Mimics of the Cytokine Receptor Common  
; TITLE OF INVENTION: Gamma Chain and Methods and Compositions for  
; TITLE OF INVENTION: Making and Using the Same  
; NUMBER OF SEQUENCES: 37  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6346602ris LLP  
; STREET: One Liberty Place, 46th Floor  
; CITY: Philadelphia  
; STATE: Pennsylvania  
; COUNTRY: USA  
; ZIP: 19103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: Windows NT  
; SOFTWARE: Wordperfect V. 8  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/020,065A  
; FILING DATE:  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/036,941  
; FILING DATE: 07-FEB-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Deluca, Mark  
; REGISTRATION NUMBER: 33,229  
; REFERENCE/DOCKET NUMBER: TJU-2291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 215-568-3100  
; TELEFAX: 215-568-3439  
; INFORMATION FOR SEQ ID NO: 13:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: both  
; MOLECULE TYPE: peptide  
; US-09-020-065A-13

Query Match 75.0%; Score 18; DB 3; Length 8;  
Best Local Similarity 50.0%; Pred. No. 4.1e+05;  
Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 1 DYRH 4

RESULT 81  
US-09-809-517A-5  
; Sequence 5, Application US/09809517A  
; Patent No. 6753136  
; GENERAL INFORMATION:  
; APPLICANT: Lohning, Corinna  
; TITLE OF INVENTION: No. 6753136el methods for displaying (poly)peptides/proteins on b  
; TITLE OF INVENTION: particles via disulfide bonds  
; FILE REFERENCE: MORPHO/11  
; CURRENT APPLICATION NUMBER: US/09/809,517A  
; CURRENT FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: EP 99114072.4  
; PRIOR FILING DATE: 1999-07-20  
; PRIOR APPLICATION NUMBER: EP 00103551.8  
; PRIOR FILING DATE: 2000-02-18

```
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic module
US-09-809-517A-5

Query Match          75.0%; Score 18; DB 4; Length 9;
Best Local Similarity 75.0%; Pred. No. 4.1e+05;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 1 EFSH 4

RESULT 82
US-08-555-579-2
; Sequence 2, Application US/08555579
; Patent No. 5763225
; GENERAL INFORMATION:
; APPLICANT: Rechsteiner, Martin
; APPLICANT: Yoo, Yung
; APPLICANT: Rote, Kevin
; TITLE OF INVENTION: Synthesis of Peptides as Cloned
; TITLE OF INVENTION: Ubiquitin Extensions
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P. O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/555,579
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sertich, Gary J.
; REGISTRATION NUMBER: 34,430
; REFERENCE/DOCKET NUMBER: UTAH:003--1\SER
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; US-08-555-579-2

Query Match          75.0%; Score 18; DB 1; Length 10;
Best Local Similarity 75.0%; Pred. No. 4.3e+02;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 2 EFMH 5

RESULT 83
US-08-159-339A-88
; Sequence 88, Application US/08159339A
```

```
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Eteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/159,339A
; FILING DATE: 29-NOV-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/926,666
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US 08/027,746
; FILING DATE: 05-MAR-1993
; APPLICATION NUMBER: US 08/103,396
; FILING DATE: 06-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-159-339A-88

Query Match          75.0%; Score 18; DB 3; Length 10;
Best Local Similarity 75.0%; Pred. No. 4.3e+02;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 6 ELRH 9

RESULT 84
US-09-406-781-2
; Sequence 2, Application US/09406781
; Patent No. 6306663
; GENERAL INFORMATION:
; APPLICANT: Kenten, John
; APPLICANT: Roberts, Steven
; TITLE OF INVENTION: CONTROLLING PROTEIN LEVELS IN EUKARYOTIC ORGANISMS
; FILE REFERENCE: 2757-3
; CURRENT APPLICATION NUMBER: US/09/406,781
; CURRENT FILING DATE: 1999-09-28
; EARLIER APPLICATION NUMBER: 60/119,851
; EARLIER FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 67
; SOFTWARE: PatentIn Ver. 2.1
```

```
; SEQ ID NO 2
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: PEST example
; OTHER INFORMATION: sequence
US-09-406-781-2

Query Match          75.0%; Score 18; DB 3; Length 10;
Best Local Similarity 75.0%; Pred. No. 4.3e+02;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 2 EFMH 5

RESULT 85
US-09-468-738A-5
; Sequence 5, Application US/09468738A
; Patent No. 6312933
; GENERAL INFORMATION:
; APPLICANT: Kimoto, No. 6312933;hihiro
; APPLICANT: Yamamoto, Hiroaki
; APPLICANT: Mitsuhashi, Kazuya
; TITLE OF INVENTION: NOVEL CARBONYL REDUCTASE, METHOD FOR PRODUCING SAID ENZYME, DNA
; TITLE OF INVENTION: ENCODING SAID ENZYME, AND METHOD FOR PRODUCING ALCOHOL USING SAID
; TITLE OF INVENTION: ENZYME
; FILE REFERENCE: 06501-050001
; CURRENT APPLICATION NUMBER: US/09/468,738A
; CURRENT FILING DATE: 1999-12-21
; PRIOR FILING DATE: 1999-12-21
; PRIOR APPLICATION NUMBER: JP 1999-171160
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: JP 1998-363130
; PRIOR FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0, reformatted using WordPerfect 5.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Kluyveromyces aestuarii
US-09-468-738A-5

Query Match          75.0%; Score 18; DB 3; Length 10;
Best Local Similarity 75.0%; Pred. No. 4.3e+02;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 5 EFAH 8

RESULT 86
US-09-020-065A-30
; Sequence 30, Application US/09020065A
; Patent No. 6346602
; GENERAL INFORMATION:
; APPLICANT: Townsend, Robert M.
; APPLICANT: Korrigold, Robert
; TITLE OF INVENTION: Peptide Mimics of the Cytokine Receptor Common
; TITLE OF INVENTION: Gamma Chain and Methods and Compositions for
; TITLE OF INVENTION: Making and Using the Same
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6346602ris LLP
; STREET: One Liberty Place, 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Wordperfect V. 8
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/020,065A
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,941
; FILING DATE: 07-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Deluca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-2291
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
; MOLECULE TYPE: peptide
US-09-020-065A-30

Query Match          75.0%; Score 18; DB 3; Length 10;
Best Local Similarity 50.0%; Pred. No. 4.3e+02;
Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 2 DYRH 5

RESULT 87
US-09-940-019-5
; Sequence 5, Application US/09940019
; Patent No. 6416986
; GENERAL INFORMATION:
; APPLICANT: Kimoto, No. 6416986;hihiro
; APPLICANT: Yamamoto, Hiroaki
; APPLICANT: Mitsuhashi, Kazuya
; TITLE OF INVENTION: NOVEL CARBONYL REDUCTASE, METHOD FOR PRODUCING SAID ENZYME, DNA
; TITLE OF INVENTION: ENCODING SAID ENZYME, AND METHOD FOR PRODUCING ALCOHOL USING SAID
; TITLE OF INVENTION: ENZYME
; FILE REFERENCE: 06501-050001
; CURRENT APPLICATION NUMBER: US/09/940,019
; CURRENT FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: 09/468,738
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: JP 1998-363130
; PRIOR FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0, reformatted using WordPerfect 5.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Kluyveromyces aestuarii
US-09-940-019-5

Query Match          75.0%; Score 18; DB 4; Length 10;
Best Local Similarity 75.0%; Pred. No. 4.3e+02;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 5 EFAH 8

RESULT 88
US-09-940-037A-5
; Sequence 5, Application US/09940037A
; Patent No. 6485948
```

GENERAL INFORMATION:  
; APPLICANT: Kimoto, No. 6485948ihiro  
; APPLICANT: Yamamoto, Hiroaki  
; APPLICANT: Mitsuhashi, Kazuya  
; TITLE OF INVENTION: NOVEL CARBONYL REDUCTASE, METHOD FOR PRODUCING SAID ENZYME, DNA  
; TITLE OF INVENTION: ENCODING SAID ENZYME, AND METHOD FOR PRODUCING ALCOHOL USING SAID  
; TITLE OF INVENTION: ENZYME  
; FILE REFERENCE: 06501-050001  
; CURRENT APPLICATION NUMBER: US/09/940,037A  
; CURRENT FILING DATE: 2000-08-27  
; PRIOR APPLICATION NUMBER: 09/468,738  
; PRIOR FILING DATE: 1999-12-21  
; PRIOR APPLICATION NUMBER: JP 1998-363130  
; PRIOR FILING DATE: 1998-12-21  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn Ver. 2.0, reformatted using WordPerfect 5.1  
; SEQ ID NO 5  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Kluyveromyces aestuarii  
US-09-940-037A-5

Query Match 75.0%; Score 18; DB 4; Length 10;  
Best Local Similarity 75.0%; Pred. No. 4.3e+02;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 5 EFAH 8

RESULT 89  
US-09-880-132-2  
; Sequence 2, Application US/09880132  
; Patent No. 6559280  
; GENERAL INFORMATION:  
; APPLICANT: Kenten, John  
; APPLICANT: Roberts, Steven  
; TITLE OF INVENTION: CONTROLLING PROTEIN LEVELS IN EUKARYOTIC ORGANISMS  
; FILE REFERENCE: 2757-6  
; CURRENT APPLICATION NUMBER: US/09/880,132  
; CURRENT FILING DATE: 2001-06-14  
; PRIOR APPLICATION NUMBER: 09/406,781  
; PRIOR FILING DATE: 1999-09-28  
; PRIOR APPLICATION NUMBER: 60/119,851  
; PRIOR FILING DATE: 1999-02-12  
; NUMBER OF SEQ ID NOS: 67  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: PEST example  
; OTHER INFORMATION: sequence  
US-09-880-132-2

Query Match 75.0%; Score 18; DB 4; Length 10;  
Best Local Similarity 75.0%; Pred. No. 4.3e+02;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFMH 5

RESULT 90  
US-08-134-231C-37  
; Sequence 37, Application US/08134231C  
; Patent No. 6562596  
; GENERAL INFORMATION:  
; APPLICANT: Silbiger, Scott M.  
; Koski, Raymond A.

TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type  
; Three (TIMP-3) Composition and Methods  
NUMBER OF SEQUENCES: 42  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett & Dunner  
STREET: 1300 I Street, N.W.  
CITY: Washington  
STATE: District of Columbia  
COUNTRY: USA  
ZIP: 20005  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/134,231C  
FILING DATE: 06-Oct-1993  
CLASSIFICATION: <Unknown>  
INFORMATION FOR SEQ ID NO: 37:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 5 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 37:  
US-08-134-231C-37

Query Match 70.8%; Score 17; DB 4; Length 5;  
Best Local Similarity 75.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 2 EFGH 5

RESULT 91  
US-08-728-160-37  
; Sequence 37, Application US/08728160  
; Patent No. 6683155  
; GENERAL INFORMATION:  
; APPLICANT: Silbiger, Scott M.  
; APPLICANT: Koski, Raymond A.  
; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type  
; TITLE OF INVENTION: Three (TIMP-3) Composition and Methods  
; NUMBER OF SEQUENCES: 41  
; CORRESPONDENCE ADDRESS:  
ADDRESSEE: Amgen Inc./Patent Operations/KMP  
STREET: 1840 Dehavilland Drive  
CITY: Thousand Oaks  
STATE: California  
COUNTRY: USA  
ZIP: 91320-1789  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/728,160  
FILING DATE:  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/134,231  
FILING DATE:  
INFORMATION FOR SEQ ID NO: 37:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 5 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear

```

; MOLECULE TYPE: protein
US-08-728-160-37

Query Match      70.8%; Score 17; DB 4; Length 5;
Best Local Similarity 75.0%; Pred. No. 4.1e+05;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 2 EFGH 5

RESULT 92
US-09-460-676B-3
; Sequence 3, Application US/09460676B
; Patent No. 6653532
; GENERAL INFORMATION:
; APPLICANT: Raap, Maik
; APPLICANT: Hever, Arnd G.
; TITLE OF INVENTION: MEANS AND METHODS FOR INFLUENCING THE
; TITLE OF INVENTION: FLOWERING BEHAVIOUR OF PLANTS
; FILE REFERENCE: 23232.0001
; CURRENT APPLICATION NUMBER: US/09/460,676B
; CURRENT FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: DE 19857654.4
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-09-460-676B-3

Query Match      70.8%; Score 17; DB 4; Length 8;
Best Local Similarity 50.0%; Pred. No. 4.1e+05;
Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 3 EYQH 6

RESULT 93
US-08-199-508-57
; Sequence 57, Application US/08199508
; Patent No. 5717058
; GENERAL INFORMATION:
; APPLICANT: Matthea, Maura-Ann H.
; APPLICANT: Stetler, Gary L.
; APPLICANT: Anderson, David C.
; TITLE OF INVENTION: Modulators of Gene Expression
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Somatogen, Inc.
; STREET: 5797 Central Avenue
; CITY: Boulder
; STATE: Colorado
; ZIP: 80301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4 Mb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: System 7.0.1
; SOFTWARE: Microsoft Word 5.0a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/199,508
; FILING DATE: February 18, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/021,536
; FILING DATE: February 23, 1993
; ATTORNEY/AGENT INFORMATION:

```

```

; NAME: No. 5717058ak, Henry P.
; REGISTRATION NUMBER: 33200
; REFERENCE/DOCKET NUMBER: 121 CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303-541-3322
; TELEFAX: 303-444-3013
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: amino acid
; TOPOLOGY: unknown to applicant
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
US-08-199-508-57

Query Match      70.8%; Score 17; DB 1; Length 10;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 4 EFLH 7

RESULT 94
US-08-441-871-2
; Sequence 2, Application US/08441871
; Patent No. 5846765
; GENERAL INFORMATION:
; APPLICANT: Matthews, David J.
; APPLICANT: Wells, James A.
; APPLICANT: Zoller, Mark J.
; TITLE OF INVENTION: Identification of No. 5846765el Substrates
; NUMBER OF SEQUENCES: 152
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,871
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/418928
; FILING DATE: 05-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/161692
; FILING DATE: 03-DEC-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/864452
; FILING DATE: 06-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09133
; FILING DATE: 03-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/743614
; FILING DATE: 09-AUG-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/715300
; FILING DATE: 14-JUN-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/683400
; FILING DATE: 10-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/621667

```

; FILING DATE: 03-DEC-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Winter, Daryl B.  
; REGISTRATION NUMBER: 32,637  
; REFERENCE/DOCKET NUMBER: 645P5C2D1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 415/225-1249  
; TELEFAX: 415/952-9881  
; TELEX: 910/371-7168  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 4 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
US-08-441-871-2

Query Match 66.7%; Score 16; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0;

QY 1 EFRH 3  
Db 2 EFRH 4

RESULT 95  
PCT-US93-01669-16

; Sequence 16, Application PC/TUS9301669  
; GENERAL INFORMATION:  
; APPLICANT: Trowbridge, Ian S.  
; APPLICANT: Collawn, Jr., James F.  
; APPLICANT: Tainer, John A.  
; APPLICANT: Kuhn, Leslie A.  
; TITLE OF INVENTION: RECEPTOR INTERNALIZATION SIGNALS  
; NUMBER OF SEQUENCES: 57  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Spensley Horn Juras & Lubitz  
; STREET: 1880 Century Park East, Suite 500  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: USA  
; ZIP: 90067  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US93/01669  
; FILING DATE: 01-MAR-1993  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/07/844,852  
; FILING DATE: 03-MAR-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Wetherell, Jr. Ph.D., John R.  
; REGISTRATION NUMBER: 31,678  
; REFERENCE/DOCKET NUMBER: PD-1636  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 455-5100  
; TELEFAX: (619) 455-5110  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 4 amino acids  
; TYPE: amino acid  
; TOPOLOGY: unknown  
; MOLECULE TYPE: Peptide  
PCT-US93-01669-16

Query Match 66.7%; Score 16; DB 5; Length 4;  
Best Local Similarity 66.7%; Pred. No. 4.1e+05;  
Matches 2; Conservative 1; Mismatches 0; Indels 0;

QY 1 EFRH 3  
Db 2 EFRH 4

QY 2 EFRH 4  
Db 1 YRH 3

RESULT 96  
US-09-260-190-2  
; Sequence 2, Application US/09260190  
; Patent No. 6096713  
; GENERAL INFORMATION:  
; APPLICANT: Green, Lawrence R.  
; APPLICANT: Blasecki, John W.  
; TITLE OF INVENTION: Pharmaceutical Angiostatic Dipeptide  
; TITLE OF INVENTION: Compositions and Methods of Use Thereof  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/260,190  
; FILING DATE: 01-MAR-1999  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/538,701  
; FILING DATE: 03-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/614,764  
; FILING DATE: 13-MAR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Powers, Margaret A.  
; REGISTRATION NUMBER: 39,804  
; REFERENCE/DOCKET NUMBER: 015542-002320US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-09-260-190-2

Query Match 66.7%; Score 16; DB 3; Length 5;  
Best Local Similarity 50.0%; Pred. No. 4.1e+05;  
Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
Db 1 EFKH 4

RESULT 97  
US-09-029-267-15  
; Sequence 15, Application US/09029267  
; Patent No. 6107057  
; GENERAL INFORMATION:  
; APPLICANT: Crawford, Kenneth  
; APPLICANT: Zaror, Isabel  
; APPLICANT: Inniss, Michael  
; TITLE OF INVENTION: Pichia Secretory Leader for Protein  
; TITLE OF INVENTION: Expression  
; NUMBER OF SEQUENCES: 40

Thu Nov 3 12:26:05 2005

;;  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Chiron Corporation  
;; STREET: 4560 Horton Street  
;; CITY: Emeryville  
;; STATE: California  
;; COUNTRY: United States  
;; ZIP: 94608  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;;  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/09/029,267  
;; FILING DATE:  
;;  
;; CLASSIFICATION:  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Chung, Ling-Fong  
;; REGISTRATION NUMBER: 36,482  
;; REFERENCE/DOCKET NUMBER: 1165.100  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (510) 601-2704  
;; TELEFAX: (510) 655-3542  
;;  
;; INFORMATION FOR SEQ ID NO: 15:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 5 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
;;  
;; US-09-029-267-15

Query Match 66.7%; Score 16; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
Db 3 EFR 5

RESULT 98  
US-09-794-927A-72  
; Sequence 72, Application US/09794927A  
; Patent No. 6727074  
; GENERAL INFORMATION:  
; APPLICANT: Gurney et al.  
; TITLE OF INVENTION: Alzheimer's Disease Secretase, APP Substrates Therefor and Uses  
; FILE REFERENCE: 29915/6280FG  
; CURRENT APPLICATION NUMBER: US/09/794,927A  
; CURRENT FILING DATE: 2001-02-27  
; PRIOR APPLICATION NUMBER: 09/416,901  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/155,493  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: 09/404,133  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: PCT/US99/20881  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: 60/101,594  
; PRIOR FILING DATE: 1998-09-24  
; NUMBER OF SEQ ID NOS: 74  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 72  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
US-09-794-927A-72

Query Match 66.7%; Score 16; DB 4; Length 5;

Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
Db 3 EFR 5

RESULT 99  
US-09-795-847B-72  
; Sequence 72, Application US/09795847B  
; Patent No. 6753163  
; GENERAL INFORMATION:  
; APPLICANT: Gurney, Mark E.  
; APPLICANT: Bienkowski, Michael J.  
; APPLICANT: Heinrikson, Robert L.  
; APPLICANT: Parodi, Luis A.  
; APPLICANT: Yan, Riqiang  
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES  
; FILE REFERENCE: 28341/6280DE  
; CURRENT APPLICATION NUMBER: US/09/795,847B  
; CURRENT FILING DATE: 2001-02-28  
; PRIOR APPLICATION NUMBER: 09/416,901  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/155,493  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: 09/404,133  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: PCT/US99/20881  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: 60/101,594  
; PRIOR FILING DATE: 1998-09-24  
; NUMBER OF SEQ ID NOS: 74  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 72  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
US-09-795-847B-72

Query Match 66.7%; Score 16; DB 4; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
Db 3 EFR 5

RESULT 100  
US-09-869-414-72  
; Sequence 72, Application US/09869414  
; Patent No. 6790610  
; GENERAL INFORMATION:  
; APPLICANT: Beinkowski et al.  
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES  
; FILE REFERENCE: 28341/6280M  
; CURRENT APPLICATION NUMBER: US/09/869,414  
; CURRENT FILING DATE: 2001-06-27  
; PRIOR APPLICATION NUMBER: 09/416,901  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/155,493  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: 09/404,133  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: PCT/US99/20881  
; PRIOR FILING DATE: 1999-09-23  
; PRIOR APPLICATION NUMBER: 60/101,594  
; PRIOR FILING DATE: 1998-09-24



; NUMBER OF SEQ ID NOS: 73  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 72  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
US-09-869-414-72

Query Match 66.7%; Score 16; DB 4; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
|||  
Db 3 EFR 5

Search completed: November 2, 2005, 09:42:33  
Job time : 44 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:31:45 ; Search time 37 Seconds  
(without alignments)  
10.402 Million cell updates/sec

Title: US-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 1079

Minimum DB seq length: 4

Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database :

PIR\_79:\*

1: PIR1:\*

2: PIR2:\*

3: PIR3:\*

4: PIR4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	13	54.2	8	B45800	serum albumin - do
2	13	54.2	8	PH1618	Ig H chain V-D-J r
3	13	54.2	8	A25836	L-serine ammonia-l
4	13	54.2	9	A31576	xylose isomerase (
5	13	54.2	10	PH1592	Ig H chain V-D-J r
6	11	45.8	5	A44692	fulicin - giant Af
7	11	45.8	6	A43129	neuropeptide GNFR
8	11	45.8	8	XGHUEU	urine glycopeptide
9	11	45.8	9	D28854	fibrinopeptide B -
10	11	45.8	9	D58503	translation elonga
11	11	45.8	9	S65433	bradykinin - horn
12	11	45.8	9	S10920	venom protein HR-3
13	11	45.8	9	S77984	cytochrome-c oxida
14	11	45.8	9	S66635	alpha-2-macroglobu
15	11	45.8	9	A43065	hydroxyproline-3-b
16	11	45.8	9	A26744	bradykinin-like pe
17	11	45.8	9	A61057	Thr-6 bradykinin -
18	11	45.8	9	A60579	bradykinin-like pe
19	11	45.8	9	A61363	bradykinin - commo
20	11	45.8	9	A61358	bradykinin-like pe
21	11	45.8	10	GMROL2	leucosulfakinin-II
22	11	45.8	10	S48182	bacterioferritin -
23	11	45.8	10	PC2044	beta-Kirilowin - M
24	11	45.8	10	A58365	neuropeptide FFRfa
25	11	45.8	10	S30348	clotting protein -
26	11	45.8	10	B60656	leucosulfakinin II
27	11	45.8	10	D46285	formaldehyde dehyd
28	10	41.7	7	I56695	hypothetical l2 pr
29	10	41.7	8	S16324	hypothetical prote

30	10	41.7	8	2	T14906	hypothetical prote
31	10	41.7	9	2	PT0231	Ig heavy chain CDR
32	10	41.7	10	2	S13224	virg protein - Agr
33	10	41.7	10	2	A30823	bothropstoxin - Ja
34	10	41.7	10	2	A44871	monodehydroascorba
35	10	41.7	10	2	P00783	NADH2 dehydrogenas
36	9	37.5	6	2	JN0861	peptidyl-dipeptida
37	9	37.5	6	2	S11024	hydrogensulfite re
38	9	37.5	9	2	C36730	hutu protein - Kle
39	9	37.5	10	1	RHPGG	gonadoliberin - pi
40	9	37.5	10	1	RHSHG	gonadoliberin - sh
41	9	37.5	10	1	A61126	gonadoliberin - sp
42	9	37.5	10	1	RHAQ1	gonadoliberin I -
43	9	37.5	10	1	RHAQ2	gonadoliberin II -
44	9	37.5	10	1	RHLMS	gonadoliberin - se
45	9	37.5	10	2	A43405	6-phosphofructo-2-
46	9	37.5	10	2	S39392	calpain (EC 3.4.22
47	9	37.5	10	2	B46030	gonadoliberin II -
48	9	37.5	10	2	S59625	beta-galactosidase
49	9	37.5	10	2	PC4374	telomeric and tetr
50	9	37.5	10	2	F41839	ribosomal protein
51	9	37.5	10	2	A46030	gonadoliberin I -
52	9	37.5	10	2	A21114	gonadoliberin - ch
53	9	37.5	10	2	H37196	bradykinin-potent
54	8	33.3	4	2	A48360	gamma subunit of p
55	8	33.3	4	2	I38888	COI intron 16 prot
56	8	33.3	4	2	P01040	carbon-monoxide de
57	8	33.3	4	2	J01273	neuropeptide Antho
58	8	33.3	4	2	PT0712	T-cell receptor be
59	8	33.3	5	2	JN0860	peptidyl-dipeptida
60	8	33.3	5	2	A32516	cholecystokinin-5
61	8	33.3	5	2	S70154	copper resistance
62	8	33.3	5	2	B37325	URF2 protein - Xan
63	8	33.3	5	2	S70154	pap fibrial regul
64	8	33.3	5	2	F22565	R-phycocerythrin ga
65	8	33.3	5	2	T10954	hypothetical prote
66	8	33.3	5	2	I40698	biocin B - Citroba
67	8	33.3	6	2	A61419	sarcosine dehydrog
68	8	33.3	6	2	I37027	prolamine PI - gor
69	8	33.3	6	2	B56979	collagen alpha 1(I
70	8	33.3	6	2	S78764	ribosomal protein
71	8	33.3	6	2	A46474	Fc epsilon RIIB -
72	8	33.3	6	2	PT0693	T-cell receptor be
73	8	33.3	6	2	A41946	T-cell receptor ga
74	8	33.3	6	2	S71349	beta-crystallin B2
75	8	33.3	6	2	PD0028	pev-kinin 2 - pena
76	8	33.3	7	1	NYPG7	hypothalamic hepta
77	8	33.3	7	2	PQ0663	membrane protein -
78	8	33.3	7	2	B39127	phosphotransferase
79	8	33.3	7	2	S42407	gramicidin S synth
80	8	33.3	7	2	A28709	phosphonoacetaldeh
81	8	33.3	7	2	PT0246	Ig heavy chain CRD
82	8	33.3	7	2	PT0520	T-cell receptor be
83	8	33.3	7	2	PT0665	T-cell receptor be
84	8	33.3	7	2	A38081	amine oxidase (cop
85	8	33.3	7	2	S29735	polyphosphate-gluc
86	8	33.3	7	2	A15398	choline oxidase (E
87	8	33.3	7	2	I46868	alpha-myosin heavy
88	8	33.3	7	2	S08606	hypothetical prote
89	8	33.3	8	2	PQ0012	cholecystokinin -
90	8	33.3	8	2	A43001	cholecystokinin -
91	8	33.3	8	2	A39892	P element, P cytot
92	8	33.3	8	2	PT0368	Ig gamma chain C r
93	8	33.3	8	2	B54823	olfactory receptor
94	8	33.3	8	2	S66296	Na+-transporting A
95	8	33.3	8	2	S37141	rpsa protein - Erw
96	8	33.3	8	2	JS0316	inulinase (EC 3.2.
97	8	33.3	8	2	JS0316	leucokinin VI - Ma
98	8	33.3	8	2	JS0318	leucokinin VIII -
99	8	33.3	8	2	H41978	calliFWRamide 8 -
100	8	33.3	8	2	E47393	neuropeptide calla

## ALIGNMENTS

## RESULT 1

B45800  
serum albumin - dog (fragment)  
C;Species: Canis lupus familiaris (dog)  
C;Date: 03-Jun-1993 #sequence\_revision 03-Jun-1993 #text\_change 31-Dec-1993  
C;Accession: B45800  
R;Carraway, R.E.; Cochran, D.E.; Boucher, W.; Mitra, S.P.  
J. Immunol. 143, 1680-1684, 1989  
A;Title: Structures of histamine-releasing peptides formed by the action of acid proteases  
A;Reference number: A45800; MUID:89341406; PMID:2474609  
A;Accession: B45800  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-8 <CAR>

Query Match 54.2%; Score 13; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
||  
Db 4 RH 5

## RESULT 2

PH1618  
Ig H chain V-D-J region (clone B-less 33) - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 02-Jun-1994 #sequence\_revision 02-Jun-1994 #text\_change 17-Mar-1999  
C;Accession: PH1618  
R;Levinson, D.A.; Campos-Torres, J.; Leder, P.  
J. Exp. Med. 178, 317-329, 1993  
A;Title: Molecular characterization of transgene-induced immunodeficiency in B-less mice  
A;Reference number: PH1580; MUID:93301609; PMID:8315387  
A;Accession: PH1618  
A;Molecule type: DNA  
A;Residues: 1-8 <LEV>  
A;Experimental source: bone marrow pre-B lymphocyte  
C;Keywords: immunoglobulin

Query Match 54.2%; Score 13; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
||  
Db 3 RH 4

## RESULT 3

A25836  
L-serine ammonia-lyase (EC 4.3.1.17) - Escherichia coli (fragment)  
C;Species: Escherichia coli  
C;Date: 24-Jan-1988 #sequence\_revision 24-Jan-1988 #text\_change 09-Jul-2004  
C;Accession: A25836  
R;Heincz, M.C.; McFall, E.  
J. Bacteriol. 123, 1163-1168, 1975  
A;Title: N-terminal amino acid sequences of D-serine deaminases of wild-type and operato  
A;Reference number: A25836; MUID:76005414; PMID:1099073  
A;Contents: K12  
A;Accession: A25836  
A;Molecule type: protein  
A;Residues: 1-8 <HEI>  
A;Cross-references: UNIPROT:Q7M194  
C;Keywords: ammonia-lyase; carbon-nitrogen lyase; carbon-oxygen lyase; hydro-lyase; seri

Query Match 54.2%; Score 13; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
||  
Db 6 RH 7

## RESULT 4

A31576  
xylose isomerase (EC 5.3.1.5), intracellular - Streptomyces sp. (fragment)  
C;Species: Streptomyces sp.  
C;Date: 31-Mar-1990 #sequence\_revision 31-Mar-1990 #text\_change 09-Jul-2004  
C;Accession: A31576  
R;Pawar, H.S.; Kannan, K.; Srinivasan, M.C.; Vartak, H.G.  
Biochem. Biophys. Res. Commun. 155, 411-417, 1988  
A;Title: Purification and characterisation of glucose (xylose) isomerase from Chainia sp  
A;Reference number: A31576; MUID:88326335; PMID:3415697  
A;Contents: Chainia sp. NCL 82-5-1  
A;Accession: A31576  
A;Molecule type: protein  
A;Residues: 1-9 <PAW>  
A;Cross-references: UNIPROT:P19149  
C;Keywords: intramolecular oxidoreductase; isomerase

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
||  
Db 1 RH 2

## RESULT 5

PH1592  
Ig H chain V-D-J region (wild-type clone 143) - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 02-Jun-1994 #sequence\_revision 02-Jun-1994 #text\_change 17-Mar-1999  
C;Accession: PH1592  
R;Levinson, D.A.; Campos-Torres, J.; Leder, P.  
J. Exp. Med. 178, 317-329, 1993  
A;Title: Molecular characterization of transgene-induced immunodeficiency in B-less mice  
A;Reference number: PH1580; MUID:93301609; PMID:8315387  
A;Accession: PH1592  
A;Molecule type: DNA  
A;Residues: 1-10 <LEV>  
A;Experimental source: bone marrow pre-B lymphocyte  
C;Keywords: immunoglobulin

Query Match 54.2%; Score 13; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 2.8e+03;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
||  
Db 3 RH 4

## RESULT 6

A44692  
fulicin - giant African snail  
C;Species: Achatina fulica (giant African snail)  
C;Date: 23-Mar-1995 #sequence\_revision 05-Apr-1995 #text\_change 09-Jul-2004  
C;Accession: A44692  
R;Ohta, N.; Kubota, I.; Takao, T.; Shimonishi, Y.; Yasuda-Kamatani, Y.; Minakata, H.; No  
Biochem. Biophys. Res. Commun. 178, 486-493, 1991  
A;Title: Fulicin, a novel neuropeptide containing a D-amino acid residue isolated from t  
A;Reference number: A44692; MUID:91315471; PMID:1859408  
A;Accession: A44692  
A;Molecule type: protein  
A;Residues: 1-5 <OHT>  
A;Cross-references: UNIPROT:P35905  
C;Keywords: amidated carboxyl end; D-amino acid; neuropeptide  
F;2/Modified site: D-asparagine (Asn) #status experimental  
F;5/Modified site: amidated carboxyl end (Val) #status experimental

Query Match 45.8%; Score 11; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
||  
3 EF 4

Db

RESULT 7  
A43129  
neuropeptide GNFFRFamide - tapeworm (*Moniezia expansa*)  
C:Species: *Moniezia expansa*  
C:Date: 10-Nov-1997 #sequence\_revision 14-Nov-1997 #text\_change 09-Jul-2004  
C:Accession: A43129  
R:Maule, A.; Shaw, C.; Halton, D.; Thim, L.  
Biochem. Biophys. Res. Commun. 193, 1054-1060, 1993  
A:Title: GNFFRFamide: A novel FMRFamide-immunoreactive peptide isolated from the sheep  
A:Reference number: A43129; MUID:93312289; PMID:8323531  
A:Accession: A43129  
A:Molecule type: protein  
A:Residues: 1-6 <NAU>  
A:Cross-references: UNIPROT:P41566  
C:Keywords: amidated carboxyl end; neuropeptide  
F:6/Modified site: amidated carboxyl end (Phe) #status predicted

Query Match 45.8%; Score 11; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
4 FR 5

Db

RESULT 8  
XGHUEU  
urine glycopeptide - human  
C:Species: *Homo sapiens* (man)  
C:Date: 20-Jun-2000 #sequence\_revision 20-Jun-2000 #text\_change 16-Aug-2004  
C:Accession: A03188  
R:Lote, C.J.; Weiss, J.B.  
Biochem. J. 123, 25P, 1971  
A:Title: Identification in urine of a low-molecular-weight polar glycopeptide containing  
A:Reference number: A03188; MUID:72062338; PMID:5126885  
A:Accession: A03188  
A:Molecule type: protein  
A:Residues: 1-8 <LOT>  
A:Cross-references: UNIPROT:P02729  
C:Comment: The identity of the glycoprotein from which this peptide is derived is unknown  
re has also been found (see PIR:XGHUE).  
C:Keywords: glycoprotein  
F:1/Binding site: carbohydrate (Cys) (covalent) #status experimental

Query Match 45.8%; Score 11; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 EFRH 4  
||  
2 EHS 5

Db

RESULT 9  
D28854  
fibrinopeptide B - olive baboon  
C:Species: *Papio anubis*, *Papio hamadryas anubis* (olive baboon)  
C:Date: 19-May-1989 #sequence\_revision 19-May-1989 #text\_change 09-Jul-2004  
C:Accession: D28854  
R:Nakamura, S.; Takenaka, O.; Takahashi, K.  
J. Biochem. 94, 1973-1978, 1983  
A:Title: Fibrinopeptides A and B of baboons (*Papio anubis*, *Papio hamadryas*, and *Theropid*

A:Reference number: A91973; MUID:84161822; PMID:6423621  
A:Accession: D28854  
A:Molecule type: protein  
A:Residues: 1-9 <NAK>  
A:Cross-references: UNIPROT:P19344  
C:Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulfide

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
6 FR 7

Db

RESULT 10  
D58503  
translation elongation factor EF-Tu - unidentified bacterium (fragment)  
C:Species: unidentified bacterium  
C:Date: 07-Feb-1997 #sequence\_revision 07-Feb-1997 #text\_change 09-Jul-2004  
C:Accession: D58503  
R:Binette, J.P.; Binette, M.B.  
submitted to the Protein Sequence Database, October 1996  
A:Description: The proteins of kidney and gallbladder stones.  
A:Reference number: A58501  
A:Accession: D58503  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-9 <BIN>  
A:Cross-references: UNIPROT:Q7M151  
A:Experimental source: human bile and stones  
C:Superfamily: translation elongation factor Tu; translation elongation factor Tu homolog  
C:Keywords: GTP binding

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
8 FR 9

Db

RESULT 11  
S65433  
bradykinin - horn fly (fragment)  
C:Species: *Haematobia irritans* (horn fly)  
C:Date: 28-Oct-1996 #sequence\_revision 13-Mar-1997 #text\_change 13-Mar-1997  
C:Accession: S65433  
R:Wijffels, G.; Fitzgerald, C.; Gough, J.; Riding, G.; Elvin, C.; Kemp, D.; Willadsen, F.  
Eur. J. Biochem. 237, 414-423, 1996  
A:Title: Cloning and characterisation of angiotensin-converting enzyme from the dipteran  
A:Reference number: S65431; MUID:96215437; PMID:8647080  
A:Accession: S65433  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-9 <WIJ>  
A:Note: the source is designated as *Haematobia irritans exigua*

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
8 FR 9

Db

RESULT 12  
S10920  
venom protein HR-3 - oriental hornet (fragment)  
C:Species: *Vespa orientalis* (oriental hornet)

C;Date: 29-Jan-1993 #sequence\_revision 29-Jan-1993 #text\_change 09-Jul-2004  
C;Accession: S10920  
R;Tsuchibae, M.U.; Akhmedova, N.U.; Kazakov, I.; Korneev, A.S.; Gagel'gans, A.I.  
Biochemistry (N.Y.) 53, 183-190, 1988  
A;Title: Low-molecular-weight peptides of venom of the giant hornet *Vespa orientalis*. S  
A;Reference number: S06445  
A;Accession: S10920  
A;Molecule type: protein  
A;Residues: 1-9 <PI>  
A;Cross-references: UNIPROT:Q7M471  
C;Keywords: venom

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
||  
5 EF 6

Db

RESULT 13  
S77984  
cytochrome-c oxidase (EC 1.9.3.1) chain Via - bigeye tuna (fragment)  
C;Species: *Thunnus obesus* (bigeye tuna)  
C;Date: 17-Sep-1997 #sequence\_revision 17-Sep-1997 #text\_change 09-Jul-2004  
C;Accession: S77984  
R;Arnold, S.; Lee, J.; Kim, M.; Song, E.; Linder, D.; Lottspeich, F.; Kadenbach, B.  
submitted to the Protein Sequence Database, June 1997  
A;Reference number: S77980  
A;Accession: S77984  
A;Molecule type: protein  
A;Residues: 1-9 <ARN>  
A;Cross-references: UNIPROT:P80975  
A;Experimental source: heart  
C;Genetics:  
A;Genome: nuclear  
C;Function:  
A;Pathway: oxidative phosphorylation; respiratory chain  
C;Keywords: electron transfer; membrane-associated complex; mitochondrial inner membrane

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
||  
5 EF 6

Db

RESULT 14  
S66635  
alpha-2-macroglobulin isoform 1 - bovine (fragment)  
C;Species: *Bos primigenius indicus* (zebu cattle)  
C;Date: 15-Feb-1997 #sequence\_revision 13-Mar-1997 #text\_change 09-Jul-2004  
C;Accession: S66635  
R;Dolmer, K.; Jenner, L.B.; Jacobsen, L.; Andersen, G.R.; Koch, T.J.; Thirup, S.; Sottr  
FEBS Lett. 372, 93-95, 1995  
A;Title: Crystallisation and preliminary X-ray analysis of the receptor-binding domain c  
A;Reference number: S66634; MUID:96032553; PMID:7556651  
A;Accession: S66635  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-9 <DOL>  
A;Cross-references: UNIPROT:Q7M2N8

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
||  
3 EF 4

Db

## RESULT 15

A43065

hydroxyproline-3-bradykinin - frog (*Helaophryne purcelli*)C;Species: *Helaophryne purcelli*

C;Date: 07-Oct-1994 #sequence\_revision 07-Oct-1994 #text\_change 09-Jul-2004

C;Accession: A43065

R;Nakajima, T.; Yasuhara, T.; Erspamer, G.F.; Visser, J.

Experientia 35, 1133, 1979

A;Title: Occurrence of Hyp(3)-bradykinin in methanol extracts of the skin of the South A

A;Reference number: A43065; MUID:80024576; PMID:488255

A;Accession: A43065

A;Molecule type: protein

A;Residues: 1-9 &lt;NAK&gt;

A;Cross-references: UNIPROT:Q7LZ17

C;Keywords: bradykinin; hydroxyproline; skin

F;3/Modified site: hydroxyproline (Pro) #status experimental

Qy 2 FR 3  
||  
Db 8 FR 9

## RESULT 18

A60579  
bradykinin-like peptide - slider turtle  
C:Species: Pseudemys scripta (slider)  
C:Date: 17-Apr-1993 #sequence\_revision 17-Apr-1993 #text\_change 18-Aug-2000  
C:Accession: A60579  
R:Conlon, J.M.; Hicks, J.W.; Smith, D.D.  
Endocrinology 126, 985-991, 1990  
A:Title: Isolation and biological activity of a novel kinin ((Thr(6))bradykinin) from the  
A:Reference number: A60579; MUID:90126625; PMID:2298179  
A:Accession: A60579  
A:Molecule type: protein  
A:Residues: 1-9 <CON>  
C:Comment: This peptide increases aortic blood flow but, unlike bradykinin in mammalian  
C:Superfamily: unassigned animal peptides  
C:Keywords: plasma

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
Db 8 FR 9

## RESULT 19

A61363  
bradykinin - common frog  
C:Species: Rana temporaria (common frog)  
C:Date: 09-Sep-1994 #sequence\_revision 09-Sep-1994 #text\_change 09-Jul-2004  
C:Accession: A61363  
R:Anastasi, A.; Erspamer, V.; Bertaccini, G.  
Comp. Biochem. Physiol. A 14, 43-52, 1965  
A:Title: Occurrence of bradykinin in the skin of Rana temporaria.  
A:Reference number: A61363  
A:Accession: A61363  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-9 <ANA>  
A:Cross-references: UNIPROT:Q7LZJ8  
C:Superfamily: unassigned animal peptides  
C:Keywords: skin

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
Db 8 FR 9

## RESULT 20

A61358  
bradykinin-like peptide I - Japanese pond frog  
C:Species: Rana nigromaculata (Japanese pond frog)  
C:Date: 09-Sep-1994 #sequence\_revision 09-Sep-1994 #text\_change 09-Jul-2004  
C:Accession: A61358  
R:Nakajima, T.  
Chem. Pharm. Bull. 16, 769-770, 1968  
A:Title: Occurrence of a new active peptide on smooth muscle and bradykinin in the skin  
A:Reference number: A61358; MUID:68412013; PMID:5677638  
A:Accession: A61358  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-9 <NAK>  
A:Cross-references: UNIPROT:Q7LZ54

C:Superfamily: unassigned animal peptides  
C:Keywords: skin

Query Match 45.8%; Score 11; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
||  
Db 8 FR 9

## RESULT 21

GMR0L2  
leucosulfakinin-II - Madeira cockroach  
N:Alternate names: LSK-II  
C:Species: Leucophaea maderae (Madeira cockroach)  
C:Date: 31-Dec-1988 #sequence\_revision 31-Dec-1988 #text\_change 09-Jul-2004  
C:Accession: A26335  
R:Nachman, R.J.; Holman, G.M.; Cook, B.J.; Haddon, W.F.; Ling, N.  
Biochem. Biophys. Res. Commun. 140, 357-364, 1986  
A:Title: Leucosulfakinin-II, a blocked sulfated insect neuropeptide with homology to ch  
A:Reference number: A26335; MUID:87048769; PMID:3778455  
A:Accession: A26335  
A:Molecule type: protein  
A:Residues: 1-10 <NAC>  
A:Cross-references: UNIPROT:P09039  
C:Comment: This peptide was isolated from head extracts. It stimulates muscle contractio  
C:Superfamily: gastrin  
C:Keywords: amidated carboxyl end; neuropeptide; pyroglutamic acid; sulfoprotein  
F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:5/Binding site: sulfate (Tyr) (covalent) #status experimental  
F:10/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 45.8%; Score 11; DB 1; Length 10;  
Best Local Similarity 25.0%; Pred. No. 8.5e+03;  
Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4  
:::  
Db 4 DYGH 7

## RESULT 22

S48182  
bacterioferritin - Rhodobacter capsulatus  
C:Species: Rhodobacter capsulatus  
C:Date: 15-Jul-1995 #sequence\_revision 19-Oct-1995 #text\_change 07-May-1999  
C:Accession: S48182  
R:Ringeling, P.L.; Davy, S.L.; Monkara, F.A.; Hunt, C.; Dickson, D.P.E.; McEwan, A.G.; t  
Eur. J. Biochem. 223, 847-855, 1994  
A:Title: Iron metabolism in Rhodobacter capsulatus. Characterisation of bacterioferritin  
A:Reference number: S48182; MUID:94333389; PMID:8055962  
A:Accession: S48182  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-10 <RIN>

Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 8.5e+03;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
||  
Db 9 EF 10

## RESULT 23

PC2044  
beta-kirilowin - Mongolian snake-gourd (fragment)  
C:Species: Trichosanthes kirilowii (Mongolian snake-gourd)  
C:Date: 14-Jul-1994 #sequence\_revision 14-Jul-1994 #text\_change 09-Jul-2004  
C:Accession: PC2044

R;Dong, T.X.; Ng, T.B.; Yeung, H.W.; Wong, R.N.S.  
 Biochem. Biophys. Res. Commun. 199, 387-393, 1994  
 A;Title: Isolation and characterization of a novel ribosome-inactivating protein, beta-k  
 A;Reference number: PC2044; MUID:94168605; PMID:8123040  
 A;Accession: PC2044  
 A;Molecule type: protein  
 A;Residues: 1-10 <DON>  
 A;Cross-references: UNIPROT:Q7M116  
 A;Experimental source: seed  
 C;Comment: This protein exhibited strong abortifacient activity, and is a ribosome inact

Query Match 45.8%; Score 11; DB 2; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.5e+03;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3

Db 5 FR 6

#### RESULT 24

A58365

neuropeptide FFRamide - blue mussel

N;Alternate names: FMRamide-related decapeptide; Mytilus FFRamide

C;Species: Mytilus edulis (blue mussel)

C;Date: 20-Nov-1996 #sequence\_revision 22-Nov-1996 #text\_change 09-Jul-2004

C;Accession: A58365

R;Fujisawa, Y.; Ikeda, T.; Nomoto, K.; Yasuda-Kamatani, Y.; Minakata, H.; Kenny, P.T.M.;

Comp. Biochem. Physiol. C 102, 91-95, 1992

A;Title: The FMRamide-related decapeptide of Mytilus contains a D-amino acid residue.

A;Reference number: A58365; MUID:93047882; PMID:1358533

A;Accession: A58365

A;Molecule type: protein

A;Residues: 1-10 <FU>

A;Cross-references: UNIPROT:P42560

A;Experimental source: anterior byssus retractor muscle

C;Keywords: amidated carboxyl end; D-amino acid; neuropeptide

F;1/Modified site: D-leucine (leu) #status experimental

F;10/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 45.8%; Score 11; DB 2; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.5e+03;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3

Db 8 FR 9

#### RESULT 25

S30348

clotting protein - signal crayfish

C;Species: Pacifastacus leniusculus (signal crayfish)

C;Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 09-Jul-2004

C;Accession: S30348

R;Kopacek, P.; Hall, M.; Soederhaell, K.

Eur. J. Biochem. 213, 591-597, 1993

A;Title: Characterization of a clotting protein, isolated from plasma of the freshwater

A;Reference number: S30348; MUID:93238739; PMID:8097463

A;Accession: S30348

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-10 <KOP>

A;Cross-references: UNIPROT:P81070; UNIPROT:Q9UAR3

Query Match 45.8%; Score 11; DB 2; Length 10;

Best Local Similarity 25.0%; Pred. No. 8.5e+03;

Matches 1; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4

Db 6 EYQY 9

#### RESULT 26

B60656

leucosulfakinin II, non-sulfated - American cockroach

C;Species: Periplaneta americana (American cockroach)

C;Date: 14-May-1993 #sequence\_revision 14-May-1993 #text\_change 09-Jul-2004

C;Accession: B60656

R;Veenstra, J.A.

Neuropeptides 14, 145-149, 1989

A;Title: Isolation and structure of two gastrin/CKK-like neuropeptides from the American

A;Reference number: A60656; MUID:90137190; PMID:2615921

A;Accession: B60656

A;Molecule type: protein

A;Residues: 1-10 <VEE>

A;Cross-references: UNIPROT:P09039

C;Keywords: amidated carboxyl end; neuropeptide, pyroglutamic acid

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;10/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 45.8%; Score 11; DB 2; Length 10;

Best Local Similarity 25.0%; Pred. No. 8.5e+03;

Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4

Db 4 DYGH 7

#### RESULT 27

D46285

formaldehyde dehydrogenase (glutathione) (EC 1.2.1.1) class III low activity form - Atla

C;Species: Gadus morhua (Atlantic cod)

C;Date: 19-Nov-1993 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004

C;Accession: D46285

R;Danielsson, O.; Jornvall, H.

Proc. Natl. Acad. Sci. U.S.A. 89, 9247-9251, 1992

A;Title: "Enzymogenesis": classical liver alcohol dehydrogenase origin from the glutathi

A;Reference number: A46285; MUID:93028441; PMID:1409630

A;Accession: D46285

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-10 <DAN>

A;Cross-references: UNIPROT:Q9PSO8

A;Note: sequence extracted from NCBI backbone (NCBI:P116272)

C;Keywords: NAD; oxidoreductase

Query Match 45.8%; Score 11; DB 2; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.5e+03;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2

Db 2 EF 3

#### RESULT 28

I56695

hypothetical L2 protein (mistranslated) - human papillomavirus type 16 (fragment)

C;Species: human papillomavirus type 16

C;Date: 18-Feb-2000 #sequence\_revision 18-Feb-2000 #text\_change 18-Feb-2000

C;Accession: I56695

R;Schneider-Maunoury, S.; Croissant, O.; Orth, G.

J. Virol. 61, 3295-3298, 1987

A;Title: Integration of human papillomavirus type 16 DNA sequences: a possible early eve

A;Reference number: I56695; MUID:87311896; PMID:3041049

A;Accession: I56695

A;Status: translated from GB/EMBL/DBJ

A;Molecule type: DNA

A;Residues: 1-7 <SCH>

A;Cross-references: GB:M30709; NID:9190253; PIDN:AAA65995.1; PID:9553616

C;Comment: This is the hypothetical translation of a viral sequence integrated into the

C;Comment: It is translated in an incorrect, -1, reading frame of the L2 protein.



Query Match 41.7%; Score 10; DB 4; Length 7;  
Best Local Similarity 33.3%; Pred. No. 2.8e+05;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 FRH 4  
Db 3 YRY 5

RESULT 29  
SI6324  
hypothetical protein 2 - Arabidopsis thaliana  
C:Species: Arabidopsis thaliana (mouse-ear cress)  
C:Date: 21-Nov-1993 #sequence\_revision 12-May-1995 #text\_change 21-Jul-2000  
C:Accession: SI6324  
R:Ruberti, I.; Sessa, G.; Lucchetti, S.; Morelli, G.  
EMBO J. 10, 1787-1791, 1991  
A:Title: A novel class of plant proteins containing a homeodomain with a closely linked  
A:Reference number: SI6323; MUID:91266907; PMID:1675603  
A:Accession: SI6324  
A:Status: translation not shown  
A:Molecule type: mRNA  
A:Residues: 1-8 <RUB>  
A:Cross-references: EMBL:X58821; NID:g16327; PIDN:CAA41624.1; PID:g579259

Query Match 41.7%; Score 10; DB 2; Length 8;  
Best Local Similarity 33.3%; Pred. No. 2.8e+05;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 EFR 3  
Db 2 EYK 4

RESULT 30  
TI4906  
hypothetical protein - parsley  
C:Species: Petroselinum crispum (parsley)  
C:Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 20-Sep-1999  
C:Accession: TI4906  
R:Feldbrugge, M.; Sprenger, M.; Dinkelbach, M.; Yazaki, K.; Harter, K.; Weisshaar, B.  
Plant Cell 6, 1607-1621, 1994  
A:Title: Functional analysis of a light-responsive plant bZIP transcriptional regulator.  
A:Reference number: Z18259; MUID:95128172; PMID:7827494  
A:Accession: TI4906  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: DNA  
A:Residues: 1-8 <FEL>  
A:Cross-references: EMBL:S75395; NID:g913201; PID:e194245

Query Match 41.7%; Score 10; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 3 RH 4  
Db 2 KH 3

RESULT 31  
PT0231  
Ig heavy chain CDR3 region (clone 1-118B) - human (fragment)  
C:Species: Homo sapiens (man)  
C:Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 16-Aug-1996  
C:Accession: PT0231  
R:Yanada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.  
J. Exp. Med. 173, 395-407, 1991  
A:Title: Preferential utilization of specific immunoglobulin heavy chain diversity and  
A:Reference number: PT0222; MUID:91108337; PMID:1899102  
A:Accession: PT0231  
A:Molecule type: DNA  
A:Residues: 1-9 <YAM>

A:Experimental source: B lymphocyte  
C:Keywords: heterotetramer; immunoglobulin

Query Match 41.7%; Score 10; DB 2; Length 9;  
Best Local Similarity 33.3%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
Qy 2 FRH 4  
Db 1 YTH 3

RESULT 32  
SI3224  
virG protein - Agrobacterium sp. (fragment)  
C:Species: Agrobacterium sp.  
C:Date: 19-Mar-1997 #sequence\_revision 01-Aug-1997 #text\_change 09-Jul-2004  
C:Accession: SI3224  
R:Tanamoto, S.; Aoyama, T.; Takanami, M.; Oka, A.  
J. Mol. Biol. 215, 537-547, 1990  
A:Title: Binding of the regulatory protein VirG to the phased signal sequences upstream  
A:Reference number: SI3224; MUID:91039316; PMID:2231718  
A:Accession: SI3224  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-10 <TAM>  
A:Cross-references: UNIPROT:Q7MOP7

Query Match 41.7%; Score 10; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 1.5e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 3 RH 4  
Db 2 KH 3

RESULT 33  
A30823  
bothriopoxin - jararacussu (fragment)  
C:Species: Bothrops jararacussu (jararacussu)  
C:Date: 01-Dec-1989 #sequence\_revision 01-Dec-1989 #text\_change 09-Jul-2004  
C:Accession: A30823  
R:Honsai-Brandenburg, M.I.; Queiroz, L.S.; Santo-Neto, H.; Rodrigues-Simioni, L.; Giglio,  
Toxinol 26, 615-627, 1988  
A:Title: Fractionation of Bothrops jararacussu snake venom: partial chemical characteriz  
A:Reference number: A30823; MUID:89020120; PMID:3176051  
A:Accession: A30823  
A:Molecule type: protein  
A:Residues: 1-10 <HOM>  
A:Cross-references: UNIPROT:Q7LZ25

Query Match 41.7%; Score 10; DB 2; Length 10;  
Best Local Similarity 25.0%; Pred. No. 1.5e+04;  
Matches 1; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
Qy 1 EFRH 4  
Db 4 ZLGH 7

RESULT 34  
A44871  
monodehydroascorbate reductase (NADH2) (EC 1.6.5.4) - soybean (fragment)  
C:Species: Glycine max (soybean)  
C:Date: 31-Mar-1993 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004  
C:Accession: A44871  
R:Dalton, D.A.; Langeberg, L.; Robbins, M.  
Arch. Biochem. Biophys. 292, 281-286, 1992  
A:Title: Purification and characterization of monodehydroascorbate reductase from soybean  
A:Reference number: A44871; MUID:92088257; PMID:1727643  
A:Accession: A44871  
A:Status: preliminary

A;Molecule type: protein  
A;Residues: 1-10 <DAL>  
A;Cross-references: UNIPROT:Q9S926  
A;Experimental source: root nodules, cv. Williams  
A;Note: Sequence extracted from NCBI backbone (NCBIP:71052)  
C;Keywords: oxidoreductase

Query Match 41.7%; Score 10; DB 2; Length 10;  
Best Local Similarity 33.3%; Pred. No. 1.5e+04;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4  
|:  
Db 4 FKY 6

## RESULT 35

PQ0783  
NADH2 dehydrogenase (EC 1.6.99.3) 30K chain - fava bean mitochondrion (fragment)  
N;Alternate names: complex I 30K chain; NADH-ubiquinone reductase 30K chain  
C;Species: mitochondrion Vicia faba (fava bean)  
C;Date: 03-May-1994 #sequence\_revision 07-Oct-1994 #text\_change 09-Jul-2004  
C;Accession: PQ0783  
R;Letexme, S.; Boutry, M.  
Plant Physiol. 102, 435-443, 1993  
A;Title: Purification and preliminary characterization of mitochondrial complex I (NADH-ubiquinone reductase)  
A;Reference number: PQ0775; MUID:94151437; PMID:8108509  
A;Accession: PQ0783  
A;Molecule type: protein  
A;Residues: 1-10 <LET>  
A;Cross-references: UNIPROT:Q7M2G0  
C;Comment: Complex I, mitochondrial NADH-ubiquinone reductase, is the first of the three complexes in the electron transport chain, ranging from 5K to 75K.  
C;Comment: This enzyme catalyzes electron transfer from endogenous NADH to ubiquinone by a series of redox reactions.  
A;Genome: mitochondrion  
C;Keywords: electron transfer; mitochondrion; oxidoreductase

Query Match 41.7%; Score 10; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 1.5e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
|:  
Db 6 KH 7

## RESULT 36

JN0861  
peptidyl-diesterase A inhibitory peptide C111 - striped bonito  
C;Species: Sarda orientalis (striped bonito)  
C;Date: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 07-May-1999  
C;Accession: JN0861  
R;Matsumura, N.; Fujii, M.; Takeda, Y.; Shimizu, T.  
Biosci. Biotechnol. Biochem. 57, 1743-1744, 1993  
A;Title: Isolation and characterization of angiotensin I-converting enzyme inhibitory peptide from the bonito.  
A;Reference number: JN0859; MUID:94080036; PMID:7764272  
A;Accession: JN0861  
A;Molecule type: protein  
A;Residues: 1-6 <MAT>  
A;Experimental source: liver  
C;Comment: The carboxyl end is essential for the protein's expression of angiotensin I-converting enzyme.  
C;Superfamily: bradykinin-potentiating peptide  
C;Keywords: angiotensin-converting enzyme inhibitor

Query Match 37.5%; Score 9; DB 2; Length 6;  
Best Local Similarity 33.3%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 FRH 4  
|:  
Db 3 YPH 5

## RESULT 37

S11024  
hydrogensulfite reductase (EC 1.8.99.3) chain 1 - Desulfovibrio thermophilus (fragment)  
N;Alternate names: bisulfite reductase; desulfosulfide reductase  
C;Species: Desulfovibrio thermophilus  
C;Date: 19-Mar-1997 #sequence\_revision 30-Jan-1998 #text\_change 30-Jan-1998  
C;Accession: S11024  
R;Paque, G.; Lino, A.R.; Czechowski, M.; Kang, L.; DerVartanian, D.V.; Moura, J.J.G.; L. Biochim. Biophys. Acta 1040, 112-118, 1990  
A;Title: Purification and characterization of bisulfite reductase (desulfosulfide reductase) from Desulfovibrio thermophilus  
A;Reference number: S11024; MUID:90335276; PMID:2165817  
A;Accession: S11024  
A;Molecule type: protein  
A;Residues: 1-6 <PAU>  
C;Keywords: oxidoreductase

Query Match 37.5%; Score 9; DB 2; Length 6;  
Best Local Similarity 33.3%; Pred. No. 2.8e+05;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
|:  
Db 4 KFK 6

## RESULT 38

C36730  
hutu protein - Klebsiella pneumoniae (fragment)  
C;Species: Klebsiella pneumoniae  
C;Date: 19-Apr-1991 #sequence\_revision 19-Apr-1991 #text\_change 08-Oct-1999  
C;Accession: C36730  
R;Schwacha, A.; Bender, R.A.  
J. Bacteriol. 172, 5477-5481, 1990  
A;Title: Nucleotide sequence of the gene encoding the repressor for the histidine utilization operon of Klebsiella pneumoniae  
A;Reference number: A36730; MUID:90368611; PMID:2203754  
A;Accession: C36730  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-9 <SCH>  
A;Cross-references: GB:M34604; NID:gl49203; PIDN:AAA25076.1; PID:gl49206

Query Match 37.5%; Score 9; DB 2; Length 9;  
Best Local Similarity 33.3%; Pred. No. 2.8e+05;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
|:  
Db 5 KYR 7

## RESULT 39

RHPGG  
gonadoliberin - pig  
C;Species: Sus scrofa domestica (domestic pig)  
C;Date: 13-Jul-1981 #sequence\_revision 13-Jul-1981 #text\_change 18-Mar-1997  
C;Accession: A01411  
R;Baba, Y.; Matsuo, H.; Schally, A.V.  
Biochem. Biophys. Res. Commun. 44, 459-463, 1971  
A;Title: Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the structure of the peptide  
A;Reference number: A90172; MUID:72114303; PMID:4946067  
A;Accession: A01411  
A;Molecule type: protein  
A;Residues: 1-10 <BAB>  
R;Matsuo, H.; Arimura, A.; Nair, R.M.G.; Schally, A.V.  
Biochem. Biophys. Res. Commun. 45, 822-827, 1971  
A;Title: Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method  
A;Reference number: A90176; MUID:72065376; PMID:4942726  
A;Contents: annotation; synthesis  
A;Note: the synthetic and natural hormones have the same physicochemical and biological activities  
R;Baba, Y.; Arimura, A.; Schally, A.V.  
Biochem. Biophys. Res. Commun. 45, 483-487, 1971  
A;Title: On the tryptophan residue in porcine LH and FSH-releasing hormone.

A:Reference number: A90175; MUID:72117544; PMID:4946275  
A:Contents: annotation  
A:Note: Trp-3 appears to be essential for biological activity  
C:Comment: This hypothalamic hormone stimulates the secretion of both luteinizing and follicle stimulating hormone  
C:Superfamily: gonadoliberein  
C:Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid  
F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 37.5%; Score 9; DB 1; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

RESULT 40  
RHSBG  
gonadoliberein - sheep  
N:Alternate names: Ovis orientalis aries, Ovis ammon aries (domestic sheep)  
C:Species: Alligator mississippiensis (American alligator)  
C:Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 18-Mar-1997  
C:Accession: A93780; A01411  
R:Butcher, R.; Butcher, M.; Amoss, M.; Ling, N.; Monahan, M.; Rivier, J.; Fellows, R.; Blumberg, P.M.; Proc. Natl. Acad. Sci. U.S.A. 69, 278-282, 1972  
A:Title: Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor  
A:Reference number: A93780; MUID:72094314; PMID:4550508  
A:Accession: A93780  
A:Molecule type: protein  
A:Residues: 1-10 <BUR>  
A:Note: the natural and synthetic hormones have the same biological activity  
C:Comment: This hypothalamic hormone stimulates the secretion of both luteinizing and follicle stimulating hormone  
C:Superfamily: gonadoliberein  
C:Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid  
F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 37.5%; Score 9; DB 1; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

RESULT 41  
A61126  
gonadoliberein - spotted ratfish  
N:Alternate names: Gonadotropin-releasing hormone  
C:Species: Hydrolagus coliei (spotted ratfish)  
C:Date: 26-May-1994 #sequence\_revision 26-May-1994 #text\_change 09-Jul-2004  
C:Accession: A61126  
R:Lovejoy, D.A.; Sherwood, N.M.; Fischer, W.H.; Jackson, B.C.; Rivier, J.E.; Lee, T. Gen. Comp. Endocrinol. 82, 152-161, 1991  
A:Title: Primary structure of gonadotropin-releasing hormone from the brain of a holocarpine fish  
A:Reference number: A61126; MUID:91340067; PMID:1678723  
A:Accession: A61126  
A:Molecule type: protein  
A:Residues: 1-10 <LOV>  
A:Cross-references: UNIPROT:P37043  
A:Experimental source: brain  
C:Superfamily: gonadoliberein  
C:Keywords: amidated carboxyl end; brain; hormone; pyroglutamic acid  
F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 37.5%; Score 9; DB 1; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

Db 1 QH 2  
:|

RESULT 42  
RHAQ1  
gonadoliberein I - American alligator  
N:Alternate names: gonadotropin-releasing hormone I  
C:Species: Alligator mississippiensis (American alligator)  
C:Date: 31-Mar-1993 #sequence\_revision 31-Mar-1993 #text\_change 09-Jul-2004  
C:Accession: A60066  
R:Lovejoy, D.A.; Fischer, W.H.; Parker, D.B.; McRory, J.E.; Lance, V.; Swanson, R. Regul. Pept. 33, 105-116, 1991  
A:Title: Primary structure of two forms of gonadotropin-releasing hormone from brains of American alligators  
A:Reference number: A60066; MUID:91352338; PMID:1882082  
A:Accession: A60066  
A:Molecule type: protein  
A:Residues: 1-10 <LOV>  
A:Cross-references: UNIPROT:P37041  
C:Superfamily: gonadoliberein  
C:Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid  
F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 37.5%; Score 9; DB 1; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

RESULT 43  
RHAQ2  
gonadoliberein II - American alligator  
N:Alternate names: gonadotropin-releasing hormone II  
C:Species: Alligator mississippiensis (American alligator)  
C:Date: 31-Mar-1993 #sequence\_revision 31-Mar-1993 #text\_change 09-Jul-2004  
C:Accession: B60066  
R:Lovejoy, D.A.; Fischer, W.H.; Parker, D.B.; McRory, J.E.; Lance, V.; Swanson, R. Regul. Pept. 33, 105-116, 1991  
A:Title: Primary structure of two forms of gonadotropin-releasing hormone from brains of American alligators  
A:Reference number: A60066; MUID:91352338; PMID:1882082  
A:Accession: B60066  
A:Molecule type: protein  
A:Residues: 1-10 <LOV>  
A:Cross-references: UNIPROT:P37043  
C:Superfamily: gonadoliberein  
C:Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid  
F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 37.5%; Score 9; DB 1; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

RESULT 44  
RHLMGs  
gonadoliberein - sea lamprey  
N:Alternate names: gonadotropin releasing hormone (GNRH)  
C:Species: Petromyzon marinus (sea lamprey)  
C:Date: 17-Mar-1987 #sequence\_revision 17-Mar-1987 #text\_change 09-Jul-2004  
C:Accession: A01412  
R:Sherwood, N.M.; Sower, S.A.; Marshak, D.R.; Fraser, B.A.; Brownstein, M.J. J. Biol. Chem. 261, 4812-4819, 1986  
A:Title: Primary structure of gonadotropin-releasing hormone from lamprey brain.  
A:Reference number: A01412; MUID:86168192; PMID:3514603

A;Accession: A01412  
A;Molecule type: protein  
A;Residues: 1-10 <SH>  
A;Cross-references: UNIPROT:P04378  
C;Comment: This hormone was isolated from the brain.  
C;Superfamily: gonadoliberin  
C;Keywords: amidated carboxyl end; hormone; pyroglutamic acid  
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F;10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 37.5%; Score 9; DB 1; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

RESULT 45  
A43405  
6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2,6-bisphosphate 2-phosphatase (EC 3.1.3.4)  
C;Species: Bos primigenius taurus (cattle)  
C;Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 09-Jul-2004  
C;Accession: A43405  
R;Ventura F.; Rosa, J.L.; Ambrosio, S.; Pilakis, S.J.; Bartrons, R.  
J. Biol. Chem. 267, 17939-17943, 1992  
A;Title: Bovine brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Evidence for  
A;Reference number: A43405; MUID:92388154; PMID:1325453  
A;Accession: A43405  
A;Molecule type: protein  
A;Residues: 1-10 <VEN>  
A;Cross-references: UNIPROT:Q7M3I3  
C;Superfamily: 6-phosphofructo-2-kinase / fructose-2,6-bisphosphate 2-phosphatase; phosphatase  
C;Keywords: phosphoric monoester hydrolase; phosphotransferase

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 4 QH 5

RESULT 46  
S39392  
calpain (EC 3.4.22.17) II light chain - pig (fragment)  
C;Species: Sus scrofa domestica (domestic pig)  
C;Date: 18-Feb-1994 #sequence\_revision 24-Jul-1998 #text\_change 29-Sep-1999  
C;Accession: S39392  
R;Crawford, C.; Brown, N.R.; Willis, A.C.  
Biochem. J. 296, 135-142, 1993  
A;Title: Studies of the active site of m-calpain and the interaction with calpastatin.  
A;Reference number: S39391; MUID:94071815; PMID:8250833  
A;Accession: S39392  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-10 <CRA>  
C;Superfamily: calpain small chain; calmodulin repeat homology  
C;Keywords: cysteine proteinase; EF hand; hydrolase

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 66.7%; Pred. No. 2.6e+04;  
Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFR 3  
:|  
Db 6 EVR 8

RESULT 47  
B46030  
gonadoliberin II - spiny dogfish  
N;Alternate names: gonadotropin-releasing hormone  
C;Species: Squalus acanthias (spiny dogfish)  
C;Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 09-Jul-2004  
C;Accession: B46030  
R;Lovejoy, D.A.; Fischer, W.H.; Ngamvongchon, S.; Craig, A.G.; Nahorniak, C.S.; Peter, R.  
Proc. Natl. Acad. Sci. U.S.A. 89, 6373-6377, 1992  
A;Title: Distinct sequence of gonadotropin-releasing hormone (GnRH) in dogfish brain pro  
A;Reference number: A46030; MUID:92335300; PMID:1631133  
A;Accession: B46030  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-10 <LOV>  
A;Cross-references: UNIPROT:P37043  
C;Superfamily: gonadoliberin  
C;Keywords: hormone; pyroglutamic acid  
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 1 QH 2

RESULT 48  
S59625  
beta-galactosidase alpha chain - Escherichia coli (fragment)  
C;Species: Escherichia coli  
C;Date: 20-Jul-1996 #sequence\_revision 13-Mar-1997 #text\_change 07-May-1999  
C;Accession: S59625  
R;Calugaru, S.V.; Hall, B.G.; Sinnott, M.L.  
Biochem. J. 312, 281-286, 1995  
A;Title: Catalysis by the large subunit of the second beta-galactosidase of Escherichia  
A;Reference number: S59625; MUID:96077156; PMID:7492325  
A;Accession: S59625  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-10 <CAL>

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:|  
Db 8 QH 9

RESULT 49  
PC4374  
telomeric and tetraplex DNA binding protein qTBP42 IV - rat (fragment)  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 28-Oct-1997 #sequence\_revision 28-Oct-1997 #text\_change 07-May-1999  
C;Accession: PC4374  
R;Sariq, G.; Weisman-Shomer, P.; Fry, M.  
Biochem. Biophys. Res. Commun. 237, 617-623, 1997  
A;Title: Telomeric and tetraplex DNA binding properties of qTBP42: A homologue of the CA  
A;Reference number: PC4371; MUID:97445086; PMID:9229414  
A;Accession: PC4374  
A;Molecule type: protein  
A;Residues: 1-10 <SAK>  
C;Comment: This protein binds either strand of the telomeric DNA as well as unimolecular

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 66.7%; Pred. No. 2.6e+04;  
Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFR 3  
:|  
Db 7 EHR 9

RESULT 50  
F41839  
ribosomal protein L16 - Acholeplasma laidlawii (fragment)  
C:Species: Acholeplasma laidlawii  
C>Date: 12-Mar-1993 #sequence\_revision 12-Mar-1993 #text\_change 09-Jul-2004  
C:Accession: F41839  
R:Lim, P.O.; Sears, B.B.  
J. Bacteriol. 174, 2606-2611, 1992  
A:Title: Evolutionary relationships of a plant-pathogenic mycoplasma-like organism and A  
A:Reference number: A41839; MUID:92210505; PMID:1556079  
A:Accession: F41839  
A:Status: preliminary; translation not shown  
A:Molecule type: DNA  
A:Residues: 1-10 <LIM>  
A:Cross-references: UNIPROT:P29221; GB:M74471  
C:Genetics:  
A:Gene: rpl16  
C:Keywords: protein biosynthesis; ribosome

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 33.3%; Pred. No. 2.6e+04;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3  
:|  
Db 8 KYR 10

RESULT 51  
A46030  
gonadoliberin I - spiny dogfish  
N:Alternate names: Gonadotropin-releasing hormone  
C:Species: Squalus acanthias (spiny dogfish)  
C>Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 09-Jul-2004  
C:Accession: A46030  
R:Lovejoy, D.A.; Fischer, W.H.; Ngamvongchon, S.; Craig, A.G.; Nahorniak, C.S.; Peter, R  
Proc. Natl. Acad. Sci. U.S.A. 89, 6373-6377, 1992  
A:Title: Distinct sequence of gonadotropin-releasing hormone (GnRH) in dogfish brain pro  
A:Reference number: A46030; MUID:92335300; PMID:1631133  
A:Accession: A46030  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-10 <LOV>  
A:Cross-references: UNIPROT:P27429  
C:Keywords: hormone; pyroglutamic acid  
F:I/Modified site: pyroglutamic acid (Gln) #status experimental

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
:|  
Db 1 QH 2

RESULT 52  
A21114  
gonadoliberin - chum salmon  
C:Species: Oncorhynchus keta (chum salmon)  
C>Date: 10-Aug-1990 #sequence\_revision 10-Aug-1990 #text\_change 09-Jul-2004  
C:Accession: A21114  
R:Sherwood, N.; Eiden, L.; Brownstein, M.; Spiess, J.; Rivier, J.; Vale, W.  
Proc. Natl. Acad. Sci. U.S.A. 80, 2794-2798, 1983  
A:Title: Characterization of a teleost gonadotropin-releasing hormone.  
A:Reference number: A21114; MUID:83195140; PMID:6341999  
A:Accession: A21114  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-10 <SHE>  
A:Cross-references: UNIPROT:P20367

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
:|  
Db 1 QH 2

RESULT 53  
H37196  
bradykinin-potentiating peptide 8 - island jararaca  
C:Species: Bothrops insularis (island jararaca)  
C>Date: 14-Feb-1992 #sequence\_revision 01-Dec-1992 #text\_change 09-Jul-2004  
C:Accession: H37196  
R:Cintra, A.C.O.; Vieira, C.A.; Giglio, J.R.  
J. Protein Chem. 9, 221-227, 1990  
A:Title: Primary structure and biological activity of bradykinin potentiating peptides f  
A:Reference number: A37196; MUID:90351557; PMID:2386615  
A:Accession: H37196  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-10 <CIN>  
A:Cross-references: UNIPROT:P30426  
C:Keywords: pyroglutamic acid  
F:I/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 37.5%; Score 9; DB 2; Length 10;  
Best Local Similarity 50.0%; Pred. No. 2.6e+04;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
:|  
Db 4 QH 5

RESULT 54  
A48360  
gamma subunit of Protein A - Methylosinus trichosporium (fragment)  
C:Species: Methylosinus trichosporium  
C>Date: 19-Nov-1993 #sequence\_revision 18-Nov-1994 #text\_change 08-Oct-1999  
C:Accession: A48360  
R:Cardy, D.B.; Laidler, V.; Salmon, G.P.; Murrell, J.C.  
Arch. Microbiol. 156, 477-483, 1991  
A:Title: The methane monooxygenase gene cluster of Methylosinus trichosporium: cloning a  
A:Reference number: A48360; MUID:92153031; PMID:1785954  
A:Contents: O83b  
A:Accession: A48360  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-4 <CAR>  
A:Cross-references: GB:S81887; MID:9245213; PIDN:AAB21391.1; PID:9245214  
A>Note: sequence extracted from NCBI backbone (NCBI:81887, NCBIP:81912)

Query Match 33.3%; Score 8; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
:|  
Db 1 H 1

RESULT 55  
I38888  
Coi intron 16 protein - Podospora anserina mitochondrion  
C:Species: mitochondrion Podospora anserina  
C>Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 07-Dec-1999  
C:Accession: I38888  
R:Cummings, D.J.; Michel, F.; McNally, K.L.  
Curr. Genet. 16, 381-406, 1989  
A:Title: DNA sequence analysis of the 24.5 kilobase pair cytochrome oxidase subunit I m

A;Reference number: A48327; MUID:90124722; PMID:2558809  
A;Accession: I38888  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-4 <CUM>  
A;Cross-references: GB:X55026; GB:M30937; GB:M61734  
C;Genetics:  
A;Genome: mitochondrion  
A;Genetic code: SGC3  
C;Keywords: mitochondrion

Query Match 33.3%; Score 8; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 4 H 4

RESULT 56  
PL0140  
carbon-monoxide dehydrogenase (EC 1.2.99.2) large chain - Pseudomonas carboxydohydrogena  
C;Species: Pseudomonas carboxydohydrogena  
C;Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 09-Jul-2004  
C;Accession: PL0140  
R;Kraut, M.; Hugendieck, I.; Herwig, S.; Meyer, O.  
Arch. Microbiol. 152, 335-341, 1989  
A;Title: Homology and distribution of CO dehydrogenase structural genes in carboxydohydrog  
A;Reference number: PL0138; MUID:90055678; PMID:2818128  
A;Accession: PL0140  
A;Molecule type: protein  
A;Residues: 1-4 <KRA>  
A;Cross-references: UNIPROT:P19916  
C;Comment: Carbon-monoxide dehydrogenase consists of three polypeptide chains: large, me  
C;Keywords: oxidoreductase

Query Match 33.3%; Score 8; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 3 H 3

RESULT 57  
JQ1273  
neuropeptide Antho-Khaamide - sea anemone (Anthopleura elegantissima)  
C;Species: Anthopleura elegantissima  
C;Date: 31-Mar-1992 #sequence\_revision 04-Dec-1992 #text\_change 09-Jul-2004  
C;Accession: JQ1273  
R;Notthacker, H.P.; Rinehart, K.L.; Grimmelikhuijzen, C.J.P.  
Biochem. Biophys. Res. Commun. 179, 1205-1211, 1991  
A;Title: Isolation of L-3-phenyllactyl-Phe-Lys-Ala-NH2 (Antho-Khaamide), a novel neuropep  
A;Reference number: JQ1273; MUID:92028852; PMID:1681803  
A;Accession: JQ1273  
A;Molecule type: protein  
A;Residues: 1-4 <NOT>  
A;Cross-references: UNIPROT:P58705  
C;Comment: The carboxyl-terminal amide probably arises from cleavage of a following glyco  
C;Keywords: amidated carboxyl end; neuropeptide; phenyllactylation  
F;1/Modified site: L-3-phenyllactic acid (Phe) #status experimental  
F;4/Modified site: amidated carboxyl end (Ala) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 4;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
|  
Db 2 FK 3

## RESULT 58

PT0712  
T-cell receptor beta chain V-D-J region (121-3BC) - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 17-Jul-1992 #sequence\_revision 17-Jul-1992 #text\_change 09-Jul-2004  
C;Accession: PT0649; PT0712  
R;Peeney, A.J.  
J. Exp. Med. 174, 115-124, 1991  
A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.  
A;Reference number: PT0509; MUID:91277601; PMID:1711558  
A;Accession: PT0649  
A;Status: translation not shown  
A;Molecule type: mRNA  
A;Residues: 1-4 <FE2>  
A;Cross-references: UNIPROT:O18345; UNIPROT:Q8BT14; UNIPROT:Q8CHG3; UNIPROT:Q64512; UNIPROT:Q64512; UNIPROT:Q64512  
A;Experimental source: day 4 postnatal thymus, strain BALB/c, 121-3BC  
A;Accession: PT0712  
A;Status: translation not shown  
A;Molecule type: DNA  
A;Residues: 1-4 <FE2>  
A;Experimental source: newborn thymus, strain BALB/c, 165-3B  
C;Keywords: T-cell receptor

Query Match 33.3%; Score 8; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 4 H 4

## RESULT 59

JN0860  
peptidyl-diesterase A inhibitory peptide C107 - striped bonito  
C;Species: Sarda orientalis (striped bonito)  
C;Date: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 07-May-1999  
C;Accession: JN0860  
R;Matsumura, N.; Fujii, M.; Takeda, Y.; Shimizu, T.  
Biosci. Biotechnol. Biochem. 57, 1743-1744, 1993  
A;Title: Isolation and characterization of angiotensin I-converting enzyme inhibitory pe  
A;Reference number: JN0859; MUID:94080036; PMID:7764272  
A;Accession: JN0860  
A;Molecule type: protein  
A;Residues: 1-5 <MAT>  
A;Experimental source: intestine  
C;Comment: The carboxyl-terminus is essential for the protein's expression of angiotensi  
C;Superfamily: bradykinin-potentiating peptide  
C;Keywords: angiotensin-converting enzyme inhibitor

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 4 H 4

## RESULT 60

A32516  
cholecystokinin-5 - dog  
N;Alternate names: CCK-5  
C;Species: Canis lupus familiaris (dog)  
C;Date: 18-Oct-1989 #sequence\_revision 18-Oct-1989 #text\_change 18-Aug-2000  
C;Accession: A32516  
R;Shively, J.; Reeve Jr., J.R.; Eysselein, V.E.; Ben-Avram, C.; Vigna, S.R.; Walsh, J.H.  
Am. J. Physiol. 252, G272-G275, 1987  
A;Title: CCK-5: sequence analysis of a small cholecystokinin from canine brain and intest  
A;Reference number: A32516; MUID:87153871; PMID:3826354  
A;Accession: A32516  
A;Molecule type: protein

A:Residues: 1-5 <SHI>  
C:Comment: This peptide corresponds to the five carboxyl-terminal residues of cholecysto  
C:Superfamily: gastrin  
P:5/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
|  
4 DF 5

Db

RESULT 61  
C41225  
copper resistance protein - Pseudomonas syringae pv. tomato (fragment)  
C:Species: Pseudomonas syringae pv. tomato  
C:Date: 19-Jun-1992 #sequence\_revision 19-Jun-1992 #text\_change 24-Jun-1993  
C:Accession: C41225  
R:Cha, J.S.; Cooksey, D.A.  
Proc. Natl. Acad. Sci. U.S.A. 88, 8915-8919, 1991  
A:Title: Copper resistance in Pseudomonas syringae mediated by periplasmic and outer mem  
A:Reference number: A41225; MUID:92020961; PMID:1924351  
C:Accession: C41225  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-5 <CHA>

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
1 H 1

Db

RESULT 62  
S70154  
URF2 protein - Xanthomonas sp.  
C:Species: Xanthomonas sp.  
C:Date: 15-Feb-1997 #sequence\_revision 13-Mar-1997 #text\_change 08-Oct-1999  
C:Accession: S70154  
R:Kholodii, G.Y.; Mindlin, S.Z.; Bass, I.A.; Yurieva, O.V.; Minakhina, S.V.; Nikiforov,  
Mol. Microbiol. 17, 1189-1200, 1995  
A:Title: Four genes, two ends, and a res region are involved in transposition of Tn5053:  
A:Reference number: S70140; MUID:96130850; PMID:8594337  
C:Accession: S70154  
A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
A:Molecule type: DNA  
A:Residues: 1-5 <KHO>  
A:Cross-references: EMBL:L40585; NID:g710572; PIDN:AAA98329.1; PID:g735909  
A:Note: the nucleotide sequence was submitted to the EMBL data Library, May 1995

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
5 H 5

Db

RESULT 63  
B37325  
pap fibrillar regulatory protein papI - Escherichia coli (fragment)  
C:Species: Escherichia coli  
C:Date: 11-Sep-1992 #sequence\_revision 11-Sep-1992 #text\_change 23-Mar-1993  
C:Accession: B37325  
R:Braaten, B.A.; Blyn, L.B.; Skinner, B.S.; Low, D.A.  
J. Bacteriol. 173, 1789-1800, 1991

A:Title: Evidence for a methylation-blocking factor (mbf) locus involved in pap pilus ex  
A:Reference number: A37325; MUID:91154136; PMID:1671857  
A:Accession: B37325  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-5 <BRA>  
A:Cross-references: GB:M63747

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
|  
3 EY 4

Db

RESULT 64  
P22565  
R-phycoerythrin gamma-A chain - red alga (Gastrocloonium coulteri) (fragment)  
C:Species: Gastrocloonium coulteri  
C:Date: 07-Mar-1988 #sequence\_revision 07-Mar-1988 #text\_change 23-Mar-1993  
C:Accession: P22565  
R:Klotz, A.V.; Glazer, A.N.  
J. Biol. Chem. 260, 4856-4863, 1985  
A:Title: Characterization of the bilin attachment sites in R-phycoerythrin.  
A:Reference number: A22565; MUID:85182601; PMID:3886644  
C:Accession: P22565  
A:Molecule type: protein  
A:Residues: 1-5 <KLO>

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 PR 3  
|  
4 YR 5

Db

RESULT 65  
T10954  
hypothetical protein 3 - spring vetch  
C:Species: Vicia sativa (spring vetch, tare)  
C:Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 16-Jul-1999  
C:Accession: T10954  
R:Christiansen, A.; Hansen, A.C.; Vijn, I.; Pallisgaard, N.; Larsen, K.; Yang, W.C.; Bis  
submitted to the EMBL Data Library, December 1995  
A:Description: A novel type of DNA binding protein interacts with a conserved sequence  
A:Reference number: Z17228  
C:Accession: T10954  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-5 <CHR>  
A:Cross-references: EMBL:X95995; NID:g13360633; PID:e225862

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
4 H 4

Db

RESULT 66  
I40698  
biotin B - Citrobacter freundii (fragment)  
C:Species: Citrobacter freundii  
C:Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 09-Jul-2004  
C:Accession: I40698  
R:Shiuan, D.; Campbell, A.  
Gene 67, 203-211, 1988

A;Title: Transcriptional regulation and gene arrangement of *Escherichia coli*, *Citrobacter*  
A;Reference number: I40697; MUID:89006280; PMID:2971595  
A;Accession: I40698  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-5 <RES>  
A;Cross-references: UNIPROT:P12997; GB:M21922; NID:g144434

Query Match 33.3%; Score 8; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 3 H 3

RESULT 67  
A61419  
sarcosine dehydrogenase (EC 1.5.99.1) - *Pseudomonas* sp. (strain WRP) (fragment)  
C;Species: *Pseudomonas* sp.  
C;Date: 07-Oct-1994 #sequence\_revision 07-Oct-1994 #text\_change 07-May-1999  
C;Accession: A61419  
R;Pinto, J.T.; Frisell, W.R.  
Arch. Biochem. Biophys. 169, 483-491, 1975  
A;Title: Characterization of the peptide-bound flavin of a bacterial sarcosine dehydroge  
A;Reference number: A61419; MUID:76038634; PMID:241294  
A;Accession: A61419  
A;Molecule type: protein  
A;Residues: 1-6 <PIN>  
C;Keywords: FAD; flavoprotein; oxidoreductase; phosphoprotein  
F;6/Modified site: 3'-FAD-histidine (His) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 6 H 6

RESULT 68  
I37027  
Protamine P1 - gorilla (fragment)  
C;Species: Gorilla gorilla (gorilla)  
C;Date: 04-Oct-1996 #sequence\_revision 04-Oct-1996 #text\_change 21-Jul-2000  
C;Accession: I37027  
R;Queralt, R.; Oliva, R.  
Gene 133, 197-204, 1993  
A;Title: Identification of conserved potential regulatory sequences of the protamine-enc  
A;Reference number: I37013; MUID:94040810; PMID:8224908  
A;Accession: I37027  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-6 <RES>  
A;Cross-references: EMBL:Z12145; NID:g22910; PIDN:CAA78129.1; PID:g579612

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
:|  
Db 4 YR 5

RESULT 69  
B56979  
collagen alpha 1(II) chain - bovine (fragment)  
N;Alternate names: collagen alpha 3(XI) chain  
C;Species: Bos primigenius taurus (cattle)  
C;Date: 03-Oct-1995 #sequence\_revision 03-Oct-1995 #text\_change 03-Oct-1995

A;Title: Structural analysis of cross-linking domains in cartilage type XI collagen. Insa  
A;Reference number: A56978; MUID:95370194; PMID:7642541  
A;Accession: B56979  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-6 <WUA>  
A;Note: the residue designated "X" is modified Lysine in collagen 1(II) some cross-linked

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 5 H 5

RESULT 70  
S78764  
ribosomal protein MRP-S23, mitochondrial - bovine (fragment)  
C;Species: Bos primigenius taurus (cattle)  
C;Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 20-Sep-1999  
C;Accession: S78764  
R;Graack, H.R.  
submitted to the Protein Sequence Database, July 1999  
A;Reference number: S78760  
A;Accession: S78764  
A;Molecule type: protein  
A;Residues: 1-6 <GRA>  
C;Keywords: mitochondrial  
F;1-6/Product: ribosomal protein MRP-S23 (fragment) #status experimental <WAT>

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 2 H 2

RESULT 71  
A46474  
Fc epsilon RI1b - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 18-Jun-1993 #sequence\_revision 18-Nov-1994 #text\_change 11-Apr-1995  
C;Accession: A46474  
R;Richards, M.L.; Katz, D.H.; Liu, F.T.  
J. Immunol. 147, 1067-1074, 1991  
A;Title: Complete genomic sequence of the murine low affinity Fc receptor for IgE. Demon  
A;Reference number: A46474; MUID:91318149; PMID:1861070  
A;Accession: A46474  
A;Status: preliminary; not compared with conceptual translation  
A;Molecule type: nucleic acid  
A;Residues: 1-6 <RIC>  
A;Note: sequence extracted from NCBI backbone (NCBI:P:45428)

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 4 H 4

RESULT 72  
PT0693  
T-cell receptor beta chain V-D-J region (154-1A) - mouse (fragment)



C;Species: Mus musculus (house mouse)  
C;Date: 17-Jul-1992 #sequence\_revision 17-Jul-1992 #text\_change 30-May-1997  
C;Accession: PT0693  
R;Feeney, A.J.  
J. Exp. Med. 174, 115-124, 1991  
A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.  
A;Reference number: PT0509; MUID:91277601; PMID:1711558  
A;Accession: PT0693  
A;Status: translation not shown  
A;Molecule type: DNA  
A;Residues: 1-6 <PEE>  
A;Experimental source: day 18 fetal thymus, strain BALB/c  
C;Keywords: T-cell receptor

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 6 H 6

RESULT 73  
A41946  
T-cell receptor gamma chain (1t.22) - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 07-May-1999  
C;Accession: A41946  
R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.  
Mol. Cell. Biol. 11, 5902-5909, 1991  
A;Title: Rearrangement and functional-site sequence analyses of T-cell receptor gamma gene  
A;Reference number: A41946; MUID:92049316; PMID:1658619  
A;Accession: A41946  
A;Status: preliminary; not compared with conceptual translation  
A;Molecule type: DNA  
A;Residues: 1-6 <WHE>  
C;Keywords: T-cell receptor

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
:|  
Db 1 YR 2

RESULT 74  
S71349  
beta-crystallin B2 - rat (fragment)  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 29-Jan-1998 #sequence\_revision 06-Feb-1998 #text\_change 07-May-1999  
C;Accession: S71349  
R;Dirks, R.P.H.; Kraft, H.J.; van Genesen, S.T.; Klok, E.J.; Pfundt, R.; Schoenmakers, J.  
Eur. J. Biochem. 239, 23-32, 1996  
A;Title: The cooperation between two silencers creates an enhancer element that controls  
A;Reference number: S71349; MUID:96305362; PMID:8706714  
A;Accession: S71349  
A;Status: translation not shown  
A;Molecule type: DNA  
A;Residues: 1-6 <DIR>  
A;Cross-references: EMBL:X83671  
A;Experimental source: strain Wistar; lens epithelial cells  
C;Genetics:  
A;Gene: CRYBB2

Query Match 33.3%; Score 8; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|

Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
Db 5 H 5

RESULT 78  
B39127  
phosphotransferase system enzyme II (EC 2.7.1.69) - Escherichia coli (fragment)  
C:Species: Escherichia coli  
C>Date: 27-Nov-1991 #sequence\_revision 27-Nov-1991 #text\_change 08-Oct-1999  
C:Accession: B39127  
R:Hardesty, C.; Ferran, C.; DiRienzo, J.M.  
J. Bacteriol. 173, 449-456, 1991  
A:Title: Plasmid-mediated sucrose metabolism in Escherichia coli: characterization of sc  
rin.  
A:Reference number: A39127; MUID:91100329; PMID:1846143  
A:Accession: B39127  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-7 <HAR>  
A:Cross-references: GB:M38416; NID:gl55142; PIDN:AAA98418.1; PID:gl55144  
C:Keywords: phosphotransferase

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
:|  
Db 2 DF 3

RESULT 79  
S42407  
gramicidin S synthetase component II - Bacillus brevis (fragment)  
C:Species: Bacillus brevis  
C>Date: 20-Oct-1994 #sequence\_revision 12-Apr-1996 #text\_change 12-Apr-1996  
C:Accession: S42407  
R:Stein, T.; Vater, J.; Kruft, V.; Wittmann-Liebold, B.; Franke, P.; Panico, M.; Mc Dow  
FEBS Lett. 340, 39-44, 1994  
A:Title: Detection of 4'-phosphopantetheine at the thioester binding site for L-valine d  
A:Reference number: S42407; MUID:94164305; PMID:8119405  
A:Accession: S42407  
A:Molecule type: protein  
A:Residues: 1-7 <STE>

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
Db 4 H 4

RESULT 80  
A28709  
phosphonoacetaldehyde hydrolase - Bacillus cereus (fragment)  
C:Species: Bacillus cereus  
C>Date: 22-Aug-1988 #sequence\_revision 22-Aug-1988 #text\_change 30-Sep-1993  
C:Accession: A28709  
R:Olson, D.B.; Hepburn, T.W.; Moos, M.; Mariano, P.S.; Dunaway-Mariano, D.  
Biochemistry 27, 2229-2234, 1988  
A:Title: Investigation of the Bacillus cereus phosphonoacetaldehyde hydrolase. Evidence  
idue.  
A:Reference number: A28709; MUID:88241058; PMID:3132206  
A:Accession: A28709  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-7 <OLS>

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
Db 7 H 7

RESULT 81  
PT0246  
Ig heavy chain CRD3 region (clone 2-103D) - human (fragment)  
C:Species: Homo sapiens (man)  
C>Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 16-Aug-1996  
C:Accession: PT0246  
R:Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.  
J. Exp. Med. 173, 395-407, 1991  
A:Title: Preferential utilization of specific immunoglobulin heavy chain diversity and j  
A:Reference number: PT0222; MUID:91108337; PMID:1899102  
A:Accession: PT0246  
A:Molecule type: DNA  
A:Residues: 1-7 <YAM>  
A:Experimental source: B lymphocyte  
C:Keywords: heterotetramer; immunoglobulin

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
Db 1 H 1

RESULT 82  
PT0520  
T-cell receptor beta chain V-D-J region (100-4F) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 17-Jul-1992 #sequence\_revision 17-Jul-1992 #text\_change 30-May-1997  
C:Accession: PT0520  
R:Feeney, A.J.  
J. Exp. Med. 174, 115-124, 1991  
A:Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.  
A:Reference number: PT0509; MUID:91277601; PMID:1711558  
A:Accession: PT0520  
A:Status: translation not shown  
A:Molecule type: mRNA  
A:Residues: 1-7 <FEE>  
A:Experimental source: adult thymus, strain BALB/c  
C:Keywords: T-cell receptor

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
|  
Db 7 H 7

RESULT 83  
PT0665  
T-cell receptor beta chain V-D-J region (121-3BM) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 17-Jul-1992 #sequence\_revision 17-Jul-1992 #text\_change 30-May-1997  
C:Accession: PT0665  
R:Feeney, A.J.  
J. Exp. Med. 174, 115-124, 1991  
A:Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.  
A:Reference number: PT0509; MUID:91277601; PMID:1711558  
A:Accession: PT0665  
A:Status: translation not shown  
A:Molecule type: mRNA

A;Residues: 1-7 <PEE>  
A;Experimental source: day 4 postnatal thymus, strain BALB/c  
C;Keywords: T-cell receptor

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
|  
Db 6 DF 7

## RESULT 84

A38081  
amine oxidase (copper-containing) (EC 1.4.3.6) - yeast (*Pichia angusta*) (fragment)

C;Species: *Pichia angusta*  
C;Date: 31-Dec-1993 #sequence\_revision 03-Feb-1994 #text\_change 20-Apr-2000  
C;Accession: A38081  
R;Mu, D.; Janes, S.M.; Smith, A.J.; Brown, D.E.; Dooley, D.M.; Klinman, J.P.  
J. Biol. Chem. 267, 7979-7982, 1992  
A;Title: Tyrosine codon corresponds to topa quinone at the active site of copper amine oxidase  
A;Reference number: A38081; MUID:92235001; PMID:1569055  
A;Accession: A38081  
A;Molecule type: protein  
A;Residues: 1-7 <MUA>  
C;Keywords: copper; oxidoreductase; quinoprotein; topaquinone  
F;4/Modified site: topaquinone (Tyr) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
|  
Db 5 EF 6

## RESULT 85

S29735  
polysphosphate-glucose phosphotransferase (EC 2.7.1.63) - *Propionibacterium freudenreichii*

C;Species: *Propionibacterium freudenreichii* subsp. *shermanii*  
C;Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 03-Jun-2002  
C;Accession: S29735  
R;Phillips, N.F.B.; Horn, P.J.; Wood, H.G.  
Arch. Biochem. Biophys. 300, 309-319, 1993  
A;Title: The polysphosphate- and ATP-dependent glucokinase from *Propionibacterium shermanii*  
A;Reference number: S29735; MUID:93143332; PMID:8380966  
A;Accession: S29735  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-7 <PHI>  
C;Keywords: phosphotransferase

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 2 H 2

## RESULT 86

A15398  
choline oxidase (EC 1.1.3.17) - *Alcaligenes* sp. (tentative sequence) (fragment)

C;Species: *Alcaligenes* sp.  
C;Date: 05-Jun-1987 #sequence\_revision 05-Jun-1987 #text\_change 09-Jul-2004  
C;Accession: A15398  
R;Ohta-Fukuyama, M.; Miyake, Y.; Emi, S.; Yamano, T.  
J. Biochem. 88, 197-203, 1980  
A;Title: Identification and properties of the prosthetic group of choline oxidase from *A. salmonicida*  
A;Reference number: A15398; MUID:81006769; PMID:6997283

A;Accession: A15398

A;Molecule type: protein

A;Residues: 1-7 <OHT>

A;Cross-references: UNIPROT:P16101

C;Keywords: oxidoreductase

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 5 H 5

## RESULT 87

I46868

alpha-myosin heavy chain - rabbit (fragment)

C;Species: *Oryctolagus cuniculus* (domestic rabbit)

C;Date: 14-Feb-1997 #sequence\_revision 14-Feb-1997 #text\_change 09-Jul-2004

C;Accession: I46868

R;Friedman, D.J.; Umeda, P.K.; Sinha, A.M.; Hsu, H.

Proc. Natl. Acad. Sci. U.S.A. 81, 3044-3048, 1984

A;Title: Characterization of genomic clones specifying rabbit alpha- and beta-ventricular

A;Reference number: I46868; MUID:84221901; PMID:6328491

A;Accession: I46868

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: DNA

A;Residues: 1-7 <PRI>

A;Cross-references: UNIPROT:Q28742; GB:K01698; NID:g165538; PIDN:AAA31415.1; PID:g165539

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 4 H 4

## RESULT 88

S08606

hypothetical protein 2 estrogen receptor 5'-region - chicken

C;Species: *Gallus gallus* (chicken)

C;Date: 02-Dec-1993 #sequence\_revision 10-Nov-1995 #text\_change 16-Aug-2004

C;Accession: S08606

R;Krust, A.; Green, S.; Argos, P.; Kumar, V.; Walter, P.; Bornert, J.M.; Chambon, P.

EMBO J. 5, 891-897, 1986

A;Title: The chicken oestrogen receptor sequence: homology with v-erbA and the human oes

A;Reference number: S07192; MUID:86247578; PMID:3755102

A;Accession: S08606

A;Status: translation not shown

A;Molecule type: mRNA

A;Residues: 1-7 <KRU>

A;Cross-references: EMBL:X03805; NID:g63378; PIDN:CAA27432.1; PID:g584490

Query Match 33.3%; Score 8; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
|  
Db 5 H 5

## RESULT 89

PQ0012

cholecystokinin - southeastern quoll

N;Alternate names: CCK

C;Species: *Dasyurus viverrinus* (southeastern quoll)

C;Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 09-Jul-2004

C;Accession: PQ0012

R;Fan, Z.W.; Eng, J.; Shaw, G.; Yalow, R.S.

Peptides 9, 429-431, 1988  
A;Title: Cholecystokinin octapeptide purified from brains of Australian marsupials.  
A;Reference number: PQ0012; MUID:88234141; PMID:3375140

A;Accession: PQ0012  
A;Molecule type: protein  
A;Residues: 1-8 <FAN>  
A;Cross-references: UNIPROT:P30369  
C;Superfamily: gastrin  
C;Keywords: amidated carboxyl end; hormone; neuropeptide; sulfoprotein  
F;2/Binding site: sulfate (Tyr) (covalent) #status predicted  
F;8/Modified site: amidated carboxyl end (Phe) #status predicted

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
:  
DB 7 DF 8

RESULT 90  
A43001  
cholecystokinin - tammar wallaby  
N;Alternate names: CCK  
C;Species: Macropus eugenii (tammar wallaby)  
C;Date: 30-Oct-1992 #sequence\_revision 30-Oct-1992 #text\_change 09-Jul-2004  
C;Accession: A43001; PQ0012  
R;Fan, Z.W.; Eng, J.; Shaw, G.; Yalow, R.S.  
Peptides 9, 429-431, 1988

A;Title: Cholecystokinin octapeptide purified from brains of Australian marsupials.  
A;Reference number: PQ0012; MUID:88234141; PMID:3375140

A;Accession: A43001  
A;Molecule type: protein  
A;Residues: 1-8 <FAN>  
A;Cross-references: UNIPROT:P30369  
C;Superfamily: Gastrin  
C;Keywords: amidated carboxyl end; hormone; neuropeptide; sulfoprotein  
F;2/Binding site: sulfate (Tyr) (covalent) #status predicted  
F;8/Modified site: amidated carboxyl end (Phe) #status predicted

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
:  
DB 7 DF 8

RESULT 91  
A39892  
P element, P cytotpe-determining - fruit fly (Drosophila melanogaster) (fragment)  
C;Species: Drosophila melanogaster  
C;Date: 24-Jan-1992 #sequence\_revision 24-Jan-1992 #text\_change 16-Feb-1997  
C;Accession: A39892  
R;Nitsabaka, E.; Mukai, T.; Yamazaki, T.  
Proc. Natl. Acad. Sci. U.S.A. 84, 7605-7608, 1987  
A;Title: Repressor of P elements in Drosophila melanogaster: cytotpe determination by a

A;Reference number: A39892  
A;Accession: A39892  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-8 <NIT>  
C;Genetics:  
A;Gene: FlyBase:P-element  
A;Cross-references: FlyBase:FBgn0003055

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3

Db 5 FK 6  
|:

## RESULT 92

PT0368  
IG gamma chain C region (gamma-1) - human (fragment)  
C;Species: Homo sapiens (man)  
C;Date: 31-Mar-1992 #sequence\_revision 31-Mar-1992 #text\_change 16-Aug-1996  
C;Accession: PT0368  
R;Miliili, M.; Fougereau, M.; Guglielmi, P.; Schiff, C.  
Mol. Immunol. 28, 753-761, 1991  
A;Title: Early occurrence of immunoglobulin isotype switching in human fetal liver.  
A;Reference number: PT0368; MUID:91312348; PMID:1906981  
A;Accession: PT0368  
A;Molecule type: mRNA  
A;Residues: 1-8 <MIL>  
A;Experimental source: fetal liver  
C;Keywords: immunoglobulin

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 H 4  
:  
DB 2 H 2

## RESULT 93

B54823  
olfactory receptor 17 - western wild mouse (fragment)  
C;Species: Mus spretus (western wild mouse)  
C;Date: 28-Apr-1995 #sequence\_revision 28-Apr-1995 #text\_change 17-Mar-1999  
C;Accession: B54823  
R;Chess, A.; Simon, I.; Cedar, H.; Axel, R.  
Cell 78, 823-834, 1994  
A;Title: Allelic inactivation regulates olfactory receptor gene expression.  
A;Reference number: A54823; MUID:94373818; PMID:8087849  
A;Accession: B54823  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-8 <CHE>

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4  
:  
DB 2 ERHN 5

## RESULT 94

S66296  
Na+-transporting ATP synthase (EC 3.6.1.-) chain c - Acetobacterium woodii (fragment)  
N;Alternate names: ATPase chain c  
C;Species: Acetobacterium woodii  
C;Date: 19-Mar-1997 #sequence\_revision 06-Jun-1997 #text\_change 07-May-1999  
C;Accession: S66296  
R;Reidlinger, J.; Mueller, V.  
Eur. J. Biochem. 223, 275-283, 1994  
A;Title: Purification of ATP synthase from Acetobacterium woodii and identification as a  
A;Reference number: S45648; MUID:94307271; PMID:8033902  
A;Accession: S66296  
A;Molecule type: protein  
A;Residues: 1-8 <REI>  
A;Experimental source: DSM 1030  
C;Keywords: hydrolase

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
:|  
Db 5 DF 6

RESULT 95  
S37141  
rpsA protein - *Erwinia chrysanthemi*  
A:Species: *Erwinia chrysanthemi*  
C:Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 09-Jul-2004  
C:Accession: S37141  
R:Doillie, A.; Tousseint, A.; Faelen, M.  
submitted to the EMBL Data Library, August 1993  
A:Description: Identification of the integration host factor genes of *E. chrysanthemi*.  
A:Reference number: S37139  
A:Accession: S37141  
A>Status: Preliminary  
A:Molecule type: DNA  
A:Residues: 1-8 <DOU>  
A:Cross-references: UNIPROT:P37985; EMBL:X74750; NID:G399669; PIDN:CAAS2769.1; PID:G5811

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
:|  
Db 2 FK 3

RESULT 96  
PT0030  
inulinase (EC 3.2.1.7) - *Aspergillus ficum* (fragment)  
N:Alternate names: inulase  
C:Species: *Aspergillus ficum*  
C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 09-Jul-2004  
C:Accession: PT0030  
R:Etalibi, M.; Baratti, J.C.  
Agric. Biol. Chem. 54, 61-68, 1990  
A>Title: Molecular and kinetic properties of *Aspergillus ficum* inulinases.  
A:Reference number: PT0030; MUID:90344234; PMID:1368526  
A:Accession: PT0030  
A:Molecule type: protein  
A:Residues: 1-8 <ETT>  
A:Cross-references: UNIPROT:O7MAU4  
C:Keywords: glycosidase; hydrolase; polysaccharide degradation

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
:|  
Db 7 YR 8

RESULT 97  
JS0316  
leucokinin VI - *Madeira cockroach*  
C:Species: *Leucophaea maderae* (*Madeira cockroach*)  
C:Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 09-Jul-2004  
C:Accession: JS0316  
R:Holman, G.M.; Cook, B.J.; Nachman, R.J.  
Comp. Biochem. Physiol. C 88, 27-30, 1987  
A>Title: Isolation, primary structure, and synthesis of leucokinins V and VI: myotropic  
A:Reference number: JS0315  
A:Accession: JS0316  
A:Molecule type: protein  
A:Residues: 1-8 <HOL>  
A:Cross-references: UNIPROT:P19988  
C:Comment: Leucokinins, a family of cephalomyotropic peptides, stimulate contractile act  
C:Keywords: amidated carboxyl end; cephalomyotropic peptide; pyroglutamic acid

F:1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F:8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 H 4  
:|  
Db 5 H 5

## RESULT 98

JS0318  
leucokinin VIII - *Madeira cockroach*  
C:Species: *Leucophaea maderae* (*Madeira cockroach*)  
C:Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 09-Jul-2004  
C:Accession: JS0318  
R:Holman, G.M.; Cook, B.J.; Nachman, R.J.  
Comp. Biochem. Physiol. C 88, 31-34, 1987  
A>Title: Isolation, primary structure and synthesis of leucokinins VII and VIII: the fin  
A:Reference number: JS0317  
A:Accession: JS0318  
A:Molecule type: protein  
A:Residues: 1-8 <HOL>  
A:Cross-references: UNIPROT:P19990  
C:Comment: Leucokinins, a family of cephalomyotropic peptides, stimulate contractile act  
C:Keywords: amidated carboxyl end; cephalomyotropic peptide  
F:8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
:|  
Db 3 DF 4

## RESULT 99

H41978  
callipMPamide 8 - *bluebottle fly* (*Calliphora vomitoria*)  
C:Species: *Calliphora vomitoria*  
C:Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 09-Jul-2004  
C:Accession: H41978  
R:Duve, H.; Johnsen, A.H.; Sewell, J.C.; Scott, A.G.; Orchard, I.; Rehfeld, J.F.; Thorpe  
Proc. Natl. Acad. Sci. U.S.A. 89, 2326-2330, 1992  
A>Title: Isolation, structure, and activity of -Phe-Met-Arg-Phe-NH-2 neuropeptides (desi  
A:Reference number: H41978; MUID:92196111; PMID:1549595  
A:Accession: H41978  
A>Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-8 <DUV>  
A:Cross-references: UNIPROT:P41863  
C:Keywords: amidated carboxyl end; neuropeptide  
F:8/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
:|  
Db 4 DF 5

## RESULT 100

E47393  
neuropeptide callatostatin 5 - *bluebottle fly* (*Calliphora vomitoria*)  
C:Species: *Calliphora vomitoria*  
C:Date: 16-Feb-1994 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004  
C:Accession: E47393  
R:Duve, H.; Johnsen, A.H.; Scott, A.G.; Yu, C.G.; Yagi, K.J.; Tobe, S.S.; Thorpe, A.

Proc. Natl. Acad. Sci. U.S.A. 90, 2456-2460, 1993  
A;Title: Callatostegins: neuropeptides from the blowfly Calliphora vomitoria with sequen  
A;Reference number: A47393; MUID:93211980; PMID:8460157  
A;Accession: E47393  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-8 <DUV>  
A;Cross-references: UNIPROT:P41841  
A;Experimental source: whole flies  
A;Note: sequence extracted from NCBI backbone (NCBIP:128482)

Query Match 33.3%; Score 8; DB 2; Length 8;  
Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2  
:|  
Db 5 DF 6

Search completed: November 2, 2005, 09:41:47  
Job time : 41 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:31:04 ; Search time 167 Seconds  
(without alignments)  
12.265 Million cell updates/sec

Title: US-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 2541

Minimum DB seq length: 4

Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database : UniProt\_03.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	17	70.8	10	2	Q63056 rattus norv
2	16	66.7	10	2	Q8TG88 pleurotus o
3	16	66.7	10	2	Q7WUG1 pseudomonas
4	14	58.3	8	2	O13591 saccharomyc
5	13	54.2	8	2	Q9Y4J4 homo sapien
6	13	54.2	8	2	Q28866 megaptera n
7	13	54.2	8	2	Q9GMH3 lagenorhync
8	13	54.2	8	2	Q9TT78 canis famli
9	13	54.2	8	2	Q7M194 escherichia
10	13	54.2	8	2	Q84156 orf virus.
11	13	54.2	8	2	P79940 xenopus lae
12	13	54.2	9	1	BS43 SERPL
13	13	54.2	9	1	NEUX_HUMAN
14	13	54.2	9	1	XYLA_STRS8
15	13	54.2	9	2	Q8MJN1
16	13	54.2	9	2	Q8MJN2
17	13	54.2	9	2	Q8MJN3
18	13	54.2	9	2	Q8MJN4
19	13	54.2	9	2	Q8MJN5
20	13	54.2	9	2	Q8MJN6
21	13	54.2	9	2	Q8MJN7
22	13	54.2	9	2	Q8MJN8
23	13	54.2	9	2	Q8MJN9
24	13	54.2	9	2	Q7JIS3
25	13	54.2	9	2	Q7JIS4
26	13	54.2	9	2	Q7JIS5
27	13	54.2	9	2	Q7JIS6
28	13	54.2	9	2	Q7JIS7
29	13	54.2	9	2	Q7JIS8
30	13	54.2	9	2	Q7JIS9
31	13	54.2	9	2	Q7JIT0

32	13	54.2	9	2	Q7JIT1	Q7jit1 lagenorhync
33	13	54.2	9	2	Q9GJV1	Q9gJV1 lagenorhync
34	13	54.2	9	2	Q9GJV2	Q9gJV2 lagenorhync
35	13	54.2	9	2	Q9GJV3	Q9gJV3 lagenorhync
36	13	54.2	9	2	Q9TT77	Q9tt77 bos taurus
37	13	54.2	9	2	Q9R7H9	Q9r7h9 haemophilus
38	13	54.2	10	2	Q8N6B1	Q8n6b1 homo sapien
39	13	54.2	10	2	Q6LCI4	Q6lci4 homo sapien
40	13	54.2	10	2	Q6IGI3	Q6igi3 bos taurus
41	13	54.2	10	2	Q9S8J8	Q9s8j8 rana muscos
42	13	54.2	10	2	O54217	O54217 staphylococ
43	12	50.0	7	2	O99182	O99182 gnatholebia
44	12	50.0	9	1	OXYT_OCTVU	OXYT_OCTVU
45	12	50.0	9	2	Q7RE58	Q7re58 plasmodium
46	12	50.0	9	2	Q6JDL5	Q6jdl5 canis famli
47	12	50.0	10	2	Q8HUB4	Q8hub4 anomobryum
48	12	50.0	10	2	Q8QE18	Q8qe18 human immun
49	11	45.8	5	1	E103_LITRU	E103_LITRU
50	11	45.8	5	1	RE21_LITRU	RE21_LITRU
51	11	45.8	5	1	RE31_LITRU	RE31_LITRU
52	11	45.8	6	1	FARP_MONEX	FARP_MONEX
53	11	45.8	7	1	FAP1_ASCSU	FAP1_ASCSU
54	11	45.8	7	2	O98866	O98866 spinacia ol
55	11	45.8	8	1	GLUR_HUMAN	GLUR_HUMAN
56	11	45.8	8	1	PPK3_PERAM	PPK3_PERAM
57	11	45.8	8	2	Q15901	Q15901 homo sapien
58	11	45.8	8	2	Q34909	Q34909 locusta mig
59	11	45.8	8	2	Q6Y2F2	Q6y2f2 citrus sine
60	11	45.8	8	2	Q6LDO5	Q6ldq5 rhodobacter
61	11	45.8	8	2	Q9R3X0	Q9r3x0 planktothri
62	11	45.8	8	2	Q9ERD2	Q9erd2 mus musculu
63	11	45.8	8	2	Q90ZV5	Q90zv5 fulica leuc
64	11	45.8	8	2	Q6VMC6	Q6vmc6 serilophus
65	11	45.8	9	1	BRK1_RANNI	BRK1_RANNI
66	11	45.8	9	1	COXE_THUOB	COXE_THUOB
67	11	45.8	9	1	FIBB_PAPAN	FIBB_PAPAN
68	11	45.8	9	1	KNL3_BOMVA	KNL3_BOMVA
69	11	45.8	9	1	KNL3_CYPDO	KNL3_CYPDO
70	11	45.8	9	1	NEUT_CAVPO	NEUT_CAVPO
71	11	45.8	9	1	NSK1_SARBU	NSK1_SARBU
72	11	45.8	9	2	Q7M471	Q7m471 vespa orien
73	11	45.8	9	2	Q7M2N8	Q7m2n8 bos indicus
74	11	45.8	9	2	Q8MEM3	Q8mem3 howittia tr
75	11	45.8	9	2	Q8S3C6	Q8s3c6 glycine max
76	11	45.8	9	2	Q7M151	Q7m151 unidentified
77	11	45.8	9	2	Q67605	Q67605 squash leaf
78	11	45.8	9	2	Q67606	Q67606 squash leaf
79	11	45.8	9	2	Q88953	Q88953 vaccinia vi
80	11	45.8	9	2	Q7LZ17	Q7lzi7 heleophryne
81	11	45.8	9	2	Q7LZJ8	Q7ljz8 rana tempor
82	11	45.8	9	2	Q7SX77	Q7sx77 geocheilone
83	11	45.8	9	2	Q9PRJ4	Q9prj4 leptoateus
84	11	45.8	9	2	Q8S599	Q8s599 moloney mur
85	11	45.8	10	1	FARP_MYTED	FARP_MYTED
86	11	45.8	10	1	LSK2_LEUMA	LSK2_LEUMA
87	11	45.8	10	1	LSK2_PERAM	LSK2_PERAM
88	11	45.8	10	1	UPA9_HUMAN	UPA9_HUMAN
89	11	45.8	10	2	Q96QT9	Q96qt9 homo sapien
90	11	45.8	10	2	Q7Z5A2	Q7z5a2 homo sapien
91	11	45.8	10	2	P82217	P82217 bombyx mori
92	11	45.8	10	2	Q8SHA8	Q8sha8 rhampholeon
93	11	45.8	10	2	Q86041	Q86041 cenothera b
94	11	45.8	10	2	Q85BV6	Q85bv6 eucalyptus
95	11	45.8	10	2	Q85V67	Q85v67 eucalyptus
96	11	45.8	10	2	Q76VI9	Q76vi9 lactococcus
97	11	45.8	10	2	Q6K669	Q6kc69 eucalyptus
98	11	45.8	10	2	Q7M1I6	Q7m1i6 trichosanthe
99	11	45.8	10	2	Q93U02	Q93uu2 escherichia
100	11	45.8	10	2	Q6JL97	Q6jl97 neisseria g

ALIGNMENTS

```

RESULT 1
Q63056
ID Q63056 PRELIMINARY; PRT; 10 AA.
AC Q63056;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Rat asialoglycoprotein receptor (ASGP) (Fragment).
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RA MEDLINE=87026895; PubMed=2945599;
RX Watts C.;
RT "Isolation and expression of cDNA clones for a rat liver
RL asialoglycoprotein receptor.";
RL Biosci. Rep. 6:527-534 (1986).
DR EMBL; M21739; AAA0763.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
KW Receptor.
FT NON TER
SQ SEQUENCE 10 AA; 1312 MW; 56ADE0CAB6CB5AA3 CRC64;

Query Match 70.8%; Score 17; DB 2; Length 10;
Best Local Similarity 50.0%; Pred. No. 1.9e+03;
Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 7 DFQH 10

RESULT 2
Q8TG88
ID Q8TG88 PRELIMINARY; PRT; 10 AA.
AC Q8TG88;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Manganese peroxidase (Fragment).
GN Name=mp3;
OS Pleurotus ostreatus (Oyster mushroom) (White-rot fungus).
OC Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Homobasidiomycetes;
OC Agaricales; Pleurotaceae; Pleurotus.
OX NCBI_TaxID=5322;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Florida 6;
RX MEDLINE=22034998; PubMed=12039783;
RX DOI=10.1128/AEM.68.6.3156-3158.2002;
RA Cohen R., Yarden O., Hadar Y.;
RT "Lignocellulose Affects Mn(2+) Regulation of Peroxidase Transcript
RT Levels in Solid-State Cultures of Pleurotus ostreatus.";
RL Appl. Environ. Microbiol. 68:3158-3158(2002).
DR EMBL; AF435445; AAC08267.1; -.
DR GO; GO:0004601; F:peroxidase activity; IEA.
KW Peroxidase.
FT NON TER
SQ SEQUENCE 10 AA; 1166 MW; CC9D0CA5B9C1E339 CRC64;

Query Match 66.7%; Score 16; DB 2; Length 10;
Best Local Similarity 66.7%; Pred. No. 3.3e+03;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 3 FXH 5

RESULT 3
Q7WUG1
ID Q7WUG1 PRELIMINARY; PRT; 10 AA.
AC Q7WUG1;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Probable ATP-binding component of ABC transporter (Fragment).
OS Pseudomonas fluorescens.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=294;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CHAO;
RA Pechy-Tarr M., Bottiglieri M., Bang Lejbolle K., Gigot-Bonnefoy C.,
RA Keel C.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY341911; AAQ17034.1; -.
DR GO; GO:0005524; F:ATP binding; IEA.
KW ATP-binding.
FT NON TER
SQ SEQUENCE 10 AA; 1262 MW; 08EF18CB11E8773B CRC64;

Query Match 66.7%; Score 16; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3
Db 7 EFR 9

RESULT 4
O13591
ID O13591 PRELIMINARY; PRT; 8 AA.
AC O13591;
DT 01-JAN-1998 (TrEMBLrel. 05, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE ORF YNL337w (Fragment).
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RA Obermaier B., Piravandi E., Rinke M.;
RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA MIPS;
RL Submitted (APR-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; Z71612; CAA96271.2; -.
FT NON TER
SQ SEQUENCE 8 AA; 1005 MW; 5CA441E449C9C720 CRC64;

Query Match 58.3%; Score 14; DB 2; Length 8;
Best Local Similarity 66.7%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 4 FNH 6

RESULT 5
Q9Y4J4
ID Q9Y4J4 PRELIMINARY; PRT; 8 AA.
AC Q9Y4J4;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

```



```
DE Runt/82nt/MTG8 protein (Fragment).
GN Name=runt/82nt/MTG8;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
(1)
RN
RP SEQUENCE FROM N.A.
RX MEDLINE=95002916; PubMed=7919324;
RA Tighe J.E., Calabi F.;
RT "Alternative out-of-frame runt/MTG8 transcripts are encoded by the
RT derivative (8) chromosome in the t(8;21) of acute myeloid leukemia
RT M2.";
RL Blood 84:2115-2121(1994).
DR EMBL; S74092; AAD14144.1; -.
FT NON_TER 8
SQ SEQUENCE 8 AA; 1067 MW; 20F414044B17244B CRC64;

Query Match 54.2%; Score 13; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 7 RH 8

RESULT 6
ID Q28866 PRELIMINARY; PRT; 8 AA.
AC Q28866;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-MAY-1999 (TrEMBLrel. 10, Last annotation update)
DE Actin protein (Fragment).
OS Name=actin;
GN Megaptera novaeangliae (Humpback whale).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Mysticeti;
OC Balaeopteridae; Megaptera.
OX NCBI_TaxID=9773;
(1)
RN
RP SEQUENCE FROM N.A.
RX MEDLINE=94285813; PubMed=7912407;
RA Palumbi S.R., Baker C.S.;
RT "Contrasting population structure from nuclear intron sequences and
RT mtDNA of humpback whales."
RL Mol. Biol. Evol. 11:426-435(1994).
DR EMBL; S73467; AAD14118.1; -.
FT NON_TER 8
SQ SEQUENCE 8 AA; 906 MW; 69C866D1F4177408 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 4 RH 5

RESULT 7
ID Q9GMH3 PRELIMINARY; PRT; 8 AA.
AC Q9GMH3;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE Actin (Fragment).
OS Lagorhynchus obscurus (Dusky dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagorhynchus.
```

```
OX NCBI_TaxID=27611;
(1)
RN
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140833; AAF98686.1; -.
FT NON_TER 1
FT NON_TER 8
SQ SEQUENCE 8 AA; 962 MW; 5BD1F417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 6 RH 7

RESULT 8
ID Q9TT78 PRELIMINARY; PRT; 8 AA.
AC Q9TT78;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Thymidylate synthase (Fragment).
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_TaxID=9615;
(1)
RN
RP SEQUENCE FROM N.A.
RX MEDLINE=21015404; PubMed=11130975;
RA Brouillette J.A., Andrew J.R., Venta P.J.;
RT "Estimate of nucleotide diversity in dogs with a pool-and-sequence
RT method.";
RL Mamm. Genome 11:1079-1086(2000).
DR EMBL; AF202073; AAF20918.1; -.
FT NON_TER 1
FT NON_TER 8
SQ SEQUENCE 8 AA; 899 MW; 6731A1E059CAA867 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 8;
Best Local Similarity 50.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 DFH 6

RESULT 9
ID Q7M194 PRELIMINARY; PRT; 8 AA.
AC Q7M194;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE L-serine ammonia-lyase (EC 4.3.1.17) (Fragment).
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
(1)
RN
RP SEQUENCE.
RX MEDLINE=76005414; PubMed=1099073;
RA Heincz M.C., McFall E.;
RT "N-terminal amino acid sequences of D-serine deaminases of wild-type
RT and operator-constitutive strains of Escherichia coli K-12.";
RL J. Bacteriol. 123:1163-1168(1975).
DR EMBL; A25836; A25836.
GO; GO:0003941; F:L-serine ammonia-lyase activity; IEA.
```

```

FT NON TER      8      8
SQ SEQUENCE      8 AA;  906 MW;  F7B1F40865BB05B6 CRC64;

Query Match
Best Local Similarity 54.2%; Score 13; DB 2; Length 8;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3 RH 4
      ||
Db      6 RH 7

RESULT 10
O84156 PRELIMINARY; PRT; 8 AA.
AC Q84156;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Similar to Vaccinia virus (Fragment).
OS Off virus.
OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC Parapoxvirus.
OX NCBI_TaxID=10258;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96010242; PubMed=7571439;
RA Mercer A.A., Lytle D.J., Whelan E.M., Fleming S.B., Sullivan J.T.;
RT "The establishment of a genetic map of orf virus reveals a pattern of
RT genomic organization that is highly conserved among divergent
RT poxviruses";
RL Virology 212:698-704(1995).
DR EMBL; U30336; AAA86400.1; -.
FT NON TER      8
SQ SEQUENCE      8 AA; 1091 MW; E24411A441F40446 CRC64;

Query Match
Best Local Similarity 54.2%; Score 13; DB 2; Length 8;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3 RH 4
      ||
Db      3 RH 4

RESULT 11
P79940 PRELIMINARY; PRT; 8 AA.
AC P79940;
DT 01-MAY-1997 (TrEMBLrel. 03, Created)
DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE XMeis1-4 protein (Fragment).
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
OC Xenopodidae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97202105; PubMed=9049632;
RA Steelman S., Moskow J.J., Muzynski K., North C., Druck T.,
RA Montgomery J.C., Huebner K., Daar I.O., Buchberg A.M.;
RT "Identification of a conserved family of Meis1-related homeobox
RT genes.";
RL Genome Res. 7:142-156(1997).
DR EMBL; U68389; AAB19199.1; -.
FT NON TER      1
SQ SEQUENCE      8 AA; 1187 MW; 278B51F37B11F40B CRC64;

Query Match
Best Local Similarity 54.2%; Score 13; DB 2; Length 8;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

FT NON TER      8      8
SQ SEQUENCE      8 AA; 906 MW;  F7B1F40865BB05B6 CRC64;

Query Match
Best Local Similarity 54.2%; Score 13; DB 2; Length 8;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3 RH 4
      ||
Db      6 RH 7

RESULT 12
BS43 SERPL STANDARD; PRT; 9 AA.
AC P83375;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Bacteriocin serracin P 43 kDa subunit (Fragment).
OS Serratia plymuthica.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Serratia.
OX NCBI_TaxID=82996;
RN [1]
RP SEQUENCE AND FUNCTION.
RC STRAIN=J7;
RX MEDLINE=22293561; PubMed=12406768;
RA Jabrane A., Sabri A., Compere P., Jacques P., Vandenberghe I.,
RA Van Beeumen J., Thonart P.;
RT "Characterization of serracin P, a phage-tail-like bacteriocin, and
RT its activity against Erwinia amylovora, the fire blight pathogen.";
RL Appl. Environ. Microbiol. 68:5704-5710(2002).
CC -I- FUNCTION: Major component of a prophage tail sheath (Probable).
CC -I- FUNCTION: Antibacterial activity against Gram-negative bacterium
CC E. amylovora.
KW Antibiotic; Bacteriocin; Direct protein sequencing.
FT NON TER      9
SQ SEQUENCE      9 AA; 1095 MW; 1E66D412C871E1FB CRC64;

Query Match
Best Local Similarity 54.2%; Score 13; DB 1; Length 9;
Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1 EFRH 4
      ::|
Db      1 DYHH 4

RESULT 13
NEUX_HUMAN STANDARD; PRT; 9 AA.
AC P04277;
DT 20-MAR-1987 (Rel. 04, Created)
DT 20-MAR-1987 (Rel. 04, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Neurotensin-related peptide (NRP) (Kinetensin).
OS Homo sapiens (Human),
OS Bos taurus (Bovine), and
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606, 9913, 9986;
RN [1]
RP SEQUENCE.
RC SPECIES=Human;
RX MEDLINE=86242180; PubMed=3087352;
RA Megard M.H., Kobayashi R., Chen C.F., Lee T.D., Reeve J.R. Jr.,
RA Shively J.E., Walsh J.H.;
RT "The amino acid sequence of kinetensin, a novel peptide isolated from
RT pepsin-treated human plasma: homology with human serum albumin,
RT neurotensin and angiotensin.";
RL Biochem. Biophys. Res. Commun. 136:983-988(1986).
RN [2]
RP SEQUENCE.
RC SPECIES=Bovine, Human, and Rabbit;
RX MEDLINE=87194805; PubMed=2437111;
RA Carraway R.E., Mitra S.P., Cochran D.E.;

```

```

RT "Structure of a biologically active neurotensin-related peptide
RT obtained from pepsin-treated albumin(s).";
RL J. Biol. Chem. 262:5968-5973(1987).
CC -I- FUNCTION: Regulation of fat digestion, lipid absorption, and blood
CC flow (Potential).
DR PIR; A38985; ABBOS
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0005179; F:hormone activity; NAS.
DR GO; GO:0007599; P:hemostasis; IDA.
DR GO; GO:0006629; P:lipid metabolism; NAS.
KW Direct protein sequencing; Hormone.
SQ SEQUENCE 9 AA; 1172 MW; C804DB4761F4140D CRC64;

Query Match 54.2%; Score 13; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4
Db 4 RH 5

RESULT 14
XYLA_STRS8
ID XYLA_STRS8 STANDARD; PRT; 9 AA.
AC P19149;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Xylose isomerase (EC 5.3.1.5) (Fragment).
GN Name=xy1A;
OS Streptomyces sp. (strain NCL 82-5-1).
OC Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC Streptomycineae; Streptomycetaceae; Streptomyces.
OX NCBI_TaxID=72593;
RN [1]
RP SEQUENCE.
RX MEDLINE=88326335; PubMed=3415697;
RA Pawar H.S., Kannan K., Srinivasan M.C., Vartak H.G.;
RT "Purification and characterisation of glucose (xylose) isomerase from
RT Chainia sp. (NCL 82-5-1).";
RL Biochem. Biophys. Res. Commun. 155:411-417(1988).
CC -I- FUNCTION: Involved in D-xylose catabolism.
CC -I- CATALYTIC ACTIVITY: D-xylose = D-xylulose.
CC -I- COFACTOR: Binds 2 magnesium ions per subunit (Potential).
CC -I- SUBUNIT: Homotetramer.
CC -I- SUBCELLULAR LOCATION: Cytoplasmic.
CC -I- SIMILARITY: Belongs to the xylose isomerase family.
DR PIR; A31576; A31576.
DR HAMAP; MF_00455; -; 1.
DR InterPro; IPR001998; Xylose isom.
DR PROSITE; PS00172; Xylose isomerase 1; PARTIAL.
DR PROSITE; PS00173; Xylose isomerase 2; PARTIAL.
KW Direct protein sequencing; Isomerase; Magnesium; Metal-binding;
KW Pentose shunt; Xylose metabolism.
FT NON_TER 9
SQ SEQUENCE 9 AA; 983 MW; F64BA1EDC5B87DD1 CRC64;

Query Match 54.2%; Score 13; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4
Db 1 RH 2

RESULT 15
Q8MJN1
ID Q8MJN1 PRELIMINARY; PRT; 9 AA.
AC Q8MJN1;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)

"Structure of a biologically active neurotensin-related peptide
RT obtained from pepsin-treated albumin(s).";
RL J. Biol. Chem. 262:5968-5973(1987).
CC -I- FUNCTION: Regulation of fat digestion, lipid absorption, and blood
CC flow (Potential).
DR PIR; A38985; ABBOS
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0005179; F:hormone activity; NAS.
DR GO; GO:0007599; P:hemostasis; IDA.
DR GO; GO:0006629; P:lipid metabolism; NAS.
KW Direct protein sequencing; Hormone.
SQ SEQUENCE 9 AA; 1172 MW; C804DB4761F4140D CRC64;

Query Match 54.2%; Score 13; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4
Db 1 RH 2

RESULT 15
Q8MJN1
ID Q8MJN1 PRELIMINARY; PRT; 9 AA.
AC Q8MJN1;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)

```

```

DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Heparin-binding EGF-like growth factor (Fragment).
OS Cebueilla pygmaea (Pygmy marmoset) (Callithrix pygmaea).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Callithrix.
OX NCBI_TaxID=9493;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;
RT "Molecular cladiatic markers in New World monkey phylogeny
RT (Platyrrhini, Primates).";
RL Mol. Phylogenet. Evol. 26:490-501(2003).
DR EMBL; AF368167; AAN01111.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.6e+06;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4
Db 6 FRY 8

RESULT 16
Q8MJN2
ID Q8MJN2 PRELIMINARY; PRT; 9 AA.
AC Q8MJN2;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Heparin-binding EGF-like growth factor (Fragment).
OS Callithrix jacchus (Common marmoset).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Callithrix.
OX NCBI_TaxID=9483;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;
RT "Molecular cladiatic markers in New World monkey phylogeny
RT (Platyrrhini, Primates).";
RL Mol. Phylogenet. Evol. 26:490-501(2003).
DR EMBL; AF368166; AAN01110.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.6e+06;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4
Db 6 FRY 8

RESULT 17
Q8MJN3
ID Q8MJN3 PRELIMINARY; PRT; 9 AA.
AC Q8MJN3;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DE Heparin-binding EGF-like growth factor (Fragment).
OS Callimico goeldii (Goeldi's marmoset).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Callimico.
OX NCBI_TaxID=9495;
RN [1]

```

RP SEQUENCE FROM N.A.  
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;  
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;  
RT "Molecular cladistic markers in New World monkey phylogeny  
(RL (Platyrrhini, Primates).";  
RL Mol. Phylogenet. Evol. 26:490-501(2003).  
DR EMBL: AF368165; AAN01109.1; -.  
DT NON\_TER 1 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;  
Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 66.7%; Pred. No. 1.6e+06;  
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 FRH 4  
Db 6 FRY 8  
RESULT 18  
Q8MJN4 PRELIMINARY; PRT; 9 AA.  
ID Q8MJN4  
AC Q8MJN4;  
DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)  
DE Heparin-binding EGF-like growth factor (Fragment).  
OS Leontopithecus rosalia (Golden lion tamarin).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae;  
OC Leontopithecus.  
OX NCBI\_TaxID=30588;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;  
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;  
RT "Molecular cladistic markers in New World monkey phylogeny  
(RL (Platyrrhini, Primates).";  
RL Mol. Phylogenet. Evol. 26:490-501(2003).  
DR EMBL: AF368164; AAN01108.1; -.  
DT NON\_TER 1 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;  
Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 66.7%; Pred. No. 1.6e+06;  
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 FRH 4  
Db 6 FRY 8  
RESULT 19  
Q8MJN5 PRELIMINARY; PRT; 9 AA.  
ID Q8MJN5  
AC Q8MJN5;  
DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)  
DE Heparin-binding EGF-like growth factor (Fragment).  
OS Leontopithecus rosalia (Brown-headed tamarin).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Saguinus.  
OX NCBI\_TaxID=9487;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;  
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;  
RT "Molecular cladistic markers in New World monkey phylogeny  
(RL (Platyrrhini, Primates).";  
RL Mol. Phylogenet. Evol. 26:490-501(2003).  
DR EMBL: AF368165; AAN01109.1; -.  
DT NON\_TER 1 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;  
Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 66.7%; Pred. No. 1.6e+06;  
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 FRH 4  
Db 6 FRY 8

```
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 2 FRH 4
   ||:
Db 6 FRY 8

RESULT 22
Q8MJN8
ID Q8MJN8 PRELIMINARY; PRT; 9 AA.
AC Q8MJN8;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Heparin-binding EGF-like growth factor (Fragment).
OS Cebus apella (Brown-capped capuchin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Cebinae; Cebus.
OX NCBI_TaxID=9515;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;
RT "Molecular cladistic markers in New World monkey phylogeny
  (Platyrrhini, Primates).";
RL Mol. Phylogenet. Evol. 26:490-501(2003).
DR EMBL; AF368160; AAN01104.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.6e+06;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 2 FRH 4
   ||:
Db 6 FRY 8

RESULT 23
Q8MJN9
ID Q8MJN9 PRELIMINARY; PRT; 9 AA.
AC Q8MJN9;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Heparin-binding EGF-like growth factor (fragment).
OS Ateles fusciceps (Brown-headed spider monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Ateles.
OX NCBI_TaxID=9508;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA Singer S.S., Schmitz J., Schwieck C., Zischler H.;
RT "Molecular cladistic markers in New World monkey phylogeny
  (Platyrrhini, Primates).";
RL Mol. Phylogenet. Evol. 26:490-501(2003).
DR EMBL; AF368159; AAN01103.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1135 MW; 38754409C6972728 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.6e+06;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 2 FRH 4
   ||:
Db 6 FRY 8

RESULT 24
Q7JIS3
ID Q7JIS3 PRELIMINARY; PRT; 9 AA.
AC Q7JIS3;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus obscurus (Dusky dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=27611;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140832; AAF98685.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3 RH 4
   ||
Db 7 RH 8

RESULT 25
Q7JIS4
ID Q7JIS4 PRELIMINARY; PRT; 9 AA.
AC Q7JIS4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=90247;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140830; AAF98683.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3 RH 4
   ||
Db 7 RH 8

RESULT 26
Q7JIS5
ID Q7JIS5 PRELIMINARY; PRT; 9 AA.
AC Q7JIS5;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
```

OC Lagenorhynchus.  
OX NCBI\_TaxID=90247;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Hare M.P., Cipriano F., Palumbi S.R.;  
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF140829; AAF98682.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
Db 7 RH 8

## RESULT 27

Q7JIS6 PRELIMINARY; PRT; 9 AA.

AC Q7JIS6;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Actin (Fragment).  
OS Lagenorhynchus obliquidens (Pacific white-sided dolphin).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;  
OC Lagenorhynchus.  
OX NCBI\_TaxID=90247;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Hare M.P., Cipriano F., Palumbi S.R.;  
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF140828; AAF98681.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
Db 7 RH 8

## RESULT 28

Q7JIS7 PRELIMINARY; PRT; 9 AA.

AC Q7JIS7;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Actin (Fragment).  
OS Lagenorhynchus obliquidens (Pacific white-sided dolphin).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;  
OC Lagenorhynchus.  
OX NCBI\_TaxID=90247;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Hare M.P., Cipriano F., Palumbi S.R.;  
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF140827; AAF98680.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
Db 7 RH 8

## RESULT 31

Q7JIT0

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
Db 7 RH 8

## RESULT 29

Q7JIS8 PRELIMINARY; PRT; 9 AA.

AC Q7JIS8;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Actin (Fragment).  
OS Lagenorhynchus obliquidens (Pacific white-sided dolphin).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;  
OC Lagenorhynchus.  
OX NCBI\_TaxID=90247;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Hare M.P., Cipriano F., Palumbi S.R.;  
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF140826; AAF98679.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
Db 7 RH 8

## RESULT 30

Q7JIS9 PRELIMINARY; PRT; 9 AA.

AC Q7JIS9;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Actin (Fragment).  
OS Lagenorhynchus acutus (Atlantic white-sided dolphin).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;  
OC Lagenorhynchus.  
OX NCBI\_TaxID=90246;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Hare M.P., Cipriano F., Palumbi S.R.;  
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF140824; AAF98677.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
Db 7 RH 8

```

ID Q7JITO PRELIMINARY; PRT; 9 AA.
AC Q7JITO
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=90246;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140823; AAF98676.1; -.
FT NON_TER 1 1
FT NON_TER 9 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 7 RH 8

RESULT 32
Q7JITI PRELIMINARY; PRT; 9 AA.
ID Q7JITI
AC Q7JITI
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=90246;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140822; AAF98675.1; -.
FT NON_TER 1 1
FT NON_TER 9 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 7 RH 8

RESULT 33
Q9GJVI PRELIMINARY; PRT; 9 AA.
ID Q9GJVI
AC Q9GJVI
DT 01-MAR-2001 (TREMBlrel. 16, Created)
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=90246;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140822; AAF98675.1; -.
FT NON_TER 1 1
FT NON_TER 9 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 7 RH 8

RESULT 34
Q9GJV2 PRELIMINARY; PRT; 9 AA.
ID Q9GJV2
AC Q9GJV2
DT 01-MAR-2001 (TREMBlrel. 16, Created)
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=90247;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140831; AAF98684.1; -.
FT NON_TER 1 1
FT NON_TER 9 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 7 RH 8

RESULT 35
Q9GJV3 PRELIMINARY; PRT; 9 AA.
ID Q9GJV3
AC Q9GJV3
DT 01-MAR-2001 (TREMBlrel. 16, Created)
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)
DE Actin (Fragment).
OS Lagenorhynchus obscurus (Dusky dolphin).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC Lagenorhynchus.
OX NCBI_TaxID=27611;
RN [1]
RP SEQUENCE FROM N.A.
RA Hare M.P., Cipriano F., Palumbi S.R.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF140834; AAF98687.1; -.
FT NON_TER 1 1
FT NON_TER 9 9
SQ SEQUENCE 9 AA; 1049 MW; 1D0EF417740862C0 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4
Db 7 RH 8

```

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
Db 7 RH 8

## RESULT 36

Q9TT77 PRELIMINARY; PRT; 9 AA.

AC Q9TT77; (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DE Wilm's tumor protein 1 (Fragment).  
GN Name=Wtl;  
OS Bos taurus (Bovine).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
OC Bovinae; Bos.  
OX NCBI\_TaxID=9913;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=21015404; PubMed=11130975;  
RA Brouillette J.A.; Andrew J.R.; Venta P.J.;  
RT "Estimate of nucleotide diversity in dogs with a pool-and-sequence method."  
RL Mamm. Genome 11:1079-1086(2000).  
DR EMBL; AF202074; AAF20919.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1231 MW; 58DDF41416D1F403 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
Db 3 RH 4

## RESULT 37

Q9R7H9 PRELIMINARY; PRT; 9 AA.

AC Q9R7H9; (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE Lipoprotein (Fragment).  
GN Name=nlpD;  
OS Haemophilus influenzae.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;  
OC Pasteurellaceae; Haemophilus.  
OX NCBI\_TaxID=727;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98083063; PubMed=9422600;  
RA Martin K.; Morlin G.; Smith A.; Nurdyke A.; Eisenstark A.; Golomb M.;  
RT "The tryptophanase gene cluster of Haemophilus influenzae type b: evidence for horizontal gene transfer."  
RL J. Bacteriol. 180:107-118(1998).  
DR EMBL; AF003252; AAB96582.1; -.  
FT NON\_TER 1  
FT NON\_TER 9  
SQ SEQUENCE 9 AA; 1152 MW; 35A017673B4412D7 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
Db 8 RH 9

## RESULT 38

Q8N6B1 PRELIMINARY; PRT; 10 AA.

AC Q8N6B1; (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)  
DE Capacitative calcium channel protein Trp1 (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Late pregnancy myometrium;  
RX MEDLINE=22181008; PubMed=12193412;  
RA Yang M.; Gupta A.; Shlykov S.G.; Corrigan B.; Tsujimoto S.;  
RA Sanborn B.M.;  
RT "Multiple Trp isoforms implicated in capacitative calcium entry are expressed in human pregnant myometrium and myometrial cells."  
RL Biol. Reprod. 67:988-994(2002).  
DR EMBL; AF483646; AAM97861.1; -.  
FT NON\_TER 1  
FT NON\_TER 1  
SQ SEQUENCE 10 AA; 1336 MW; 0DD0C0B401F40724 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 1.7e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RH 4  
Db 5 RH 6

## RESULT 39

Q6LCI4 PRELIMINARY; PRT; 10 AA.

AC Q6LCI4; (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Na+-phosphate cotransporter type II (Fragment).  
GN Name=NPT2;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=93317607; PubMed=8327470;  
RA Magagnin S.; Werner A.; Markovich D.; Sorribas V.; Stange G.;  
RA Biber J.; Murer H.;  
RT "Expression cloning of human and rat renal cortex Na/Pi cotransport.";  
RL Proc. Natl. Acad. Sci. U.S.A. 90:5979-5983(1993).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=96293539; PubMed=8693007; DOI=10.1073/pnas.93.14.7409;  
RA Hartmann C.M.; Hewson A.S.; Kos C.H.; Hilfiker H.; Souncounou Y.;  
RA Murer H.; Tenenhouse H.S.;  
RT "Structure of murine and human renal type II Na+-phosphate cotransporter genes (Npt2 and NPT2).";  
RL Proc. Natl. Acad. Sci. U.S.A. 93:7409-7414(1996).  
DR EMBL; U56682; AAD14854.1; -.  
FT NON\_TER 1  
FT NON\_TER 10  
SQ SEQUENCE 10 AA; 1221 MW; 3F555CCAB1B40AA8 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 10;  
Best Local Similarity 66.7%; Pred. No. 1.7e+04;  
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;



QY 1 EFR 3  
:||  
7 DFR 9

Db

RESULT 40

Q6IG13 PRELIMINARY; PRT; 10 AA.

AC Q6IG13; (TREMBlrel. 27, Created)

DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)

DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)

DE RTN1-Cw (Fragment).

GN Name=RTN1;

OS Bos taurus (Bovine).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;

OC Bovinae; Bos.

OX NCBI\_TaxID=9913;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=22715887; PubMed=12832288;

RA Oertle T.; Klinger M.; Stuermer C.A.; Schwab M.E.;

RT "A reticular rhapsody: phylogenetic evolution and nomenclature of the RTN/Nogo gene family.";

RL FASEB J. 17:1238-1247(2003).

CC -1- MISCELLANEOUS: The sequence shown here is derived from an EMBL/GenBank/DBJ third party annotation (TPA) entry.

CC EMBL; BK003968; DA002043.1; -;

DR InterPro; IPR001951; Histone\_H4.

DR PROSITE; PS00047; HISTONE\_H4; UNKNOWN\_1.

FT NON\_TER 1

SQ SEQUENCE 10 AA; 1136 MW; 317406F4033DD867 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 1.7e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RH 4  
:||  
7 RH 8

Db

RESULT 41

Q958J8 PRELIMINARY; PRT; 10 AA.

AC Q958J8; (TREMBlrel. 19, Created)

DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)

DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)

DE Cytochrome c oxidase subunit I (Fragment).

GN Name=COI;

OS Rana muscosa.

OC Mitochondrion.

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Neobatrachia; Ranioidea; Ranidae; Rana.

OX NCBI\_TaxID=160500;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=21184280; PubMed=11286498; DOI=10.1006/mpev.2000.0908;

RA Macey J.R.; Strasburg J.L.; Brisson J.A.; Vredenburg V.T.;

RA Jennings M.; Larson A.;

RT "Molecular phylogenetics of western North American frogs of the Rana boylii species group.";

RL Mol. Phylogenet. Evol. 19:131-143(2001).

DR EMBL; AF314026; AAK56898.1; -;

DR GO; GO:0005739; C:mitochondrion; IEA.

KW Mitochondrion.

FT NON\_TER 10

SQ SEQUENCE 10 AA; 1335 MW; COD380C9D371F1A9 CRC64;

Query Match 54.2%; Score 13; DB 2; Length 10;  
Best Local Similarity 66.7%; Pred. No. 1.7e+04;

Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 FRH 4  
:||  
3 FTH 5

Db

RESULT 42

O54217 PRELIMINARY; PRT; 10 AA.

AC O54217; (TREMBlrel. 06, Created)

DT 01-JUN-1998 (TREMBlrel. 06, Last sequence update)

DT 01-JUN-1998 (TREMBlrel. 06, Last annotation update)

DE Transposase (fragment).

GN Name=tnp1;

OS Staphylococcus epidermidis.

OC Plasmid pCH01.

OC Bacteria; Firmicutes; Bacillales; Staphylococcus.

OX NCBI\_TaxID=1182;

RN [1]

RP SEQUENCE FROM N.A.

RX STRAIN=BN 280;

RA Heidrich C.; Pag U.; Josten M.; Metzger J.; Jack R.W.; Bierbaum G.;

RA Jung G.; Sahl H.G.;

RT "Isolation, characterization and sequence of the novel lantibiotic RTN1-280 and its biosynthetic gene cluster.";

RL Appl. Environ. Microbiol. 64:3140-3146(1998).

DR EMBL; Y14023; CAA74345.1; -;

KW Plasmid.

FT NON\_TER 10

SQ SEQUENCE 10 AA; 1453 MW; 05A05FD32B4409DB CRC64;

Query Match 54.2%; Score 13; DB 2; Length 10;  
Best Local Similarity 66.7%; Pred. No. 1.7e+04;  
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFR 3  
:||  
8 QFR 10

Db

RESULT 43

O99182 PRELIMINARY; PRT; 7 AA.

AC O99182; (TREMBlrel. 10, Created)

DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)

DT 01-MAY-1999 (TREMBlrel. 10, Last annotation update)

DE Cytochrome oxidase I (Fragment).

GN Name=COI;

OS Gnatholebias zonatus.

OC Mitochondrion.

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;

OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;

OC Cyprinodontiformes; Aplocheilidae; Rivulinae; Gnatholebias.

OX NCBI\_TaxID=135316;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=20072928; PubMed=10603257; DOI=10.1006/mpev.1999.0656;

RA Murphy W.J.; Thomerson J.E.; Collier G.E.;

RT "Phylogeny of the Neotropical killifish family Rivulidae (Cyprinodontiformes, Aplocheiloidei) inferred from mitochondrial DNA sequences.";

RL Mol. Phylogenet. Evol. 13:289-301(1999).

DR EMBL; AF002591; AAD01074.1; -;

DR GO; GO:0005739; C:mitochondrion; IEA.

KW Mitochondrion.

FT NON\_TER 1

SQ SEQUENCE 7 AA; 899 MW; 672721F6CB572030 CRC64;

Query Match 50.0%; Score 12; DB 2; Length 7;  
Best Local Similarity 33.3%; Pred. No. 1.6e+06;  
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
: :  
3 YQH 5

Db

RESULT 44  
OXYT OCTVU STANDARD; PRT; 9 AA.  
AC P80027;  
DT 01-MAR-1992 (Rel. 21, Created)  
DT 01-MAR-1992 (Rel. 21, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Cephalotocin.  
OS Octopus vulgaris (Octopus).  
OC Eukaryota; Metazoa; Mollusca; Cephalopoda; Coleoidea; Neocoleoidea;  
OC Octopodiformes; Octopoda; Incirrata; Octopodidae; Octopus.  
OX NCBI\_TaxID=6645;  
[1]

RP TISSUE=Nerve endings;  
RC MEDLINE=92270139; PubMed=1589145; DOI=10.1016/0304-3940(92)90514-8;  
RA Reich G.;  
RT "A new peptide of the oxytocin/vasopressin family isolated from nerves  
of the cephalopod Octopus vulgaris.";  
RL Neurosci. Lett. 134:191-194(1992).  
CC -1- FUNCTION: Has a role in the neurosecretory system of the vena  
cava.  
CC -1- SUBCELLULAR LOCATION: Secreted.  
CC -1- SIMILARITY: Belongs to the vasopressin/oxytocin family.  
DR InterPro; IPR000981; Neurhyp horm.  
DR Pfam; PF00220; Hormone 4; 1.  
KW PROSITE; PS00264; NEUROHYPOPHYS HORM; 1.  
KW Amidation; Direct protein sequencing; Hormone.  
FT DSULFID 1 6 Glycine amide.  
FT MODRES 9 9  
SQ SEQUENCE 9 AA; 1072 MW; 17FF476EB45409DB CRC64;

Query Match 50.0%; Score 12; DB 1; Length 9;  
Best Local Similarity 66.7%; Pred. No. 1.6e+06;  
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 FRH 4  
: :  
3 FRN 5

Db

RESULT 45  
Q7RES8 PRELIMINARY; PRT; 9 AA.  
AC Q7RES8;  
DT 01-MAR-2004 (TrEMBLrel. 26, Created)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Hypothetical protein.  
GN Name=PY05210;  
OS Plasmodium yoelii yoelii.  
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.  
OX NCBI\_TaxID=73239;  
[1]

RP SEQUENCE FROM N.A.  
RC STRAIN=17XNL;  
RC PubMed=12368865; DOI=10.1038/nature01099;  
RA Carlton J.M., Anguioi S.V., Suh B.B., Koolij T.W., Perteau M.,  
RA Silva J.C., Ermolaeva M.D., Allen J.E., Sellenet J.D., Koo H.L.,  
RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,  
RA Shallow S.J., van Aken S.E., Riedmuller S.B., Feidblyum T.V.,  
RA Cho J.K., Quackenbush J., Sedegah M., Shoabi A., Cummings L.M.,  
RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,  
RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,

van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,  
RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,  
RA Carucci D.J.;  
RT "Genome sequence and comparative analysis of the model rodent malaria  
parasite Plasmodium yoelii yoelii.";  
RL Nature 419:512-519(2002).  
CC -1- CAUTION: The sequence shown here is derived from an  
EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
preliminary data.  
DR EMBL; AABL01001641; EAA17207.1; -.  
KW Hypothetical protein.  
SQ SEQUENCE 9 AA; 1131 MW; 6178E9CB13387734 CRC64;

Query Match 50.0%; Score 12; DB 2; Length 9;  
Best Local Similarity 50.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4  
: :  
6 EPHN 9

Db

RESULT 46  
Q6JDL5 PRELIMINARY; PRT; 9 AA.  
AC Q6JDL5;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Ectonucleotide pyrophosphatase/phosphodiesterase 1 (Fragment).  
GN Name=ENPPI;  
OS Canis familiaris (Dog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
OX NCBI\_TaxID=9615;  
[1]

RP SEQUENCE FROM N.A.  
RX PubMed=15233990; DOI=10.1016/j.ygeno.2004.04.001;  
RA Housley D.J.E., Ritzert E., Venter P.J.;  
RT "Comparative radiation hybrid map of canine chromosome 1 incorporating  
SNP and indel polymorphisms.";  
RL Genomics 84:248-264(2004).  
DR EMBL; AY514708; AAT44554.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 9 9  
SQ SEQUENCE 9 AA; 1051 MW; 5DE6240B05A76447 CRC64;

Query Match 50.0%; Score 12; DB 2; Length 9;  
Best Local Similarity 50.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4  
: :  
6 ERKH 9

Db

RESULT 47  
Q8HUB4 PRELIMINARY; PRT; 10 AA.  
AC Q8HUB4;  
DT 01-MAR-2003 (TrEMBLrel. 23, Created)  
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Ribosomal protein L16 (Fragment).  
GN Name=rpl16;  
OS Anomobryum julaceum.  
OG Chloroplast.  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Bryophyta;  
OC Bryopsida; Bryidae; Bryales; Bryaceae; Anomobryum.  
OX NCBI\_TaxID=67232;  
[1]

RP SEQUENCE FROM N.A.  
RA Pedersen N., Cox C.J., Hedenas L.;

```
RT "Phylogeny of the Moss Family Bryaceae Inferred from Chloroplast DNA
RL Sequences and Morphology."
RL Syst. Bot. 28:471-482(2003).
DR EMBL; AF546765; AANG2980.1; -.
DR GO; GO:0009507; C:chloroplast; IEA.
DR GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW Chloroplast; Ribosomal protein.
FT NON_TER 1
FT NON_TER 10
SQ SEQUENCE 10 AA; 1326 MW; 6314C32409C321B4 CRC64;

Query Match 50.0%; Score 12; DB 2; Length 10;
Best Local Similarity 66.7%; Pred. No. 3e+04;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 3
Db 5 KFR 7

RESULT 48
Q8QE18 PRELIMINARY; PRT; 10 AA.
AC Q8QE18;
DT 01-JUN-2002 (TRENBLrel. 21, Created)
DT 01-JUN-2002 (TRENBLrel. 21, Last sequence update)
DT 01-JUN-2003 (TRENBLrel. 24, Last annotation update)
DE Truncated envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroviral viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22961413; PubMed=14601597; DOI=10.1089/0892220322493139;
RA Masharsky A.E., Klimov N.A., Kozlov A.P.;
RT "Molecular cloning and analysis of full-length genome of HIV type 1
RT strains prevalent in countries of the former Soviet Union.";
RT AIDS Res. Hum. Retroviruses 19:933-939(2003).
DR EMBL; AF413977; AAL78427.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
KW Envelope protein.
FT NON_TER 1
FT NON_TER 1
SQ SEQUENCE 10 AA; 1274 MW; A9FD6C8544326D6 CRC64;

Query Match 50.0%; Score 12; DB 2; Length 10;
Best Local Similarity 33.3%; Pred. No. 3e+04;
Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 7 YQH 9

RESULT 49
EI03 LITRU STANDARD; PRT; 5 AA.
AC P82099;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Electrin 3.
OS Litoria rubella (Desert tree frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC Pelodyadinae; Litoria.
OX NCBI_TaxID=104895;
RN [1]
RP SEQUENCE.
RC TISSUE=Skin secretion;
RA Wabnitz P.A., Bowie J.H., Tyler M.J., Wallace J.C.;
RT "Peptides from the skin glands of the Australian buzzing tree frog
RT Litori electrica. Comparison with the skin peptides from Litoria
```

```
RT rubella.";
RL Aust. J. Chem. 52:639-645(1999).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Skin.
KW Amidation; Amphibian defense peptide; Direct protein sequencing.
FT MOD_RES 5
FT MOD_RES 5 Methionine amide.
SQ SEQUENCE 5 AA; 630 MW; 668761F2C9A00000 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 5;
Best Local Similarity 66.7%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 1 FVH 3

RESULT 50
RE21 LITRU STANDARD; PRT; 5 AA.
ID RE21 LITRU STANDARD; PRT; 5 AA.
AC P82071;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Rubellidin 2.1.
OS Litoria rubella (Desert tree frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC Pelodyadinae; Litoria.
OX NCBI_TaxID=104895;
RN [1]
RP SEQUENCE, AND MASS SPECTROMETRY.
RC TISSUE=Skin secretion;
RA Steinborner S.T., Wabnitz P.A., Waugh R.J., Bowie J.H., Gao C.,
RA Tyler M.J., Wallace J.C.;
RT "The structure of new peptides from the Australian red tree frog
RT 'Litoria rubella'. The skin peptide profile as a probe for the study
RT of evolutionary trends of amphibians.";
RL Aust. J. Chem. 49:955-963(1996).
CC -!- FUNCTION: Shows neither neuropeptide activity nor antibiotic
CC activity.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
CC -!- MASS SPECTROMETRY: MW=626; METHOD=FAB; RANGE=1-5; NOTE=Ref.1.
KW Amphibian defense peptide; Direct protein sequencing.
SQ SEQUENCE 5 AA; 626 MW; 6DD9C9CB10300000 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFR 2
Db 2 EFR 3

RESULT 51
RE31 LITRU STANDARD; PRT; 5 AA.
ID RE31 LITRU STANDARD; PRT; 5 AA.
AC P82072;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Rubellidin 3.1.
OS Litoria rubella (Desert tree frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC Pelodyadinae; Litoria.
OX NCBI_TaxID=104895;
RN [1]
RP SEQUENCE, AND MASS SPECTROMETRY.
RC TISSUE=Skin secretion;
RA Steinborner S.T., Wabnitz P.A., Waugh R.J., Bowie J.H., Gao C.,
```

```
RA Tyler M.J., Wallace J.C.;
RT 'The structure of new peptides from the Australin red tree frog
RT "litoria rubella". The skin peptide profile as a probe for the study
RT of evolutionary trends of amphibians.";
RL Aust. J. Chem. 49:955-963(1996).
CC -1- FUNCTION: Shows neither neuropeptide activity nor antibiotic
CC activity.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
CC -1- MASS SPECTROMETRY: MW:655; METHOD: FAB; RANGE: 1-5; NOTE: Ref. 1.
KW Amidation; Amphibian defense peptide; Direct protein sequencing.
FT MOD RES 5 Threonine amide.
SQ SEQUENCE 5 AA; 656 MW; 71A9C9CB10300000 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2
Db 2 EF 3

RESULT 52
FARP MONEX STANDARD; PRT; 6 AA.
ID FARP_MONEX
AC P41966;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE FMRFamide-like neuropeptide GNFRPF-amide.
OS Moniezia expansa (Sheep tapeworm).
OC Eukaryota; Metazoa; Platyhelminthes; Cestoda; Eucestoda;
OC Cyclophyllidae; Anoplocephalidae; Moniezia.
OX NCBI_TaxID=28841;
RN [1]
RP SEQUENCE.
RX MEDLINE=93312289; PubMed=8323531;
RA Maule A.G.; Shaw C.; Halton D.W.; Thim L.;
RT "GNFRFamide: a novel FMRFamide-immunoreactive peptide isolated from
RT the sheep tapeworm, Moniezia expansa.";
RL Biochem. Biophys. Res. Commun. 193:1054-1060(1993).
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC family.
DR PIR; A43129; A43129.
KW Amidation; Direct protein sequencing; Neuropeptide.
FT MOD RES 6 Phenylalanine amide.
SQ SEQUENCE 6 AA; 787 MW; 69D405C9C4481000 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
Db 4 FR 5

RESULT 53
FAFI_ASCSU STANDARD; PRT; 7 AA.
ID FAFI_ASCSU
AC P31889;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE FMRFamide-like neuropeptide AFI.
OS Ascaris suum (Pig roundworm) (Ascaris lumbricoides).
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Ascarididae; Ascaridoidea;
OC Ascarididae; Ascaris.
OX NCBI_TaxID=6253;
RN [1]
RP SEQUENCE.
```

```
RX MEDLINE=90180465; PubMed=2627377;
RA Cowden C.; Stretton A.O.W.; Davis R.E.;
RT "AF1, a sequenced bioactive neuropeptide isolated from the nematode
RT Ascaris suum.";
RL Neuron 2:1465-1473(1989).
CC -1- FUNCTION: Potent modulator of inhibitory motoneurons. Reduces the
CC input resistance and blocks slow oscillatory potentials in these
CC cells.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Found in the nerve cords and a variety of
CC ganglia particularly in the anterior regions.
CC -1- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC family.
KW Amidation; Direct protein sequencing; Neuropeptide.
FT MOD RES 7 Phenylalanine amide.
SQ SEQUENCE 7 AA; 953 MW; 69D40059CB144350 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2
Db 3 EF 4

RESULT 54
O98866 PRELIMINARY; PRT; 7 AA.
ID O98866
AC O98866;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Cytochrome b/f subunit IV (Fragment).
OS Spinacia oleracea (Spinach).
OG Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC Caryophyllales; Amaranthaceae; Spinacia.
OX NCBI_TaxID=3562;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=86120353; PubMed=3003688;
RA Sijben-Mueller G.; Hallick R.B.; Alt J.; Westhoff P.; Herrmann R.G.;
RT "Spinach plastid genes coding for initiation factor IF-1, ribosomal
RT protein S11 and RNA polymerase alpha-subunit.";
RL Nucleic Acids Res. 14:1029-1044(1986).
DR EMBL; X03496; CAA27215.1; -.
DR GO; GO:0009507; C:chloroplast; IEA.
KW Chloroplast.
FT NON TER 1
SQ SEQUENCE 7 AA; 907 MW; 644729D77409C420 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
Db 2 FR 3

RESULT 55
GLUR HUMAN STANDARD; PRT; 8 AA.
ID GLUR_HUMAN
AC P02729;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 03-JUN-2004 (Rel. 44, Last annotation update)
DE Urine glycopeptide.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

```

OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=72062338; PubMed=5126885;
RA Loe C.J., Weiss J.B.;
RT "Identification in urine of a low-molecular-weight highly polar
RT glycopeptide containing cysteinyl-galactose.";
RL Biochem. J. 123:25P-25P(1971).
CC -1- FUNCTION: The identity of the glycoprotein from which this peptide
CC is derived is unknown. No physiological function has been
CC attributed. An erythrocyte membrane glycopeptide having a similar
CC structure has also been found.
DR PIR; A03188; XGHUEU.
KW GO; GO:000576; C:extracellular; NAS.
DR Direct protein sequencing; Glycoprotein.
FT CARBOHYD 1 1 S-linked (Gal. . .).
SQ SEQUENCE 8 AA; 855 MW; C2D87A1F5B1E5B1E CRC64;

Query Match 45.8%; Score 11; DB 1; Length 8;
Best Local Similarity 50.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 EFRH 4
DB 2 EHS 5

RESULT 56
ID_FPK3_PERAM STANDARD; PRT; 8 AA.
AC P82618;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Pyrokinin-3 (Pep-PK-3) (FXPR-amide).
OS Periplaneta americana (American cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattodea;
OC Blattidae; Periplaneta.
OX NCBI_TaxID=6978;
RN [1]
RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
RC TISSUE=Retrocerebral complex;
RX MEDLINE=99212469; PubMed=10196736; DOI=10.1016/S0965-1748(98)00117-9;
RA Predel R., Kellner R., Nachman R.J., Holman G.M., Rapus J., Gaede G.;
RT "Differential distribution of pyrokinin-isoforms in cerebral and
RT abdominal neurohemal organs of the American cockroach.";
RL Insect Biochem. Mol. Biol. 29:139-144(1999).
RN [2]
RP TISSUE SPECIFICITY.
RX MEDLINE=20189894; PubMed=10723010;
RA Predel R., Eckert M.;
RT "Tagma-specific distribution of FXPRlamides in the nervous system of
RT the American cockroach.";
RL J. Comp. Neurol. 419:352-363(2000).
CC -1- FUNCTION: Mediates visceral muscle contractile activity (myotropic
CC activity).
CC -1- TISSUE SPECIFICITY: Corpora cardiaca.
CC -1- MASS SPECTROMETRY: MW=996.5; METHOD=MALDI; RANGE=1-8; NOTE=Ref.1.
CC -1- SIMILARITY: Belongs to the pyrokinin family.
KW Amidation; Direct protein sequencing; Neuropeptide; Pyrokinin.
FT MOD RES 8 8 Leucine amide.
SQ SEQUENCE 8 AA; 997 MW; 0B34177409D772C7 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 4 FR 5
```

```

RESULT 57
Q15901
ID Q15901 PRELIMINARY; PRT; 8 AA.
AC Q15901;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Homo sapiens (clone XP7B11B) (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RA Lee C.-C., Yazdani A., Wehnert M., Bailey J., Couch L., Xiong M.,
RA Coolbaugh M.I., Chinault C.A., Baldini A., Lindsay E.A., Zhao Z.-Y.,
RA Caskey C.T.H.;
RT "Isolation of chromosome-specific genes by reciprocal probing of
RT arrayed cDNAs and cosmid libraries.";
RL Hum. Mol. Genet. 0:0-0(1995).
DR EMBL; L32080; AAA73891.1; -.
FT NON_TER 1 1
FT NON_TER 8 8
SQ SEQUENCE 8 AA; 860 MW; 37D72878676729CB CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2
DB 1 EF 2

RESULT 58
Q34909
ID Q34909 PRELIMINARY; PRT; 8 AA.
AC Q34909;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Cytochrome b (Fragment).
OS Locusta migratoria (Migratory locust).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Orthoptera; Caelifera; Acridomorpha;
OC Acridoidea; Acrididae; Oedipodinae; Locusta.
OX NCBI_TaxID=7004;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88223478; PubMed=2836084;
RA McCracken A., Uhlenbusch I., Gellissen G.;
RT "Structure of the cloned Locusta migratoria mitochondrial genome:
RT restriction mapping and sequence of its ND-1 (URF-1) gene.";
RL Curr. Genet. 11:625-630(1987).
DR EMBL; X05286; CAA28905.1; -.
DR GO; GO:0005739; C:mitochondrion; IEA.
KW Mitochondrion.
FT NON_TER 1 1
FT NON_TER 8 8
SQ SEQUENCE 8 AA; 1019 MW; FB833723304B45B6 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;
Best Local Similarity 25.0%; Pred. No. 1.6e+06;
Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 EFRH 4
DB 5 KLKH 8

RESULT 59
```

```
Q6Y2F2
ID Q6Y2F2 PRELIMINARY; PRT; 8 AA.
AC Q6Y2F2;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Vacuolar invertase (Fragment).
OS Citrus sinensis (Sweet orange).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Sapindales; Rutaceae; Citrus.
OX NCBI_TaxID=2711;
RN [1]
RP SEQUENCE FROM N.A.
RA An X., Zhang S., Xu C., Qin Q.;
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY190016; AA073818.1; -.
FT NON TER 8
SQ SEQUENCE 8 AA; 1013 MW; FE21E1FB4771AA6 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;
Best Local Similarity 33.3%; Pred. No. 1.6e+06;
Matches 1; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 FRH 4
Db 5 YHH 7

RESULT 60
Q6LDQ5
ID Q6LDQ5 PRELIMINARY; PRT; 8 AA.
AC Q6LDQ5;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Nitrogen fixation protein (nifQ) (Fragment).
OS Rhodospirillum rubrum (Strain 1302).
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhodobacterales;
OC Rhodobacteraceae; Rhodobacter.
OX NCBI_TaxID=1061;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=89213944; PubMed=2708314;
RA Moreno-Vivian C., Hennecke S., Pfehler A., Klipp W.;
RT "Open reading frame 5 (ORF5), encoding a ferredoxin-like protein, and
RT nifQ are cotranscribed with nifE, nifN, nifX, and ORF4 in Rhodospirillum
RT rubrum."
RL J. Bacteriol. 171:2591-2598(1989).
DR EMBL; M26323; AAA26145.1; -.
FT NON TER 1
SQ SEQUENCE 8 AA; 890 MW; 2CC40DDDB0769CB CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2
Db 1 EF 2

RESULT 61
Q9R3X0
ID Q9R3X0 PRELIMINARY; PRT; 8 AA.
AC Q9R3X0;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit
DE (Fragment).
GN Name=rbcl;
OS Planktothrix rubescens.
```

```
OC Bacteria; Cyanobacteria; Oscillatoriales; Planktothrix.
OX NCBI_TaxID=59512;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=BC-Pla 9316, BC-Pla 9401, BC-Pla 9402, BC-Pla 9303, and
RC BC-Pla 9307;
RX MEDLINE=20005589; PubMed=10537197;
RA Beard S.J., Handley B.A., Hayes P.K., Walsby A.E.;
RT "The diversity of gas vesicle genes in Planktothrix rubescens from
RT Lake Zurich."
RL Microbiology 145:2757-2768(1999).
DR EMBL; AJ132249; CAB59537.1; -.
DR EMBL; AJ132248; CAB59534.1; -.
FT NON TER 1
SQ SEQUENCE 8 AA; 957 MW; 33D1AAA685BB19CB CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2
Db 1 EF 2

RESULT 62
Q9ERD2
ID Q9ERD2 PRELIMINARY; PRT; 8 AA.
AC Q9ERD2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Galactose-1-phosphate uridylyl transferase (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=129/D3;
RA Leslie N.D., Bai S.;
RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF314226; AAG31161.1; -.
DR GO; GO:0016740; F:transferase activity; IEA.
KW Transferase.
FT NON TER 8
SQ SEQUENCE 8 AA; 854 MW; ECBDC409D1ADDD6 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3
Db 5 FR 6

RESULT 63
Q90ZV5
ID Q90ZV5 PRELIMINARY; PRT; 8 AA.
AC Q90ZV5;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Adenylate kinase (Fragment).
OS Fulica leuconotus.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Gruiformes; Rallidae; Fulica.
OX NCBI_TaxID=156758;
RN [1]
RP SEQUENCE FROM N.A.
RA Shapiro L.H., Dumbacher J.P.;
RT "Adenylate kinase intron 5: a new nuclear locus for avian
```

RT systematics.";  
RL Auk 118:248-255(2001).  
DR EMBL; AF307898; AAK43537.1; -.  
DR GO; GO:0016301; F:kinase activity; IEA.  
KW Kinase  
FT NON\_TER 1 1  
FT NON\_TER 8 8  
SQ SEQUENCE 8 AA; 994 MW; 96333B19CB1B1866 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
Db 4 EF 5

## RESULT 64

Q6VMC6  
ID Q6VMC6 PRELIMINARY; PRT; 8 AA.

DT 05-JUL-2004 (TREMELrel. 27, Created)  
DT 05-JUL-2004 (TREMELrel. 27, Last sequence update)  
DT 05-JUL-2004 (TREMELrel. 27, Last annotation update)  
DE Myoglobin (Fragment).  
OS Serilophus lunatus (silver-breasted broadbill).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Archosauria; Aves; Neognathae; Passeriformes; Eurylaimidae;  
OC Serilophus.  
OX NCBI\_TaxID=239386;  
RN [1]

RP SEQUENCE FROM N.A.  
RA Fielde J., Zuccon D., Irestedt M., Johansson U.S., Ericson P.G.P.;  
RT "Spayoya enigma: a New World representative of 'Old World  
suboscines'";  
RL Proc. R. Soc. Lond., B, Biol. Sci. 0:0-0(2003).  
DR EMBL; AY338736; AAQ62892.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 8 8  
SQ SEQUENCE 8 AA; 943 MW; 8109C1F2C965B046 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
Db 7 FR 8

## RESULT 65

BRKI\_RANNI  
ID BRKI\_RANNI STANDARD; PRT; 9 AA.

AC Q7L254;  
DT 05-JUL-2004 (Rel. 44, Created)  
DT 05-JUL-2004 (Rel. 44, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Bradykinin-like peptide I.  
OS Rana nigromaculata (Japanese pond frog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranioidea; Ranidae; Rana.  
OX NCBI\_TaxID=8409;  
RN [1]

RP SEQUENCE.  
RC TISSUE=Skin;  
RX MEDLINE=68412013; PubMed=5677638;  
RA Nakajima T.;

RT "Occurrence of a new active peptide on smooth muscle and bradykinin in  
the skin of Rana nigromaculata hallowell.";  
RL Chem. Pharm. Bull. 16:769-770(1968).  
CC -!- FUNCTION: Induces smooth muscle contraction.  
CC -!- SUBCELLULAR LOCATION: Secreted.

CC -!- SIMILARITY: Belongs to the bradykinin family.  
DR PIR; A61358; A61358.  
KW Bradykinin; Direct protein sequencing; Vasodilator.  
SQ SEQUENCE 9 AA; 1017 MW; 3687D771A9C86777 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
Db 8 FR 9

## RESULT 66

COXE\_THUOB  
ID COXE\_THUOB STANDARD; PRT; 9 AA.

AC P80975;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Cytochrome c oxidase polypeptide Via (EC 1.9.3.1) (Fragment).  
OS Thunnus obesus (Bigeye tuna).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Scombroidei;  
OC Scombridae; Thunnus.  
OX NCBI\_TaxID=8241;  
RN [1]

RP SEQUENCE.  
RC TISSUE=Heart;  
RX MEDLINE=97454291; PubMed=9310366;  
RA Arnold S., Lee I., Kim M., Song E., Linder D., Lottspeich F.,  
RT Kadenbach B.;  
RT "The subunit structure of cytochrome-c oxidase from tuna heart and  
liver";

RL Eur. J. Biochem. 248:99-103(1997).  
CC -!- FUNCTION: This protein is one of the nuclear-coded polypeptide  
chains of cytochrome c oxidase, the terminal oxidase in  
mitochondrial electron transport.

CC -!- CATALYTIC ACTIVITY: 4 ferrocyclochrome c + O(2) = 4 ferricytochrome  
c + 2 H(2)O.

CC -!- SUBCELLULAR LOCATION: Mitochondrial inner membrane.

CC -!- SIMILARITY: Belongs to the cytochrome c oxidase Via family.

DR PIR; S77984; S77984.

DR InterPro; IPR001349; COX6A.

DR PROSITE; PS01329; COX6A; PARTIAL.

KW Direct protein sequencing; Inner membrane; Mitochondrion;

Oxidoreductase.

FT NON\_TER 1 1

FT NON\_TER 9 9

SQ SEQUENCE 9 AA; 1136 MW; 62E072C9CB0776DB CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.6e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
Db 5 EF 6

## RESULT 67

FIBB\_PAPAN  
ID FIBB\_PAPAN STANDARD; PRT; 9 AA.

AC P19344;

DT 01-NOV-1990 (Rel. 16, Created)

DT 01-NOV-1990 (Rel. 16, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE Fibrinogen beta chain [Contains: Fibrinopeptide B] (Fragment).

GN Name=FCB;

OS Papio anubis (Olive baboon).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;  
 OC Cercopithecinae; Papio.  
 OC NCBI\_TaxID=9555;  
 RN [1]

RP SEQUENCE.  
 RX MEDLINE=84161822; PubMed=6423621;  
 RA Nakamura S., Takenaka O., Takahashi K.;  
 RT "Fibrinopeptides A and B of baboons (Papio anubis, Papio hamadryas,  
 RT and Theropithecus gelada); their amino acid sequences and evolutionary  
 RT rates and a molecular phylogeny for the baboons.";

RL J. Biochem. 94:1973-1978(1983).  
 CC -1- FUNCTION: Fibrinogen has a double function: yielding monomers that  
 CC polymerize into fibrin and acting as a cofactor in platelet  
 CC aggregation.

CC -1- SUBUNIT: Hexamer containing 2 sets of 3 nonidentical chains  
 CC (alpha, beta and gamma), linked to each other by disulfide bonds.  
 CC -1- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin,  
 CC which cleaves fibrinopeptides A and B from alpha and beta chains,  
 CC and thus exposes the N-terminal polymerization sites responsible  
 CC for the formation of the soft clot.

DR PIR; D28854; D28854; Fibrinogen C.

DR InterPro; IPR002181; Fibrinogen C.

DR PROSITE; PS00514; FBRIN\_AG\_C\_DOMAIN; PARTIAL.

KW Blood coagulation; Direct protein sequencing; Plasma.

FT PEPTIDE 1 9 Fibrinopeptide B.

FT NON TER 1 9

SQ SEQUENCE 9 AA, 1076 MW, DDFE409C7287B06 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3

Db 6 FR 7

RESULT 68

KNL3\_BOMVA

ID -KNL3\_BOMVA STANDARD; PRT; 9 AA.

AC P83058;

DT 28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE [Thr6]bradykinin.

OS Bombina variegata (Yellow-bellied toad).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.

OX NCBI\_TaxID=8348;

RN [1]

RP SEQUENCE, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.

RC TISSUE=Skin secretion;

RX MEDLINE=22217713; PubMed=12230583;

RA Chen T., Orr D.F., Bjourson A.J., McClean S., O'Rourke M., Hirst D.G.,

RA Rao P., Shaw C.;

RT "Novel bradykinins and their precursor cDNAs from European yellow-

RT bellied toad (Bombina variegata) skin.";

RL Eur. J. Biochem. 269:4693-4700(2002).

CC -1- FUNCTION: Produces in vitro relaxation of rat arterial smooth

CC muscle and constriction of intestinal smooth muscle.

CC -1- SUBCELLULAR LOCATION: Secreted.

CC -1- TISSUE SPECIFICITY: Skin.

CC -1- SIMILARITY: Belongs to the bradykinin family.

KW Amphibian defense peptide; Bradykinin; Direct protein sequencing;

KW Vasodilator.

SQ SEQUENCE 9 AA, 1074 MW, 3393D771A9C86777 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3

Db 6 FR 7

Db 8 FR 9

RESULT 69

KNL3\_CYPDO

ID -KNL3\_CYPDO STANDARD; PRT; 9 AA.

AC P83659;

DT 05-JUL-2004 (Rel. 44, Created)

DT 05-JUL-2004 (Rel. 44, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE [Thr6]bradykinin.

OS Cyphononyx dorsalis (Spider wasp).

OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

OC Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Vespoidea;

OC Pompilidae; Cyphononyx.

OX NCBI\_TaxID=246466;

RN [1]

RP SEQUENCE, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS

RP SPECTROMETRY.

RC TISSUE=Venom;

RX MEDLINE=21203862; PubMed=11306139; DOI=10.1016/S0041-0101(00)00262-2;

RA Konno K., Hisada M., Naoki H., Itagaki Y., Yasuhara T., Juliano M.A.,

RA Juliano L., Palma M.S., Yamane T., Nakajima T.;

RT "Isolation and sequence determination of peptides in the venom of the

RT spider wasp (Cyphononyx dorsalis) guided by matrix-assisted laser

RT desorption/ionization time of flight (MALDI-TOF) mass spectrometry.";

RL Toxicon 39:1257-1260(2001).

CC -1- FUNCTION: Produces in vitro relaxation of rat arterial smooth

CC muscle and constriction of intestinal smooth muscle (By

CC similarity).

CC -1- SUBCELLULAR LOCATION: Secreted.

CC -1- TISSUE SPECIFICITY: Expressed by the venom gland.

CC -1- MASS SPECTROMETRY: MW=1074.58; METHOD=MALDI; RANGE=1-9;

CC NOTE=Ref.1.

CC -1- SIMILARITY: Belongs to the bradykinin family.

DR GO; GO:0005615; C:extracellular space; IDA.

DR GO; GO:0045776; P:negative regulation of blood pressure; ISS.

DR GO; GO:0045987; P:positive regulation of smooth muscle contra. .; ISS.

KW Bradykinin; Direct protein sequencing; Vasodilator.

SQ SEQUENCE 9 AA, 1074 MW, 3393D771A9C86777 CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3

Db 8 FR 9

RESULT 70

NEUU\_CAVPO

ID -NEUU\_CAVPO STANDARD; PRT; 9 AA.

AC P34966;

DT 01-FEB-1994 (Rel. 28, Created)

DT 01-FEB-1994 (Rel. 28, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE Neuromedin U-9 (NmU-9).

GN Name=NmU;

OS Cavia porcellus (Guinea pig).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.

OX NCBI\_TaxID=10141;

RN [1]

RP SEQUENCE.

RC TISSUE=Small intestine;

RX MEDLINE=90341105; PubMed=2381877; DOI=10.1016/0196-9781(90)90066-E;

RA Murphy R., Turner C.A., Furness J.B., Parker L., Giraud A.;

RT "Isolation and microsequence analysis of a novel form of neuromedin U

RT from guinea pig small intestine.";

RL Peptides 11:613-617(1990).

CC -1- FUNCTION: Stimulates uterine smooth muscle contraction and causes

CC selective vasoconstriction.



```

CC -|- SUBCELLULAR LOCATION: Secreted.
CC -|- SIMILARITY: Belongs to the Nmu family.
CR InterPro; IPR008199; NMu.
DR Pfam; PF02070; NMu; 1.
DR PROSITE; PS00967; NMu; 1.
KW Amidation; Direct protein sequencing; Hormone.
FT MOD_RES 9 9 Asparagine amide.
SQ SEQUENCE 9 AA; 1169 MW; 1ECF177409C729DB CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3
Db 5 FR 6

RESULT 71
ID NSK1_SARBU STANDARD; PRT; 9 AA.
AC P41492;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Neosulfakinin-I (NEB-SK-I).
OS Sarcophaga bullata (Grey flesh fly) (Neobellieria bullata).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;
OC Sarcophagidae; Sarcophaga.
OX NCBI_TaxID=7385;
RN [1]
RP SEQUENCE.
RC TISSUE=Head;
RX MEDLINE=93083101; PubMed=1360367;
RA Fonagy A., Schoofs L., Proost P., van Damme J., de Loof A.;
RT "Isolation and primary structure of two sulfakinin-like peptides from
the fleshfly, Neobellieria bullata.";
RL Comp. Biochem. Physiol. 103C:135-142 (1992).
CC -|- FUNCTION: Myotropic peptide.
CC -|- SUBCELLULAR LOCATION: Secreted.
CC -|- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
DR InterPro; IPR001651; Gastrin.
DR PROSITE; PS00259; GASTRIN; 1.
KW Amidation; Direct protein sequencing; Neuropeptide; Sulfation.
FT MOD_RES 4 4 Sulfotyrosine (potential).
FT MOD_RES 9 9 Phenylalanine amide (potential).
SQ SEQUENCE 9 AA; 1187 MW; 8B0A0891E86B5AAA CRC64;

Query Match 45.8%; Score 11; DB 1; Length 9;
Best Local Similarity 25.0%; Pred. No. 1.6e+06;
Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EPRH 4
Db 3 DYGH 6

RESULT 72
ID Q7M471 PRELIMINARY; PRT; 9 AA.
AC Q7M471;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Venom protein HR-3 (Fragment).
OS Vespa orientalis (Oriental hornet).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Vespoidea;
OC Vespidae; Vespinae; Vespa.
OX NCBI_TaxID=7447;
RN [1]
RP SEQUENCE.

RA Tuichibaev M.U., Akhmedova N.U., Kazakov I., Korneev A.S.,
RA Gagel'gans A.I.;
RT "Low-molecular-weight peptides of venom of the giant hornet Vespa
RT orientalis. Structure and function.";
RL Biochemistry 53:183-190(1988).
DR PIR; S10920; 1
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1029 MW; 9C27C729CB11F2D5 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2
Db 5 EF 6

RESULT 73
ID Q7M2N8 PRELIMINARY; PRT; 9 AA.
AC Q7M2N8;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Alpha-2-macroglobulin isoform 1 (Fragment).
OS Bos indicus (Zebu).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovinae; Bos.
OX NCBI_TaxID=9915;
RN [1]
RP SEQUENCE.
RX MEDLINE=96032553; PubMed=7556651; DOI=10.1016/0014-5793(95)00960-H;
RA Dolmer K., Jenner L.B., Jacobsen L., Andersen G.R., Koch T.J.,
RA Thirup S., Sottrup-Jensen L., Nyborg J.;
RT "Crystallisation and preliminary X-ray analysis of the receptor-
RT binding domain of human and bovine alpha(2)-macroglobulin.";
RL FEBS Lett. 372:93-95(1995).
DR PIR; S66635; S66635.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1095 MW; 87B02DD9D769CB1A CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2
Db 3 EF 4

RESULT 74
ID Q8MEM3 PRELIMINARY; PRT; 9 AA.
AC Q8MEM3;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Ribosomal protein 16 (Fragment).
GN Name=rpl16;
OS Howittia trilocularis.
OG Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Malvales; Malvaceae; Malvoideae; Howittia.
OX NCBI_TaxID=183272;
RN [1]
RP SEQUENCE FROM N.A.
RA Pfeil B.E., Brubaker C.L., Craven L.A., Crisp M.D.;
RT "Phylogeny of Hibiscus and the tribe Hibisceae (Malvaceae) using

```

```
RT chloroplast DNA sequences of ndhF and the rpl16 intron.";
RL Sbst. Bot. 27:333-350(2002).
DR EMBL; AF384615; AAM50387.1; -.
DR GO; GO:0009507; C:chloroplast; IEA.
DR GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW Chloroplast; Ribosomal protein.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1256 MW; 6351D32409D411B4 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 5 FR 6

RESULT 75
Q883C6 PRELIMINARY; PRT; 9 AA.
AC Q883C6;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE SNF RAD 54-like protein (Fragment).
OS Glycine max (Soybean).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids 1; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Glycine.
OX NCBI_TaxID=3847;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21258784; PubMed=11361330; DOI=10.1007/s004380000418;
RA Meksem K., Lightfoot D., Gibson P.;
RA Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
RT "Conversion of AFLP bands into high-throughput DNA markers.";
RL Mol. Genet. Genomics 265:207-214(2001).
RN [2]
RP SEQUENCE FROM N.A.
RA Meksem K., Lightfoot D., Gibson P.;
RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
RT EMBL; AF489439; AAM14563.1; -.
FT NON_TER 1
FT NON_TER 9
SQ SEQUENCE 9 AA; 1070 MW; DC20A69735A2C599 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EF 2
DB 1 EF 2

RESULT 76
Q7M151 PRELIMINARY; PRT; 9 AA.
AC Q7M151;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Translation elongation factor EF-Tu (Fragment).
OS unidentified bacterium.
OC Bacteria; environmental samples.
OX NCBI_TaxID=2338;
RN [1]
RP SEQUENCE.
RA Binette J.P., Binette M.B.;
RA Submitted (OCT-1996) to the PIR data bank.
DR PIR; D58503; D58503.
FT NON_TER 1
```

---

```
FT NON_TER 9
SQ SEQUENCE 9 AA; 1233 MW; 0E92DB59D6C7741B CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 8 FR 9

RESULT 77
Q67605 PRELIMINARY; PRT; 9 AA.
AC Q67605;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE AL1 protein (Fragment).
GN Name=AL1;
OS Squash leaf curl virus (SgLCV).
OC Viruses; ssDNA viruses; Geminiviridae; Begomovirus.
OX NCBI_TaxID=10829;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CV-R;
RX MEDLINE=91082450; PubMed=1984669;
RA Lazarowitz S.G.;
RT "Molecular characterization of two bipartite geminiviruses causing squash leaf curl disease: role of viral replication and movement functions in determining host range.";
RL Virology 180:70-80(1991).
DR EMBL; M63155; AAA47823.1; -.
FT NON_TER 9
SQ SEQUENCE 9 AA; 1118 MW; 2B30D5B457645417 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 8 FR 9

RESULT 78
Q67606 PRELIMINARY; PRT; 9 AA.
AC Q67606;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE AL1 protein (Fragment).
GN Name=AL1;
OS Squash leaf curl virus (SgLCV).
OC Viruses; ssDNA viruses; Geminiviridae; Begomovirus.
OX NCBI_TaxID=10829;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CV-E;
RX MEDLINE=91082450; PubMed=1984669;
RA Lazarowitz S.G.;
RT "Molecular characterization of two bipartite geminiviruses causing squash leaf curl disease: role of viral replication and movement functions in determining host range.";
RL Virology 180:70-80(1991).
DR EMBL; M63157; AAA47822.1; -.
FT NON_TER 9
SQ SEQUENCE 9 AA; 1118 MW; 2B30D5B457645417 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 8 FR 9
```

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
 Db 8 FR 9

RESULT 79

Q88953 Q88953 PRELIMINARY; PRT; 9 AA.

AC Q88953; 1996 (TrEMBLrel. 01, Created)

DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)

DE 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)

DT Serpins (Fragment).

GN Name=B13R/SPI-2;

OS Vaccinia virus.

OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;

OC Orthopoxvirus.

OX NCBI\_TaxID=10245;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=95131144; PubMed=7831769;

RA Kettle S., Blake N.W., Law K.M., Smith G.L.;

RT "Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5

RT and 40K, intracellular polypeptides that do not affect virus virulence

RT in a murine intranasal model."

RL Virology 206:136-147(1995).

DR EMBL; S75133; AAC60736.1; -.

FT NON\_TER 1 1

SQ SEQUENCE 9 AA; 1081 MW; 9584D05B0409C05A CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
 Db 4 FR 5

RESULT 80

Q7LZ17 Q7LZ17 PRELIMINARY; PRT; 9 AA.

AC Q7LZ17;

DT 01-MAR-2004 (TrEMBLrel. 26, Created)

DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)

DE Hydroxyproline-3-bradykinin.

OS Heleophryne purcelli (Cape ghost frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Heleophrynidae;

OC Heleophryne.

OX NCBI\_TaxID=31911;

RN [1]

RP SEQUENCE.

RA Nakajima T., Yasuhara T., Erspamer G.F., Visser J.;

RT "Occurrence of HYP(3)-bradykinin in methanol extracts of the skin of

RT the South African leptodactylid frog Heleophryne purcelli."

RL Experientia 35:1133-1133(1979).

DR PIR; A43065; A43065.

SQ SEQUENCE 9 AA; 1060 MW; 3393D775B9C86777 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
 Db 8 FR 9

RESULT 81

Q88953 Q88953 PRELIMINARY; PRT; 9 AA.

AC Q88953; 1996 (TrEMBLrel. 01, Created)

DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)

DE Serpins (Fragment).

GN Name=B13R/SPI-2;

OS Vaccinia virus.

OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;

OC Orthopoxvirus.

OX NCBI\_TaxID=10245;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=95131144; PubMed=7831769;

RA Kettle S., Blake N.W., Law K.M., Smith G.L.;

RT "Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5

RT and 40K, intracellular polypeptides that do not affect virus virulence

RT in a murine intranasal model."

RL Virology 206:136-147(1995).

DR EMBL; S75133; AAC60736.1; -.

FT NON\_TER 1 1

SQ SEQUENCE 9 AA; 1081 MW; 9584D05B0409C05A CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Q7LZJ8 Q7LZJ8 PRELIMINARY; PRT; 9 AA.

AC Q7LZJ8;

DT 01-MAR-2004 (TrEMBLrel. 26, Created)

DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE Bradykinin.

OS Rana temporaria (European common frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Neobatrachia; Ranioidea; Ranidae; Rana.

OX NCBI\_TaxID=8407;

RN [1]

RP SEQUENCE.

RA Anastasi A., Erspamer V., Bertaccini G.;

RT "Occurrence of bradykinin in the skin of Rana temporaria."

RL Comp. Biochem. Physiol. 14:43-52(1965).

DR PIR; A61363; A61363.

SQ SEQUENCE 9 AA; 1060 MW; 3393D775B9C86777 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3  
 Db 8 FR 9

RESULT 82

Q7SX77 Q7SX77 PRELIMINARY; PRT; 9 AA.

AC Q7SX77;

DT 01-OCT-2003 (TrEMBLrel. 25, Created)

DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)

DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)

DE Calmodulin (fragment).

OS Geochelone nigra (Galapagos giant tortoise).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Testudines; Cryptodira; Testudinidae; Testudinidae; Geochelone.

OX NCBI\_TaxID=66189;

RN [1]

RP SEQUENCE FROM N.A.

RX PubMed=15062813; DOI=10.1016/j.jympev.2004.02.004;

RA Calzone A., Gentile G., Burns C., Sezzi E., Bergman W., Ruelle M.,

RA Saltonstall K., Powell J.R.;

RT "Extreme difference in rate of mitochondrial and nuclear evolution in

RT a large ectotherm, Galapagos tortoises."

RL Mol. Phylogenet. Evol. 31:794-798(2004).

DR EMBL; AY101709; AAM47114.1; -.

DR EMBL; AY101712; AAM47117.1; -.

FT NON\_TER 1 1

FT NON\_TER 9 9

SQ SEQUENCE 9 AA; 1039 MW; 2E3D0769CAA041A8 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EF 2  
 Db 8 EF 9

RESULT 83

Q9PRJ4 Q9PRJ4 PRELIMINARY; PRT; 9 AA.

AC Q9PRJ4;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)

DE Bradykinin.

OS Lepisosteus osseus (Long-nosed gar), and

OS Amia calva (Bowfin).

Query Match 45.8%; Score 11; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.6e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Semionotiformes; Lepisosteidae;
OC Lepisosteus
OX NCBI_TaxID=34771, 7924;
RN [1]
RP MEDLINE=95380361; PubMed=7651903; DOI=10.1016/0196-9781(94)00202-H;
RX Conlon J.M., Platzack B., Marra L.E., Youson J.H., Olson K.R.;
RA "Isolation and biological activity of [Trp5]bradykinin from the plasma
RT of the phylogenetically ancient fish, the bowfin and the longnosed
RT gar.";
RL Peptides 16:485-489(1995).
SQ SEQUENCE 9 AA; 1099 MW; 3393D775A3786777 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 8 FR 9

RESULT 84
Q85599 PRELIMINARY; PRT; 9 AA.
AC Q85599
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE Moloney murine sarcoma virus (strain HT1) mos/env 3' junction.
DE (Fragment).
OS Moloney murine leukemia virus.
OC Viruses; Retroviruses; Retroviridae; Gammaretrovirus.
OX NCBI_TaxID=11801;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=83164305; PubMed=6300424;
RA Donoghue D.J., Hunter T.;
RT "Recombination junctions of variants of Moloney murine sarcoma virus:
RT Generation and divergence of a mammalian transforming gene.";
RL J. Virol. 45:607-617(1983).
DR EMBL; K03107; AAA46493.1; -.
FT NON TER 1
FT SEQUENCE 9 AA; 932 MW; 410B2DD6409CDD3 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 4 FR 5

RESULT 85
FARP_MYTED STANDARD; PRT; 10 AA.
AC P42560;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE FMRamide-like neuropeptide ALAGDHFFRF-amide.
OS Mytilus edulis (Blue mussel).
OC Eukaryota; Metazoa; Mollusca; Bivalvia; Pteriomorpha; Mytiloida;
OC Mytiloidae; Mytilidae; Mytilus.
OX NCBI_TaxID=6550;
RN [1]
RP SEQUENCE.
RX MEDLINE=93047883; PubMed=1358534; DOI=10.1016/0742-8413(92)90104-F;
RA Walker R.J.;
RT "Neuroactive peptides with an RFamide or Famide carboxyl terminal.";
RL Comp. Biochem. Physiol. 102C:213-222(1992).
```

```
CC -I- SUBCELLULAR LOCATION: Secreted.
CC -I- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC family.
DR PIR; A58365; A58365
KW Amidation; Direct protein sequencing; Neuropeptide.
FT MOD_RES 10 10 Phenylalanine amide.
SQ SEQUENCE 10 AA; 1180 MW; C2F80CC9C1EAA87D CRC64;

Query Match 45.8%; Score 11; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 5.1e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FR 3
DB 8 FR 9

RESULT 86
LSK2_LEUMA STANDARD; PRT; 10 AA.
ID LSK2_LEUMA
AC P67802; P09039;
DT 01-NOV-1988 (Rel. 09, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Leucosulfakinin-II (LSK-II).
OS Leucophaea maderae (Madeira cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blatteroidea;
OC Blatteridae; Leucophaea.
OX NCBI_TaxID=6988;
RN [1]
RP SEQUENCE.
RX MEDLINE=87048769; PubMed=3778455;
RA Nachman R.J., Holman G.M., Cook B.J., Haddon W.F., Ling N.;
RT "Leucosulfakinin-II, a blocked sulfated insect neuropeptide with
RT homology to cholecystokinin and gastrin.";
RL Biochem. Biophys. Res. Commun. 140:357-364(1986).
CC -I- FUNCTION: Changes the frequency and amplitude of contractions of
CC the cockroach hindgut. Stimulates muscle contraction of hindgut.
CC -I- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
DR PIR; A26335; GMR022.
DR InterPro; IPR001651; Gastrin.
DR PROSITE; PS00259; GASTRIN; 1.
KW Amidation; Direct protein sequencing; Hormone;
KW Pyrrolidone carboxylic acid; Sulfation.
FT MOD_RES 1 1 Pyrrolidone carboxylic acid.
FT MOD_RES 5 5 Sulfotyrosine.
FT MOD_RES 10 10 Phenylalanine amide.
SQ SEQUENCE 10 AA; 1255 MW; 9B4F5391E86B5AAA CRC64;

Query Match 45.8%; Score 11; DB 1; Length 10;
Best Local Similarity 25.0%; Pred. No. 5.1e+04;
Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 4 DYGH 7

RESULT 87
LSK2_PERAM STANDARD; PRT; 10 AA.
ID LSK2_PERAM
AC P67803; P09039;
DT 01-NOV-1988 (Rel. 09, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Leucosulfakinin-II (LSK-II).
OS Periplaneta americana (American cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidae;
OC Blattidae; Periplaneta.
OX NCBI_TaxID=6978;
RN [1]
```

SEQUENCE.  
RP TISSUE=Corpora cardiaca;  
RC MEDLINE=90137190; PubMed=2615921; DOI=10.1016/0143-4179(89)90038-3;  
RA Venstra J.A.;  
RT "Isolation and structure of two gastrin/CCK-like neuropeptides from  
the American cockroach homologous to the leucokininins.";  
RL Neuropeptides 14:145-149(1989).  
CC -!- FUNCTION: Changes the frequency and amplitude of contractions of  
the cockroach hindgut. Stimulates muscle contraction of hindgut.  
CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
DR PIR: B60656; B60656.  
DR InterPro: IPR001651; Gastrin.  
DR PROSITE: PS00259; GASTRIN; 1.  
KW Amidation; Direct protein sequencing; Hormone;  
KW Pyrrolidone carboxylic acid.  
FT MOD\_RES 10 10 Pyrrolidone carboxylic acid.  
FT MOD\_RES 10 10 Phenylalanine amide.  
SQ SEQUENCE 10 AA; 1255 MW; 9B4F5391E86B5AAA CRC64;  
Query Match 45.8%; Score 11; DB 1; Length 10;  
Best Local Similarity 25.0%; Pred. No. 5.1e+04;  
Matches 1; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
Qy 1 EFRH 4  
Db 4 DYGH 7  
RESULT 88  
UPA9 HUMAN STANDARD; PRT; 10 AA.  
ID UPA9 HUMAN  
AC P30095;  
DT 01-APR-1993 (Rel. 25, Created)  
DT 01-APR-1993 (Rel. 25, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Unknown protein from 2D-PAGE of plasma (Spot 35) (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE.  
RC TISSUE=Plasma;  
RX MEDLINE=93092937; PubMed=1459097;  
RA Hughes G.J., Frutiger S., Paquet N., Ravier F., Pasquali C.,  
RA Sanchez J.-C., James R., Tisset J.-D., Bjellqvist B.,  
RA Hochstrasser D.F.;  
RT "Plasma protein map: an update by microsequencing.";  
RL Electrophoresis 13:707-714(1992).  
CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown  
protein is: 7.2, its MW is: 15 kDa.  
DR SWISS-2DPAGE; P30095; HUMAN.  
KW Direct protein sequencing.  
FT NON\_TER 1 1  
FT NON\_TER 10 10  
SQ SEQUENCE 10 AA; 1233 MW; 37AD72B409C681B7 CRC64;  
Query Match 45.8%; Score 11; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 FR 3  
Db 6 FR 7  
RESULT 89  
Q96QT9 PRELIMINARY; PRT; 10 AA.  
ID Q96QT9  
AC Q96QT9;  
DT 01-DEC-2001 (TREMBLrel. 19, Created)  
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)  
DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)

DE Protein tyrosine phosphatase 1B (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=21326081; PubMed=11316810; DOI=10.1074/jbc.M101354200;  
RA Fukuda T., Tonks N.K.;  
RT "The reciprocal role of Egr-1 and Sp family proteins in regulation of  
the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-  
tyrosine kinase.";  
RL J. Biol. Chem. 276:25512-25519(2001).  
DR EMBL; AY029236; AAKJ1734.1; --  
FT NON\_TER 10 10  
SQ SEQUENCE 10 AA; 1314 MW; AC08E219CB133B16 CRC64;  
Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 EF 2  
Db 6 EF 7  
RESULT 90  
Q7ZSA2 PRELIMINARY; PRT; 10 AA.  
ID Q7ZSA2  
AC Q7ZSA2;  
DT 01-OCT-2003 (TREMBLrel. 25, Created)  
DT 01-OCT-2003 (TREMBLrel. 25, Last sequence update)  
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)  
DE Hypothetical protein.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Testis;  
RA Fraisl P., Forss-Petter S., Berger J.;  
RL Submitted (JUL-2003) to the EMBL/GenBank/DBSJ databases.  
DR EMBL; AJ577571; CAB2153.1; --  
KW Hypothetical protein.  
SQ SEQUENCE 10 AA; 1086 MW; 622094D8786769D4 CRC64;  
Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 FR 3  
Db 2 FR 3  
RESULT 91  
P82217 PRELIMINARY; PRT; 10 AA.  
ID P82217  
AC P82217;  
DT 01-OCT-2001 (TREMBLrel. 18, Created)  
DT 01-OCT-2001 (TREMBLrel. 18, Last sequence update)  
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
DE Unknown protein from 2D-page (Fragment).  
OS Bombyx mori (Silk moth).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysa; Bombycoidea;  
OC Bombycidae; Bombyx.  
OX NCBI\_TaxID=7091;  
RN [1]  
RP SEQUENCE.  
RC STRAIN=XINHANG X KEMING; TISSUE=Body wall, and Fat body;  
RX MEDLINE=21177481; PubMed=11280994;

RA Zhong B.X.;  
RT "Protein database for several tissues derived from five instar of  
RL silkworm.";  
RL I Chuan Hsueh Pao 28:217-224 (2001).  
FT NON TER 10  
SQ SEQUENCE 10 AA; 1148 MW; DC779AB32AE451A9 CRC64;  
  
Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 EF 2  
Db 2 EF 3  
  
RESULT 92  
Q8SHA8  
ID Q8SHA8 PRELIMINARY; PRT; 10 AA.  
AC Q8SHA8  
DT 01-JUN-2002 (TrEMBLrel. 21, Created)  
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Cytochrome c oxidase subunit I (Fragment).  
GN Name=COI;  
OS Rhampholeon spectrum (Spectral pygmy chameleon).  
OG Mitochondrion.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Lepidosauria; Squamata; Iguania; Acrodonta; Chamaeleonidae;  
OC Rhampholeon.  
OX NCBI\_TaxID=179929;  
[1]  
RN  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22169767; PubMed=12182400; DOI=10.1006/mpev.2001.1076;  
RA Townsend T., Larson A.;  
RT "Molecular phylogenetics and mitochondrial genomic evolution in the  
RT chamaeleonidae (Reptilia, Squamata).";  
RL Mol. Phylogenet. Evol. 23:22-36(2002).  
[2]  
RN  
RP SEQUENCE FROM N.A.  
RX Townsend T.M., Larson A.L.;  
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF448772; AAL90598.1; -;  
DR GO; GO:0005739; C:mitochondrion; IEA.  
KW Mitochondrion.  
FT NON TER 10  
SQ SEQUENCE 10 AA; 1279 MW; 35BF8E27336409D7 CRC64;  
  
Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 2 FR 3  
Db 4 FR 5  
  
RESULT 93  
Q96041  
ID Q96041 PRELIMINARY; PRT; 10 AA.  
AC Q96041  
DT 01-FEB-1997 (TrEMBLrel. 02, Created)  
DT 01-FEB-1997 (TrEMBLrel. 02, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE NADH-ubiquinone oxidoreductase subunit 3 (Fragment).  
GN Name=nad3;  
OS Oenothera bertiana (Bertero's evening primrose).  
OG Mitochondrion.  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC Myrtales; Onagraceae; Oenothera.  
OX NCBI\_TaxID=3950;  
[1]  
RN

RP SEQUENCE FROM N.A.  
RX MEDLINE=94019250; PubMed=8413195;  
RA Schuster W.;  
RT "Ribosomal protein gene rpl5 is cotranscribed with the nad3 gene in  
RT Oenothera mitochondria.";  
RL Mol. Gen. Genet. 240:445-449(1993).  
DR EMBL; X69553; CAA49285.1; -;  
DR GO; GO:0005739; C:mitochondrion; IEA.  
KW Mitochondrion; Ubiquinone.  
FT NON TER 10  
SQ SEQUENCE 10 AA; 1097 MW; 723067B0476DD9CB CRC64;  
  
Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 EF 2  
Db 3 EF 4  
  
RESULT 94  
Q85BV6  
ID Q85BV6 PRELIMINARY; PRT; 10 AA.  
AC Q85BV6  
DT 01-JUN-2003 (TrEMBLrel. 24, Created)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)  
DT 03-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Ribosomal protein L2 (fragment).  
GN Name=rpl2;  
OS Eucalyptus grandis (Flooded gum).  
OG Chloroplast  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC Myrtales; Myrtaceae; Eucalyptus.  
OX NCBI\_TaxID=71139;  
[1]  
RN  
RP SEQUENCE FROM N.A.  
RX Jones M.E., Shepherd M., Henry R.J., Delves A., Schoer L.;  
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF502101; AAP30806.1; -;  
DR EMBL; AF502103; AAP30808.1; -;  
DR GO; GO:0009507; C:chloroplast; IEA.  
DR GO; GO:0003735; F:structural constituent of ribosome; IEA.  
KW Chloroplast; Ribosomal protein.  
FT NON TER 1  
SQ SEQUENCE 10 AA; 1305 MW; 5387F0141409C057 CRC64;  
  
Query Match 45.8%; Score 11; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 5.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 2 FR 3  
Db 5 FR 6  
  
RESULT 95  
Q85V67  
ID Q85V67 PRELIMINARY; PRT; 10 AA.  
AC Q85V67  
DT 01-JUN-2003 (TrEMBLrel. 24, Created)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Ribosomal protein L2 (fragment).  
GN Name=rpl2;  
OS Eucalyptus grandis (Flooded gum).  
OG Chloroplast  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC Myrtales; Myrtaceae; Eucalyptus.  
OX NCBI\_TaxID=71139;  
[1]  
RN

1

```

AC Q93UU2;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Orf.
OS Escherichia coli O157:H7.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=83334;
RN [1]
RP SEQUENCE FROM N.A.
RA Miyamoto T., Ichioika N., Sasaki C., Kobayashi H., Honjoh K., Iio M.,
RA Hatano S.;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB061018; BAB47190.1; -.
SQ SEQUENCE 10 AA; 1236 MW; DF344CBAB409D5A6 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 5.1e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3
Db 5 FR 6

RESULT 100
Q6JL97 PRELIMINARY; PRT; 10 AA.
AC Q6JL97;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE NuOL (Fragment).
GN Name=nuoL;
OS Neisseria gonorrhoeae.
OC Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales;
OC Neisseriaceae; Neisseria.
OX NCBI_TaxID=485;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MS11;
RX PubMed=15084227;
RA Snyder L.A., Davies J.K., Saunders N.J.;
RT "Microarray genotyping of key experimental strains of Neisseria
RT gonorrhoeae reveals gene complement diversity and five new neisserial
RT genes associated with Minimal Mobile Elements.";
RL BMC Genomics 5:23-23(2004).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=MS11;
RA Snyder L.A.S., Davies J.K., Saunders N.J.;
RL Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY386266; AAS16521.1; -.
FT NON TER 1
SQ SEQUENCE 10 AA; 1227 MW; BACCB286379D1A6 CRC64;

Query Match 45.8%; Score 11; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 5.1e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FR 3
Db 9 FR 10

Search completed: November 2, 2005, 09:41:08
Job time : 176 secs

```



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:25:50 ; Search time 168 Seconds

(without alignments)  
9.953 Million cell updates/sec

Title: us-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1865214 seqs, 418043040 residues

Total number of hits satisfying chosen parameters: 1865214

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Published Applications AA:\*

- 1: /cgn2\_6/ptodata/2/pubpaa/US07\_PUBCOMB.pep.\*
- 2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pep.\*
- 3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep.\*
- 4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pep.\*
- 5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep.\*
- 6: /cgn2\_6/ptodata/2/pubpaa/PCTUS\_PUBCOMB.pep.\*
- 7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep.\*
- 8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pep.\*
- 9: /cgn2\_6/ptodata/2/pubpaa/US09A\_PUBCOMB.pep.\*
- 10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pep.\*
- 11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep.\*
- 12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep.\*
- 13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep.\*
- 14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pep.\*
- 15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pep.\*
- 16: /cgn2\_6/ptodata/2/pubpaa/US10D\_PUBCOMB.pep.\*
- 17: /cgn2\_6/ptodata/2/pubpaa/US10E\_PUBCOMB.pep.\*
- 18: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pep.\*
- 19: /cgn2\_6/ptodata/2/pubpaa/US11A\_PUBCOMB.pep.\*
- 20: /cgn2\_6/ptodata/2/pubpaa/US11\_NEW\_PUB.pep.\*
- 21: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep.\*
- 22: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	100.0	4	9 US-09-808-037-1	Sequence 1, Appli
2	24	100.0	4	9 US-09-975-932-8	Sequence 8, Appli
3	24	100.0	4	14 US-10-084-380A-8	Sequence 8, Appli
4	24	100.0	4	14 US-10-162-889-1	Sequence 1, Appli
5	24	100.0	4	15 US-10-384-788-1	Sequence 1, Appli
6	24	100.0	4	15 US-10-618-856-1	Sequence 1, Appli
7	24	100.0	4	17 US-10-481-642-5	Sequence 5, Appli
8	24	100.0	4	17 US-10-749-522-1	Sequence 1, Appli
9	24	100.0	4	18 US-10-625-854-27	Sequence 27, Appli
10	24	100.0	4	20 US-11-073-526-1	Sequence 1, Appli
11	24	100.0	5	18 US-10-505-313-287	Sequence 287, App

12	24	100.0	5	18 US-10-625-854-15	Sequence 15, Appli
13	24	100.0	5	18 US-10-625-854-28	Sequence 28, Appli
14	24	100.0	6	9 US-09-808-037-7	Sequence 7, Appli
15	24	100.0	6	9 US-09-975-932-6	Sequence 6, Appli
16	24	100.0	6	14 US-10-084-380A-6	Sequence 6, Appli
17	24	100.0	6	14 US-10-162-889-7	Sequence 7, Appli
18	24	100.0	6	15 US-10-384-788-7	Sequence 7, Appli
19	24	100.0	6	15 US-10-618-856-7	Sequence 7, Appli
20	24	100.0	6	16 US-10-622-087-75	Sequence 75, Appli
21	24	100.0	6	16 US-10-622-087-84	Sequence 84, Appli
22	24	100.0	6	16 US-10-622-087-85	Sequence 85, Appli
23	24	100.0	6	16 US-10-622-087-88	Sequence 88, Appli
24	24	100.0	6	16 US-10-622-087-90	Sequence 90, Appli
25	24	100.0	6	17 US-10-749-522-7	Sequence 7, Appli
26	24	100.0	6	18 US-10-810-881A-101	Sequence 101, App
27	24	100.0	6	18 US-10-810-881A-111	Sequence 111, App
28	24	100.0	6	18 US-10-505-313-285	Sequence 285, App
29	24	100.0	6	18 US-10-625-854-3	Sequence 3, Appli
30	24	100.0	6	18 US-10-625-854-16	Sequence 16, Appli
31	24	100.0	6	18 US-10-625-854-29	Sequence 29, Appli
32	24	100.0	6	18 US-10-625-854-41	Sequence 41, Appli
33	24	100.0	6	20 US-11-073-526-7	Sequence 7, Appli
34	24	100.0	7	9 US-09-867-847-5	Sequence 5, Appli
35	24	100.0	7	14 US-10-337-970-8	Sequence 8, Appli
36	24	100.0	7	16 US-10-481-954-4	Sequence 4, Appli
37	24	100.0	7	17 US-10-825-958-5	Sequence 5, Appli
38	24	100.0	7	18 US-10-810-881A-100	Sequence 100, App
39	24	100.0	7	18 US-10-505-313-256	Sequence 256, App
40	24	100.0	7	18 US-10-505-313-257	Sequence 257, App
41	24	100.0	7	18 US-10-505-313-286	Sequence 286, App
42	24	100.0	7	18 US-10-625-854-4	Sequence 4, Appli
43	24	100.0	7	18 US-10-625-854-17	Sequence 17, Appli
44	24	100.0	7	18 US-10-625-854-30	Sequence 30, Appli
45	24	100.0	7	18 US-10-625-854-42	Sequence 42, Appli

ALIGNMENTS

RESULT 1

US-09-808-037-1  
; Sequence 1, Application US/09808037  
; Patent No. US20020052311A1  
; GENERAL INFORMATION:  
; APPLICANT: SOLOMON, Beka  
; APPLICANT: HANAN, Eilat  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF  
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS  
; FILE REFERENCE: SOLOMON-2D  
; CURRENT APPLICATION NUMBER: US/09/808,037  
; CURRENT FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
US-09-808-037-1

Query Match 100.0%; Score 24; DB 9; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
||||

```
Db          1 EFRH 4

RESULT 2
US-09-975-932-8
; Sequence 8, Application US/09975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
; APPLICANT: CHAIN, Daniel G.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
; FILE REFERENCE: CHAIN1B
; CURRENT APPLICATION NUMBER: US/09/975,932
; CURRENT FILING DATE: 2001-10-15
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 8
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-975-932-8

Query Match      100.0%; Score 24; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy'          1 EFRH 4
            1 EFRH 4
            ||||
Db          1 EFRH 4

RESULT 3
US-10-084-380A-8
; Sequence 8, Application US/10084380A
; Publication No. US20030073655A1
; GENERAL INFORMATION:
; APPLICANT: Mindset Biopharmaceutical Inc.
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide, pharmaceutical compo
; FILE REFERENCE: P-4815-US1
; CURRENT APPLICATION NUMBER: US/10/084,380A
; CURRENT FILING DATE: 2002-02-28
; PRIOR FILING DATE: 1997-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 4
; TYPE: PRT
; ORGANISM: human
US-10-084-380A-8

Query Match      100.0%; Score 24; DB 14; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 EFRH 4
            1 EFRH 4
            ||||
Db          1 EFRH 4

RESULT 4
US-10-084-380A-8

Query Match      100.0%; Score 24; DB 14; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 EFRH 4
            1 EFRH 4
            ||||
Db          1 EFRH 4

US-10-162-889-1
; Sequence 1, Application US/10162889
; Publication No. US2003007752A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME
; TITLE OF INVENTION: USEFUL IN DIAGNOSING
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON-2B
; CURRENT APPLICATION NUMBER: US/10/162,889
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-162-889-1

Query Match      100.0%; Score 24; DB 14; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 EFRH 4
            1 EFRH 4
            ||||
Db          1 EFRH 4

RESULT 5
US-10-384-788-1
; Sequence 1, Application US/10384788
; Publication No. US20040013647A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE
; FILE REFERENCE: SOLOMON-2D.2
; CURRENT APPLICATION NUMBER: US/10/384,788
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: 60/371,735
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 09/808,037
; PRIOR FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/830,954
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: 10/162,889
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: 60/152,417
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-384-788-1
```

```
Query Match      100.0%; Score 24; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      1 EFRH 4

RESULT 6
US-10-618-856-1
; Sequence 1, Application US/10618856
; Publication No. US20040052766A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY
; FILE REFERENCE: SOLOMON=2A
; CURRENT APPLICATION NUMBER: US/10/618,856
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: US/09/473,653A
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-618-856-1

Query Match      100.0%; Score 24; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      1 EFRH 4

RESULT 7
US-10-481-642-5
; Sequence 5, Application US/10481642
; Publication No. US20050053575A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A D
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH
; TITLE OF INVENTION: USING SAME
; FILE REFERENCE: SOLOMON=4.1A PCT
; CURRENT APPLICATION NUMBER: US/10/481,642
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-481-642-5

Query Match      100.0%; Score 24; DB 17; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      1 EFRH 4
```

```
RESULT 8
US-10-749-522-1
; Sequence 1, Application US/10749522
; Publication No. US20050089510A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eliat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/749,522
; CURRENT FILING DATE: 2004-01-02
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-749-522-1

Query Match      100.0%; Score 24; DB 17; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      1 EFRH 4

RESULT 9
US-10-625-854-27
; Sequence 27, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 4
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-27

Query Match      100.0%; Score 24; DB 18; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      1 EFRH 4

RESULT 10
```

```
US-11-073-526-1
; Sequence 1, Application US/11073526
; Publication No. US2005015287A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAGNOSIS AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON-2C
; CURRENT APPLICATION NUMBER: US/11/073,526
; CURRENT FILING DATE: 2005-03-08
; PRIOR FILING DATE: 2005-03-08
; PRIOR FILING DATE: 2001-08-07
; PRIOR FILING DATE: 2000-08-31
; PRIOR FILING DATE: 2000-07-31
; PRIOR FILING DATE: 1999-12-29
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-11-073-526-1

Query Match      100.0%; Score 24; DB 20; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      1 EFRH 4

RESULT 11
US-10-505-313-287
; Sequence 287, Application US/10505313
; Publication No. US20050169925A1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 287
; LENGTH: 5
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; peptide 3 A beta
US-10-505-313-287

Query Match      100.0%; Score 24; DB 18; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      1 EFRH 4

US-10-625-854-15
; Sequence 15, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR FILING DATE: 2002-07-24
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-15

Query Match      100.0%; Score 24; DB 18; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      2 EFRH 5

RESULT 12
US-10-625-854-15
; Sequence 15, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR FILING DATE: 2002-07-24
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-15

Query Match      100.0%; Score 24; DB 18; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      1 EFRH 4

RESULT 13
US-10-625-854-28
; Sequence 28, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR FILING DATE: 2002-07-24
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-28

Query Match      100.0%; Score 24; DB 18; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      1 EFRH 4

RESULT 14
US-09-808-037-7
; Sequence 7, Application US/09808037
; Patent No. US20020052311A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
```

Thu Nov 3 12:26:07 2005

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF  
; FILE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS

; FILE REFERENCE: SOLOMON=2D  
; CURRENT APPLICATION NUMBER: US/09/808,037  
; CURRENT FILING DATE: 2001-03-15  
; PRIOR APPLICATION NUMBER: 09/629,971  
; PRIOR FILING DATE: 2000-07-31  
; PRIOR APPLICATION NUMBER: US 09/473,653  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: US 60/152,417  
; PRIOR FILING DATE: 1999-09-03  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide  
; US-09-808-037-7

Query Match 100.0%; Score 24; DB 9; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 15  
US-09-975-932-6  
; Sequence 6, Application US/09975932  
; Publication No. US20020086847A1  
; GENERAL INFORMATION:  
; APPLICANT: CHAIN, Daniel G.  
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,  
; FILE REFERENCE: CHAIN1B  
; CURRENT APPLICATION NUMBER: US/09/975,932  
; CURRENT FILING DATE: 2001-10-15  
; PRIOR APPLICATION NUMBER: 09/402,820  
; PRIOR FILING DATE: 1999-10-12  
; PRIOR APPLICATION NUMBER: PCT/US98/06900  
; PRIOR FILING DATE: 1998-04-09  
; PRIOR APPLICATION NUMBER: 60/041,850  
; PRIOR FILING DATE: 1997-04-09  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 6  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-975-932-6

Query Match 100.0%; Score 24; DB 9; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

Search completed: November 2, 2005, 09:35:19  
Job time : 169 secs

3

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:21:35 ; Search time 42 Seconds  
(without alignments)  
7.109 Million cell updates/sec

Title: US-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents\_AA.\*

- 1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep.\*
- 2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep.\*
- 3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep.\*
- 4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep.\*
- 5: /cgn2\_6/ptodata/1/iaa/PTCUS\_COMB.pep.\*
- 6: /cgn2\_6/ptodata/1/iaa/backfiles.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	100.0	4	US-09-579-012-24	Sequence 24, Appl
2	24	100.0	7	US-09-579-012-25	Sequence 25, Appl
3	24	100.0	10	US-08-371-930-12	Sequence 12, Appl
4	24	100.0	10	US-09-724-961-5	Sequence 5, Appl
5	24	100.0	10	US-09-724-961-6	Sequence 6, Appl
6	24	100.0	10	US-09-724-961-7	Sequence 7, Appl
7	24	100.0	10	US-09-724-961-8	Sequence 8, Appl
8	24	100.0	10	US-09-724-961-9	Sequence 9, Appl
9	24	100.0	10	US-09-724-961-10	Sequence 10, Appl
10	24	100.0	10	US-09-724-961-11	Sequence 11, Appl
11	24	100.0	10	US-09-580-018-5	Sequence 5, Appl
12	24	100.0	10	US-09-580-018-6	Sequence 6, Appl
13	24	100.0	10	US-09-580-018-7	Sequence 7, Appl
14	24	100.0	10	US-09-580-018-8	Sequence 8, Appl
15	24	100.0	10	US-09-580-018-9	Sequence 9, Appl
16	24	100.0	10	US-09-580-018-10	Sequence 10, Appl
17	24	100.0	10	US-09-580-018-11	Sequence 11, Appl
18	24	100.0	10	US-09-724-551-5	Sequence 5, Appl
19	24	100.0	10	US-09-724-551-6	Sequence 6, Appl
20	24	100.0	10	US-09-724-551-7	Sequence 7, Appl
21	24	100.0	10	US-09-724-551-8	Sequence 8, Appl
22	24	100.0	10	US-09-724-551-9	Sequence 9, Appl
23	24	100.0	10	US-09-724-551-10	Sequence 10, Appl
24	24	100.0	10	US-09-724-551-11	Sequence 11, Appl
25	24	100.0	10	PCT-US94-01712-12	Sequence 12, Appl
26	24	100.0	11	US-08-352-179-23	Sequence 23, Appl
27	24	100.0	11	US-09-264-709A-6	Sequence 6, Appl

28	24	100.0	12	5	PCT-US94-07043A-2	Sequence 2, Appl
29	24	100.0	13	4	US-09-723-384-2	Sequence 2, Appl
30	24	100.0	13	4	US-09-724-961-72	Sequence 72, Appl
31	24	100.0	13	4	US-09-724-552-2	Sequence 2, Appl
32	24	100.0	13	4	US-09-580-018-72	Sequence 72, Appl
33	24	100.0	13	4	US-09-723-927-2	Sequence 2, Appl
34	24	100.0	13	4	US-09-724-489-2	Sequence 2, Appl
35	24	100.0	13	4	US-09-724-477-2	Sequence 2, Appl
36	24	100.0	13	4	US-09-723-762-2	Sequence 2, Appl
37	24	100.0	13	4	US-09-201-430-2	Sequence 2, Appl
38	24	100.0	13	4	US-09-724-551-72	Sequence 72, Appl
39	24	100.0	13	4	US-10-815-353-2	Sequence 2, Appl
40	24	100.0	13	4	US-10-816-529-2	Sequence 2, Appl
41	24	100.0	15	2	US-08-609-090-1	Sequence 1, Appl
42	24	100.0	16	1	US-08-302-808-10	Sequence 10, Appl
43	24	100.0	16	2	US-08-659-984A-20	Sequence 20, Appl
44	24	100.0	16	2	US-08-986-948-10	Sequence 10, Appl
45	24	100.0	16	3	US-08-660-531-20	Sequence 20, Appl

ALIGNMENTS

RESULT 1

US-09-579-012-24  
; Sequence 24, Application US/09579012  
; Patent No. 6670195  
; GENERAL INFORMATION:  
; APPLICANT: Jorge GHISO  
; APPLICANT: Ruben VIDAL  
; APPLICANT: Blas FRANGIONE  
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish  
; FILE REFERENCE: 32004-16277  
; CURRENT APPLICATION NUMBER: US/09/579,012  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/136238  
; PRIOR FILING DATE: 1999-05-26  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 24  
; LENGTH: 4  
; TYPE: PRT  
; ORGANISM: consensus sequence  
US-09-579-012-24

Query Match	100.0%	Score 24;	DB 4;	Length 4;
Best Local Similarity	100.0%	Pred. No. 4.1e+05;		
Matches	4;	Conservative	0;	Mismatches 0;
		Indels	0;	Gaps 0;
QY	1 EFRH 4			
Db	1 EFRH 4			

RESULT 2

US-09-579-012-25  
; Sequence 25, Application US/09579012  
; Patent No. 6670195  
; GENERAL INFORMATION:  
; APPLICANT: Jorge GHISO  
; APPLICANT: Ruben VIDAL  
; APPLICANT: Blas FRANGIONE  
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish  
; FILE REFERENCE: 32004-16277  
; CURRENT APPLICATION NUMBER: US/09/579,012  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/136238  
; PRIOR FILING DATE: 1999-05-26  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 25

```
; LENGTH: 7
; TYPE: PRT
; ORGANISM: epitope
US-09-579-012-25

Query Match      100.0%; Score 24; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      3 EFRH 6

RESULT 3
US-08-371-930-12
; Sequence 12, Application US/08371930
; Patent No. 5578451
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/371.930
; FILING DATE:
; CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/019,208
; FILING DATE: February 18, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/154001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-08-371-930-12

Query Match      100.0%; Score 24; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      3 EFRH 6

RESULT 4
US-09-724-961-5
; Sequence 5, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
```

---

```
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-5

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
Db      7 EFRH 10

RESULT 5
US-09-724-961-6
; Sequence 6, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
```



```
; OTHER INFORMATION: peptide)
US-09-724-961-6

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      6 EFRH 9

RESULT 6
US-09-724-961-7
; Sequence 7, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-8

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      4 EFRH 7

RESULT 8
US-09-724-961-9
; Sequence 9, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-9

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
```

```
; OTHER INFORMATION: peptide)
US-09-724-961-6

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      6 EFRH 9

RESULT 6
US-09-724-961-7
; Sequence 7, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-7

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
      ||||
Db      5 EFRH 8

RESULT 7
US-09-724-961-8
; Sequence 8, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
```

```
Db      3 EFRH 6
||||
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
; US-09-724-961-11

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
||||
Db      1 EFRH 4
||||

RESULT 11
US-09-580-018-5
; Sequence 5, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
; US-09-580-018-5

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
||||
Db      7 EFRH 10
||||

RESULT 12
US-09-580-018-6
; Sequence 6, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
US-09-580-018-6

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EPRH 4
        ||||
Db      6 EPRH 9

RESULT 13
US-09-580-018-7
; Sequence 7, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
US-09-580-018-7

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EPRH 4
        ||||
Db      5 EPRH 8

RESULT 14
US-09-580-018-8
; Sequence 8, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 10
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-8

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EPRH 4
        ||||
Db      4 EPRH 7

RESULT 15
US-09-580-018-9
; Sequence 9, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-9

Query Match      100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EPRH 4
        ||||
Db      3 EPRH 6

Search completed: November 2, 2005, 09:32:25
Job time : 44 secs
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:04:09 ; Search time 164 Seconds  
(without alignments)  
9.433 Million cell updates/sec

Title: US-10-618-856-1  
Perfect score: 24  
Sequence: 1 EFRH 4

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_16Dec04:\*

1: geneseqp1980s:\*

2: geneseqp1990s:\*

3: geneseqp2000s:\*

4: geneseqp2001s:\*

5: geneseqp2002s:\*

6: geneseqp2003as:\*

7: geneseqp2003bs:\*

8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	24	100.0	4	2 AAW70870	Beta-amy1
2	24	100.0	4	6 AAO16062	Neurologi
3	24	100.0	4	6 ABP70744	Antigenic
4	24	100.0	4	7 AD875167	Human amy
5	24	100.0	4	7 AD836574	Beta-amy1
6	24	100.0	4	8 ADJ88108	Human bet
7	24	100.0	4	8 ADJ71364	N-termina
8	24	100.0	4	8 ADJ71377	N-termina
9	24	100.0	4	8 ADP90808	Protein/p
10	24	100.0	5	6 ADA90172	Anti-Abet
11	24	100.0	5	8 ADJ71378	N-termina
12	24	100.0	5	8 ADJ71365	N-termina
13	24	100.0	5	8 ADJ71352	N-termina
14	24	100.0	6	2 AAW70868	Beta-amy1
15	24	100.0	6	6 AAB47109	Epitope #
16	24	100.0	6	6 AAO16067	Neurologi
17	24	100.0	6	6 ADA90170	Anti-Abet
18	24	100.0	6	7 AD875165	Human amy
19	24	100.0	6	8 ADJ88114	fd phage
20	24	100.0	6	8 ADJ71366	N-termina
21	24	100.0	6	8 ADJ71379	N-termina
22	24	100.0	6	8 ADJ71340	N-termina
23	24	100.0	6	8 ADJ71353	N-termina
24	24	100.0	6	8 ADK52251	Human amy
25	24	100.0	6	8 ADK52264	Guinea pi

26	24	100.0	6	8 ADK52261	Rabbit am
27	24	100.0	6	8 ADK52260	Primate a
28	24	100.0	6	8 ADK52266	Amyloid b
29	24	100.0	6	8 ADQ82427	N-termina
30	24	100.0	6	8 ADQ82432	N-termina
31	24	100.0	6	8 ADQ82430	N-termina
32	24	100.0	6	8 ADQ82433	N-termina
33	24	100.0	6	8 ADQ82434	N-termina
34	24	100.0	6	8 ADQ82436	N-termina
35	24	100.0	6	8 ADQ82431	N-termina
36	24	100.0	6	8 ADQ82423	N-termina
37	24	100.0	6	8 ADQ82424	N-termina
38	24	100.0	6	8 ADQ82428	N-termina
39	24	100.0	6	8 ADQ82435	N-termina
40	24	100.0	6	8 ADQ82429	N-termina
41	24	100.0	6	8 ADQ82425	N-termina
42	24	100.0	6	8 ADQ82422	N-termina
43	24	100.0	6	8 ADQ82421	N-termina
44	24	100.0	6	8 ADQ82437	N-termina
45	24	100.0	6	8 ADQ82386	Natural N

ALIGNMENTS

RESULT 1

AAW70870	
ID	AAW70870 standard; peptide; 4 AA.
XX	
AC	AAW70870;
XX	
DT	04-FEB-1999 (first entry)
XX	
DE	Beta-amyloid peptide epitope.
XX	
KW	Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW	amyloid deposit; Alzheimer's disease.
XX	
OS	Synthetic.
OS	Homo sapiens.
XX	
PN	WO9844955-A1.
XX	
PD	15-OCT-1998.
XX	
PF	09-APR-1998; 98WO-US006900.
XX	
PR	09-APR-1997; 97US-0041850P.
XX	
PA	(MIND-) MINDSET LTD.
PA	(MCIN/) MCINNIS P A.
XX	
PI	Chain DG;
XX	
DR	WPI; 1998-594476/50.
XX	
PT	Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT	use of recombinant DNA encoding an antibody specific for the N- or C-
XX	terminus of an amyloid-beta peptide.
XX	
PS	Example 1; Page 47; 58pp; English.
XX	
CC	The present sequence represents a peptide epitope derived from beta-
CC	amyloid precursor protein peptide. The specification describes a method
CC	for prevention or inhibition of progression of Alzheimer's disease. The
CC	method comprises administering a composition comprising a recombinant DNA
CC	molecule containing a gene encoding a recombinant antibody end-specific
CC	for the N-terminus or the C-terminus of an amyloid-beta peptide, operably
CC	linked to a promoter which is expressed in the central nervous system.
CC	The recombinant antibody molecules prevent the accumulation of beta-
CC	amyloid peptides in the extracellular space, interstitial fluid and
CC	cerebrospinal fluid and the aggregation of such peptides into amyloid
CC	deposits in the brain. They also inhibit the progression of Alzheimer's

CC disease by inhibiting the interaction of beta-amyloid peptides mediating  
 CC Alzheimer's disease induced neurotoxicity and inhibiting the Alzheimer's  
 CC disease induced complement activation and cytokine release involved in  
 CC the inflammatory process

XX SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 2; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 2  
 AAO16062  
 ID AAO16062 standard; peptide; 4 AA.

XX AC AAO16062;

XX DT 27-FEB-2003 (first entry)

XX DE Neurological/CNS disease treatment method-related peptide #1.

XX KW Vaccine; gene therapy; neurological disease; CNS disorder;  
 KW central nervous system disorder; olfactory system; Alzheimer's disease;  
 KW Creutzfeldt-Jakob disease; Huntington's chorea; Parkinson's disease;  
 KW viral infection of the brain; brain tumour; lysosomal storage disease;  
 KW multiple sclerosis.

XX OS Unidentified.

XX PN WO200274243-A2.

XX PD 26-SEP-2002.

XX PF 15-MAR-2002; 2002WO-US008042.

XX PR 15-MAR-2001; 2001US-00808037.

XX PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.  
 PA (MCIN/) MCINNIS P.

XX PI Solomon B, Frenkel D;

XX DR WPI; 2003-040542/03.

XX PT Treating or diagnosing neurological diseases of the central nervous  
 PT system, e.g. Alzheimer's disease, comprises displaying a polypeptide or  
 PT diagnostic agent on viral display vehicle and introducing or detecting  
 PT the display vehicle.

XX PS Example 9; Page 138; 214pp; English.

XX CC The invention comprises a method for treating a neurological disease or a  
 CC central nervous system (CNS) disorder. The method involves displaying a  
 CC therapeutic molecule capable of treating the neurological disease or CNS  
 CC disorder on a viral display vehicle. The viral display vehicle is then  
 CC introduced into the olfactory system of a subject to treat the disease or  
 CC disorder. The method of the invention is useful for preventing, treating  
 CC and diagnosing neurological diseases or CNS disorders, such as:  
 CC Alzheimer's disease; Creutzfeldt-Jakob disease; Huntington's chorea; viral  
 CC infections of the brain; brain tumours; lysosomal storage diseases;  
 CC Parkinson's disease; and multiple sclerosis. The present amino acid  
 CC sequence represents a peptide which was used in the invention

XX SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 6; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 3  
 ABP70744

ID ASP70744 standard; peptide; 4 AA.

XX AC ABP70744;

XX DT 15-MAY-2003 (first entry)

XX DE Antigenic peptide, SEQ ID 5.

XX KW Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;  
 KW plaque-forming disease; Alzheimer's disease; SAA amyloidosis;  
 KW hereditary Icelandic syndrome; senility; multiple myeloma;  
 KW Creutzfeldt-Jakob disease; Kuru; Gerstmann-Straussler-Scheinker disease;  
 KW fatal familial insomnia; scrapie; bovine spongiform encephalitis;  
 KW antigenic; multiantigen.

XX OS Synthetic.

XX PN WO2003000719-A2.

XX PD 03-JAN-2003.

XX PF 20-JUN-2002; 2002WO-US019567.

XX PR 20-JUN-2001; 2001US-0299201P.

XX PR 12-APR-2002; 2002US-037171P.

XX PA (UYRA-) UNIV RAMOT.

XX PA (MCIN/) MCINNIS P.

XX PI Mcinnis P, Solomon B;

XX DR WPI; 2003-239139/23.

XX PT Antigenic product has dendritic polymer built on core molecule having  
 PT terminal functional groups to which antigenic peptide that has epitope of  
 PT deposit-forming polypeptide involved in plaque-forming disease is joined.

XX PS Claim 6; Page 44; 70pp; English.

XX CC The present invention relates to antigenic products (A), comprising a  
 CC dendritic polymer built on a core molecule which is at least difunctional  
 CC to provide branching and containing up to 16 terminal functional groups  
 CC to which an antigenic peptide, that comprises an epitope of a deposit-  
 CC forming polypeptide involved in plaque-forming disease, is joined by  
 CC covalent bonds. The antigenic products are useful for eliciting an immune  
 CC response against a deposit-forming polypeptide involved in a plaque-  
 CC forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,  
 CC hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-  
 CC Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal  
 CC familial insomnia, scrapie or bovine spongiform encephalitis, by  
 CC administering the antigenic product to a subject in need of it. The  
 CC present sequence is one such antigenic peptide, which was used to  
 CC illustrate the invention

XX SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 6; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 4  
ADB75167  
ID ADB75167 standard; peptide; 4 AA.  
XX AC ADB75167;  
XX DT 04-DEC-2003 (first entry)  
XX DE Human amyloid beta peptide SEQ ID NO:8.  
XX KW antibody; amyloid beta peptide; amyloid beta; neurotropic; neuroprotective;  
XX KW antibody therapy; Alzheimer's disease; mild cognitive impairment;  
XX KW cerebral amyloid angiopathy; congophilic angiopathy; Down's syndrome;  
XX KW inclusion body myositis; neurotoxicity; beta amyloid precursor protein;  
XX KW APP; human.  
XX OS Homo sapiens.  
XX PN WO2003074081-A1.  
XX PD 12-SEP-2003.  
XX PF 21-OCT-2002; 2002WO-US031590.  
XX PR 28-FEB-2002; 2002US-00084380.  
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.  
XX PI Chain DG;  
XX WPI; 2003-731651/69.  
XX DR New antibody that is targeted to amyloid beta peptide, or its fragment,  
XX PT useful for treating a subject having Alzheimer's disease, or a disease or  
XX PT disorder characterized by amyloid beta deposition, e.g. cognitive  
XX PT impairment or dementia.  
XX PS Disclosure; Page 60; 63pp; English.  
XX CC The present invention describes an antibody that is targeted to amyloid  
XX CC beta peptide, or its fragment. Also described: (1) an antibody that is  
XX CC free-end specific and is targeted to: (a) the free N-terminus of amyloid  
XX CC beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the  
XX CC first amino acid of amyloid beta-peptide is aspartate; (c) the free N-  
XX CC terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;  
XX CC (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,  
XX CC Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-  
XX CC terminus-truncated amyloid beta-peptide fragment; (2) a single chain or  
XX CC artificial antibody that is free-end specific and is targeted to the free  
XX CC C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a  
XX CC pharmaceutical composition comprising the antibody, and a carrier. The  
XX CC antibody targeted to amyloid beta peptide has neurotropic and  
XX CC neuroprotective activities, and can be used in antibody therapy. The  
XX CC antibody or its fragment is useful for manufacturing a medicament for  
XX CC treating a subject having Alzheimer's disease, or a disease or disorder  
XX CC characterised by amyloid beta deposition (e.g. mild cognitive impairment,  
XX CC cerebral amyloid angiopathy or congophilic angiopathy, Alzheimer's  
XX CC disease associated with Down's syndrome or inclusion body myositis), or  
XX CC for delaying, inhibiting or suppressing accumulation of amyloid beta  
XX CC peptide, or the neurotoxicity of amyloid beta peptide or its fragment.  
XX CC Amyloid beta peptide are derived from beta amyloid precursor protein  
XX CC (APP). The present sequence represents an amyloid beta peptide which is  
XX CC used in the exemplification of the present invention.  
XX SQ Sequence 4 AA;  
Query Match 100.0%; Score 24; DB 7; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
DB 1 EFRH 4  
RESULT 6  
ADJ88108  
ID ADJ88108 standard; peptide; 4 AA.  
XX

RESULT 5  
ADE36574  
ID ADE36574 standard; peptide; 4 AA.  
XX AC ADE36574;  
XX DT 29-JAN-2004 (first entry)  
XX DE Beta-amyloid (Abeta) peptide 3-6 SEQ ID NO:2.  
XX KW immune response; beta-secretase cleavage site; amyloid precursor protein;  
XX KW APP; neurotropic; neuroprotective; vaccine; passive immunisation;  
XX KW Alzheimer's disease.  
XX OS Synthetic.  
XX PN WO2003076455-A2.  
XX PD 18-SEP-2003.  
XX PF 04-MAR-2003; 2003WO-US006388.  
XX PR 05-MAR-2002; 2002US-0361344P.  
XX PA (UYRA-) UNIV RAMOT AT TEL AVIV LTD.  
XX PA (MCIN/) MCINNIS P.  
XX PI Solomon B;  
XX WPI; 2003-865017/80.  
XX DR Immunizing composition, useful for treating Alzheimer's disease by  
XX PT inhibiting processing of amyloid precursor protein, also antibodies for  
XX PT passive immunization.  
XX PS Disclosure; SEQ ID NO 2; 76pp; English.  
XX CC The present invention describes an immunising composition (A) comprising:  
XX CC (a) an antigenic product (I) which induces an immune response against the  
XX CC beta-secretase cleavage site of amyloid precursor protein (APP); and (b)  
XX CC a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)  
XX CC a molecule (II) comprising the antigen-binding part of an antibody (Ab)  
XX CC directed against the beta-secretase cleavage site of APP; (2) a  
XX CC filamentous bacteriophage (FB) that displays (II), where this is a single  
XX CC chain Ab, on its surface; and (3) a composition containing FB. (A) has  
XX CC neurotropic and neuroprotective activities, and can be used in vaccines or  
XX CC passive immunisation. (A) inhibits the cleavage of APP and so prevents  
XX CC the formation of beta-amyloid. (A) can be used to induce an immune  
XX CC response against the beta-secretase cleavage site of APP, specifically  
XX CC for treatment and prevention of Alzheimer's disease. The molecule (II)  
XX CC that contains the antigen-binding part of an Ab directed against the  
XX CC cleavage site, or a filamentous phage that displays such an Ab (as a  
XX CC single-chain molecule) can be used similarly, for passive immunisation.  
XX CC The present sequence represents a beta-amyloid (Abeta) peptide which is  
XX CC used in the exemplification of the present invention.  
XX SQ Sequence 4 AA;  
Query Match 100.0%; Score 24; DB 7; Length 4;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 EFRH 4  
DB 1 EFRH 4  
RESULT 6  
ADJ88108  
ID ADJ88108 standard; peptide; 4 AA.  
XX







PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.  
 PA (MORP-) MORPHOSYS AG.  
 XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
 PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
 XX WPI; 2003-663848/62.  
 XX  
 XX New antibody molecule capable of specifically recognizing two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 PT diseases associated with amyloidogenesis or amyloid-plaque formation  
 PT (e.g. dementia).  
 XX  
 XX Disclosure; Page 265; 312pp; English.  
 XX  
 XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (I), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (I) and recovering (I) from the culture; (5) a composition comprising (I)  
 CC or an antibody molecule produced by method (4); (6) a kit comprising (I),  
 CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (I); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta4/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (I), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (I) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disinfection of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX  
 XX Sequence 5 AA;

Query Match 100.0%; Score 24; DB 6; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 11  
 ADJ71378  
 ID ADJ71378 standard; peptide; 5 AA.

AC ADJ71378;

XX 06-MAY-2004 (first entry)

DE N-terminal truncated beta-amyloid peptide, SEQ ID 41.

XX Neurotropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX Homo sapiens.

XX Key Location/Qualifiers  
 FH Modified-site 1 /note= "Pyroglutamic acid"  
 FT XX  
 FT WO2004013172-A2.  
 PN 12-FEB-2004.  
 PD 18-JUL-2003; 2003WO-EP007833.  
 XX 24-JUL-2002; 2002EP-00447147.  
 XX 06-AUG-2002; 2002US-0401497P.  
 XX (INNO-) INNOGENETICS NV.  
 XX Delacourte A, Sergeant N;  
 PI WPI; 2004-180423/17.  
 XX New beta-amyloid or amyloid precursor protein preparation, useful as a  
 DR prophylactic vaccine or a therapeutic for preventing or treating a  
 PT disease associated with beta-amyloid formation and/or aggregation, e.g.  
 PT Alzheimer's disease.  
 PT Claim 4; Page 62; 104pp; English.  
 XX  
 XX The present invention relates to preparations (I) comprising a beta-  
 CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-  
 CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal  
 CC fragment. The beta-amyloid or APP preparations are useful for  
 CC manufacturing a prophylactic vaccine or a therapeutic, or as a  
 CC prophylactic vaccine for the prevention, or as a therapeutic for the  
 CC treatment of a disease associated with beta-amyloid formation and/or  
 CC aggregation, such as Alzheimer's disease.  
 XX Sequence 5 AA;

Query Match 100.0%; Score 24; DB 8; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
 ||||  
 Db 1 EFRH 4

RESULT 12  
 ADJ71365  
 ID ADJ71365 standard; peptide; 5 AA.

AC ADJ71365;

XX 06-MAY-2004 (first entry)

DE N-terminal truncated beta-amyloid peptide, SEQ ID 28.

XX Neurotropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX Homo sapiens.

PN WO2004013172-A2.

XX 12-FEB-2004.

XX 18-JUL-2003; 2003WO-EP007833.

XX 24-JUL-2002; 2002EP-00447147.

PR 06-AUG-2002; 2002US-0401497P.

XX (INNO-) INNOGENETICS NV.

XX



```

SQ Sequence 6 AA;
Query Match 100.0%; Score 24; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
Db 3 EFRH 6

RESULT 15
AAB47109
ID AAB47109 standard; peptide; 6 AA.
AC AAB47109;
XX
XX 04-JUN-2001 (first entry)
XX
XX Epitope #1 used in treatment of plaque forming disease.
XX Human; prion protein; plaque forming disease; display vehicle; kuru;
XX aggregating protein; amyloid plaque; brain; early onset; senility;
XX Alzheimer's disease; late onset; pre-symptomatic; SAA amyloidosis;
XX hereditary Icelandic syndrome; multiple myeloma; scrapie; BSE; CJD;
XX bovine spongiform encephalopathy; Creutzfeldt-Jakob Disease; FFI;
XX Gerstmann-Strausler-Sheinker Disease; GSS; fatal familial insomnia.
XX
XX Synthetic.
XX
XX OS
XX WO200118169-A2.
XX
XX PN
XX 15-MAR-2001.
XX
XX PD
XX
XX PF 31-AUG-2000; 2000WO-IL000518.
XX
XX PR 03-SEP-1999; 99US-0152417P.
XX
XX PR 29-DEC-1999; 99US-00473653.
XX
XX PR 31-JUL-2000; 2000US-00629971.
XX
XX (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
XX
XX Solomon B, Frenkel D, Hanan E;
XX
XX WPI; 2001-244564/25.
XX
XX Treating amyloidogenic disease such as Alzheimer's disease, BSE or CJD
XX comprises presentation of plaque derived antigens or epitopes on a
XX display vehicle, and introducing the vehicle into the recipient.
XX
XX Example; Page 50; 120pp; English.
XX
XX This peptide is based on the N-terminal fragment of beta-amyloid peptide
XX (beta-AP) and was fused to the minor coat protein of fd phage. This
XX peptide may be used in the method of the invention. The invention
XX provides an agent for treating a plaque forming disease. The polypeptide
XX is displayed on a display vehicle and is capable of eliciting antibodies
XX capable of disaggregating the aggregating protein and/or of preventing
XX aggregation of the aggregating protein. This reduces formation of amyloid
XX plaques in the brain of victims of plaque forming diseases, e.g. early
XX onset Alzheimer's disease, late onset Alzheimer's disease, pre-
XX symptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
XX syndrome, senility, multiple myeloma, scrapie, bovine spongiform
XX encephalopathy (BSE), kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-
XX Streusler-Sheinker Disease (GSS) and fatal familial insomnia (FFI)
XX
XX Sequence 6 AA;
Query Match 100.0%; Score 24; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4

```

Db 3 EFRH 6

Search completed: November 2, 2005, 09:27:50  
Job time : 167 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:12:39 ; Search time 38 Seconds  
(without alignments)  
10.128 Million cell updates/sec

Title: US-10-618-856-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 79:\*\*

1: pir1:\*\*

2: pir2:\*\*

3: pir3:\*\*

4: pir4:\*\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	100.0	39	A48544	neuropeptide F - b
2	24	100.0	42	PN0512	beta-amyloid prote
3	24	100.0	52	C91112	hypothetical prote
4	24	100.0	57	A60045	Alzheimer's diseas
5	24	100.0	57	F60045	Alzheimer's diseas
6	24	100.0	57	D60045	Alzheimer's diseas
7	24	100.0	57	E60045	Alzheimer's diseas
8	24	100.0	57	G60045	Alzheimer's diseas
9	24	100.0	57	B60045	Alzheimer's diseas
10	24	100.0	57	B89981	truncated transpos
11	24	100.0	84	PQ0438	Alzheimer's diseas
12	24	100.0	82	G96025	hypothetical prote
13	24	100.0	89	C82331	hypothetical prote
14	24	100.0	91	T16095	hypothetical prote
15	24	100.0	94	B86195	hypothetical prote
16	24	100.0	97	RCBP22	abc2 protein - pha
17	24	100.0	97	H84901	hypothetical prote
18	24	100.0	106	G72059	conserved hypothet
19	24	100.0	106	D85653	CT466 hypothetical
20	24	100.0	116	B89964	truncated transpos
21	24	100.0	123	G95878	probable Rm2011-2
22	24	100.0	132	JQ0737	RnpA protein - Mic
23	24	100.0	133	AH2580	PTS system, IIA co
24	24	100.0	133	F97362	PTS enzyme IIA, m
25	24	100.0	134	B86720	conserved hypothet
26	24	100.0	136	B56338	phospholipase A2 (
27	24	100.0	136	A87681	conserved hypothet
28	24	100.0	139	F64502	hypothetical prote
29	24	100.0	141	A99796	hypothetical prote

30	24	100.0	141	2	G85662	unknown protein pr
31	24	100.0	141	2	D85605	unknown in IS5c8 l
32	24	100.0	141	2	A99803	hypothetical prote
33	24	100.0	141	2	B85611	unknown protein in
34	24	100.0	143	2	F75475	3-dehydroquinat d
35	24	100.0	145	2	AD2740	3-dehydroquinat d
36	24	100.0	148	2	B89960	3-dehydroquinat d
37	24	100.0	152	2	D75367	hypothetical prote
38	24	100.0	155	2	AC1187	B. subtilis Ydck p
39	24	100.0	155	2	AB1545	B. subtilis Ydck p
40	24	100.0	156	2	T02166	cysteine proteinas
41	24	100.0	162	2	B97521	3-dehydroquinat d
42	24	100.0	166	2	A28127	myosin light chain
43	24	100.0	167	2	T34963	hypothetical prote
44	24	100.0	176	2	H72201	conserved hypothet
45	24	100.0	176	2	D95322	hypothetical prote

ALIGNMENTS

RESULT 1

A48544

neuropeptide F - brown garden snail

C:Species: Helix aspersa (brown garden snail)

C>Date: 19-Nov-1993 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004

C:Accession: A48544

R:Leung, P.S.; Shaw, C.; Maule, A.G.; Thim, L.; Johnston, C.F.; Irvine, G.B.

Regul. Pept. 41, 71-81, 1992

A:Title: The primary structure of neuropeptide F (NPF) from the garden snail, Helix asp

A:Reference number: A48544; MUID:93087780; PMID:1472263

A:Accession: A48544

A:Status: preliminary

A:Molecule type: protein

A:Residues: 1-39 <LEU>

A:Cross-references: UNIPROT:P41321

A:Experimental source: circumesophageal ganglia

A>Note: sequence extracted from NCBI backbone (NCBIP:120485)

Query Match 100.0%; Score 24; DB 2; Length 39;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 13 EFRH 16

RESULT 2

PN0512

beta-amyloid protein - guinea pig (fragment)

C:Species: Cavia porcellus (guinea pig)

C>Date: 31-Dec-1993 #sequence\_revision 31-Dec-1993 #text\_change 09-Jul-2004

C:Accession: PN0512

R:Shimohigashi, Y.; Matsumoto, H.; Takano, Y.; Saito, R.; Iwata, T.; Kamiya, H.; Ohno, ;

Biochem. Biophys. Res. Commun. 193, 624-630, 1993

A:Title: Receptor-mediated specific biological activity of a beta-amyloid protein fragm

A:Reference number: PN0512; MUID:93290653; PMID:7685598

A:Accession: PN0512

A:Molecule type: protein

A:Residues: 1-42 <SHI>

A:Cross-references: UNIPROT:Q7M088

C:Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase

C:Keywords: alternative splicing; amyloid

Query Match 100.0%; Score 24; DB 2; Length 42;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
Db 3 EFRH 6

RESULT 3  
C91112  
hypothetical protein ECs3867 [imported] - Escherichia coli (strain O157:H7, substrain R)  
C;Species: Escherichia coli  
C;Date: 18-Jul-2001 #sequence\_revision 18-Jul-2001 #text\_change 09-Jul-2004  
C;Accession: C91112  
R;Hayashi, T.; Makino, K.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.  
gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.  
DNA Res. 8, 11-22, 2001  
A;Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic  
A;Reference number: A99629; MUID:21156231; PMID:11258796  
A;Accession: C91112  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-52 <HAY>  
A;Cross-references: UNIPROT:Q8X2N9; GB:BA000007; PIDN:BAB37290.1; PID:gl3363339; GSPDB:G  
A;Experimental source: strain O157:H7, substrain RMD 050952  
C;Genetics:  
A;Gene: ECs3867

Query Match 100.0%; Score 24; DB 2; Length 52;  
Best Local Similarity 100.0%; Pred. No. 29;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
||||  
Db 24 EFRH 27

RESULT 4  
A60045  
Alzheimer's disease amyloid beta/A4 protein precursor - dog (fragment)  
C;Species: Canis lupus familiaris (dog)  
C;Date: 01-Dec-1992 #sequence\_revision 01-Dec-1992 #text\_change 28-Jul-1995  
C;Accession: A60045  
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
Brain Res. Mol. Brain Res. 10, 299-305, 1991  
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
A;Reference number: A60045; MUID:92017079; PMID:1656157  
A;Accession: A60045  
A;Molecule type: mRNA  
A;Residues: 1-57 <JOH>  
A;Cross-references: EMBL:X56125  
A;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
||||  
Db 8 EFRH 11

RESULT 5  
F60045  
Alzheimer's disease amyloid beta/A4 protein precursor - pig (fragment)  
C;Species: Sus scrofa domestica (domestic pig)  
C;Date: 01-Dec-1992 #sequence\_revision 01-Dec-1992 #text\_change 13-Aug-1999  
C;Accession: F60045  
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
Brain Res. Mol. Brain Res. 10, 299-305, 1991  
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
A;Reference number: A60045; MUID:92017079; PMID:1656157  
A;Accession: F60045  
A;Molecule type: mRNA  
A;Residues: 1-57 <JOH>  
A;Cross-references: EMBL:X56127; NID:gl1895; PIDN:CAA39592.1; PID:gl1896  
A;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
||||  
Db 8 EFRH 11

RESULT 6  
D60045  
Alzheimer's disease amyloid beta/A4 protein precursor - bovine (fragment)  
C;Species: Bos primigenius taurus (cattle)  
C;Date: 01-Dec-1992 #sequence\_revision 01-Dec-1992 #text\_change 28-Jul-1995  
C;Accession: D60045  
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
Brain Res. Mol. Brain Res. 10, 299-305, 1991  
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
A;Reference number: A60045; MUID:92017079; PMID:1656157  
A;Accession: D60045  
A;Molecule type: mRNA  
A;Residues: 1-57 <JOH>  
A;Cross-references: EMBL:X56124  
A;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
||||  
Db 8 EFRH 11

RESULT 7  
E60045  
Alzheimer's disease amyloid beta/A4 protein precursor - sheep (fragment)  
C;Species: Ovis sp. (sheep)  
C;Date: 01-Dec-1992 #sequence\_revision 01-Dec-1992 #text\_change 28-Jul-1995  
C;Accession: E60045  
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
Brain Res. Mol. Brain Res. 10, 299-305, 1991  
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
A;Reference number: A60045; MUID:92017079; PMID:1656157  
A;Accession: E60045  
A;Molecule type: mRNA  
A;Residues: 1-57 <JOH>  
A;Cross-references: EMBL:X56130  
A;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
||||  
Db 8 EFRH 11

RESULT 8  
G60045  
Alzheimer's disease amyloid beta/A4 protein precursor - guinea pig (fragment)  
C;Species: Cavia porcellus (guinea pig)  
C;Date: 01-Dec-1992 #sequence\_revision 01-Dec-1992 #text\_change 28-Jul-1995  
C;Accession: G60045  
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
Brain Res. Mol. Brain Res. 10, 299-305, 1991  
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
A;Reference number: A60045; MUID:92017079; PMID:1656157  
A;Accession: G60045  
A;Molecule type: mRNA

A;Residues: 1-57 <JOH>  
 A;Cross-references: EMBL:X56126  
 C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
 C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;  
 Best Local Similarity 100.0%; Pred. No. 32;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 ||||  
 Db 8 EFRH 11

RESULT 9  
 B60045  
 Alzheimer's disease amyloid beta/A4 protein precursor - polar bear (fragment)  
 C;Species: Ursus maritimus (polar bear)  
 C;Date: 01-Dec-1992 #sequence\_revision 01-Dec-1992 #text\_change 09-Jul-2004  
 C;Accession: B60045  
 R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
 Brain Res. Mol. Brain Res. 10, 299-305, 1991  
 A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
 A;Reference number: A60045; MUID:92017079; PMID:1656157  
 A;Accession: B60045  
 A;Molecule type: mRNA  
 A;Residues: 1-57 <JOH>  
 A;Cross-references: UNIPROT:Q29149; EMBL:X56128; NID:92165; PIDN:CAA39593.1; PID:q2166  
 C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
 C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;  
 Best Local Similarity 100.0%; Pred. No. 32;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 ||||  
 Db 8 EFRH 11

RESULT 10  
 B89981  
 truncated transposase [imported] - Staphylococcus aureus (strain N315)  
 C;Species: Staphylococcus aureus  
 C;Date: 10-May-2001 #sequence\_revision 10-May-2001 #text\_change 09-Jul-2004  
 C;Accession: B89981  
 R;Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oguc  
 ma, A.; Mizutani-Ui, Y.; Kobayashi, N.; Sawano, T.; Inoue, R.; Kaito, C.; Sekimizu, K.;  
 C.; Shiba, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiramatsu, K.  
 Lancet 357, 1225-1240, 2001  
 A;Title: Whole genome sequencing of methicillin-resistant Staphylococcus aureus.  
 A;Reference number: A89758; MUID:21311952; PMID:11418146  
 A;Accession: B89981  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-57 <KUR>  
 A;Cross-references: UNIPROT:Q995W5; GB:BA000018; PID:G13701716; PIDN:BA843009.1; GSPDB:G  
 A;Experimental source: strain N315  
 C;Genetics:  
 A;Gene: truncated-tnp

Query Match 100.0%; Score 24; DB 2; Length 57;  
 Best Local Similarity 100.0%; Pred. No. 32;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 ||||  
 Db 30 EFRH 33

RESULT 11  
 P00438  
 Alzheimer's disease amyloid A4 protein precursor - rabbit (fragment)

C;Species: Oryctolagus cuniculus (domestic rabbit)  
 C;Date: 30-Sep-1993 #sequence\_revision 19-Oct-1995 #text\_change 19-Oct-1995  
 C;Accession: P00438; C60045  
 R;Davidson, J.S.; West, R.L.; Kotikalapudi, P.; Maroun, L.E.  
 Biochem. Biophys. Res. Commun. 188, 905-911, 1992  
 A;Title: Sequence and methylation in the beta/A4 region of the rabbit amyloid precursor  
 A;Reference number: P00438; MUID:93075180; PMID:1445331  
 A;Accession: P00438  
 A;Molecule type: DNA  
 A;Residues: 1-82 <DAV>  
 A;Cross-references: GB:M83558; GB:M83657  
 R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.  
 Brain Res. Mol. Brain Res. 10, 299-305, 1991  
 A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,  
 A;Reference number: A60045; MUID:92017079; PMID:1656157  
 A;Accession: C60045  
 A;Molecule type: mRNA  
 A;Residues: 12-68 <JOH>  
 A;Cross-references: EMBL:X56129  
 C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i  
 C;Keywords: alternative splicing; Alzheimer's disease; amyloid; Down's syndrome

Query Match 100.0%; Score 24; DB 2; Length 82;  
 Best Local Similarity 100.0%; Pred. No. 48;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 ||||  
 Db 19 EFRH 22

RESULT 12  
 G96025  
 hypothetical protein SMB20779 [imported] - Sinorhizobium meliloti (strain 1021) magaplas  
 C;Species: Sinorhizobium meliloti  
 C;Date: 24-Aug-2001 #sequence\_revision 24-Aug-2001 #text\_change 09-Jul-2004  
 C;Accession: G96025  
 R;Finan, T.M.; Weidner, S.; Wong, K.; Buhmester, J.; Chain, P.; Vorholter, F.J.; Hernan  
 Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001  
 A;Title: The complete sequence of the 1,683-kb pSymB megaplasmid from the N2-fixing endo  
 A;Reference number: A95842; MUID:21396508; PMID:11481431  
 A;Accession: G96025  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-84 <KUR>  
 A;Cross-references: UNIPROT:Q92TN7; GB:AL591985; PIDN:CAC49871.1; PID:G15141359; GSPDB:B  
 A;Experimental source: strain 1021, megaplasmid pSymB  
 R;Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubler,  
 peia, D.; Chain, P.; Cowie, A.; Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.;  
 L.; Hyman, R.W.; Jones, T.  
 Science 293, 668-672, 2001  
 A;Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure,  
 hebault, P.; Vandenbol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.  
 A;Title: The composite genome of the legume symbiont Sinorhizobium meliloti.  
 A;Reference number: A96039; MUID:21368234; PMID:11474104  
 A;Contents: annotation  
 C;Genetics:  
 A;Gene: SMB20779  
 A;Genome: plasmid

Query Match 100.0%; Score 24; DB 2; Length 84;  
 Best Local Similarity 100.0%; Pred. No. 49;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 ||||  
 Db 15 EFRH 18

RESULT 13  
 C82331  
 hypothetical protein VC0383 [imported] - Vibrio cholerae (strain N16961 serogroup O1)  
 C;Species: Vibrio cholerae

C;Date: 18-Aug-2000 #sequence\_revision 20-Aug-2000 #text\_change 09-Jul-2004  
 C;Accession: C82331  
 R;Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.; Dodson, R.J.; Chardson, D.; Ermolaeva, M.D.; Vamathevan, J.; Basse, S.; Qin, H.; Dragoi, I.; Sellers, F. I., R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.  
 Nature 406, 477-483, 2000  
 A;Title: DNA Sequence of both chromosomes of the cholera pathogen *Vibrio cholerae*.  
 A;Reference number: A82035; MUID:20406833; PMID:10952301  
 A;Accession: C82331  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-89 <HEI>  
 A;Cross-references: UNIPROT:Q9KUX5; GB:AB004126; GB:AB003852; NID:g9654802; PIDN:AAF9355  
 A;Experimental source: serogroup O1; strain N16961; biotype El Tor  
 C;Genetics:  
 A;Gene: VC0383  
 A;Map position: 1

Query Match 100.0%; Score 24; DB 2; Length 89;  
 Best Local Similarity 100.0%; Pred. No. 52;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 Db 45 EFRH 48

RESULT 14  
 T16095  
 hypothetical protein F18E9.6 - *Caenorhabditis elegans*  
 C;Species: *Caenorhabditis elegans*  
 C;Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
 C;Accession: T16095  
 R;Leimbach, D.  
 submitted to the EMBL Data Library, June 1995  
 A;Description: The sequence of *C. elegans* cosmid F18E9.  
 A;Reference number: Z18460  
 A;Accession: T16095  
 A;Status: preliminary; translated from GB/EMBL/DDBJ  
 A;Molecule type: DNA  
 A;Residues: 1-91 <LEI>  
 A;Cross-references: UNIPROT:Q19566; EMBL:U29614; NID:g868285; PID:g868290; PIDN:AAA68811  
 A;Experimental source: strain Bristol N2  
 C;Genetics:  
 A;Gene: CESP:F18E9.6

Query Match 100.0%; Score 24; DB 2; Length 91;  
 Best Local Similarity 100.0%; Pred. No. 53;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 Db 86 EFRH 89

RESULT 15  
 B86195  
 hypothetical protein [imported] - *Arabidopsis thaliana*  
 C;Species: *Arabidopsis thaliana* (mouse-ear cress)  
 C;Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004  
 C;Accession: B86195  
 R;Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso, Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; ansen, N.F.; Hughes, B.; Huizar, L.  
 Nature 408, 816-820, 2000  
 A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C. C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziali, Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
 A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
 A;Title: Sequence and analysis of chromosome 1 of the plant *Arabidopsis*.  
 A;Reference number: A86141; MUID:21016719; PMID:11130712  
 A;Accession: B86195

A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-94 <STO>  
 A;Cross-references: UNIPROT:Q9LNE5; GB:AE005172; NID:g8810463; PIDN:AAF80124.1; GSPDB:GN C;Genetics:  
 A;Map position: 1

Query Match 100.0%; Score 24; DB 2; Length 94;  
 Best Local Similarity 100.0%; Pred. No. 55;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4  
 Db 31 EFRH 34

Search completed: November 2, 2005, 09:31:39  
 Job time : 41 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 2, 2005, 09:04:29 ; Search time 177 Seconds  
(without alignments)  
11.572 Million cell updates/sec

Title: US-10-618-856-1  
Perfect score: 24  
Sequence: 1 EFRH 4

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : UniProt\_03: \*  
1: uniprot\_sprot: \*  
2: uniprot\_trembl: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	24	100.0	25	2 Q7R843	Q7R843 plasmodium
2	24	100.0	33	2 Q9UC33	Q9UC33 homo sapien
3	24	100.0	38	2 Q8CM52	Q8CM52 staphylococ
4	24	100.0	38	2 Q8CN66	Q8CN66 staphylococ
5	24	100.0	38	2 Q8CNR0	Q8CNR0 staphylococ
6	24	100.0	38	2 Q8CNT8	Q8CNT8 staphylococ
7	24	100.0	38	2 Q8CP00	Q8CP00 staphylococ
8	24	100.0	38	2 Q8CPT7	Q8CPT7 staphylococ
9	24	100.0	38	2 Q8CPX2	Q8CPX2 staphylococ
10	24	100.0	39	1 NPF HELAS	P41321 helix asper
11	24	100.0	42	2 Q7M088	Q7M088 cavia porce
12	24	100.0	43	2 Q7UT20	Q7UT20 rhodopirell
13	24	100.0	45	2 Q6V7T6	Q6V7T6 burkholderi
14	24	100.0	45	2 Q8CQ63	Q8CQ63 staphylococ
15	24	100.0	48	2 Q8CN63	Q8CN63 staphylococ
16	24	100.0	52	2 Q8WZ99	Q8WZ99 homo sapien
17	24	100.0	52	2 Q8XZ99	Q8XZ99 escherichia
18	24	100.0	54	2 Q64RK3	Q64RK3 bacteroides
19	24	100.0	55	2 Q7UGM8	Q7UGM8 rhodopirell
20	24	100.0	57	1 A4 URSM4	Q29149 ursus marit
21	24	100.0	57	2 Q93SW5	Q93SW5 staphylococ
22	24	100.0	57	2 Q8DGN4	Q8DGN4 synechococ
23	24	100.0	58	1 A4 CANFA	Q28280 canis famli
24	24	100.0	58	1 A4 RABIT	Q28748 oryctolagus
25	24	100.0	58	1 A4 SHEEP	Q28757 ovis aries
26	24	100.0	59	1 A4 BOVIN	Q28053 bos taurus
27	24	100.0	61	2 Q63YH0	Q63YH0 burkholderi
28	24	100.0	62	2 Q65802	Q65802 bovine vira
29	24	100.0	62	2 Q65804	Q65804 bovine vira
30	24	100.0	62	2 Q65805	Q65805 bovine vira
31	24	100.0	65	2 Q6IIT6	Q6IIT6 drosophila

32	24	100.0	67	2 Q98LA2	Q98LA2 rhizobium 1
33	24	100.0	68	2 Q14885	Q14885 homo sapien
34	24	100.0	69	2 Q98MZ4	Q98MZ4 rhizobium 1
35	24	100.0	73	2 Q8GX82	Q8GX82 arabidopsis
36	24	100.0	76	2 Q87L89	Q87L89 vibrio para
37	24	100.0	76	2 Q8DCK3	Q8DCK3 vibrio vuln
38	24	100.0	77	2 Q6LM57	Q6LM57 photobacter
39	24	100.0	80	2 Q8GR41	Q8GR41 enterococcu
40	24	100.0	80	2 Q7TCM4	Q7TCM4 untyped hum
41	24	100.0	84	2 Q92TN7	Q92TN7 rhizobium m
42	24	100.0	88	2 Q7MHA4	Q7MHA4 vibrio vuln
43	24	100.0	89	2 Q9KUX5	Q9KUX5 vibrio chol
44	24	100.0	90	2 Q8VZU1	Q8VZU1 arabidopsis
45	24	100.0	90	2 Q8CMD7	Q8CMD7 staphylococ

## ALIGNMENTS

RESULT 1  
Q7R843 PRELIMINARY; PRT; 25 AA.  
AC Q7R843; (Tremblrel. 26, Created)  
DT 01-MAR-2004 (Tremblrel. 26, Last sequence update)  
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)  
DE Hypothetical protein (Fragment).  
GN Name=PY07380;  
OS Plasmodium yoelii yoelii.  
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.  
OX NCBI\_TaxID=73239;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=17XNL;  
RX PubMed=12368865; DOI=10.1038/nature01099;  
RA Carlton J.M., Angiuoli S.V., Suh B.B., Kooij T.W., Perteu M., Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L., Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L., Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblum T.V., Cho J.K., Quackenbush J., Sedegah M., Shoabi A., Cummings L.M., Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A., Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B., van Lin L.H., Jense C.J., Waters A.P., Smith H.O., White O.R., Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J., Carucci D.J.;  
RT "Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii";  
RL Nature 419:512-519(2002).  
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is preliminary data.  
DR EMBL; AABL01002689; EAA19793.1; -.  
KW Hypothetical protein.  
FT NON\_TER 1  
SQ SEQUENCE 25 AA; 3303 MW; 1A5AB86BD78F4422 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 25;  
Best Local Similarity 100.0%; Pred. No. 99;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4  
|||  
Db 10 EFRH 13

RESULT 2  
Q9UC33 PRELIMINARY; PRT; 33 AA.  
ID Q9UC33  
AC Q9UC33; (Tremblrel. 13, Created)  
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
DT 01-MAY-2000 (Tremblrel. 13, Last annotation update)  
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)  
DE Beta-amyloid peptide (Fragment).

```
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=3024877; PubMed=1406936; DOI=10.1038/359325a0;
RA Seibert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.,
RA Sinha S., Schlossmacher M., Whaley J., Swindlehurst C.;
RT "Isolation and quantification of soluble Alzheimer's beta-peptide from
RT biological fluids.";
RL Nature 359:325-327(1992).
DR HSP; Q16019; 1BA4.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0005488; F:binding; IEA.
DR InterPro; IPR001255; Beta-APP.
DR Pfam; PF03494; Beta-APP; 1.
DR PRINTS; PR00204; BETAAMYLOID.
SQ SEQUENCE 33 AA; 3674 MW; B1DFE2F4167ABD0 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 3
ID Q8CM52 PRELIMINARY; PRT; 38 AA.
AC Q8CM52;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DE Truncated transposase.
GN OrderedLocusNames=SE0257;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016744; AAO03854.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4448 MW; A40B39C53421AD0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 30 EFRH 33

RESULT 4
ID Q8CM66 PRELIMINARY; PRT; 38 AA.
AC Q8CM66;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DE Truncated transposase.
GN OrderedLocusNames=SE1982;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
```

```
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016750; AAO05623.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4458 MW; 8BDB2172728B9946 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 30 EFRH 33

RESULT 5
ID Q8CNRO PRELIMINARY; PRT; 38 AA.
AC Q8CNRO;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DE Truncated transposase.
GN OrderedLocusNames=SE1539;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016749; AAO05138.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4434 MW; A415C75C6B85FC4B CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 30 EFRH 33

RESULT 6
ID Q8CNT8 PRELIMINARY; PRT; 38 AA.
AC Q8CNT8;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DE Truncated transposase.
GN OrderedLocusNames=SE1454;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
```

```

RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593 (2003).
DR EMBL; AE016748; AAO05053.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4404 MW; F50B21726435EC91 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 30 EPRH 33

RESULT 7
Q8CP00 PRELIMINARY; PRT; 38 AA.
AC Q8CP00;
DT 01-MAR-2003 (TReMBLrel. 23, Created)
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SEI319;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;

RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593 (2003).
DR EMBL; AE016748; AAO04918.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4495 MW; B1D109D5DC4F3B0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 30 EPRH 33

RESULT 8
Q8CPT7 PRELIMINARY; PRT; 38 AA.
AC Q8CPT7;
DT 01-MAR-2003 (TReMBLrel. 23, Created)
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0668;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;

RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593 (2003).
DR EMBL; AE016748; AAO04918.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4495 MW; B1D109D5DC4F3B0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 30 EPRH 33

RESULT 9
Q8CPX2 PRELIMINARY; PRT; 38 AA.
AC Q8CPX2;
DT 01-MAR-2003 (TReMBLrel. 23, Created)
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0590;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;

RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593 (2003).
DR EMBL; AE016745; AAO04187.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4395 MW; A40B39DF8421AD0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 30 EPRH 33

RESULT 10
NPFLHELAS STANDARD; PRT; 39 AA.
AC P41321;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Neuropeptide F (NPF).
OS Helix aspersa (Brown garden snail).
OC Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Stylommatophora;
OC Sigmurethra; Helicoidea; Helicidae; Helix.
OX NCBI_TaxID=6535;
RN [1]
RP SEQUENCE.
RC TISSUE=Circumoesophageal ganglion;
RX MEDLINE=93087780; PubMed=1472263; DOI=10.1016/0167-0115(92)90515-V;
RA Leung P.S., Shaw C., Maule A.G., Thim L., Johnston C.F., Irvine G.B.;
RT "The primary structure of neuropeptide F (NPF) from the garden snail,
```

```

RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593 (2003).
DR EMBL; AE016746; AAO04265.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4534 MW; A40B3F052E90E80E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 30 EPRH 33

RESULT 9
Q8CPX2 PRELIMINARY; PRT; 38 AA.
AC Q8CPX2;
DT 01-MAR-2003 (TReMBLrel. 23, Created)
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0590;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;

RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593 (2003).
DR EMBL; AE016745; AAO04187.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4395 MW; A40B39DF8421AD0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EPRH 4
DB 30 EPRH 33

RESULT 10
NPFLHELAS STANDARD; PRT; 39 AA.
AC P41321;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Neuropeptide F (NPF).
OS Helix aspersa (Brown garden snail).
OC Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Stylommatophora;
OC Sigmurethra; Helicoidea; Helicidae; Helix.
OX NCBI_TaxID=6535;
RN [1]
RP SEQUENCE.
RC TISSUE=Circumoesophageal ganglion;
RX MEDLINE=93087780; PubMed=1472263; DOI=10.1016/0167-0115(92)90515-V;
RA Leung P.S., Shaw C., Maule A.G., Thim L., Johnston C.F., Irvine G.B.;
RT "The primary structure of neuropeptide F (NPF) from the garden snail,
```

```
RT Helix aspersa.;
RL Regul. Pept. 41:71-81(1992).
CC -i- FUNCTION: May have an important physiological role in
CC neuroregulation.
CC -i- SUBCELLULAR LOCATION: Secreted.
CC -i- TISSUE SPECIFICITY: Neuronal somata and fibers.
CC -i- SIMILARITY: Belongs to the NPY family.
DR PIR: A48544; A48544.
DR HSSP: P41967; IK8V.
DR InterPro: IPR001955; Pancreatic_hormn.
DR Pfam: PF00159; Hormone 3; 1.
DR PROSITE: PS0265; PANCREATIC_HORMONE 1; 1.
DR PROSITE: PS0276; PANCREATIC_HORMONE 2; 1.
KW Amidation; Direct protein sequencing; Neuropeptide.
FT MOD_RES 39 39 Phenylalanine amide
SQ SEQUENCE 39 AA; 4855 MW; 4B54AA7414CAAE33 CRC64;

Query Match 100.0%; Score 24; DB 1; Length 39;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 13 EFRH 16

RESULT 11
Q7M088 PRELIMINARY; PRT; 42 AA.
AC Q7M088;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Beta-amyloid protein (fragment).
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP SEQUENCE.
RX MEDLINE=93290653; PubMed=7685598;
RA Shimohigashi Y., Matsumoto H., Takano Y., Saito R., Iwata T.,
RA Kamiya H., Ohno M.;
RT "Receptor-mediated specific biological activity of a beta-amyloid
RT protein fragment for NK-1 substance p receptors.";
RL Biochem. Biophys. Res. Commun. 193:624-630(1993).
DR PIR: PNO512; PNO512.
DR HSSP: Q16019; 11YT.
DR GO: GO:0016021; C:integral to membrane; IEA.
DR GO: GO:0005488; F:binding; IEA.
DR InterPro: IPR001255; Beta-APP.
DR Pfam: PF03494; Beta-APP; 1.
DR PRINTS: PR00204; BETAAMYLOID.
FT NON_TER 1
FT NON_TER 42
SQ SEQUENCE 42 AA; 4514 MW; 3AC85563D7858C37 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 42;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 12
Q7UT20 PRELIMINARY; PRT; 43 AA.
AC Q7UT20;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)

DE Hypothetical protein.
DE OrderedLocusNames=RB4166;
OS Rhodopirellula baltica.
OC Bacteria; Planctomycetes; Planctomycetacia; Planctomycetales;
OC Planctomycetaceae; Pirellula.
OX NCBI_TaxID=117;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=1;
RX MEDLINE=22735913; PubMed=12835416; DOI=10.1073/pnas.1431443100;
RA Gloeckner F.O., Kube M., Bauer M., Teeling H., Lombardot T.,
RA Ludwig W., Gade D., Beck A., Borzym K., Heitmann K., Rabus R.,
RA Schlesner H., Amann R., Reinhardt R.;
RT "Complete genome sequence of the marine planctomycete Pirellula sp.
RT strain 1.";
RL Proc. Natl. Acad. Sci. U.S.A. 100:8298-8303(2003).
DR EMBL: BX294140; CAD73621.1; -.
KW Complete proteome; Hypothetical protein.
SQ SEQUENCE 43 AA; 5428 MW; 3106E49B67D19882 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 43;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 19 EFRH 22

RESULT 13
Q6V7T6 PRELIMINARY; PRT; 45 AA.
AC Q6V7T6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Gp6.
OS Burkholderia cepacia phage Bcep22.
OC Viruses; dsDNA viruses, no RNA stage; Caudovirales; Podoviridae.
OX NCBI_TaxID=242527;
RN [1]
RP SEQUENCE FROM N.A.
RA Summer E.J., Cordova M., Parkinson B.C., Fuller A.C., Kitsopoulos K.,
RA Parks B., Rambo L., Rothwell S., Mebane L.M., Carlile T.M., No E.G.,
RA Gonzalez C.M., Young R.F.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY349011; AAQ54942.1; -.
SQ SEQUENCE 45 AA; 5701 MW; 8C2B468B47A94BF9 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 45;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 7 EFRH 10

RESULT 14
Q8CQ63 PRELIMINARY; PRT; 45 AA.
AC Q8CQ63;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0355;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
```

RX PubMed=12950922;  
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,  
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,  
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;  
RT "Genome-based analysis of virulence genes in a non-biofilm-forming  
ST Staphylococcus epidermidis strain (ATCC 12228).";  
RL Mol. Microbiol. 49:1577-1593(2003).  
DR EMBL; AE016745; AA003952.1; -.  
KW Complete proteome.  
SQ SEQUENCE 45 AA; 5238 MW; 7E3C1EB6774709DB CRC64;  
  
Query Match 100.0%; Score 24; DB 2; Length 45;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 EFRH 4  
Db 37 EFRH 40  
  
RESULT 15  
Q8CN63  
ID Q8CN63 PRELIMINARY; PRT; 48 AA.  
AC Q8CN63;  
DT 01-MAR-2003 (TReMBLrel. 23, Created)  
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)  
DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)  
DE Truncated transposase.  
GN Ordered locus names=SE1990;  
OS Staphylococcus epidermidis.  
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.  
OX NCBI\_TaxID=1282;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=ATCC 12228;  
RX PubMed=12950922;  
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,  
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,  
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;  
RT "Genome-based analysis of virulence genes in a non-biofilm-forming  
ST Staphylococcus epidermidis strain (ATCC 12228).";  
RL Mol. Microbiol. 49:1577-1593(2003).  
DR EMBL; AE016750; AA005631.1; -.  
KW Complete proteome.  
SQ SEQUENCE 48 AA; 5719 MW; 62AF02B5272219C7 CRC64;  
  
Query Match 100.0%; Score 24; DB 2; Length 48;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 EFRH 4  
Db 40 EFRH 43  
  
Search completed: November 2, 2005, 09:30:56  
Job time : 182 secs

1